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Å  Ångström  
Ac  acetyl  
Alk  alkyl  
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Ar  aryl  
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Bn  benzyl  
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Bu  butyl  
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calc.  calculated  
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DFT  density functional theory  
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TM  transition metal  
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Based on the environmental issues that have risen during the last decades, new and 
efficient processes are in high demand for replacing old and waste-generating 
technologies in order to provide a sustainable future for the next generation. This 
paradigm shift reflects that we are now aware of our present practices having 
enormous impact on future generations, this is now also observed in molecular 
synthesis. Thus, due to the increased need for sustainable molecular syntheses, new 
strategies and technologies are highly desired. Catalysis represents one significant 
approach for the minimization of the environmental footprint as was recognized by 
Anastas and Werner in their 12 Principles of Green Chemistry.[1] Apart from that, 
catalysis can provide new disconnections to the practitioner in a step-, atom- and 
resource economical manner.[2] 
 
1.1. Transition Metal-Catalyzed C–H Functionalizations 
 
The design of mild, robust and predictable reactions for forging C–C and C–Het bonds 
is of outmost importance in organic synthesis, as these methods would facilitate the 
synthesis of a plethora of life-saving drugs, among others, in an expedient and efficient 
manner. In this context, transition metal-catalyzed reactions represent one of the most 
well-established and reliable approaches for the synthesis of these scaffolds. 
Transition metals offer an enormous amount of modes of action, thus providing a new 
avenue for new types of disconnections, which have been inaccessible by "traditional" 
chemistry. Among the plethora of reaction manifolds, metathesis[3] and cross-
coupling[4] have truly revolutionized the way we approach organic synthesis. The 
understanding of the distinct mechanistic steps of these reaction manifolds led to 
significant advancements, thus cross-coupling has been sharpened into a modular and 
predictable tool, with applications in academia and industries. Among the transition 
metals, palladium[5] is the most used for cross-couplings, due to general and mild 
reaction conditions that are typically employed. Thus, many palladium-catalyzed cross-
couplings reaction have been developed, namely Kumada-Corriu,[6] Negishi,[7] Magita-
Kosogi-Stille,[8] Suzuki-Miyaura,[9] Hiyama[10] cross-coupling enabled the expedient 
synthesis of biaryls via the coupling of an aryl halides or pseudo-halides with various 
organometallic nucleophiles (Scheme 1.1.1a). In addition, the Mizoroki-Heck 
reaction[11] enabled the alkenylation of an aryl halides or pseudo-halides, the 




pseudo-halides and the Tsuji-Trost[13] reaction enabled the substitutive allylation of allyl 
electrophiles with various organic and organometallic nucleophiles. The translational 
nature of these new reaction manifolds was recognized with the Nobel Prize in 
Chemistry in 2010 to A. Suzuki, E.-i. Negishi and R. F. Heck.[14] While these methods 
entirely changed the way synthetic chemists think and practice organic chemistry,[15] 
they still require pre-functionalized materials, thus jeopardizing the atom- and step-
economy of this approach. Furthermore, some organometallic nucleophiles utilized are 
either air- or moisture- sensitive, such as organomagnesium reagents used in the 
Kumada-Corriu cross-coupling or organozinc reagents used in the Negishi cross-
coupling. Lastly, organostannane reagents used in Stille coupling are typically toxic. 
Thus, the chemical waste associated with the preparation of the starting materials and 
the stoichiometric byproducts of these reaction significantly intensifies their 
environmental footprint. To bypass these shortcomings, the synthetic community in 
search of a more straightforward approach for molecular synthesis, demonstrated that 
C–H functionalization provides a sustainable alternative to the "traditional" cross-
coupling technologies.[16] In this approach, the organometallic nucleophile is replaced 
by an inert C–H bond, therefore eliminating the need for multi-step sequences for 
accessing the sensitive and potentially toxic organic nucleophile (Scheme 1.1b). 
Interestingly, the stitching of two carbon atoms bearing a hydrogen atom via an 
oxidative C–H/C–H functionalization represents a priori an ideal transformation, albeit 
a stoichiometric oxidant is normally required (Scheme 1.1c). 
 
 
Scheme 1.1.1. Conceptual advantages of C–H functionalization over classical cross-
couplings. 
 
Due to the inherit benefits of the C–H functionalization approach in terms of atom- and 
step-economy, great efforts had been devoted to the understanding of the C–H bond 
cleavage step. Excluding the radical-type outer-sphere mechanisms, the 
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organometallic C–H bond cleavage mainly proceeds via five different pathways, 
depending by on nature of the metal, ligands and the oxidation state (Scheme 1.1.2).[17] 
These modes of C–H activation are oxidative addition, σ-bond metathesis, 1,2-
addition, electrophilic substitution and base-assisted metalation. C–H bond cleavage 
by oxidative addition is typically observed in electron-rich metal centers, thus 
cyclometalation with d8-electron configuration at iridium(I), rhodium(I) and ruthenium(0) 
typically occurs via this pathway. The key interaction of the σ* orbital of the C–H bond 
with the metal center induces a formal two-electron transfer from the metal to the 
ligand. Cyclometalation via σ-bond metathesis is considered the main mechanistic 
pathway for high-valent early transition metals. In addition, this mode of action has 
been proposed to be operative with metal hydrides and metal alkyl complexes. The 
1,2-addition is observed for metals with a M=X bond, mostly group IV and V metal 
imido-complexes. This mode of action usually takes place with early transition metals. 
C–H bond cleavage via electrophilic substitution is generally observed with electron-
poor late transition metals. A classic example is palladium(II)-mediated C(sp2)–H 
activation. Mechanistic investigations demonstrated that electron-rich arenes react 
preferentially to electron-poor ones, analogous to "classical" electrophilic substitution. 
The base-assisted metalation is observed for complexes bearing a chelating base, e.g. 
carboxylate or carbonate and resembles the electrophilic substitution, but with the 
assistance from the coordinated base. Under this mechanistic manifold the C–H bond 





Scheme 1.1.2. Different modes of organometallic C–H bond cleavage. 
 
Among these different modes of transition-metal catalyzed C–H bond cleavage base-
assisted metalation is by far the most practical in terms of mildness and robustness 
and consequently the most studied. Thus, based on the transition state structure and 
the resulting accumulation of partial charges, the base-assisted metalation pathway 
can be further categorized (Scheme 1.1.3).[18] For a deprotonative transition state as 
first put forward by Sakaki,[19] the term concerted metalation-deprotonation (CMD) was 
introduced by Fagnou.[20] The same mode of action, although featuring an agostic 
interaction between the C–H bond and the metal center, was also studied by 
Macgregor and Davies and named ambiphilic metal ligand activation (AMLA).[21] Due 
to the deprotonative nature of this pathway, a preferential activation of electron-
deficient substrates is observed through kinetic C–H acidity control. In contrast, the 
base-assisted internal electrophilic substitution (BIES) was introduced by Ackermann 
for the preferred activation of electron-rich substrates and proceeds in a 
deptotonative/electrophilic substitution-type pathway.[22] 




Scheme 1.1.3. Comparison of transition state structures in base-assisted metalation. 
 
C–H functionalization has been established as a transformative tool with applications 
ranging from natural product synthesis[23] and material sciences[24] to predominantly 
medicinal chemistry.[25] Otherwise unreactive C–H bonds are utilized as latent 
functional groups enabled by a variety of diverse reaction manifolds. Although this 
implies a straightforward approach towards molecular complexity, site-selectivity 
issues arise, since organic molecules typically display multiple C–H bonds with 
comparable dissociation energies. Thus, different approaches have been developed 
for achieving synthetically useful selectivities (Scheme 1.1.4a). Selectivity can be 
achieved by the inherit properties of the molecule. For instance, based on electronic 
or steric factors. This approach is limited albeit powerful for specific type of substrates. 
Another approach, perhaps the most well-established and predictable, relies on Lewis-
basic functionalities that chemoselectively bring the catalyst into close proximity to a 
specific C–H bond to enable the crucial chelation-assisted C–H cleavage.[16c] During 
the last two decades, directed C–H functionalization has flourished with many major 
contributions with regards to the type of substrates, reactions and transition metals 
used. Chelation-assisted C–H activation has matured into an indispensable tool for 
molecular synthesis, as it allows a reliable and predictable manifold for the 
functionalization of inert C–H bonds under exceedingly mild conditions (Scheme 
1.1.4b). Great efforts from the synthetic community have established the use of 
precious 4d and 5d metals, as well as more recently Earth-abundant 3d transition 





Scheme 1.1.4. Strategies for selectivity control and typical directing groups. 
 
A remarkable testament to the transformative application of C–H functionalization is its 
use in natural product synthesis, allowing disconnections previously unimaginable. 
Furthermore, the continuous efforts from the synthetic community to shape C–H 
functionalization into a mild and robust method is reflected by its applications to 
complex settings in many total synthesis campaigns. In Scheme 1.1.5, three examples 
are presented where various modes of action are utilized to construct key structural 
motifs. Ellman used rhodium(III)-catalyzed C–H hydroarylation of sugar-derived 
nitroalkene 2 directed by a tertiary amide en route to (+)-pancratistatin (4).[27] This 
Michael-type addition occurred with excellent levels of diastereoselectivity. 
Furthermore, the nitro group that was essential for achieving a regioselective addition, 
subsequently was reduced to afford the trans-fused 3,4-dihydroisoquinolin-1(2H)-one 
moiety. Among the transition metals, palladium is the most prominent in terms of 
directed C(sp3)–H functionalization assisted by a plethora of different directing groups 
and under various reaction manifolds. Reisman utilized the well-established 8-
aminoquinoline (AQ) as the bidentate directing group to functionalize the cyclobutane 
ring by forging a key C–C bond in their total synthesis of (+)-psiguadial B (8).[28] The 
C–H alkenylation with the vinyl-iodide 6 occurred with excellent cis stereoselectivity, 
without racemization. Although the use of exogenous directing groups provides a 
robust and predictable site-selective C–H activation regime, their utilization is in 
contrast to atom-and step-economic nature of C–H functionalization as the installation 
and subsequent removal of the directing group requires additional steps. Thus, the use 
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of sterically control iridium(I)-catalyzed C–H borylation of fully protected tryptophan 
derivative 9 by Baran demonstrates the remarkable efficiency of such approach.[29] As 
it is already established, the choice of the N,N-ligand is crucial for achieving good 
turnover numbers and to improve the site-selectivity.[16k] As it is expected, 4d and 5d 
transition metals have dominated this area since methods catalyzed by them have 
been developed much earlier than those with 3d transition metals.[26] 
 
 





1.2. Ruthenium-Catalyzed C–H Activation 
 
During the last two decades enormous progress has been made in C–H 
functionalization via organometallic C–H bond cleavage, thus providing a new 
synthetic toolbox for molecular synthesis. In terms of the transition metals used in these 
methods, 4d and 5d transition metals have been the metals of choice. Despite having 
established a plethora of reaction manifolds under mild reaction conditions, 
sustainability and resource-economy issues arise, since most of these metals are 
expensive and potentially toxic. However, although ruthenium is a 4d transition metal, 
it is cost-effective and offers a wide range of distinct catalytic applications.[30] 
One of the earliest examples of ruthenium-catalyzed C–H activation was reported by 
Lewis and Smith in 1986,[31] inspired by earlier stoichiometric studies by Chatt.[32] In an 
elegant approach, using the first transient directing group approach,[33] the ruthenium-
catalyzed hydroarylation of ethylene gas with phenol 13 was realized, affording a 
mixture of mono- and disubstituted products (Scheme 1.2.1). Despite the harsh 
reaction conditions, this report clearly provided the impetus for further applications of 
ruthenium-catalyzed C–H activation. 
 
 
Scheme 1.2.1. First ruthenium catalyzed C–H alkylation via phosphite assistance. 
 
Almost a decade later, Murai published his seminal work on ruthenium(0)-catalyzed 
C–H hydroarylation of unisomerizable olefins 19 via ketone assistance (Scheme 
1.2.2).[34] The ruthenium precatalyst RuH2(CO)(PPh3)3 upon heating generated a 
ruthenium(0) species that enabled the crucial C–H cleavage via an oxidative addition 
resulting in a ruthenium hydride species that inserted into the olefin, that underent 
reductive elimination giving rise to linear anti-Markovnikov addition products. The 
reaction manifold proved applicable to many aromatic ketones 18 and various olefins 
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19 resulting in chemo- and site-selective functionalization under relatively mild and 
synthetically-useful reaction conditions. 
 
 
Scheme 1.2.2. Ruthenium-catalyzed C–H hydroarylation via ketone assistance. 
 
After this early contributions, many ruthenium-catalyzed C–H activation reactions have 
been well established, including arylations,[35] alkylations,[36] amination/amidations,[37] 
oxygenations,[38] among others. Importantly, the user-friendly, air- and moisture-stable 
[RuCl2(p-cymene)]2 and related complexes have provided a robust and reliable 
solution even on large scale. Among these reaction manifolds, hydroarylation[39] is 
perhaps the most appealing since theoretically nearly perfect atom-economy is 
observed. In addition, olefins are widely available and inexpensive. Thus, the 
hydroarylation manifold has been expanded greatly with activated olefins being the 
most widely used coupling partners. It should be stated that under oxidative conditions, 
alkenylation regime can be operative by employing chemical oxidants,[40] molecular 




Ackermann demonstrated that various activated olefins, such as α,β-unsaturated 
esters, amides and ketones, are suitable substrates under ruthenium(II)-catalysis via 
weak-amide assistance (Scheme 1.2.3a).[43] Remarkably, water outperformed 
common organic solvents, showcasing the robustness of the ruthenium(II)-catalysis. 
Furthermore, the single component ruthenium carboxylate complex Ru(O2CMes)2(p-
cymene) proved to be similarly efficient catalyst. This method tolerated a wide range 
of substituents both at the arene scaffold as well as at the olefin coupling partner. 
Lastly, this strategy enabled the functionalization of anilides and under oxidative 
conditions allowed expedient access to isoquinolines. Recently, Zhang employed the 
transient directing group strategy for the hydroarylation of maleimides with aromatic 
benzaldehydes under ruthenium(II)-catalysis (Scheme 1.2.3b).[44] In this method, the 
condensation of the benzaldehyde 24 and the aniline 26, resulted the formation of the 
corresponding aldimine, this transient species enabled the site-selective C–H cleavage 
and subsequent functionalization. The intramolecular hydroarylation of suitably 
tethered olefins is also feasible under ruthenium(II)-catalysis as Sahoo reported the 
methyl phenyl sulfoxime (MPS) directed cyclization (Scheme 1.2.3c).[45] Under mild 
reaction conditions various substrates 28 were efficiently converted to 2,3-
dihydrobenzofuran and indoline derivatives 29. Furthermore, the directing group could 
be easily employed for a sequential C–H functionalization at the remaining ortho-
position. 




Scheme 1.2.3. Ruthenium(II)-catalyzed C–H hydroarylation with activated olefins. 
 
These contributions, among others, demonstrated the remarkable efficacy of 
ruthenium(II)-catalysis for the C–H hydroarylation of activated olefins either via 
electronic or via topological activation. The general and practical utilization of unbiased 
olefins under ruthenium(II)-catalysis was elegantly developed by Ackermann in 2013 
(Scheme 1.2.4a).[46] Thus, various (hetero)-arenes 30, such as pyrazoles, pyridines 
and indoles among others, were efficiently alkylated with a plethora of olefins 31, 
featuring many sensitive functional groups via the key assistance by the bulky 
potassium carboxylate KO2CMes. Remarkably, also fluorinated olefins proved to 
besuitable substrates under otherwise similar reaction conditions. Control experiments 
ruled out the formation of ruthenium(0) species as the key intermediate. Despite that 
the cleavage of C(sp2`)–H bonds under ruthenium-catalysis is well established and has 




though having lower BDE, is significantly more challenging and only palladium 
provides a robust and general platform for various C(sp3`)–H functionalizations. Thus, 
Ackermann devised a protocol for the C–H functionalization of pyrrolidine rings via 
pyridine assistance under ruthenium catalysis (Scheme 1.2.4b).[47] The key for the 
selective functionalization was the use of bisphosphine ligand BINAP in combination 
with RuCl2(PPh3)2 that allowed the cleavage of the C–H bond proximal to the nitrogen 
and subsequent hydroarylation of the olefin 31. The authors demonstrated that this 
method was applicable to a wide variety of substrates that featured sensitive functional 
groups. Remarkably, aryl bromides were chemoselectively used, overriding the 
tendency towards arylative manifolds. 
 
 
Scheme 1.2.4. Ruthenium(II)-catalyzed C–H hydroarylation with unactivated olefins 
31. 
 
The proximity-induced C–H functionalization by transition metals is a powerful tool for 
molecular synthesis, albeit limited in terms of the C–H bonds that can be efficiently 
functionalized, since cyclometalation is required. Therefore, strategies for remote 
functionalization of C–H bonds are in high demand since the powerful C–H 
functionalization manifold would be applied to a plethora of C–H bonds.[48] The most 
prominent strategies require either the use of mediators, for example norbornene 
derivatives in a Catellani-type manifold,[49] or the installation of elaborate templates[50] 
that direct the transition metal to the proximity of meta or even para C–H bond of the 
arene. These methods rely on the metalation of the remote C–H bond and subsequent 
functionalization. A mechanistically different approach was unraveled in a catalytic 
fashion by Ackermann in 2011, when the ortho-alkylation of ketimines was 
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investigated.[36b] After careful examination of the reaction with electron-rich phenyl 
pyridine 35 significant amounts of meta-alkylated product 38 were isolated in 
combination with the expected ortho-alkylated product 37 (Scheme 1.2.5). This 
unexpected result led to extensive mechanistic investigations in order to shed light into 
this mysterious reaction manifold and provided the stimulus for the development of a 
robust platform for ruthenium-catalyzed meta-C–H functionalizations via unique σ-
activation. These studies led to the development of mild reaction conditions for the 
decarboxylative ortho-alkylation.[36c, 51] 
 
 
Scheme 1.2.5. First ruthenium(II)-catalyzed meta C–H alkylation with primary alkyl-
bromide 36. 
 
After this early report, the Ackermann group demonstrated that this strategy is 
applicable for the meta-C–H alkylations using secondary alkyl bromides 40 via 
carboxylate-assisted ortho-ruthenation, leading to the formation of meta-alkylated 
arenes 41 with excellent levels of position-selectivity (Scheme 1.2.6a).[52] A plethora of 
heteroarenes served as efficient directing groups, including pyridines, pyrimidines, and 
azoles. Detailed mechanistic studies suggested a reversible C–H ruthenation and 
subsequent site-selective alkylation, which was proposed to be guided by the effect of 
the Ru–C(sp2) σ-bond, including para-to-the-ruthenium radical addition. Moreover, 
addition of the typical radical scavenger, TEMPO fully inhibited the reaction, providing 
strong evidence that radical species are involved in the reaction. In 2015, Ackermann 
reported on the ruthenium-catalyzed tertiary meta-C–H alkylation of arenes and aniline 
derivatives (Scheme 1.2.6b).[53] Similarly, carboxylate-assisted cycloruthenation was 
key to the success, as Piv-Val-OH was employed as the ligand for ruthenium-catalyzed 
C–H bond cleavage. A plethora of arenes and aniline derivatives were efficiently 
functionalized with various tertiary alkyl bromides, featuring sensitive functional 




regioselective meta-alkylation of aniline derivative completely overriding the innate 
reactivity that usually would lead to ortho- and para-substituted derivatives via an 
electrophilic aromatic substitution type manifold. Almost at the same time, Frost 
reported a related tertiary meta-C–H alkylation, albeit this protocol was restricted to the 
functionalization of 2-aryl-pyridines.[54] Since organofluorine compounds play a key role 
in agrochemicals, pharmaceuticals, and material sciences, the site-selective 
incorporation of fluorine-containing groups into arenes is in high demand.[55] Thus, by 
the synergy of phosphine 46 and carboxylate ligand in ruthenium(II) catalysis, 
Ackermann realized the meta-C–H mono- and difluoromethylations using alkyl 
bromides 44 (Scheme 1.2.6c).[56] Subsequently, Wang reported on a dual ruthenium 
and palladium catalysis approach for a related transformation.[57] Recently, Ackermann 
reported on the meta-selective benzylation of a plethora of arenes 39 with primary and 
secondary benzyl chlorides 48 (Scheme 1.2.6d).[58] Similarly, the synergy of 
triphenylphosphine 49 and acetate ligand in ruthenium(II) catalysis led to the switch in 
selectivity, as the same group had already demonstrated the ortho-benzylation under 
ruthenium(II) catalysis.[36d] It is noteworthy that this synergistic ruthenium manifold was 
fully compatible with a plethora of biomolecules, such as peptides, nucleotides, lipids 
and sugars. Detailed mechanistic studies shed light on the reaction mechanism, 
suggesting a radical pathway to be operative. Reports that combine a reagent-
controlled generation of benzyl radical with ruthenium(II) catalysis have also been 
disclosed, but the harsh reaction conditions severely jeopardize their synthetic utility.[59] 




Scheme 1.2.6. Ruthenium(II)-catalyzed meta C–H alkylation. 
 
One limitation of the aforementioned strategies is that they required a non-removable 
strongly coordinating directing group, except from the pyrimidine-aniline 
functionalization. To bypass this impediment, Ackermann elegantly developed the 
meta-C–H alkylation of ketimines 51 that upon acidic hydrolysis furnished the meta-
decorated ketones 52 (Scheme 1.2.7).[60] The method showed excellent levels of 




electrophilic functional groups and saturated heterocycles, among others. In addition, 
since acetophenones are highly versatile building blocks the functionalized ketones 52 
were efficiently transformed into a myriad of structural motifs, such as phenols, 
anilines, benzoic acids, and indoles. 
 
 
Scheme 1.2.7. Ruthenium(II)-catalyzed meta C–H alkylation via ketimine-assistance. 
 
These manifolds for the meta-alkylation of arenes typically are catalyzed by air- and 
moisture-stable [RuX2(p-cymene)]n complexes with or without the synergistic effect of 
carboxylate or phosphine ligands. A major breakthrough, in terms of both mechanistic 
and synthetic application, was achieved by Ackermann by using the well-defined 
arene-ligand-free Ru(OAc)2(PPh3)2 as the catalyst for the regioselective meta-
alkylation of various (hetero)arenes (Scheme 1.2.8).[61] 
 
 
Scheme 1.2.8. Arene-ligand-free ruthenium(II)-catalyzed meta C–H alkylation. 
 
The ruthenium-catalyzed meta-functionalization is not restricted to the formation of C–
C bonds but has also found application to the construction of C–Het bonds. In this 
context, Frost reported on a meta-selective C–H sulfonylation of 2-aryl-pyridines 53 
using [RuCl2(p-cymene)]2 and arylsulfonyl chlorides 54 (Scheme 1.2.9a).[62] Their initial 
rational for the meta-selectivity was attributed to the formation a ruthenacycle which 
directs an electrophilic-type sulfonylation para-to-the-ruthenium.[63] Based on 
subsequent mechanistic studies a radical-type addition was suggested for the C–S 
bond forming step, by ruthenium-promoted sulfonyl radical generation. Subsequentely, 
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Ackermann developed the first heterogeneous meta-C–H bromination utilizing 
Ru@SiO2 and NBS as the brominating agent (Scheme 1.2.9b).[64] Interestingly this 
heterogeneous catalytic system outperformed our commonly used ruthenium 
complexes and led to the site-selective bromination of various (hetero)arenes and 
purine bases. Furthermore, the sustainable nature of this heterogeneous manifold was 
reflected by the ease of recycling the catalyst and subsequent reuse of up to seven 
times without loss of efficacy. Very recently, Ackermann disclosed an unprecedented 
hybrid ruthenium catalyst for the remote C–H alkylation of a plethora of arenes.[65] In 
2018, Zhang reported on the meta-C–H chlorination of various arenes, including 
purines and benzodiazepines, under a combination of ruthenium(0) catalyst with a N-
heterocyclic carbene ligand, PIFA as terminal oxidant and N-chloro-2,10-
camphorsultam as chlorinating agent, albeit with limited efficiency (Scheme 1.2.9c).[66] 
 
 




1.3. Manganese-Catalyzed C–H Activation 
 
Despite major advances in C–H activation, the continuous demand for sustainable and 
eco-friendly approaches, forced the synthetic community away from the use of 4d and 
5d transition metals. Thus, Earth-abundant 3d transition metals offer an excellent 
alternative,[26] and more specifically, manganese as the third most abundant transition 
metal is particularly cost-effective.[67] Stoichiometric studies on manganese C–H 
activation has already reported in 1970 by Stone and Bruce, for the cyclometalation of 
azobenezene (60) with Mn2(CO)10 as the manganese source (Scheme 1.3.1).[68] 
Thereafter, several examples of reactions involving manganacycles have been 
reported by Nicholson/Main,[69] Woodgate,[70] and Liebeskind,[71] among others, 
showcasing the potential of these intermediates and motivating the synthetic 
community to develop catalytic manifolds. 
 
 
Scheme 1.3.1. Pioneering example of stoichiometric C–H activation by manganese 
and selected isolated manganacycles. 
 
1.3.1. Manganese-Catalyzed C–H Activation: Early Report 
 
In 2007, Kuninobu and Takai demonstrated that MnBr(CO)5 could facilitate the addition 
of aromatic C–H bonds onto electrophilic aldehydes, in the presence of silanes 
(Scheme 1.3.2).[72] The reaction had broad scope in terms of the directing groups and 
the aldehydes used. Imidazoles and oxazolines were shown to be effective directing 
groups. Remarkably when chiral oxazolines were used highly diastereoselective 
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addition to the aldehydes occurred. In addition, presumably due to the capping of the 
resulting alcohol as the silyl-ether, electron-poor and electron-rich aldehydes were 
used, despite the tendency of the later for reversible additions.[73] In terms of the 
mechanism of this pioneering transformation, some mechanistic evidence led to the 
hypothesis that the C–H bond cleavage occurred via oxidative addition leading to a 
Mn(III)-hydride species, and then the C–Mn bond underwent selective insertion into 
the aldehyde followed by silyl protection via formation of H2. 
 
 
Scheme 1.3.2. Manganese(I,III)-catalyzed addition of aromatic C(sp2)–H onto 




1.3.2. Manganese-Catalyzed C–H Hydroarylation 
 
After the early contribution of Kuninobu and Takai and together with the clear 
movement towards sustainable synthesis by utilizing Earth-abundant metals as 
catalysts, Wang reported on the addition of aromatic and alkenyl C(sp2)–H bonds to 
aldehydes and nitriles, providing a straightforward route to secondary alcohols and 
ketones respectively (Scheme 1.3.3a).[74] In contrast to the previous report by 
Kuninobu and Takai, extensive optimization revealed that a combination of Me2Zn and 
ZnBr2 was essential for an efficient reaction. The organozinc reagent presumably 
activates the manganese precatalyst by forming in situ the more reactive MnMe(CO)5, 
which was shown to be catalytically active, thus realizing silane-free conditions. The 
Lewis acid coordinates to the electrophile making it prone to nucleophilic addition. 
Concurrently, Ackermann demonstrated that ketones, despite being inherently less 
reactive, can be effective coupling partners under manganese catalysis.[75] After 
extensive screening of various metal salts, MnBr(CO)5 and Mn2(CO)10 were the only 
catalysts that enabled the selective C2 addition of activated ketones to the indole 
derivatives, under user-friendly reaction conditions (Scheme 1.3.3b). This method 
clearly overrides the innate reactivity of indole for C3 electrophilic substitution manifold. 
Recently, Glorius realized the formylation of arenes by one-pot manganese(I) and 
iron(III)relay catalysis (Scheme 1.3.3c).[76] The mild nature and robustness of 
manganese catalysis was reflected by the preparative ease of the methodology since 
the hydroxymethylated product was directly used for the iron catalyzed oxidation 
without any purification yielding the desired products in good yields. 
 




Scheme 1.3.3. Manganese-catalyzed C–H addition to carbonyl compounds. 
 
Since nitrogen containing compounds play an important role in pharmaceutical and 
medicinal industries isocyanates and imines were also explored as coupling partners 
under manganese(I) catalysis. Thus, Ackermann developed the aminocarbonylation of 
indoles and pyrroles under additive free reaction conditions, taking advantage of 
reactive and versatile isocyanates (Scheme 1.3.4a).[77] The robustness of this method 
was clearly reflected by the site-selective functionalization of various indoles and 
pyrroles featuring sensitive electrophilic functional groups, such as bromides, iodides 
and ketones. Detailed mechanistic studies supported a facile and reversible C–H 
activation step. Imines, were envisioned as a suitable substrate for the addition on the 
highly nucleophilic C–Mn bonds. Thus, Wang reported on the chemoselective addition 
of C(sp2)–H of ketones 76 to electron-deficient imines taking advantage of their 
previous established system featuring Me2Zn and ZnBr2 (Scheme 1.3.4b).[78] Fine-
tuning of the reaction temperature enabled the divergent access to either the benzylic 
amines 78 or the exo-olefinic-containing isoindolines via subsequent condensation 
under slightly more forcing reactions conditions. Expanding on their previous report, 




manganese-catalyzed C–H activation, under organozinc reagent-free reaction 
conditions.[75] Thus, the use of nBu2O as solvent under additive-free reaction 
conditions enabled excellent functional group tolerance for the C2 functionalization 
of indoles, completely bypassing any Friedel-Crafts regime. Moreover, they 
showcased that the directing group can be efficiently removed in good yield 
producing synthetically useful indole derivatives (Scheme 1.3.4c). 
 
 
Scheme 1.3.4. Manganese-catalyzed C–H addition to isocyanates 74 and imines 77 
or 79. 
 
The reactivity of manganese(I) complexes in C–H activation is not restricted to addition 
reactions to electrophilic C–Het multiple bonds, but hydroarylation regime of alkynes and 
alkenes is also feasible. Thus, Wang and coworkers reported on the manganese-
catalyzed C–H alkenylation by means of hydroarylation of terminal alkynes (Scheme 
1.3.5a).[79] Remarkably the catalytic system consisting of MnBr(CO)5 and Cy2NH 
performed well, without signs of side-reactions of the terminal alkynes, providing an 
efficient route for the construction of highly functionalized alkenes. Computational 
studies suggested a base-promoted C–H activation step and a C(sp)–H mediated 
   1. Introduction 
 
23 
protodemetalation pathway. Subsequently, Lei and Li realizing the limitation of 
Wang’s report, devised a catalytic manifold containing catalytic amounts of 
MnBr(CO)5, DIPEA and PhCO2H that was able to utilize internal alkynes as well 
(Scheme 1.3.5b).[80] Later, Wang demonstrated that aromatic N–H imidates can be 
engaged in the hydroarylation regime to access synthetically useful nitriles, 
showcasing that imidates can direct ortho-manganation and act as masked nitriles 
(Scheme 1.3.5c).[81] Notably, internal alkynes 83 reacted in a highly regioselective 
fashion, providing trisubstituted alkenes albeit in low yields. Regioselective 
hydroarylation of alkynes 87 bearing heteroatoms at the α-position remains a 
synthetic challenge due to facile β-heteroatom elimination and the high synthetic 
value of the obtained allylic systems bearing heteroatoms. Thus, Ackermann realized 
a highly selective hydroarylation regime of indole derivatives with propargylic 
carbonates under manganese(I) catalysis, featuring a crucial Brønsted acid-
catalyzed protodemetalation, to ensure that the normally facile β-heteroatom 
elimination is completely suppressed (Scheme 1.3.5d).[82] Notable features of the 
protocol included short reaction times that were achieved by performing the reaction 
in flow and wide diversification of the obtained allylic carbonates. Later, Glorius 
demonstrated that propargylic carbonates under manganese(I) catalysis provided the 
corresponding allenes through a migratory insertion/β-oxygen elimination manifold.[83] 
In contrast to Ackermann’s system for the hydroarylation of propargylic carbonates, 





Scheme 1.3.5. Manganese(I)-catalyzed C─H hydroarylation of alkynes. 
 
Alkenes bearing electron-withdrawing groups have been widely used in C─H 
activation reactions under precious metal catalysis, and since they are modular 
motifs and readily available their implementation in the manganese-catalyzed C–H 
activation is highly desirable. Inspired by their earlier report on the hydroarylation of 
alkynes by manganese catalysis Wang utilized α,β-unsaturated carbonyls to gain 
access to formally alkylated arenes (Scheme 1.3.6a).[84] Their catalytic system of 
choice consisting of MnBr(CO)5 and Cy2NH proved efficient for promoting this 
conjugate addition with high levels of mono-selectivity. In addition, Gong and Song 
extended the methodology to maleimides 25, devising a direct route towards 
   1. Introduction 
 
25 
decorated five-membered nitrogen hetorocycles (Scheme 1.3.6b).[85] Taking 
advantage of the outstanding robustness of manganese(I) catalysis, Glorius 
developed a protocol for the in situ generation of α,β-unsaturated ketones 22 from 
the corresponding α-diazo ketones catalyzed by a silver salt, that were swiftly 
employed in a hydroarylation regime (Scheme 1.3.6c).[86] Allenes 94 offer diverse 
reactivity manifolds due to their structure, mainly based on the nature of their 
substitution pattern. Wang employed 1,1-dialkyl allenes for the allylations of arenes 
obtained from the migratory insertion on the resulting manganacycle to the less 
substituted double bond (Scheme 1.3.6d).[87] Notably, when 1,1-dimethylallene 94a 
was employed prenylated arenes 95 were obtained, highlighting the synthetic utility of 
their method, as prenyl groups are found in a plethora of natural products. 
 
 




1.3.3. Manganese-Catalyzed Substitutive C─H Activation 
1.3.3.1. Manganese-Catalyzed C–H Allylation 
 
The allyl group is frequently used in organic synthesis, since it is easily converted to 
a myriad of other functional groups by well-established methods. Thus, the 
development of novel and sustainable allylation reactions is of utmost importance. To 
this end, Ackermann developed the first manganese-catalyzed reaction employing 
synthetically useful ketimines and substituted allyl-methyl-carbonates (Scheme 
1.3.7a).[88] The catalytic system consisting of MnBr(CO)5 and NaOAc proved 
extremely tolerant towards a variety of electrophilic functional groups, as well as 
nucleophilic/coordinating functional groups. Along the same lines, Ackermann and 
coworkers utilized the highly versatile allyl substituted cyclic carbonate to gain access 
to allylic alcohols, remarkably, water outperformed common organic solvents once 
again highlighting the sustainable nature of manganese(I)-catalysis (Scheme 
1.3.7b).[89] Thereafter, Zhang demonstrated that 3-bromo-3,3-difluoropropene was 
reactive under manganese catalysis for the 3,3-difluoroallylation of pyridones among 
other arenes (Scheme 1.3.7c).[90] Recently, Wang employed their established catalytic 
system consisting of MnBr(CO)5 and a combination of Me2Zn and Cu(OTf)2 for the 
efficient ortho-allylation of aromatic ketones (Scheme 1.3.7d).[91] Detailed 
mechanistic studies demonstrated the importance of both additives for the crucial 
cyclometalation step. In 2018, Glorius reported on the manganese catalyzed 
propargylation of arenes by means of regioselective allene insertion followed by β-
bromine elimination, notably, K3PO4, and H2O were crucial for good regioselectivity.[92] 




Scheme 1.3.7. Manganese(I)-catalyzed substitutive C─H allylations. 
 
1.3.3.2. Manganese-Catalyzed C–H Cyanation 
 
In 2016, Ackermann reported on the first manganese-catalyzed C─H cyanation of 
arenes with NCTS, among others, as user-friendly cyanating reagent (Scheme 
1.3.8).[93] After extensive optimization, the authors demonstrated that a combination of 
MnBr(CO)5, with co-catalytic amounts of Cy2NH and ZnCl2 were optimal for the 
efficient cyanation of indole moieties. Mechanistic and computational studies shed 
light on the mechanism of the reaction highlighting a heterobimetallic regime. The 




transfer via an addition/elimination reaction manifold. 
 
 
Scheme 1.3.8. Manganese(I)-catalyzed C─H cyanation. 
 
1.3.4. Domino Processes Initiated by Manganese-Catalyzed C–H Activation 
 
Domino reactions are increasingly useful for the construction of complex molecular 
architectures in a sustainable and step-economic fashion. Despite their undeniable 
merits, the design of efficient domino reactions is not straightforward due to the 
possible side-reactions that can jeopardize their efficacy. Thus, their use commonly 
requires careful design and precise optimization of the reaction conditions to ensure 
productive transformations.[94] Robust and mild catalytic processes are ideal for this 
highly important endeavor, thus manganese-catalyzed C–H activation has been used 
as a viable platform for the construction of multiple bonds in a single reaction vessel. 
Thus, Ackermann realized the synthesis of cis-β-amino acid esters 109, by 
intercepting the intermediate formed after the insertion of a manganacycle to an 
acrylate (Scheme 1.3.9a).[95] The proposed intermediate possess a highly 
nucleophilic character, that enabled the diastereoselective intramolecular addition to 
the tethered imine. Subsequently, Ding, Peng and co-workers, reported a related 
method using allenes to form similar scaffolds possessing an exocyclic olefin. [96] In 
2017, Ackermann used methylenecyclopropanes 111 that upon C–C cleavage by the 
cyclometallated complex furnished a manganese dienolate that was able to insert 
into the imine forging a five membered ring. Concurrently, zinc-mediated Michael 
addition of the electron-rich aniline to the newly formed α,β-unsaturated ester led to 
the formation of the fused tetrahydroquinoline scaffolds (Scheme 1.3.9b).[97] In the 
same year, Wang devised a different approach for the synthesis of fused 
tetrahydroquinolines, using aromatic ketimines and 1,1-disubstituted allenes. Upon 
formation of the corresponding allylated ketimines, AgOTf catalyzed Povarov 
reaction led to the fused tetrahydroquinolines.[98] Notably, a different diastereoisomer 
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was formed, highlighting a complementary working mode. Recently, Chang and Li 
reported a manganese-catalyzed cascade for the synthesis of medium sized rings 
(Scheme 1.3.9c).[99] Their approach relied on the insertion of an alkyne into 
manganacycle, addition of the Mn–C bond to a tethered ketone, forming a 
bicycle[3.2.0]heptane system that under the basic reaction conditions ring expanded 
via a retro-aldol reaction. 
 
 
Scheme 1.3.9. Manganese(I)-catalyzed domino reactions via insertion of newly 
formed C–Mn bonds to imines and ketones. 
 
In 2017, the groups of Rueping[100]and Wang/Li[101] independently reported on the 
manganese-catalyzed hydroarylation of electron-deficient allenes 116 or 118 
followed by a Smiles rearrangement, resulting in the migration of the heteroaryl 
directing group (Scheme 1.3.10a and 1.3.10b). Interestingly, Rueping demonstrated 




at lower temperature, the hydroarylation product is observed via a protodemetalation 
pathway, whereas at higher temperature the intermediate of the allene insertion is 
able to engage in a Smiles rearrangement. Later, Lu and Wang achieved a related 
transformation using ketenimines 120, thus after insertion to C=N bond, migration of 
the pyrimidine directing group was also observed (Scheme 1.3.10c).[102] Very 
recently, Ruan utilized ketenimines under rhenium and manganese catalysis with 6-
indole-purines as substates, interestingly, the reaction proceeded without migration 
of the directing group.[103] 
 
 
Scheme 1.3.10. Domino manganese(I)-catalyzed C–H activation/Smiles 
rearrangement. 
 
In 2019, Ackermann envisioned a sequence that after C–H allenylation the tethered 
allene would engage in a series of Diels-Alder reactions with the pyridine directing 
group, furnishing a highly decorated polycyclic system. After careful optimization, the 
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combination of MnBr(CO)5, NaOAc and BPh3 was capable of promoting this domino 
sequence (Scheme 1.3.11a).[104] Computational studies revealed the crucial role of the 
Lewis-acid, as a promoter for the inverse-electron demand Diels-Alder, followed by 
extrusion of HCN to furnish the desired product 124. At the same time, Li developed 
a related transformation, using Cy2NH instead of the BPh3 and prolonged reaction 
times, thus they were able to access fused indole scaffolds when pyrimidine was used 
as the directing group on the indole moiety (Scheme 1.3.11b).[105] 
 
 
Scheme 1.3.11. Manganese(I)-catalyzed C–H activation/Diels Alder domino reaction. 
 
1.4. Late-Stage Functionalization of Peptides via C–H Activation 
1.4.1. Functionalization of Amino Acid Derivatives via C–H Activation 
 
The ability to functionalize amino acids to gain access to new scaffolds is of paramount 
importance for various fields of chemistry. This approach offers an atom-economical 
route towards a diverse set of building blocks, taking advantage the existence of the 
stereocenter, thus avoiding the need for developing asymmetric syntheses of these 
derivatives. Despite this conceptual asset, the sensitive nature of some amino acids 
requires very mild reaction conditions in order to avoid loss of the stereointegrity of the 
amino acid derivative. In this regard, in 2006 Corey demonstrated that the 8-
aminoquinoline directing group could be used for the functionalization of a plethora of 
amino acids (Scheme 1.4.1).[106] Under palladium catalysis, the β-C(sp3)–H 




Interestingly, when valine or isoleucine were used in these methods, γ-primary C(sp3)–
H over β-tertiary C(sp3)–H activation was observed, presumably due to steric reasons. 
Despite the limited scope of these transformations, the synthetic community 




Scheme 1.4.1. Palladium-catalyzed acetoxylation and arylation of amino acids. 
 
After this early report, many groups expanded on this approach, by utilizing different 
directing groups, which are more user-friendly in terms of their removal, and by 
developing new transformation to unlock new parts of the chemical space. Thus, in 
2012, Daugulis achieved the arylation of amino acid derivatives featuring various 
directing groups at the C-terminus (Scheme 1.4.2a).[107] Remarkably, they recognized 
that 2-methylthio-aniline was an efficient directing group for palladium catalysis and 
was easily removed under acidic conditions. With the optimized reactions conditions 
in hand, various (hetero)arylalanine derivatives 133 were obtained in good yields. The 
early examples of the amino acid C(sp3)–H functionalization typically used bidentate 
directing groups to ensure good reactivities and turnover numbers. Thus, in 2014, Yu 
introduced an electron-deficient amide as a monodentate directing group for C(sp3)–H 
activation (Scheme 1.4.2b).[108] In this work, a pyridine ligand was crucial for an efficient 
reaction. Thus, alanine derivatives were efficiently arylated under palladium catalysis. 
Importantly, the reaction occurred in a stereoselective fashion and allowed sequential 
arylation. Based on this report, Yu expanded on the monodentate C(sp3)–H arylation 
by using the native carboxylic acid as the directing group (Scheme 1.4.2c).[109] Despite 
this advancement, this method was not as efficient as the amide directed C–H 
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arylation. The directed C(sp3)–H functionalization of amino acid derivatives is not 
restricted to the formation of C–C bonds, as in 2015 Shi developed the oxidative C–H 
fluorination using Selectfluor as the oxidant and fluoride source (Scheme 1.4.2d).[110] 
This method tolerated sensitive functional groups and gave rise to a plethora of 
fluorinated amino acid derivatives 142 in a stereo- and position-selective fashion albeit 
with moderate efficacy. 
 
 




Apart from the synthesis of amino acid derivatives as building blocks for various 
purposes, the transformative nature of C(sp3)–H activation of amino acid derivatives 
was demonstrated by Chen in the total synthesis of Celegentin C (Scheme 1.4.3).[111] 
More specifically, leucine derivative 143 was arylated in stero-, site- and 
chemoselective fashion using iodinated tryptophan derivative 144 under palladium 
catalysis. Gratifyingly, the stereochemical outcome of the reaction matched the one 
found in the natural product thus providing an easy route to this exotic linkage of 
leucine and tryptophan. 
 
 
Scheme 1.4.3. Palladium-catalyzed C(sp3)–H arylation en route to Celegentin C 146. 
 
Another application that demonstrated the translation potential of palladium-catalyzed 
C(sp3)–H arylation was reported by Kazmaier when under 8-aminoquinoline 
assistance, a key precursor 149 of the natural product Abyssenine A 150 was 
expediently obtained (Scheme1.4.4).[112] Remarkably, the phthalyl protection on the 
nitrogen was not essential, and Boc-protected N-methylated alanine was a viable 
substrate simplifying the overall synthetic plan. In addition, N-methylated amino acids 
are important structural motifs in various biologically active cyclic peptides and other 
natural products.[113] 




Scheme 1.4.4. Palladium-catalyzed C(sp3)–H arylation en route to Abyssenine A. 
 
The C–H functionalization of amino acids is not restricted to C(sp3)–H, but C(sp2)–H 
can also be functionalized under different metal catalysis. Among the amino acids that 
have been functionalized, tryptophan is the best studied. For the site-selective 
functionalization of tryptophan different strategies have been used, such as 
introduction of directing groups or the use of the innate reactivity of the indole core. 
The nucleophilic character of the indole moiety has been exploited under electrophilic 
palladium(II) catalysis for the diversification of tryptophan and tryptophan containing-
peptides (vide infra). On the other hand, Ackermann enabled the functionalization of 
the C2 position of the tryptophan derivatives via the incorporation of a nitrogen based 
directing group on the indole moiety. Thus under manganese(I) catalysis the 
substitutive cyanation,[93] allylation via C–H/C–C activation[114] and allylation via C–
H/C–O activation[89] were achieved (Scheme 1.4.5). Despite these elegant findings, 





Scheme 1.4.5. Manganese-catalyzed C(sp2)–H functionalization of tryptophan 
derivatives 151 and 153. 
 
1.4.2. Functionalization of Peptides via C–H Activation 
 
These undisputed advances have provided new avenues for the functionalization of a 
plethora of amino acids, thus enabling the facile synthesis of functionalized peptides 
and proteins via iterative peptide synthesis protocols. Whereas this approach has 
significantly boosted molecular synthesis, the direct functionalization of peptides 
represents a more efficient and elegant strategy, albeit more challenging. Specifically, 
the sensitive nature of many peptides requires mild catalytic manifolds that can 
selectively engage in productive pathways with the desired amino acid in the presence 
of myriad of other functional groups.  
In 2010, Albericio and Lavilla developed the C2 arylation of tryptophans and 
tryptophan-containing peptides 158 under electrophilic palladium catalysis (Scheme 
1.4.6).[115] Remarkably, the reaction tolerated unprotected amino acids and the key to 
this efficient method was the use of acidic phosphate buffer that was sufficient to 
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solubilize the peptides at 80 °C under microwave irradiation. In addition, they 
demonstrated that this method allowed the arylation of tryptophan derivatives in DMF 
as solvent at 150 °C. This method was expanded to the functionalization of biologically 
relevant tryptophan-containing diketopiperazines.[116] 
 
 
Scheme 1.4.6. Palladium-catalyzed C–H arylation of tryptophan-containing peptides. 
 
The sensitive nature of peptides requires mild reaction conditions, thus Ackermann 
unravelled a room temperature C2-arylation of tryptophan-containing peptides 158 with 
iodonium salts 160 (Scheme 1.4.7).[117] The high reactivity of these arylating agents 
required careful optimization that showed acetic acid or water as the most suitable 
solvents. Under the optimized reaction conditions, a plethora of peptides, containing 
various functional groups, were functionalized in a site- and chemo-selective fashion, 
under exceedingly mild reaction conditions that did not jeopardize the stereo-integrity 





Scheme 1.4.7. Room temperature palladium-catalyzed C–H arylation of tryptophan-
containing peptides 158. 
 
Subsequently, Fairlamb demonstrated that reactive aryl diazonium salts 161 can also 
be utilized for the C2 selective arylation of tryptophan moieties by palladium catalysis 
(Scheme 1.4.8).[118] The reaction tolerated several functional groups on the aryl 
scaffold and was extended to tryptophan containing peptides 158, albeit with limited 
scope. This protocol was an extension of their previously reported oxidative C2-
arylation of tryptophan moieties with aryl boronic acids.[119] 
 
 
Scheme 1.4.8. Palladium-catalyzed C–H arylation of tryptophan moieties with aryl 
diazonium salts 161. 
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These early and elegant reports were based on the well-established palladium-
catalyzed C–H activation manifolds. However, the use of other transition metals in the 
functionalization of peptides would be highly desirable, to devise new reaction 
pathways. Thus, in 2017 Ackermann developed the first ruthenium-catalyzed arylation 
of tryptophan-containing peptides 162 under the crucial carboxylate assistance,[120] 
building on their earlier studies (Scheme 1.4.9).[121] After considerable optimization, 
pentafluorobenzoic acid was identified as the optimal carboxylic acid that facilitated the 
carboxylate-assisted C–H cleavage. Remarkably, this manifold allowed the efficient 
synthesis of larger peptides via C–H ligation and the late-stage fluorescent labeling of 
peptides. Moreover, a slight modification in the reaction conditions allowed the C–H 
arylation to be conducted in aqueous medium. 
 
 
Scheme 1.4.9. Ruthenium-catalyzed C–H arylation of tryptophan-containing peptides 
moieties with aryl bromides 163. 
 
Very recently, Ackermann unravelled an elegant strategy for the C7-selective 
amidation of tryptophan-containing peptides 165 under rhodium(III)-catalysis, using the 
highly modular and easily accessible dioxazolones 166 (Scheme 1.4.10).[122] This 
strategy relied on the reversible C–H activation step and subsequent rate-limiting C–N 




the optimized reaction conditions a plethora of peptides, possessing a myriad of 
different functional groups, were amidated in a chemo- and site-selective fashion. 
Furthermore, the modular nature of dioxazolones 166 allowed the expedient stitch of 




Scheme 1.4.10. Rhodium-catalyzed C7–H amidation of tryptophan-containing 
peptides. 
 
In the quest for more sustainable strategies for late-stage functionalization via C–H 
activation the development of novel methodologies utilizing Earth-abundant, non-toxic 
3d transition metals is in high demand and is a very active research field. In 2017, 
Ackermann disclosed the first manganese(I)-catalyzed C–H alkynylations of 
tryptophan-containing peptides using modular bromo-alkynes 168 (Scheme 
1.4.11).[123] This regime tolerated a wide range of functional groups, such as azides 
and NH-free tryptophans. Remarkably, after considerable optimization the reaction 
was expediently expanded to alkyl- and aryl-bromoalkynes by using BPh3, that 
presumably accelerates the key β-bromide elimination. This approach enormously 
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enhanced the potential for bioorthogonal post-synthetic modifications as a plethora of 
alkyne handles can be chemo- and site-selectively incorporated into a peptide. 
 
Scheme 1.4.11. Manganese-catalyzed C–H alkynylation of tryptophan-containing 
peptides. 
 
Despite those undisputed advances, C(sp3)–H activation is often more challenging for 
organometallic C–H activation. This issue is significantly more prominent in peptides, 
since they possess multiple C(sp3)–H in close proximity to multiple Lewis-basic 
functional groups that can pose selectivity hurdles. Thus, since the early stages of 
practical C–H activation, the utilization of a designed directing group was necessary 
with rare exceptions. In this context, Yu demonstrated that the peptidic backdone can 
act as directing groups under palladium catalysis, if the C–H to be functionalized is 
positioned at the N-terminus (Scheme 1.4.12).[124] Thus, various tri- and tetrapeptides, 
possessing an alanine residue at the N-terminus were chemo- and site-selectively 
arylated, presumably via the intermediacy of a palladacycle under the peptidic 





Scheme 1.4.12. Palladium-catalyzed C(sp3)–H arylation of peptides 170 via 
bidentate backbone assistance. 
 
Recently, Weng and Ackermann demonstrated that the side chain of asparagine, 
containing the Lewis-basic primary amide moiety, could direct a site-selective C(sp3)–
H arylation of alanine moieties, via an unprecedented 5,6-fused palladacycle (Scheme 
1.4.13).[125] This method allowed the expedient synthesis of various tri-, tetra-, penta- 
and even hexapeptides 172 functionalized with a plethora of aryl moieties. The 
translational potential of the method was demonstrated by the expedient access to 
AGRP loop analogues that were subsequently incorporated into cyclic octapeptides. 
 
 
Scheme 1.4.13. Palladium-catalyzed C(sp3)–H arylation of peptides via asparagine 
assistance. 
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Very recently, Kazmaier unravelled a mono selective arylation of N-methylated-alanine 
moieties, positioned at the C-terminus, via the key bidentate assistance of 8-
aminoquinoline or 2-methylthio-aniline (Scheme 1.4.14).[126] Remarkably, N-phthaloyl 
protection was not crucial at the alanine residue, thus enabling the straightforward 
functionalization of various peptides with a plethora of densely functionalized aryl 
iodides 130, featuring heterocycles and halogenated phenols leading to halogenated 
tyrosine derivative found in many bioactive peptides.[127] 
 
 
Scheme 1.4.14. Palladium-catalyzed C–H arylation of N-methylated alanine-
containing peptides 174. 
 
Secondary C(sp3)–H functionalizations are significantly more challenging endeavor 
due to steric hindrance and stereoselectivity issues, in combination with chemo- and 
site-selectivity issues. Thus, the functionalization of amino acid residues possessing a 
substituent at the β-position is highly desirable. In this context, Bull disclosed the β-
syn-arylation of Cbz-protected proline moieties by 8-aminoquinoline assistance.[128] 
Shortly after, Kazmaier developed mild reaction conditions for the stereoselective β-
syn-arylation of proline-containing peptides (Scheme 1.4.15).[129] Furthermore, this 
methodology exhibited excellent stereo- and site-selectivity in the functionalization of 





Scheme 1.4.15. Palladium-catalyzed C–H arylation of proline-containing peptides. 
 
The functionalization of terminal amino acids of the peptide chain is not only restricted 
to the C-terminus, indeed the incorporation of a suitable directing group at the N-
terminus is also feasible. Thus, Shi after installing the 2-picolinic acid at the N-terminus, 
that acted as a bidentate directing group, achieved the palladium-catalyzed site-
selective δ C–H alkylation with maleimides 25 of isoleucine-containing peptides 178 
(Scheme 1.4.16).[130] The observed selectivity was attributed to the easier primary δ 
over the secondary γ C(sp3)–H activation, thus limiting the protocol for functionalizing 
peptides featuring amino acids equipped with γ -methyl groups at the N-terminus. 
 
 
Scheme 1.4.16. Palladium-catalyzed δ C(sp3)–H alkylation with maleimides 25. 
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Despite these undisputed advances on C(sp3)–H functionalization of peptides, these 
methodologies enabled the modification of amino acids only at the N- or C-terminus, 
thus significantly hampering their translational potential. In contrast, in 2018, 
Ackermann disclosed the site-selective palladium-catalyzed primary and secondary 
C(sp3)–H arylation of structurally complex peptides under triazole assistance (Scheme 
1.4.17).[131] The selection of triazole-based amide as the bidentate directing group as 
an peptide isostere was based on its presence in various bioactive peptidomimetics as 
they share common electronical and topological properties.[132] Furthermore, the highly 
modular synthesis of 1,2,3-triazoles allows the expedient access to various 
peptides.[133] Thus, the incorporation of the triazole based directing group led to the 
efficient functionalization of various amino acids such as alanine and phenylalanine, 
among others, in a stereo-, chemo- and site- selective fashion. This strategy tolerated 
plethora of sensitive functional groups on the aryl scaffold. Having established a robust 
protocol for the functionalization of amino acids derivatives, they installed a peptidic 
backbone on the triazole core, via a 1,4 substitution pattern, thus obtaining triazole-
peptidomimetics destined for palladium-catalyzed C–H arylation. After considerable 
optimization, larger peptides were selectively arylated in the presence of many C–H 
bonds, leading to functionalized and ligated peptides. 
 
 





Having established a reliable platform for the internal C(sp3)–H arylation of triazole 
containing peptidomimetics, the authors expanded this manifold for the late-stage 
labeling of peptides using iodo-BODIPY dyes 182 as the arylating agent (Scheme 
1.4.18).[134] Hence by means of palladium catalysis with co-catalytic amounts of 1-
adamantanecarboxylic acid various amino acid derivatives were efficiently labeled with 
various BODIPY dyes, possessing distinct fluorescent properties, under triazole 
assistance. This approach, after standard protecting group manipulations, led to the 
synthesis of fluorescent Fmoc-protected amino acids, destined for the synthesis of 
larger peptides via SPPS. Furthermore, the primary and secondary C(sp3)–H labeling 
was efficiently applied to the internal functionalization of larger peptidomimetics. 




Scheme 1.4.18. Palladium-catalyzed C–H labeling. 
 
1.4.3. Peptide Macrocyclization via C–H Activation 
 
One of the earliest examples of C–H macrocyclization for the synthesis of cyclic 
peptides was reported in 2012 by James, where tryptophan residues were 
intramolecularly arylated under palladium catalysis using a suitably positioned tethered 




benzoic acid was used, in N,N-dimethylformamide as solvent at 130 °C (Scheme 
1.4.19). Thus, the relatively harsh reaction conditions limited the scope of this 
transformation to a few specifically engineered linear precursors, that possessed an 
ortho or meta substitution pattern at the aryl iodide scaffold. This enabled the 
necessary conformational rigidity for a successful intramolecular reaction, without 
extensive side-reactions. Despite these limitations, this provided the impetus for further 
applications as milder and more selective reaction manifolds were rapidly developed. 
 
 
Scheme 1.4.19. Palladium-catalyzed C–H macrocyclization via C2 tryptophan 
arylation. 
 
Palladium-catalyzed C(sp2)–H arylations of tryptophan moieties was later exploited by 
Albericio and Lavilla for the synthesis of stapled peptides using linear precursors 
equipped with an iodinated phenylalanine of tyrosine moiety (Scheme 1.4.20).[136] After 
an extensive optimization, a mixture of N,N-dimethylformamide and acidic phosphate 
buffer solution at 80 °C under microwave irradiation was crucial for solubilizing the 
linear peptide 186 and ensuring sufficient macrocyclization. Thus, a number of cyclic 
peptides were synthesized possessing many sensitive functional groups, providing 
access to biaryl-containing peptides, a structural motif found in myriad of biologically 
active natural products.[137] Furthermore, this strategy was efficient for the bis-
cyclization of the linear precursor containing two tryptophan residues, on the N- and 
C-terminus, and a bis-iodinated tyrosine residue, leading to a fused bis-macrocyclic 
peptide. 




Scheme 1.4.20. Palladium-catalyzed synthesis of stapled peptides. 
 
Recently, Wang applied the backbone-directed C(sp2)–H ortho-alkenylation of 
phenylalanine derivatives in a macrocyclization setting, for the synthesis of E-olefin-
containing cyclic peptides under palladium catalysis (Scheme 1.4.21).[138] Remarkably, 
the reaction occurred selectively at the δ position of the phenylalanine residue 
positioned at the C-terminus, both for the intra- and intermolecular manifold, giving rise 
to ligated and cyclic peptides in a site- and chemoselective fashion. Furthermore, the 









This oxidative alkenylation manifold was recently expanded to tryptophan-containing 
peptides. Thus, NH-free tryptophan moieties were alkenylated with a tethered alkene 
selectively at the C2-position (Scheme 1.4.22).[139] As before, the method was 
efficiently applied for the synthesis of ligated and cyclic peptides with excellent levels 
of site- and chemoselectivity. This methodology tolerated some amino acids and 
forged from 18 to 26-membered rings albeit with moderate efficiency, presumably due 
to the sensitive nature of the linear precursors 190. 
 
 
Scheme 1.4.22.Palladium-catalyzed C(sp2)–H alkenylation towards cyclic peptides. 
 
In 2017, Ackermann unravelled a 3d-metal, namely manganese,-catalyzed 
alkynylation regime for the late-stage diversification of peptides (Scheme 1.4.23).[123] 
The chemoselective nature and robustness of this manifold enabled facile access to 
cyclic peptides via a regioselective insertion/BPh3 enabled β-bromide elimination 
pathway. 
 




Scheme 1.4.23. Manganese-catalyzed C–H alkynylation towards cyclic peptide 192. 
 
The C–H macrocyclization manifold en route to cyclic peptides is not restricted to 
C(sp2)–H activation but is also applied to the more challenging C(sp3)–H activation. 
Thus, in 2017, Noisier, Albericio[140] and Wang[141] independently reported the 
backbone-directed macrocyclization of peptides featuring alanine and iodinated 
phenylalanine residues linked together via a peptidic chain (Scheme 1.4.24). Both 
protocols demonstrated high levels of site-and chemoselectivities. Remarkably, in this 
manifold detrimental dimerizations were not observed, in sharp contrast to the previous 
tryptophan-based macrocyclization methodologies. This can be attributed to the 
favorable conformational change during the backbone-directed C–H activation that 
forces the chain to adopt a suitable conformation for the crucial oxidative addition step. 
Furthermore, Wang demonstrated that their method could be utilized for the formal 
synthesis of Celogentin C 146 via a diastereoselective C–H macrocyclization leading, 





Scheme 1.4.24. Palladium-catalyzed intramolecularC(sp3)–H activation towards 
cyclic peptides 195. 
 
In 2018 He, Qi, Liu and Chen developed a C-terminus→N-terminus macrocyclization 
by employing the 8-aminoquinoline directing group under palladium catalysis. Under 
the optimized reaction conditions, featuring Pd(OAc)2 at as low as 2 mol %, ortho-
phenylbenzoic acid as ligand in tBuOH various linear precursors 196, featuring 
protected and some unprotected amino acids, were efficiently cyclized under high 
dilution conditions (Scheme 1.4.25).[142] Remarkably, this manifold enabled the 
synthesis of highly-strained 13-membered ortho- or meta-cyclophanes, featuring bent 
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arenes. In addition, larger cyclic peptides were smoothly obtained in good yields, albeit 
without stereocontrol at the newly formed stereocenter. The use of an electron-rich 8-
aminoquinoline surrogate, developed by Daugulis,[143] allowed the oxidative cleavage 
of the directing group. 
 
 
Scheme 1.4.25. Palladium-catalyzed macrocyclization under C-terminus bidentate 
assistance. 
 
Recently, Chen utilized picolinic acid as the directing group for the N-terminus→C-
terminus C(sp3)–H macrocyclization. Thus, various linear peptides 198 with amino 
acids with γ-C–H positioned at the N-terminus equipped with a suitably tethered aryl 
iodide moiety at the C-terminus were efficiently cyclized in a stereo- and site-selective 
fashion (Scheme 1.4.26).[144] Remarkably, this robust protocol tolerated a plethora of 
coordinating groups found in the side chains of amino acids, such as amides, amines 
and guanidine groups, without loss of catalytic efficiency. Furthermore, the linear 
precursors were easily obtained under standard SPPS techniques, thus facilitating the 
rapid and facile synthesis of a library of cyclic peptides. Lastly, the directing group was 
cleanly removed by treatment with zinc in acidic aqueous solution yielding the free-





Scheme 1.4.26. Palladium-catalyzed macrocyclization by N-terminus bidentate 
assistance. 
 





The development of novel and robust C–H functionalization strategies for the 
expedient diversification of molecules of interest is gaining recent momentum, with 
translational impact on natural product synthesis,[23, 145] material chemistry[24] and 
medicinal chemistry.[25a, 25b, 25e] The modular nature of the late-stage C–H 
functionalization strategy allows an atom- and step-economical exploration of the 
chemical space. In this regard, 4d and 5d transition metals have dominated the field, 
relying heavily on significant advancements in palladium-catalyzed cross-coupling 
technologies. The implementation of Earth-abundant transition metals in C–H 
activation has recently gained considerable momentum, due to the generally lower cost 
and toxicity of 3d transition metals compared to their 4d and 5d counterparts.[26, 146] 
Thus, the aim of this thesis is directed towards the development of efficient strategies 
for the late-stage functionalization of (bio)molecules en route to complex molecular 
architectures. Furthermore, in order to address the increasing need for more 
environmentally-benign C–H transformations, the focus is shifted to inexpensive 3d 
transition metals, mainly manganese. 
Among the most common ways to ensure sustainability in molecular synthesis, the 
one-pot strategy is arguably the most straightforward. In this context, elegant domino 
strategies are most effective, as several new bonds are forged in a single synthetic 
operation.[94f] Hence, one-pot reactions are still highly desirable, for the same reasons, 
but require a sequential addition of reagents. However, these strategies require robust 
catalysts and precise optimization of the reaction conditions to ensure productive 
transformations. Thus, within this thesis, a new protocol for the remote functionalization 
was intended to be merged with the well-established ruthenium-catalyzed ortho-C–H 
arylation in an one-pot fashion. Detailed mechanistic studies were performed to 
delineate the unique reactivity of the ruthenium-catalyzed remote C–H alkylation 






Scheme 2.1. Ruthenium-catalyzed meta-/ortho-difunctionalization. 
 
Despite undisputed advances, C(sp3)–H activation is often more challenging for 
organometallic C–H activation.[16e] Palladium-catalyzed C–H activation has been 
recognized as a reliable tool for this valuable transformation. Recently, the mild and 
robust nature of this regime led to the efficient functionalization of peptides. Inspired 
by these advances, we decided to probe the utilization of a suitable sugar-fragment for 
the late-stage glycosylation of peptides (Scheme 2.2). To enhance the impact of this 
methodology on medical chemistry, modular triazole-based peptidomimetics were 
explored as the substrates. 
 
 
Scheme 2.2. Palladium-catalyzed C–H glycosylation. 
 
Despite significant advances in the functionalization of amino acids and peptides via 
C–H activation, these methods have heavily relied on arylative strategies, with very 
few exceptions.[25b, 25g, 147] In the context of sustainable molecular syntheses, 
hydroarylation manifolds exhibit perfect atom-economy. Furthermore, ruthenium-
catalysis has been established as one of the most powerful regimes in the realm of C–
H activation, albeit with limited applications in the late-stage functionalization of 
peptides.[120] Thus, we became interested in exploiting the potent ruthenium catalysis 
in an hydroarylation regime for the late-stage diversification and ligation of peptides. 
Thus, tryptophan was selected as the amino acid to be functionalized due to the ease 
of incorporating a suitable guiding group onto the indole moiety (Scheme 2.3). 




Scheme 2.3. Peptide functionalization under ruthenium-catalysis. 
 
Chelation-assisted C–H activation has matured into an indispensable tool for molecular 
synthesis, as it allows a reliable and predictable strategy for the functionalization of 
inert C–H bonds under exceedingly mild conditions. Early efforts have established the 
use of precious metals for C(sp2)–H and C(sp3)–H functionalizations. Thus, various 
directing groups ranging from nitrogen containing heterocycles to amides and 
carboxylic acids, among others, have been elegantly utilized.[16c] Recently, the quest 
towards sustainability has encouraged the synthetic community to explore Earth-
abundant 3d transition metals, as they are typically inexpensive and less toxic.[26] 
However, the functionalization of peptides with 3d transition metals is still in its 
infancy.[123] 
The incorporation of reactive functional groups in peptides in a site-selective fashion is 
of paramount importance in modern chemical biology. Traditionally, very reactive 
residues, such as cysteine or lysine, have been exploited for the functionalization of 
peptides and proteins via condensation, (cyclo)additions and more recently cross-
coupling manifolds. Thus, the functionalization of inert C–H bonds will greatly enhance 
our ability to diversify biomolecules. In this context, C–H activation has lately made 
significant strides by utilizing precious transition metals. Therefore, we decided to 
explore whether the versatile manganese-catalyzed C–H allylation[88-89, 92] could be 
employed for the site-selective functionalization of peptides. The choice of the 
protected Morita-Baylis-Hillman adducts as allylating agents was based on the final 







Scheme 2.4. Manganese-catalyzed C–H allylation of peptides. 
 
The late-stage modification of peptides is not restricted to the incorporation of small 
substituents. Indeed, the stitching of two distinct biomolecules together results in 
multifunctional hybrids with many potential applications. More importantly, the coupling 
of two large peptide fragments is an elegant alternative to traditional iterative peptide 
couplings, that is routinely utilized. Thus, taking into consideration the remarkable 
robustness and mildness of manganese(I)-catalysis, our aim was to develop a 
manganese-catalyzed C–H peptide ligation. Furthermore, the intramolecular variant of 
this manifold could give rise to a challenging macrocyclization (Scheme 2.5). For this 
transformation careful optimization of the reaction conditions was required to ensure 
productive reactions. In order to unlock the full potential of this strategy modular 
propiolates were selected as the coupling partner. 
 
 
Scheme 2.5. Manganese-catalyzed C–H ligation and macrocyclization. 
 
The labeling of peptides is of paramount importance in many fields of chemical biology, 
particularly as a tool for the elucidation of biological functions. Traditionally, the labeling 
of peptides and proteins relies either on lengthy de novo strategies, utilizing fluorescent 
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building blocks, or on the late-stage labeling of polar residues, such as cysteine or 
lysine. Inspired by the success of the manganese(I)-catalyzed C–H activation manifold, 
we decided to probe the modular hydroarylation approach for the labeling of 
tryptophan-containing peptides (Scheme 2.6). To this end, BODIPY fluorophores were 
chosen, as their modular nature can swiftly provide versatile probes. 
 
 
Scheme 2.6. Manganese-catalyzed C–H labeling. 
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3. Results and Discussion 
 
3.1. Sequential meta-/ortho-C–H Functionalization of Aryl Oxazolines via 
Ruthenium Catalysis 
 
During the beginning of the utilization of C–H activation in molecular synthesis, the 
ortho-functionalization was the most widely used, as many reaction types that had 
been developed relied on the proximity induced C–H cleavage. Whereas, these 
advancements had profound impact on the synthetic organic chemistry, they are 
inherently restricted to ortho-functionalization. To unlock the full potential of C–H 
activation, new strategies for the functionalization of remote C–H bonds had to be 
developed. In this regard, if the selective meta or para C–H cleavage can be achieved, 
the downstream functionalization of the organometallic intermediate would result in a 
plethora of new remote transformation, under similar reaction conditions utilized for 
ortho-functionalization. Recently, strategies for achieving remote metalation have been 
developed, based on substrate control,[16k] templates,[48, 50] traceless directing group 
(formal meta-functionalization),[148] and elaborate mediators,[49] ligands[149] and 
catalysts[36b, 52-53] (Scheme 3.1.1). In contrast these strategies, σ-activation via 
cycloruthenation is unique, since it relies on the ortho-cycloruthenation that directs the 
addition of a nucleophilic or electrophilic alkyl radical para-to-the-ruthenium. 
 
 
Scheme 3.1.1. Strategies for remote C–H functionalization. 
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Despite, the powerful nature of σ-activation via cycloruthenation, to date only strongly 
coordinating directing groups, such as pyridines and pyrazoles, have been utilized. 
These auxiliary groups are usually difficult to remove, or to transform to other 
synthetically useful functional groups, with scarce exceptions.[60] These, limitations 
severely limit the broad utilization of such methodologies. Thereby, we became 
interested in the development of an atom- and step-economical method for the meta-
alkylation of versatile aryl oxazolines, which are surrogates of carboxylic acids. We 
chose as coupling partners the reactive and modular α-bromo carbonyl compounds. 
Furthermore, we reasoned that the powerful ruthenium-catalyzed ortho-C–H activation 
manifold could be combined with the meta-functionalization manifold in a sequential 
difunctionalization regime. 
 
3.1.1. Optimization Studies for Ruthenium-Catalyzed meta-C–H Alkylation via 
Oxazoline Assistance 
 
After initial optimization for the remote ruthenium-catalyzed alkylation via strongly 
coordinating pyrimidine assistance by Dr. K. Korvorapun, we probed whether the 
powerful ruthenium-catalyzed meta-alkylation regime could be applicable for the 
functionalization of synthetically useful oxazolines. Hence, we chose the 
functionalization of 2-phenyl-4,5-dihydrooxazole 217a with methyl 2-bromohexanoate 
218a under ruthenium catalysis as our model system (Table 3.1.1). Thus, we 
commenced our studies for the desired functionalization by probing different 
ruthenium-based catalytic systems employing PPh3 as the ligand and K2CO3 as the 
base (entries 1-5). Carboxylate assistance was found to be essential for the envisioned 
remote alkylation process, whereas, 1,4-dioxane was shown to be the optimal solvent 
(entry 7). The reaction showed similar efficiency even at 40 °C (entry 9), further 
reflecting the high catalytic efficacy of the ruthenium(II)-biscarboxylate catalysis 
manifold. Control experiment demonstrated the crucial role of the phosphine additive 
(entry 10), suggesting a synergistic regime to be operative. 
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Table 3.1.1. Optimization of the ruthenium-catalyzed meta-alkylation of oxazoline 
217a. 
 
Entry [Ru] Solvent Yield (%) 
1 - 1,4-dioxane - 
2 Ru3(CO)12 1,4-dioxane - 
3 [RuCl2(p-cymene)]2 1,4-dioxane (<5) 
4 [RuCl2(p-cymene)]2 1,4-dioxane (<5)a, b 
5 [Ru(O2CMes)2(p-cymene)] toluene (17) 
6 [Ru(O2CMes)2(p-cymene)] DCE (10) 
7 [Ru(O2CMes)2(p-cymene)] 1,4-dioxane 76 
8 [Ru(O2CAd)2(p-cymene)] 1,4-dioxane 73 
9 [Ru(O2CMes)2(p-cymene)] 1,4-dioxane 65c 
10 [Ru(O2CMes)2(p-cymene)] 1,4-dioxane (<5)a 
Reaction conditions: 217a (0.50 mmol), 218a (1.5 mmol), [Ru] (10 mol %), PPh3 
(10 mol %), K2CO3 (1.0 mmol), solvent (2.0 mL), 60 °C, 20 h. Yields of isolated 
product. Conversion are given in parentheses based on 1H-NMR analysis with 
CH2Br2 as internal standard. a Without PPh3. b With AgSbF6 (20 mol %). c The 
reaction was performed at 40 °C. 
 
3.1.2. Scope of the Ruthenium-Catalyzed meta-C–H Functionalization via 
Oxazoline Assistance 
 
With the optimized reaction conditions in hand for the ruthenium(II)-catalyzed meta-
alkylation of 2-aryl-oxazolines 217 with 2-bromo carbonyl compounds 218 we explored 
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its versatility by probing different aryl-oxazolines 217 as substates (Scheme 3.1.2). The 
robustness of our alkylation manifold was reflected by the gram scale synthesis of 
alkylated oxazoline 219, with similar efficiency, even when utilizing a reduced catalyst 
loading. To our delight, electron-rich and electron-deficient arenes 217 were smoothly 
alkylated in a chemo- and site-selective fashion. Thus, many functional groups at the 
para-position of the aryl moiety, such as fluoro, chloro, bromo and trifluormethyl were 
well tolerated, exclusively leading to meta-functionalizations. In addition, ortho-
substituted aryl oxazolines 217h and 217i were regioselectively alkylated leading to 
the more sterically-hindered 1,2,3-substitued oxazolines 219ha and 217ia. 
Unfortunately, meta-substituted oxazolines led to unsatisfactory results under 
otherwise similar reaction conditions. Furthermore, dimethylamino, cyano and pyridine 
groups were not tolerated on the aryl moiety. 
  




Scheme 3.1.2. Ruthenium(II)-biscarboxylate catalysis for the meta-alkylation via 
oxazoline assistance. a Gram-scale, [Ru(O2CMes)2(p-cymene)] (45) (5.0 mol %), 
PPh3 (5.0 mol %). 
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Next, the substitution pattern on the unsaturated heterocyclic ring was investigated. 
Thus, alkylated and arylated oxazolines as well as their six-membered counterpart, 
oxazines, were subjected to our remote-alkylation manifold (Scheme 3.1.3). To our 
delight, alkyl and aryl substituents α to the oxygen were well tolerated, and meta-
alkylated oxazolines 220a and 220b were obtained in a site-selective fashion. 
Unfortunately, substituents α to the nitrogen were not tolerated, presumably due to the 
increased steric hindrance during the key cycloruthenation step. Lastly, oxazine 220c 




Scheme 3.1.3. Ruthenium(II)-biscarboxylate catalysis for the meta-alkylation via N-
coordination with various heterocycles. 
 
Next, the substrate scope of the α-bromo carbonyl compound partner was investigated 
(Scheme 3.1.4). Thus, various α-bromo esters were efficiently employed in our remote-
alkylation manifold, remarkably the meta-functionalized oxazoline 222 featuring the 
primary alkyl bromide moiety was obtained with excellent levels of chemoselectivity, 
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completely bypassing ortho-alkylative regimes.[36a-c] Unfortunately, α-bromo ketones 
and amides gave unsatisfactory results under otherwise similar reaction conditions. 
 
 
Scheme 3.1.4. Ruthenium(II)-biscarboxylate catalysis for the meta-alkylation with 
various α-bromo esters 218. 
 
Having established a mild and robust methodology for the meta-alkylation of a variety 
of substituted oxazolines with modular α-bromo esters and taking into consideration 
the powerful ruthenium-catalyzed ortho-C–H activation manifolds, we probed whether 
a sequential meta-/ortho-C–H difunctionalization type of regime could be 
unraveled.[150] We reasoned whether upon completion of the meta-C–H alkylation the 
addition of an appropriate coupling partner would lead to the site-selective 1,4-
difunctionalization of arene moiety by sterically-controlled C–H cycloruthenation. 
Among the plethora of ruthenium(II)-catalyzed reactions, the ortho-arylation was 
selected as the most suitable, due to its remarkable robustness.[151] To our delight, 
after completion of the reaction of 2-phenyl-4,5-dihydrooxazole (217a) with methyl 2-
bromohexanoate (218a), and hence resulting in the formation of meta-alkylated 
oxazoline 219aa, the simple addition of bromo arene 163a led to the site-selective 
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formation of difunctionalized oxazoline 223aa. Key features of this sequential method 
that led to the observed selectivity are a) the initial meta-functionalization is remarkably 
mono-selective and b) the introduced meta substituent is large enough to block its 
ortho positions. Thus, our strategy allowed for the chemo- and site-selective 
difunctionalization under ruthenium(II)-biscarboxylate catalysis, under two 
mechanistically distinct pathways. Encouraged by this finding, the scope with regards 
to the aryl electrophile 163 was explored (Scheme 3.1.5). Electron-rich arenes 163 
bearing methyl, tert-butyl and methoxy substituents were efficiently employed leading 
to the desired products 223ab, 223ac and 223ad with excellent levels of site-
selectivity. Furthermore, fluorinated aryl bromides 163e and 163f, featuring distinct 
substitution patterns, were also smoothly employed. Moreover, difunctionalized 
oxazolines 223ag and 223ah bearing trifluoromethyl groups were obtained in an 
efficient and site-selective manner. 
 




Scheme 3.1.5. Ruthenium(II)-biscarboxylate catalysis for the one-pot meta-/ortho-
difunctionalization via oxazoline assistance. a Aryl iodide 163g was used. 
 
Having established a robust and site-selective manifold for the 1,4-difunctionalization 
of aryl oxazolines 223 with various aryl electrophiles, we moved on to explore the 
generality of our process with regards to the oxazoline moiety (Scheme 3.1.6). Thus, 
substituted oxazoline 221a and oxazine 22ac were subjected to our sequential meta-
/ortho-functionalization approach. Under the optimized reaction conditions both 
scaffolds were selectively difunctionalized leading to the desired oxazoline 224aa and 
oxazine 224ca, respectively. Thereby, our approach led to the synthesis of 1,2,4-
trisubstituted arenes via ruthenium-catalyzed difunctionalization, hence we became 
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intrigued to probe whether tetrasubstituted arenes could be obtained. Remarkably, 
when para-substituted oxazolines 217 were utilized in our difunctionalization manifold, 




Scheme 3.1.6. One-pot ruthenium(II)-biscarboxylate catalysis for the meta-/ortho-
difunctionalization of various oxazolines. 
 
3.1.3. Diversification of the Functionalized Oxazolines 
 
Our strategy provided an expedient access to various mono- and difunctionalized 
oxazolines 219 and 223. Since oxazolines are versatile building blocks in organic 
synthesis, we probed whether we could modify this scaffold to other valuable functional 
group (Scheme 3.1.7). Thus, oxazoline 219aa was subjected to acidic hydrolysis 
conditions resulting in the formation of the di-acid 226 in excellent yield. The di-acid 
226 was then reductively decarboxylated under photoredox conditions, thereby 
obtaining the meta-alkylated benzoic acid 227. 









To shed light into the ruthenium(II)-catalyzed meta-alkylation, mechanistic studies 
were conducted next. Competition experiments between electron-rich and electron-
deficient aryl oxazolines 217 were performed under our optimized reaction conditions 
(Scheme 3.1.8). The results, showed a slight preference for electron-rich oxazolines, 




Scheme 3.1.8. Intermolecular competition experiments for the ruthenium-catalyzed 
meta-alkylation via oxazoline assistance. 
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Next, the key cycloruthenation step was examined. Initially, an H/D exchange 
experiment with deuterated methanol was performed. The recovered starting material 
217a and the product 219aa showed significant levels of H/D scrambling, suggesting 
a reversible cycloruthenation (Scheme 3.1.9). Furthermore, the larger D-incorporation 
in the least hindered ortho-position of the product 219aa showcased the observed 
positional selectivity of our meta-/ortho-difunctionalization regime. 
 
 
Scheme 3.1.9. H/D exchange experiment with CD3OD. 
 
After confirming a reversible C–H cycloruthenation, experiments to determine the 
deuterium kinetic isotope effect were conducted (Scheme 3.1.10). To this end, an 
intermolecular competition experiment between 217a and [D]5-217a was performed 
resulting in a minor KIE of kH/kD = 1.3. Furthermore, the KIE was also determined via 
the comparison of the relative reaction rates of 217a and [D]5-217a, by independent 
experiments, under the optimized reaction conditions. Similarly, 217a showed only a 
slightly higher reaction rate than [D]5-217a, therefore strongly suggesting that the C–H 
activation step is not kinetically relevant. Hence, the crucial C–H-cycloruthenation is 
fast. 
Additional mechanistic studies, performed by Dr. K. Korvorapun, revealed the 
involvement of radical species in the mechanism. This was strongly suggested by 
inhibition of the reaction by radical scavengers, the trapping of the stabilized alkyl 
radical as the TEMPO-adduct, the loss of the stereogenic information from an 
enantioenriched alkyl bromide during the conversion to the product and finally by the 
detection of an alkyl radical species by spin-trap label EPR studies. Furthermore, to 
rationalize the positional selectivity of the meta-alkylation manifold, computation 
studies, analyzing Fukui Indices, were performed by Dr. T. Rogge, which showcased 
that the dissociation of the p-cymene ligand from the ruthenium catalyst was crucial for 
achieving the observed selectivity. Recent studies by Ackermann also support an 
arene ligand-free manifold for a plethora of meta-alkylations via N-assistance.[61] 
3. Results and Discussion 
 
72 
y = 0.75x - 0.7
R² = 0.99



















Scheme 3.1.10. KIE experiments for the ruthenium-catalyzed meta-alkylation via 
oxazoline assistance. 
 
3.1.4. Proposed Catalytic Cycle for the Ruthenium-Catalyzed C–H meta-Alkylation 
via Oxazoline Assistance 
 
Based on our mechanistic and computational findings we propose a plausible catalytic 
cycle to commence by reversible and facile carboxylate-assisted C–H cycloruthenation 
(Scheme 3.1.11). Thereafter, SET occurs from the ruthenium(II) complex 229 to the 
alkyl halide 218, generating after halide transfer the cyclometalated ruthenium(III) 
intermediate 229. Radical addition on the aromatic moiety then proceeds at the 
position para-to-the-ruthenium, leading to species 231, subsequent re-aromatization 
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furnishes ruthenacycle 232. Finally, protodemetalation delivers the desired meta-
substituted product 233, and at the same time regenerates the catalytically active 
ruthenium(II) complex 228. 
 
 
Scheme 3.1.11. Plausible catalytic cycle for the ruthenium-catalyzed meta-alkylation.  
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3.2. Palladium-Catalyzed C(sp2)–H and C(sp3)–H Late-Stage Glycosylation 
 
Sugars are a class of biomolecules which have notably found applications to inter alia 
drug development.[152] Thus, the efficient and precise manipulation of naturally 
occurring sugar motifs is of utmost importance in terms of synthetic applications as 
well as pharmaceutical applications. In this context, glycopeptides hold a special place 
as many glycopeptides, such vancomycin, telavancin and ramoplanin, among others, 
exhibit high antibiotic potency.[153] The assembly of these daunting targets typically 
require many synthetic steps, therefore their expedient implementation in clinical 
settings is severely hindered. Furthermore, the elucidation of key structure-activity 
relationships that is necessary for developing highly potent antibiotics is resource- and 
time-intensive. Recently, palladium-catalyzed C–H activation has made some initial 
forays with a few C(sp2)–H glycosylation strategies by utilizing aryl iodides,[154] 1-iodo-
glucals,[155] or glycosyl halides,[156] in arylation, vinylation or alkylation manifolds, 
respectively (Scheme 3.2.1). Very recently, manganese catalysis gave expedient 
access to allylated glycopeptides featuring a C(sp2)–C(sp3) bond between a tryptophan 
residue and a sugar scaffold.[157] 
 
 
Scheme 3.2.1. Selected emerging strategies for C–H glycosylations. 
 
Therefore, we became interested in the development of an atom- and step-economical 
method for the late-stage C–H glycosylation of arenes and peptides. Despite the 
significant recent progress in the late-stage functionalization of amino acids and 
peptides,[25b, 25g, 147] the efficient functionalization of sugar scaffolds is still in its infancy 
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as many potential pitfalls could appear. This is the case due to the sensitivity of the 
densely functionalized polyoxygenated rings and to the stereochemical issues 
associated with the chiral environment. Hence, we decided to probe whether palladium 
catalysis, via bidentate assistance, could be used for establishing a reliable platform 
for the late-stage glycosylation by utilizing 1-iodo-glucals. Furthermore, the reliable 
palladium catalysis would potentially allow not only the C(sp2)–H but also the 
significantly more challenging C(sp3)–H glycosylation. To this end, the modular family 
of triazole-based directing group was selected, since this would allow the 
implementation of this approach to the internal peptide glycosylation. 
 
3.2.1. Scope of the Palladium-Catalyzed C(sp2)–H Glycosylation 
 
Initial optimization studies, performed by J. Wu, showcased the importance of the 
bidentate directing group on the benzoic acid moiety. Among the commonly utilized 
bidentate directing groups examined, the triazole-based directing group, TAM, 
demonstrated the highest efficacy for the desired C(sp2)–H glycosylation by utilizing 
iodo-glucal 235. Thus, under the optimized reaction conditions, consisting of catalytic 
amounts of palladium acetate along with stoichiometric amounts of silver carbonate in 
1,4-dioxane at 80 °C, various (hetero)arenes were chemo- and site-selectively 
glycosylated (Scheme 3.2.2). More precisely, substituted arenes with electron-
donating and electron-withdrawing groups were efficiently converted to the desired C-
aryl glycosides 236, featuring methyl, fluoro, and trifluoromethyl groups. Moreover, 1-
substituted pyrene-derived benzamide 234d was selectively glycosylated at the C2 
and not at the peri C10 position, due to the preferential formation of the 5,5 fused 
bicyclic palladacycle over the 5,6 fused bicyclic palladacycle. The para-substituted 
benzamides 234 gave inseparable mixtures of mono- and di-functionalized products, 
thus limiting their applicability in this methodology. Furthermore, heteroarenes 
equipped with the TAMBu directing group were similarly glycosylated, under the 
optimized reaction conditions. Thus, electron-rich five-membered heterocycles, such 
thiophene and furan, were efficiently converted to the corresponding C-aryl glycosides 
236e and 236f. 




Scheme 3.2.2. Late-stage C(sp2)–H glycosylation en route to C-aryl glycosides. a 
Performed by J. Wu. 
 
3.2.2. Scope of the Palladium-Catalyzed C(sp3)–H Glycosylation 
 
Having established a robust and site-selective C(sp2)–H glycosylation approach, we 
probed whether the powerful palladium catalysis could be utilized for the late-stage 
C(sp3)–H glycosylation of amino-acids and peptides. This approach would lead to the 
synthesis of C-alkyl glycosides. In this context, under slightly modified reaction 
conditions, consisting of catalytic amounts of palladium trifluoroacetate and 1-
adamantanecarboxylic acid along with stoichiometric amounts of silver carbonate in 
1,4-dioxane at 80 °C, a plethora of amino acid derivatives 237 were chemo- and site-
selectively glycosylated. Remarkably, the challenging secondary C(sp3)–H activation 
proceeded with excellent levels of stereocontrol, due to the formation of the least 
sterically congested palladacycle.[131] Thus, decorated phenylalanine moieties 238, 
featuring amino acids and natural products on the side chain, were efficiently 
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glycosylated with the iodo-glucal 235. Gratifyingly, various amino acids, such as valine, 
isoleucine, phenylalanine and proline, as well as menthol and cholesterol were 
succesfully utilized affording the glycopeptides 238a-238d and glycolamino acid 
hybrids 238e and 238f (Scheme 3.2.3). 
 
 
Scheme 3.2.3 Palladium-catalyzed C(sp3)–H glycosylation of amino acid derivatives 
237. 
3. Results and Discussion 
 
78 
In order to illustrate the robustness of our C(sp3)–H activation strategy, we probed 
whether the unprecedented late-stage glycosylation of internal peptides was feasible 
within our catalytic manifold (Scheme 3.2.4). The triazole-based directing group, an 
amide surrogate sharing common electronical and topological properties with peptide 
bonds, is suitable for the incorporation in larger peptides. To our delight, the 
corresponding peptidomimetics proved viable substrates for the late-stage 
glycosylation. Thus, various tetra- and pentapeptides 239 were chemo- and site-
selectively glycosylated under our palladium-catalyzed manifold in a late-stage 
fashion. This approach paves the way for more time- and resource-economical 
syntheses of glycopeptides without relying on lengthy and costly de novo syntheses. 
 
 
Scheme 3.2.4 Late-stage C(sp3)–H glycosylation via internal triazole assistance. a 
Performed by J. Wu.  
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3.3. Ruthenium(II)-Catalyzed Peptide C–H Functionalization via Hydroarylation 
 
Thus far, the functionalization of amino acids and peptides via C–H activation has 
relied heavily on arylative manifolds, with scarce exceptions. Hence, methodologies 
that enable the formation of C–Het or C–C(sp3) bonds are in high demand as this will 
unlock a vast section of chemical space, beyond the aromatic flattened structures. 
Recently, oxygenations,[106] amidations,[122] fluorinations,[110] and silylations[158] have 
been disclosed using palladium or rhodium catalysis. In this context, the C–H alkylation 
of amino acids and peptides have been reported utilizing primary alkyl halides under 
palladium catalysis (Scheme 3.3.1).[49c, 159] 
 
 
Scheme 3.3.1. Representative examples of amino acid or peptide functionalization 
via the formation of C–Het or C–C(sp3) bonds. 
 
Therefore, we became interested in developing an atom- and step-economical method 
for chemo- and site-selective alkylation of tryptophan-containing peptides via a C–H 
activation manifold. Thus, ruthenium-catalysis was chosen due to its relative low-cost, 
among other 4d transition metals, and its remarkable functional group tolerance.[120] 
We recognized that the choice of alkylating agent is crucial for achieving high levels of 
chemoselectivity. In this context, electrophilic alkyl halides could prove detrimental for 
the functionalization of complex peptides due to possible alkylation of polar residues 
via nucleophilic substitution pathways. Thus, acrylates were selected as modular 
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alkylating agents via a hydroarylation mechanism. This strategy would allow, among 
others, the expedient ligation of peptides and stitching of various biomolecules leading 
to multifunctional conjugates.[160] 
 
3.3.1. Acid-Enabled C–H Cleavage and Protodemetalation 
 
Initial optimization studies by Dr. A. Schischko for the alkylation of tryptophan derivative 
241a with ethyl acrylate 22a showcased that catalytic amounts of [RuCl2(p-cymene)]2 
in acetic acid under air were suitable for ensuring chemo- and site-selective 
functionalization (Scheme 3.3.2a). Importantly, Dr. A. Schischko demonstrated the 
importance of acetic acid as solvent, since its use was crucial for achieving high 
turnover numbers. An H/D exchange experiment with deuterated acetic acid was 
conducted, and the recovered starting material 241a showed significant levels of D 
incorpotation, suggesting a reversible and fast cycloruthenation (Scheme 3.3.2b). To 
unravel the mode of action of acetic acid, computational studies were performed by Dr. 
T. Rogge that provided strong support for a facile C–H cycloruthenation and rate-
limiting protodemetalation by the acetic acid solvent. 
 
 
Scheme 3.3.2. a) Ruthenium(II)-catalyzed C–H alkylation of tryptophan derivative 
241a. b) Acid-enabled facile H/D exchange. 
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3.3.2. Scope of the Ruthenium(II)-Catalyzed Peptide Alkylation 
 
With the optimized reaction conditions in hand we explored the generality of our 
hydroarylation manifold, utilizing a plethora of tryptophan-containing peptides[121] and 
α,β-unsaturated carbonyl compounds. Initially, the functional group tolerance with 
regards to the coupling partner was examined (Scheme 3.3.3). Thus, tryptophan 
derivative 241 was coupled with various substituted phenol acrylates with excellent 
levels of chemo- and site-selectivity. Remarkably, electrophilic functional groups on 
the arene moiety, such as bromide, cyano and nitro, were well tolerated, as it is 
reflected from the examples 242ab-242ad. Furthermore, substrates bearing 
substituents at the meta- and even ortho-position on the phenol ring were efficiently 
converted to the desired alkylated tryptophan derivatives 242ae-242ag. The acidic 
conditions, under which our hydroarylation manifold is performed motivated us to 
investigate whether carboxylic acid-free tryptophan derivative 241b could be a viable 
substrate. Gratifyingly, alkylated tryptophan derivatives 242be and 242bh, featuring 
aryl and benzyl acrylates, were obtained in a chemo- and site-selective fashion, albeit 
with slightly diminished efficiency. Moreover, Dr. A. Schischko demonstrated that α,β-
unsaturated ketones, thioesters and maleimides are viable coupling partners under 
otherwise similar reaction conditions. 
 




Scheme 3.3.3. Ruthenium(II)-catalyzed C–H alkylation of tryptophan derivative 241 
via hydroarylation. 
 
Having established a robust and reliable method for the stitching of various α,β-
unsaturated carbonyl compounds to the C2 position of tryptophan derivative 241a, we 
probed whether more complex acrylates could be used. Thus, acrylates containing 
natural products, drug scaffolds and fluorescent tags were employed (Scheme 3.3.4). 
To our delight, eugenol containing acrylate gave rise to the conjugate 242ai in excellent 
yield. For the functionalization with the eugenol acrylate 22i a mixture of toluene and 
acetic acid was used as solvent, in order to diminish the acid-catalyzed isomerization 
of the allyl moiety to the more substituted styryl-type. Furthermore, ibuprofen 
containing acrylate 22k was smoothly employed generating the amino acid-drug 
conjugate 242ak in excellent yield. Finally, the fluorescent labeling of tryptophan 
derivative 241a was efficiently accomplished with pyrene containing acrylate 22j. 
 




Scheme 3.3.4. Ruthenium(II)-catalyzed C–H conjugation. a Toluene/AcOH 1/1 was 
used as solvent. 
 
After demonstrating a broad substrate scope with regards to the α,β-unsaturated 
carbonyl compounds, the generality of our hydroarylation reaction was assessed in the 
setting of C–H functionalization of structurally complex peptides. Thus, various di- and 
tripeptides were employed in our C–H alkylation regime, featuring a diverse set of 
functional groups. More precisely, dipeptides containing isoleucine, methionine, 
proline and glutamine were chemo- and site-selectively alkylated with aryl and alkyl 
substituted acrylates (Scheme 3.3.5). Remarkably, the oxidation prone thioether 
moiety found in the methionine-containing dipeptide 243b was smoothly employed in 
our method. Along these lines, the 2,5-diketopiperazine moiety found in numerous 
naturally occurring cyclic dipeptides, such as in Brevianamide F derivative 243c, was 
well tolerated. Motivated by the robustness of our ruthenium(II)-catalyzed C–H 
alkylation manifold for the site-selective functionalization of dipeptides we probed 
whether tripeptides would be viable substrates. Thereby, alkylated tripeptides 244 
featuring NH-free indole moiety, aryl bromide and fluorescent pyrene tag were 
3. Results and Discussion 
 
84 
efficiently obtained under the optimized reaction conditions, without signs of 
epimerization. 
 
Scheme 3.3.5. Ruthenium(II)-catalyzed C–H alkylation of di- and tripeptides. a 
Performed by Dr. A. Schischko. 
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Having demonstrated that the modular α,β-unsaturated esters are suitable substrates 
for the site-selective functionalization of di- and tripeptides, we investigated the 
efficiency of our method with the more reactive α,β-unsaturated ketones (Scheme 
3.3.6). Thus, di- and tripeptides were subjected to our ruthenium(II)-catalyzed C–H 
alkylation manifold. To our delight, peptides featuring protected lysine, cysteine and 
aspartic acid were efficiently converted to the desired alkylated peptides 246a-246c 




Scheme 3.3.6. Ruthenium(II)-catalyzed C–H alkylation of di- and tripeptides with 
methyl vinyl ketone (245). 
 
Intrigued by the robustness of our ruthenium(II)-catalyzed C–H alkylation and taking 
into consideration the modular nature of α,β-unsaturated carbonyl compounds we 
probed if our regime would be suitable for the C–H ligation of peptides. To put this 
hypothesis into practice we examined the stitching of various peptide-containing 
acrylates to the tryptophan derivative 241a (Scheme 3.3.7). To our delight, a diverse 
set of acrylates linked to N- or C- terminus or even to the hydroxy group of serine 
proved viable substrates, giving rise to peptides 248a-248d with distinct ligation 
patterns. In the case of phenylalanine derived acrylate 247b N-phthaloyl protection 
was crucial to suppress competing aza-Michael pathways. Hence, under the optimized 
reaction conditions unnatural di-, tri- and tetrapeptides were obtained in good yields. 




Scheme 3.3.7. Ruthenium(II)-catalyzed C–H ligation of tryptophan derivatives. 
 
Motivated by these results, we pursued on expanding this strategy to the ligation of 
more complex peptides. Thus, di-and tripeptides were used as substrates in our C–H 
ligation approach with various peptide- or drug-derived acrylates (Scheme 3.3.8). To 
our delight, our regime gave expedient access to various tetra- and hexapeptides 242 
via an C2-selective alkylation manifold. Lastly, the conjugation of tripeptide 243e with 
ibuprofen-derived acrylate 22k was efficiently accomplished giving rise to hybrid 
molecule 249d. 




Scheme 3.3.8. Ruthenium(II)-catalyzed C–H ligation of peptides. 
 
3.3.3. Late-Stage Removal of the Pyridyl Group 
 
With a robust and reliable alkylation manifold in hand for the late-stage diversification 
and ligation of structurally complex tryptophan-containing peptides we focused on the 
removal of the essential 2-pyridyl directing group, under mild reaction conditions 
without jeopardizing the peptidic backbone. Hence, selective N-methylation with 
methyl triflate followed by hydrogenation of the resulting pyridinium salt led to the 
cleavage of the directing group providing the NH-free indole-containing peptides 250a-
250c (Scheme 3.3.9). Remarkably, the C–H alkylation and directing group cleavage 
proceeded without erosion of the enantiopurity of the alkylated amino acid 250a. 
Accordingly, alkylated and ligated peptides were smoothly employed in this sequence 
yielding the desired derivatives in moderate yields. 




Scheme 3.3.9. Traceless removal of the 2-azinyl group. 
 
3.3.4. Peptide Alkenylation via Ruthenium(II)-Catalyzed Hydroarylation 
 
The ruthenium(II)-catalyzed hydroarylation is not restricted to alkenes but it is also 
applicable to alkynes.[80, 161] Notably, electronically unbiased alkynes are typical 
coupling partners in ruthenium-catalyzed C–H activation,[41c, 42a, 42b, 42e, 162] in sharp 
contrast to alkenes that generally require an additional activating group. Thus, we 
challenged whether the acid-enabled hydroarylation manifold we had developed for 
activated alkenes could be expanded to alkynes. We commenced our optimization 
studies by probing various reaction conditions for the envisioned C–H alkenylation of 
tryptophan derivative 153 with diphenylacetylene 251 utilizing catalytic amounts of 
[RuCl2(p-cymene)]2 and stoichiometric amounts HOAc at 100 °C, in various solvents 
(Table 3.3.1). Among a representative set of solvents toluene proved to be optimal 
(entry 2), giving rise to the desired functionalized amino acid 252 in 85% yield. Then, 
ruthenium(II)-biscarboxylate complexes were assessed (entries 4-7), with 
[Ru(OAc)2(p-cymene)] providing the best result. Remarkably, our hydroarylation 
manifold did not require the use of silver(I) salts for the generation of the a cationic 
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Table 3.3.1. Optimization studies for ruthenium(II)-catalyzed alkenylation via a 
hydroarylation manifold. 
 
Entry [Ru] Solvent Yield (%) 
1 [RuCl2(p-cymene)]2 1,4-dioxane 43 
2 [RuCl2(p-cymene)]2 toluene 85 
3 [RuCl2(p-cymene)]2 DMF - 
4 [Ru(OCMes)2(p-cymene)] toluene 79 
5 [Ru(OAc)2(p-cymene)] toluene 87 
6 [Ru(MeCN)6][SbF6]2 toluene - 
7 [Ru(tBuCN)6][PF6]2 toluene - 
Reaction conditions: 153 (0.15 mmol), 251 (0.22 mmol), [Ru] (10 mol %), 
HOAc (1.0 equiv), solvent (0.6 mL), 100 °C, 15 h. Yields of isolated product. 
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3.4. 3d-Transtion Metal-Catalyzed Allylation of Drug Scaffolds and Peptides 
 
Recently, the growing importance of peptides and proteins in therapeutic and 
biomedical applications has provided enormous motivation to the synthetic community 
for developing mild and robust methodologies for the chemo- and site-selective 
modification of peptides.[163] Traditionally, the existing methods for late-stage, post-
assembly, modification of peptides are limited mainly to reactions based on polar 
nucleophilic side chains, found mainly in cysteine and lysine.[164] Recently, the powerful 
cross-coupling regime has enabled the modification of peptides equipped with the 
appropriate handles, that are generally unnatural.[165] Thus, these strategies are 
generally not suitable for the modification of hydrophobic amino acids. In this regard, 
C–H functionalization has proven invaluable, as omnipresent C–H bonds are 
substituted with a plethora of functional groups. During the last decade, C–H activation 
has become an increasingly viable tool for molecular syntheses.[25a, 25e] Enormous 
efforts have been devoted to establishing C–H functionalizations of amino acids and 
peptides using toxic 4d transition metals, mainly palladium and ruthenium,[25b, 147, 166] 
whilst Earth-abundant 3d transition metal catalysis continues to be scarce.[123] 
Manganese complexes typically demonstrate low toxicity, thus its utilization in late-
stage C–H functionalization of peptides is highly desirable. Furthermore, the site-
selective incorporation of functional groups that enable plethora of post-synthetic 
manipulations are highly desirable, rapidly expanding the chemical space. In this 
regard, α,β-unsaturated carbonyl compounds are one the most widely used synthetic 
handles for the modification of peptides and proteins due to their highly electrophilic 
character.[167] 
Therefore, we became interested in the development of an atom- and step economical 
method for the incorporation of α,β-unsaturated carbonyl moiety into the peptidic chain 
via a C–H activation manifold (Scheme 3.4.1). Thus, manganese catalysis was chosen 
due to its lower toxicity and cost-effectiveness as well as high natural abundance of 
manganese.[26] Recognizing the remarkable efficiency of manganese(I)-catalyzed C–
H allylation,[88-89, 91] we probed whether the Morita-Baylis-Hillman (MBH) adducts,[168] 
possessing a bis-electrophilic character, could be suitable substrates for the chemo- 
and site-selective functionalization of tryptophan-containing peptides. 




Scheme 3.4.1. Manganese(I)-catalyzed incorporation of α,β-unsaturated carbonyl 
moiety to peptides. 
 
3.4.1. Optimization Studies for C–H Allylation of Peptides Under Manganese(I) 
Catalysis 
 
We commenced our optimization studies by probing various reaction conditions for the 
envisioned C–H allylation of tryptophan derivative 241a with Boc-protected MBH-
adduct 253a with catalytic amounts of MnBr(CO)5 and NaOAc at 80 °C, in various 
solvents (Table 3.4.1). Among the tested solvents, 1,4-dioxane provided the highest 
isolated yield (entry 3), albeit reactions in toluene and DCE gave nearly quantitative 
yields as well (entries 1 and 2). The nature of the leaving group was then examined. 
This demonstrated the essential role of the carbonate moiety, as both free MBH adduct 
and acetyl-protected-MBH adduct failed to provide the desired product 254a (entries 4 
and 5). This can be attributed either to the need for pre-coordination of the leaving 
group prior to the migratory insertion or to the ease of β-oxygen elimination of the 
different leaving groups. Control experiments revealed the importance of NaOAc, that 
presumably leads to the formation of Mn(OAc)(CO)5, thus facilitating the initial C–H 
activation step via carboxylate assistance,[17a] and the essential nature of the 
MnBr(CO)5 (entries 6 and 7). Notably, the reaction proceeded without erosion of the 
enantiointegrity of the tryptophan scaffold, demonstrating the exceedingly mild nature 
of this manganese(I)-catalyzed allylation manifold. 
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Table 3.4.1. Optimization studies for the manganese(I)-catalyzed allylation of 
tryptophan derivative 241a with MBH adduct 253. 
 
Entry Solvent Additive R Yield (%) 
1 toluene NaOAc Boc 93 
2 DCE NaOAc Boc 93 
3 1,4-dioxane NaOAc Boc 98 
4 1,4-dioxane NaOAc H --- 
5 1,4-dioxane NaOAc Ac --- 
6 1,4-dioxane --- Boc 73 
7 1,4-dioxane NaOAc Boc ---a 
Reaction conditions: 241a (0.20 mmol), 253 (0.40 mmol), MnBr(CO)5 (10 mol 
%), additive (30 mol %), solvent (0.6 mL), 16 h. Yields of isolated product. a 
Without MnBr(CO)5. 
 
3.4.2. Scope of the Manganese(I)-Catalyzed C–H Allylation of Tryptophan-
Containing Peptides and Biomolecules 
 
With the optimized reaction conditions in hand, we first tested different tryptophan 
derivatives with orthogonal protecting groups in order to provide access to 
functionalized amino acids suitable for peptide synthesis, featuring the reactive α,β-
unsaturated ester moiety (Scheme 3.4.2). Thus, 254a and 254b were isolated in 
excellent yields. Remarkably, the Boc-Trppy-OBn was allylated in excellent yield even 
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on gram-scale, demonstrating the user-friendly nature of this manganese(I)-catalyzed 
C–H allylation. In addition, different MBH-adducts were efficiently converted under this 
allylation manifold, thus 254c and 254b were isolated in excellent yields, albeit with 
moderate E/Z ratio. After establishing a robust strategy for the functionalization of 
amino acids, we investigated whether tryptophan-containing dipeptides 243 were 
suitable substrates (Scheme 3.4.2). Gratifyingly, a plethora of dipeptides 243 were 
efficiently functionalized under the optimized reaction conditions with the excellent 
levels of chemo- and site-selectivity. Precisely, dipeptides with aliphatic and aromatic 
amino acids, like leucine, isoleucine, and phenylalanine were well tolerated, leading to 
the functionalized dipeptides 255a, 255b and 255c in a chemo- and site-selective 
fashion. Moreover, the terminal primary amide featured in the dipeptide 243k did not 
affect the efficacy of our C–H allylation manifold. The brevianamide F derivative 243c, 
bearing the 2,5-diketopiperazine moiety found in a myriad of natural products,[169] was 
efficiently functionalized under the optimized reaction conditions. Furthermore, 
hydroxyl-containing amino acids, such as serine and tyrosine, were well tolerated, as 
reflected by the chemo- and site-selective allylation of dipeptides 243n and 243o, 
completely bypassing the innate reactivity for oxa-Michael addition that would lead, 
after E1cB of the -OBoc group, to the O-allylation. Remarkably, the methionine-
containing dipeptide 243b, featuring the oxidation prone sulfide, was efficiently 
allylated without the formation of undesired oxidation by-products. 




Scheme 3.4.2. Manganese(I)-catalyzed C–H allylation of dipeptides. * Performed by 
R. Yin. 
 
Having established a robust method for the late-stage diversification of various 
dipeptides we shifted our attention to the functionalization of more complex peptides 
in order to demonstrate the full potential of our C–H allylation regime. Thus, tripeptides 
containing free NH-tryptophan and 4-iodo-phenylalanine were efficiently functionalized 
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in a chemo- and site-selective fashion, giving rise to allylated tripeptides with good to 
excellent yields (Scheme 3.4.3). Hence, the highly predictable positional selectivity of 
the manganese(I)-catalyzed C–H allylation was reflected by the selective 
functionalization of peptides 243p, 243q and 243r, featuring two different tryptophan 
residues, one equipped with the directing group and the other without protecting or 
directing group without signs of aza-Michael byproducts. Remarkably, tripeptide 243s 
featuring the tryptophan moiety in the middle of the peptidic sequence was efficiently 
functionalized despite the increased steric hindrance, albeit with diminished efficiency. 




Scheme 3.4.3. Manganese(I)-catalyzed C–H allylation of tripeptides. 
 
To further test the versatility of our manganese(I)-catalyzed C–H allylation we next 
examined whether even larger peptides could be efficiently allylated in a site-selective 
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fashion. To our delight, tetra- and pentapeptides were identified as suitable substrates 
providing the desired functionalized peptides in excellent yields (Scheme 3.4.4). 
Notably, protected hydroxyl-containing amino acids such as serine and threonine, and 
orthogonally protected lysine were well tolerated, leading to site- and chemo-
selectively functionalized peptides 255s and 255t. 
 
 
Scheme 3.4.4. Manganese(I)-catalyzed C–H allylation of tetra-and pentapeptides. 
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The modularity of the MBH-adducts enabled the synthesis of hybrid molecules via the 
manganese(I)-catalyzed C–H allylation, utilizing natural product-derived MBH-adducts 
253d, 253e and 253f (Scheme 3.4.5). Thus, the assembly of peptide/terpene and 
peptide/steroid conjugates was efficiently achieved under the optimized reaction 
conditions, utilizing menthol, borneol and cholesterol tethered MBH-adducts. More 
precisely, the di- and tetrapeptides were functionalized in a chemo- and site-selective 




Scheme 3.4.5. Manganese(I)-catalyzed synthesis of peptide conjugates 256 via C–H 
allylation. 
 
Having established a mild and robust method for the late-stage functionalization of 
structurally complex peptides with versatile protected MBH-adducts, we probed 
whether our approach could be employed for the diversification of drug-like scaffolds 
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(Scheme 3.4.6). The implementation of the C–H activation strategy in the late-stage 
functionalization of drugs can be straightforward, as many drugs typically possess 
nitrogen containing heterocycles that are powerful coordinating groups for various 
transition metals, yet the presence of these Lewis-basic functionalities can also pose 
selectivity and inhibition issues.[25e] Thus, we were delighted to achieve the selective 
functionalization of benzodiazepines. In this case, the imine-type nitrogen provided the 
crucial chelation-assistance to the manganese catalyst in order to enable the proximity 
induced C–H cleavage and subsequent allylation. Notably, Diazepam 257c was 
functionalized under the optimized reaction conditions in a chemo- and site-selective 
fashion. Thus, the functionalization of drug-like and drugs scaffolds was accomplished 
by means of non-toxic and Earth-abundant manganese(I)-catalyzed C–H activation. 
 
 
Scheme 3.4.6. Manganese(I)-catalyzed C–H allylation of benzodiazepines. * 
Performed by R. Yin. 
 
The generality of this method is also mirrored by the chemo- and site-selective 
functionalization of unnatural nucleoside 259, featuring the purine derivative 6-phenyl-
purine as nucleobase (Scheme 3.4.7). Here, the purine core acts as the essential 
chelating element to direct the C–H activation. The robustness of our method allowed 
the complete tolerance of the densely functionalized furanose core, free alcohols, acid-
sensitive acetals, together with the nitrogen-rich purine scaffold that could engage in 
undesired coordination with the manganese(I)-catalyst, normally leading to diminished 
reaction efficiency. Despite these potential pitfalls, the manganese(I)-catalysis gave 
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expedient access to functionalized nucleotides and nucleotide/natural product 
conjugates, featuring the α,β-unsaturated ester moiety. 
 
 
Scheme 3.4.7. Manganese(I)-catalyzed C–H allylation of nucleotides 259. 
 
3.4.3. Synthetic Applications of the Manganese(I)-Catalyzed C–H Allylation 
Manifold 
 
Recognizing the incompatibility of the protected MBH-adduct with the free-thiol moiety 
found in cysteine, we envisioned that a peptide dimer featuring a disulfide bond could 
act as an atom-economical protecting group surrogate. Thus, symmetric cystine-
containing tetrapeptide 261 was employed in a two-fold C–H functionalization strategy 
to obtain the difunctionalized tetrapeptide with excellent chemo- and site-selectivity 
(Scheme 3.4.8a). Subsequent triphenylphosphine-mediated disulfide reduction yielded 
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the desired functionalized dipeptide 262 in 71% yield over two steps. Remarkably, 
dipeptide 262 consists of highly nucleophilic thiol moiety and highly electrophilic α,β-
unsaturated ester moiety, demonstrating the mild nature and chemoselectivity of our 
strategy. Having established a robust method for the incorporation of the reactive α,β-
unsaturated ester moiety in structurally complex peptides, we probed whether Michael-
type addition of various polar or radical nucleophiles could be applicable in a late-stage 
fashion, thus fully exploiting the bis-electrophilic nature of the protected MBH-adducts. 
To put this hypothesis into practice, the allylated amino acid 254 was efficiently 
converted via a sulfa-Michael addition of Boc-Cys-OMe 263 to the α,β-unsaturated 
ester with moderate stereocontrol, generating a diastereoisomeric mixture of the 
unnatural dipeptide 264 (Scheme 3.4.8b). Furthermore, radical addition to α,β-
unsaturated ester via a nickel-catalyzed Giese coupling using N-hydroxy-phthalimide 
derived redox active ester as radical precursor yielded the functionalized amino acid 
derivatives 265 and 266, albeit with moderate stereocontrol.[170] Regarding the nickel-
catalyzed Giese coupling, slight modification from the reported conditions was crucial 
in order to avoid the addition of the cyclohexyl radical to the pyridine ring via a Minisci 
type manifold, thus the redox active ester was used as the limiting reagent. 




Scheme 3.4.8. a) Access to functionalized cysteine-containing dipeptide. b) Late-
stage ligation via polar and radical type Michael addition. 
 
3.4.4. Manganese(I)-Catalyzed Macrocyclization via an Allylation Manifold 
 
Motivated by the unique robustness of our method, we probed the utility of the 
intramolecular C–H activation towards tryptophan-based macrocycles. To this end, we 
incorporated the conformationally unbiased linker 1,5-aminopentanol, which in devoid 
of a β-turn motif, into the tryptophan scaffold (Table 3.4.2). To our delight, after a short 
optimization the desired 15-membered macrocycle 268 was obtained in 57% yield, 
featuring the highly reactive exocyclic olefin. Further testament to the user-friendly and 
robust nature of our C–H allylation manifold is the straightforward scale-up of the 
macrocyclization in 1.0 mmol scale, obtaining the desired macrocycle 268 in even 
slightly better yield.  
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Table 3.4.2. Optimization studies for the manganese(I)-catalyzed C–H 
macrocyclization. 
 
3.4.5. Late-Stage Removal of the Pyridyl Group 
 
After the development of an efficient and reliable method for the late-stage 
diversification of structurally complex peptides featuring the 2-pyridyl moiety as the 
directing group, we were pleased to be able to remove the directing group via a 
methylation/hydrogenation manifold (Scheme 3.4.9). Thus, selective N-methylation 
with methyl triflate followed by hydrogenation of the resulting pyridinium salt led to the 
labile aminal that after hydrolysis yielded the peptide 269 with the free indole scaffold, 
with concurrent hydrogenation of the olefin. Hence, functionalized amino acids were 
easily employed in this sequence yielding the desired derivative in moderate yields. 
Lastly, the 15-membered macrocycle 268 reacted efficiently under the reaction 
conditions giving rise to the azine group-free macrocycle as a diastereoisomeric 
mixture. 
 
Entry Concentration (mM) t (h) Yield (%) 
1 20 20 53 
2 20 40 62 
3 40 20 57 (62)a 
Reaction conditions: 267 (0.20 mmol), MnBr(CO)5 (10 mol %), NaOAc (30 
mol %), 1,4-dioxane, reaction time (t). Yields of isolated product.  a On 1.0 
mmol scale, by G. Sirvinskaite. 




Scheme 3.4.9. Traceless removal of the directing group. 
 
3.4.6. Manganese(I)-Catalyzed C–H Allylation of Heteroarenes with Protected 
MBH-Adducts 
 
The efficiency of our manganese(I)-catalyzed C–H allylation of peptides with protected 
MBH-adducts 253a prompted us to explore the feasibility of the functionalization of 
simpler heteroarenes, at exceedingly mild reaction conditions (Table 3.4.3). Thus, we 
began our optimization studies for the allylation of 1-(pyridin-2-yl)-1H-indole 270a 
employing similar reaction conditions to those already developed for the 
functionalization of tryptophan-containing peptides, albeit with reduced catalyst 
loading. The allylated heteroarene 271a was isolated in excellent yield (entry 1). 
Hence, the solvent effect was evaluated at lower reaction temperatures (entries 2-5), 
with 1,4-dioxane outperforming the solvents that were tested at 60 °C (entry 2). 
Gratifyingly, the desired allylation proceeded efficiently at 40 °C (entry 6). Further 
lowering of the reaction temperature at 25 °C led to slightly diminished efficiency, albeit 
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Table 3.4.3. Optimization studies for the manganese(I)-catalyzed allylation of indole 
270a. 
 
Entry Solvent Temperature (°C) Yield (%) 
1 1,4-dioxane 80 98 
2 1,4-dioxane 60 98 
3 DCE 60 97 
4 TFE 60 98 
5 H2O 60 90 
6 1,4-dioxane 40 95 
7 1,4-dioxane 25 68 
Reaction conditions: 270a (0.25 mmol), 253a (0.38 mmol), MnBr(CO)5 (5.0 
mol %), NaOAc (30 mol %), solvent (1.0 mL), 16 h. Yields of isolated product. 
 
With the optimized reaction conditions in hand, we on explored the substrate scope of 
our allylation regime with diversely-decorated indole and pyrrole derivatives equipped 
with the 2-pyridyl or 2-pyrimydyl directing group (Scheme 3.4.10). 3-Substituted indole 
derivates 270 featuring bromo, keto or protected amine groups, among others, were 
efficiently allylated, albeit they required a higher reaction temperature, presumably due 
the increased steric hindrance. Next, the effect of the substitution pattern on the 4, 5 
and 6 position on the indole scaffold was investigated. To our delight, a plethora of 
functional groups, including fluorides, bromides, iodide, esters and nitro, were 
efficiently tolerated, leading to the desired allylated heteroarenes 271 in a chemo- and 
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site-selective fashion. Furthermore, pyrrole derivatives were also viable substrates 
under standard reactions, whereas requiring higher reaction temperature to ensure 
good conversions. Remarkably, the two-fold C–H allylation of the unsubstituted pyrrole 




Scheme 3.4.10. Manganese(I)-catalyzed C–H allylation of indoles and pyrroles 270. 
a Reaction at 80 °C. b 3.0 equiv of 253a were used. 
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3.4.7. Late-Stage Cobalt(III)-Catalyzed C–H Allylation of Tryptophan-Containing 
Peptides 
 
Cobalt(III)-catalysis has emerged as a powerful strategy for the functionalization of 
inert C–H bonds.[171] Particularly, substitutive C–H allylations on simple (hetero)arenes 
have been well-established,[172] as the allyl moiety is easily transformed to a variety of 
valuable functional groups. Motivated by these reports, Dr. M. Lorion developed the 
allylation of tryptophan residues 243 with allyl acetate 272, utilizing cationic 
[Cp*Co(MeCN)3](SbF6)2 as the catalyst along with co-catalytic amounts of pivalic acid. 
Thus, the scope of this method was investigated with various amino acid derivatives 
and small peptides 243 (Scheme 3.4.11). The C–H allyaltions showed good functional 
group tolerance and robustness, as the addition of superstoichiometric amounts of H2O 
did not diminish the desired reactivity. Furthermore, peptides bearing primary amides, 
NH-free indoles, and free carboxylic acids were efficiently allylated in a chemo- and 
site-selective fashion. 
 




Scheme 3.4.11. Cobalt(III)-catalyzed C–H allylation . a In the presence of H2O(10 
equiv). b With 10 mol % of [Cp*Co(MeCN)3](SbF6)2. 
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3.5. Manganese(I)-Catalyzed Peptide C–H Ligation and Macrocyclization 
 
Peptides are responsible for a plethora of biological events, thus, they have been 
utilized as therapeutics for the treatment of many types of diseases.[173] Furthermore, 
peptides and proteins are essential for proteomics, diagnosis and drug delivery. While 
natural peptides, such as insulin, are of great importance in present drug market and 
drug discovery programs, new strategies for enhancing their activities, making them 
more suitable drug candidates, have appeared.[174] In this context, unnatural amino 
acids, unconventional linkages or cyclization of linear precursors offer new avenues 
for expanding the viable chemical space (Scheme 3.5.1). Traditionally, peptide 
syntheses rely on iterative coupling/deprotection regime, that has been automated, 
enabling facile access to large peptides.[175] 
 
 
Scheme 3.5.1. Bioactive cyclic peptides featuring exotic linkages. 
 
This strategy can be used to produce native peptides as well as unnatural peptides by 
using amino acids with modified side chains. Despite the enormous applications of 
SPPS, unnatural linkages within the peptidic backbone are not easily accessible. In 
this context, new methods for the chemo- and site-selective stitching of a peptidic 
fragment with another peptidic or sugar fragment are of utmost importance as 
multifunctional conjugates are produced.[176] In addition, more recently, medicinal and 
biological chemists have shifted their attention to cyclic peptides, due to their 
recognized pharmacological advantages of these macrocyclic molecules over their 
acyclic counterparts.[177] This can be partially attributed to improved membrane 
permeability and metabolic resistance. Macrocycles are conformationally constrained 
molecules. However, due to their large ring sizes they have appreciable degrees of 
flexibility and hence exist in distinct conformations. Due to this subtle conformational 
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interplay, they can adopt various conformations with minimum entropic cost, thus, 
enabling efficient binding to biological targets. 
As a consequence, we became interested in the development of an atom- and step-
economical method for the C–H ligation and macrocyclization of tryptophan-containing 
peptides. Despite the significant progress in the late-stage functionalization of amino 
acids and peptides, this is mainly achieved by noble metal-catalyzed C–H activation 
manifolds.[25g] While these regimes enabled the assembly of challenging cyclic 
peptides, toxic and costly palladium catalysts were required, which, among others 
could prove detrimental due to their costs and trace metal impurities of the toxic and 
precious metal. In contrast, 3d-transition metal-catalyzed C–H activation has only 
recently gained considerable attention.[26] Hence, we decided to probe whether non-
toxic manganese(I) complexes can enable the peptide stitching and macrocyclization. 
In order to develop a user-friendly and robust methodology, the functionalization of 
tryptophan moieties with modular propiolates was envisioned. 
 
3.5.1. Optimization Studies for Peptide Stitching via C–H Hydroarylation of 
Propiolates with Tryptophan-Containing Peptides 
 
At the outset of our optimization studies we chose tryptophan derivative 153 featuring 
the 2-pyridyl as directing group, ethyl propiolate 211a as the coupling partner and 
catalytic amounts of MnBr(CO)5 in combination with NaOAc at 100 °C as our initial 
conditions (Table 3.5.1). After testing various polar, non-polar, protic and aprotic 
solvents, 1,4-dioxane and DME showed the best results, as the desired product was 
isolated in excellent yields with complete E-selectivity (entries 3 and 4). Interestingly, 
manganese(I)-catalysis showed reasonable reactivity even in the presence water 
(entry 6), albeit with a diminished isolated yield. In consideration of the near 
quantitative yield obtained at 100 °C, further efforts to reduce the reaction temperature, 
in order to provide a milder reaction protocol, demonstrated that the reaction was 
efficient even at 60 °C, similarly providing the product in near quantitative yield (entry 
8). Control experiments showed the importance of NaOAc, that presumably enabled 
the formation of Mn(OAc)(CO)5 thus facilitating the C–H activation step via carboxylate 
assistance,[17a] and the essential nature of the MnBr(CO)5 (entries 10 and 11). Under 
the optimized reaction conditions, serine-derived propiolate 211b was tested giving 
rise to the unnatural dipeptide 274b in 86% yield (entry 12). To increase the efficiency 
of the unnatural dipeptide formation higher reaction temperatures were tested (entries 
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13 and,14). Gratifyingly, the desired product was obtained in 95% (E/Z ≥ 95:5) at 100 
°C. Notably, the reaction proceeded without erosion of the enantiointegrity of the 
tryptophan scaffold, demonstrating the mild nature of this manganese(I) hydroarylation 
manifold. 
 
Table 3.5.1. Optimization studies for the manganese(I)-catalyzed C–H alkenylation. 
 
Entry R Solvent Temperature (°C) 
Yield 
(%) 
1 OEt toluene 100 37 
2 OEt DCE 100 83 
3 OEt DME 100 97 
4 OEt 1,4-dioxane 100 98 
5 OEt DMF 100 --- 
6 OEt H2O 100 43 
7 OEt 1,4-dioxane 80 97 
8 OEt 1,4-dioxane 60 97 
9 OEt 1,4-dioxane 40 58 
10 OEt 1,4-dioxane 60 85a 
11 OEt 1,4-dioxane 60 ---b 
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12 R1 1,4-dioxane 60 86 
13 R1 1,4-dioxane 80 90 
14 R1 1,4-dioxane 100 95 
Reaction conditions: 153 (0.15 mmol), 211 (0.23 mmol), MnBr(CO)5 (10 mol %), 
NaOAc (30 mol %), solvent (0.6 mL), 16 h. Yields of isolated product. a Without 
NaOAc. b Without MnBr(CO)5. 
 
3.5.2. Manganese(I)-Catalyzed C–H Stitching 
 
With the optimized reactions in hand, we probed whether different propiolates 211 
featuring amino acids could be suitable substrates (Scheme 3.5.2). Thus, valine- and 
tryptophan-derived propiolates, featuring an amide linkage, provided the desired 
dipeptides in good to excellent yields. Gratifyingly, peptide 274d was formed in site-
selective fashion, despite the presence of a second tryptophan moiety. 
 
 
Scheme 3.5.2. Manganese(I)-catalyzed synthesis of unnatural dipeptides. a 
Performed by G. Sirvinskaite. 
 
Encouraged by the efficient synthesis of unnatural dipeptides we examined whether 
under the optimized reaction conditions tripeptides could be obtained in chemo- and 
site-selective fashion (Scheme 3.5.3). To our delight, our methodology was able to 
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stitch various dipeptides with the serine-derived propiolate 211b, showcasing the mild 
and chemo-selective nature of manganese(I)-catalyzed hydroarylation manifold. Thus, 
dipeptides containing aliphatic and aromatic side chains were efficiently utilized. In 
addition, dipeptide containing protected aspartic acid was utilized giving rise to the 
desired tripeptide 275c in 84%. Moreover, dipeptides containing free serine and 
tyrosine, possessing unprotected hydroxyl and phenol groups were efficiently 
converted with excellent levels of chemo-selctivity, as the potentially competing oxa-
Michael addition was not observed. In addition, dipeptide featuring methionine was 
employed, giving rise to the sulfide containing tripeptide 275f is 88% yield. Lastly, 
dipeptide 243ad bearing the nitrogen-rich guanidine group was efficiently converted to 
the desired tripeptide, albeit with a moderate stereoselectivity. 




Scheme 3.5.3. Manganese(I)-catalyzed synthesis of unnatural tripeptides. 
 
The site-selective functionalization of dipeptides en route to tripeptides was not limited 
to linear peptides. Thus, cyclic dipeptides featuring the 2,5-diketopiperazine scaffold, 
were utilized in this methodology providing expedient access to derivatives of 
Brevianamide F 277a and Fellutanine A 277b in excellent yields (Scheme 3.5.4). 




Scheme 3.5.4. Manganese(I)-catalyzed C–H functionalization of 2,5-
diketopiperazines. a Performed by G. Sirvinskaite. 
 
Motivated by our chemo- and site-selective method to stitch peptides via C–H 
hydroarylation we strode to expand our approach to more complex peptides 243 and 
propiolates 211. In sharp contrast to the traditional peptide syntheses that rely on 
iterative couplings, this strategy would provide a more step-economical and 
convergent methodology for the synthesis of large peptides (Scheme 3.5.5). Thus, 
tetrapeptides were readily synthesized bearing protecting cysteine and unprotected 
tyrosine among other amino acids. Furthermore, tripeptide-derived propiolate 211f was 
efficiently used as coupling partner with the dipeptide 243ac providing the 
pentapeptide 276k in excellent yield. Moreover, our strategy gave rise to hexapeptides, 
via either a 4+2 or a 5+1 approach, in site-selective fashion and good yields, utilizing 
peptides bearing protected serine and threonine as well as NH-free tryptophan. 




Scheme 3.5.5. Manganese(I)-catalyzed assembly of large peptides via C–H 
hydroarylation. a Performed by G. Sirvinskaite. 
 
Our hydroarylation manifold was not restricted to activated and terminal alkynes. 
Indeed, symmetrical diaryl alkynes 82 were also efficiently converted to the desired 
trisubstituted-olefin containing tryptophan derivatives 277a and 277b under otherwise 
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similar reaction conditions (Scheme 3.5.6). Aryl-substituted propiolates gave 
inseparable mixtures of regioisomers, limiting their synthetic application. 
 
 
Scheme 3.5.6. Manganese(I)-catalyzed synthesis of tryptophan derivatives 153, 
bearing trisubstituted olefins. 
 
The ability to stitch fragments that perform two distinct functions, based on their 
molecular architecture, is of utmost importance since new multi-functional molecules 
arise.[160b-d] Thus, we became intrigued to investigate whether our strategy could be 
employed for this purpose (Scheme 3.5.7). Gratifyingly, Boc-Trppy-OH was efficiently 
sewed with the menthol-derived propiolate 211f, giving rise to the alkenylated product 
279a destined for iterative peptide synthesis. Furthermore, dipeptide 243ac, featuring 
orthogonally bis-protected lysine, was efficiently used, allowing the selective expansion 
of the peptide chain via selective N-deprotection. The coumarin-based fluorescent tag 
was easily incorporated into the tryptophan moiety ensuring access to an amino acid 
with altered fluorescent properties. Lastly, sugar fragments, featuring protected 
galactopyranose and glucofuranose, were efficiently utilized under this methodology 
providing the glucopeptides 279d and 279e in excellent yields. 




Scheme 3.5.7. Manganese(I)-catalyzed synthesis of hybrid molecules 279 via C–H 
hydroarylation. a Performed by G. Sirvinskaite. 
 
3.5.3. Synthetic Applications of the Manganese(I)-Catalyzed Hydroarylation 
Manifold 
 
The user-friendly nature of our hydroarylation manifold was reflected by the efficient 
gram-scale (5.0 mmol) synthesis of the functionalized amino acid 274a and 274b in 
near quantitative yields (Scheme 3.5.8a). The robustness of this process is showcased 
by the high catalytic efficiency even in reduced catalyst loading under otherwise similar 
reaction conditions. Furthermore, in order to obtain alkenylated peptides with free 
cysteine, a two-fold C–H activation strategy of cystine-containing peptide 261 was 
employed, where the disulfide bond acts as an atom-economical protecting-group 
surrogate (Scheme 3.5.8b). Thus, the two-fold C–H functionalization followed by 
triphenylphosphine-mediated disulphide reduction yielded the desired thiol-containing 
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peptide in 61% over two steps. The cystine-containing peptide 261 possessing two 
azinyl-tryptophan residues, allows the sequential functionalization, after judicious 
tuning of the stoichiometry of the initial C–H functionalization, under two distinct 
reaction manifolds (Scheme 3.5.8b). Therefore, the manganese(I)-catalyzed 
hydroarylation manifold, utilizing the serine-derived propiolate as the limiting reagent 
to ensure synthetically useful mono-selectivity, was combined with manganese(I)-
catalyzed allylation with protected MBH-adducts, thus affording the difunctionalized 
tetrapeptide in 67% yield over two steps. The orchestration of the sequential 




Scheme 3.5.8. a) Gram-scale manganese(I)-catalyzed hydroarylation. b) Late-stage 
functionalizations of cystine-containing peptide 261. 
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3.5.4. Manganese(I)-Catalyzed Macrocyclization via a Hydroarylation Manifold 
 
Having established a reliable method for the ligation of peptides with peptides, sugars 
and natural products, via a C–H hydroarylation manifold, we probed whether this 
strategy could be expanded to the synthesis of cyclic peptides via a C–H 
macrocyclization. The synthesis of macrocycles is a challenging transformation,[178] 
since fine-tuning of the reaction conditions has to be performed for different classes of 
molecules as even small conformational changes of the starting material can lead to 
side-reactions.[179] This holds especially true for peptides, since their conformation is 
sequence dependent. Thus, the macrocyclization disconnection for the cyclization of a 
pentapeptide is not obvious and various disconnections have to be examined in order 
to develop efficient macrocyclization. In addition, traditional macrolactamization 
methods, like carbodiimides, active esters, phosphonium salts and aminium/uronium 
salts, can potentially lead to epimerization of the residue that is activated due to the 
slow rate of the amide formation.[180] Thus, alternative methods have been developed 
featuring cross-coupling, olefin-metathesis and recently C–H activation strategies.[181] 
In the field of C–H macrocyclization palladium has dominated, with many examples in 
C(sp2)–H and C(sp3)–H bond activations, leading to the elegant formal synthesis of 
Celogentin C by Wang.[141] To examine whether our C–H hydroarylation manifold is 
suitable for this demanding transformation, linear precursor 282 was reacted under 
high dilution conditions, utilizing higher catalyst loading to ensure synthetically useful 
reaction rates (Table 3.5.2). Gratifyingly, the desired 15-membered cyclic amide was 
isolated in 64% at 5 mM concentration. Remarkably the formation of dimer was not 
observed under the reaction conditions tested, based on careful LC-MS analysis, thus 
facilitating the isolation of the macrocycle.  
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Table 3.5.2. Optimization studies for the manganese(I)-catalyzed C–H 
macrocyclization. 
 
Entry Concentration (mM) Yield (%) 
1 20 27 
2 10 38 
3 5 64 
Reaction conditions: 282 (0.15 mmol), MnBr(CO)5 (20 mol %), NaOAc (60 mol 
%), 1,4-dioxane, 16 h. Yields of isolated product. 
 
With the optimized reaction conditions in hand, we tested various dipeptides 284 
bearing the tethered propiolate moiety. The reaction proceeded efficiently for aliphatic 
and aromatic amino acids embedded in the peptidic sequence, providing the desired 
18-membered macrocycles in good to excellent yields and E-selectivity (Scheme 
3.5.9). The excellent positional selectivity was reflected by the synthesis of cyclic 
dipeptide 285e featuring two different tryptophan moieties, one bearing the 2-pyridyl 
directing group while the other having its indole scaffold unprotected. 




Scheme 3.5.9. Manganese(I)-catalyzed synthesis of cyclic dipeptides 285 via C–H 
hydroarylation. 
 
Motivated by the remarkable efficiency of the synthesis of cyclic dipeptides 285 by our 
hydroarylation manifold we probed whether longer linear precursors can be effectively 
cyclized under this method. Thus, tri- and tetrapeptides were used as substrates for 
this manganese(I)-catalyzed macrocyclization (Scheme 3.5.10). Pleasingly, in all the 
cases good to excellent yields were observed along with excellent stereo- and chemo-
selectivities. The cyclization of peptides at a residue that is not at a terminal position is 
challenging, due to steric hindrance and conformational restraints. In addition, 
traditional directing groups incorporated at the C or N terminus, as is the case for the 
majority of palladium-catalyzed C–H macrocyclizations, would fall short in this type of 
transformation. Gratifyingly, peptide 287a, featuring the tryptophan residue in the 
middle of the peptidic sequence, was obtained in 65%. Remarkably, the high efficiency 
in the assembly of 287a, compared to its simpler counterpart 285d, where tryptophan 
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is at the terminal position, demonstrated the generality of our manganese(I)-catalyzed 
hydroarylation manifold that is not hampered by the steric hindrance or the 
conformational flexibility of the linear peptides. 
 
 
Scheme 3.5.10. Manganese(I)-catalyzed synthesis of cyclic tri- and tetrapeptides via 
C–H hydroarylation. 
 
Thus far, our method gave expedient access to cyclic peptides via a Trp→C terminus 
macrocyclization strategy utilizing α,ω-aminoalcohols as linkers. In order to 
complement our approach we recognized that the propiolate could be introduced in the 
peptidic chain at the N terminus or at the side chain of amino acids that bear the proper 
handle e.g. serine, threonine and lysine (Scheme 3.5.11a). Thus, the propiolate moiety 
was installed in the N-terminus of tetra- and pentapeptides and under prolonged 
reaction times and under higher dilution conditions, the desired peptides 289a, 289b 
and 289c were obtained in good to excellent yields leading to 17- and 20-membered 
macrocycles. The higher dilution conditions were required as the lower reactivity of the 
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propiolamide moiety resulted in lower macrocyclization rate and as a consequence led 
to degradation pathways. The prolonged reaction time balanced the lower reaction rate 
at the higher dilution conditions. Serine was selected as the alcohol containing amino 
acid suitable for the installation of the propiolate moiety (Scheme 3.5.11b). Gratifyingly, 
under the optimized reaction conditions cyclic tetrapeptides 289d and 289e were 
efficiently obtained in good yields and excellent chemo- and stereoselectivities. 
 
 
Scheme 3.5.11. a) Trp →N terminus manganese(I)-catalyzed cyclization. b) 
Trp→Ser manganese(I)-catalyzed cyclization. 
 
3.5.5. Traceless Removal of the Pyridyl Group from the Cyclic Peptide 285d 
 
After the development of an efficient and reliable method for the synthesis of cyclic 
peptides featuring the 2-pyridyl moiety, we were delighted to be able to remove the 
directing group via a methylation/hydrogenation manifold (Scheme 3.5.12). Thus, 
selective N-methylation with methyl triflate and subsequent hydrogenation of the 
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resulting pyridinium salt gave the labile aminal, that after hydrolysis yielded the cyclic 
peptide 290with the NH-free indole scaffold. 
 
 
Scheme 3.5.12. Traceless removal of the directing group. 
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3.6. Manganese(I)-Catalyzed C–H BODIPY-Labeling of Tryptophan-Containing 
Peptides 
 
Small molecules had long been regarded as the ultimate drug scaffolds. However, in 
recent years, the pharmaceutical industries have experienced a paradigm shift, as the 
use of peptides, proteins and monoclonal antibodies is now experiencing a 
renaissance.[173] Hence, apart from purely academic endeavor, the elucidation of the 
working mode of bioactive peptides is of utmost importance, with immediate 
translational potential. The fluorescent labeling of peptides has been recognized as an 
efficient tool for shedding light into various biological pathways.[182] Among many dyes 
that have been attached to biomolecules, BODIPYs hold a special place due to their 
highly tunable nature and physiochemical properties.[183] More precisely, the BODIPY 
core, that is responsible for their fluorescent properties can be easily modified giving 
rise to fluorescent molecules with a large emission maxima (λexc) window.[184] 
Furthermore, they are biocompatible and generally have a high cell permeability. 
These properties enable their utilization in many biological studies.[185] Recently, a 
palladium-catalyzed C(sp2)–H and C(sp3)–H BODIPY-labeling was reported 
showcasing the translational potential of C–H activation regime.[134, 186] Thus, the 
development of new methods for the incorporation of these scaffolds in peptides are 
highly desirable, especially when a modular strategy can be achieved. 
Hence, we became interested in developing an atom- and step-economical method for 
the C–H labeling of tryptophan-containing peptides. During the last decade, noble 
metal-catalyzed C–H functionalizations of amino acids and peptides have provided an 
efficient strategy for late-stage diversification under mild and robust conditions.[25b, 25g, 
147] In this context, and despite the recent momentum towards Earth-abundant 3d 
transition metal-catalyzed C–H activation, this sustainable approach for the 
diversification of amino acids and peptides continues to be limited. Inspired by this 
advances, Dr. J. Son probed a strategy for a divergent assembly of fluorescent 
peptides with tunable optical properties by identifying internal bromoalkynes and 
terminal alkynes as appropriate substrates, via an alkynylation[123] or alkenylation[79-80] 
manifold, respectively. Thus, by employing these strategies, we could gain access to 
fluorescent imaging probes, where the phenyl-BODIPY fluorescent core would be 
stitched to the indole-moiety of the tryptophan amino acid via a linear alkynyl or a bent 
alkenyl spacer, while at the same time extending the conjugate π-system to fine-tune 
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the fluorogenic behavior. In addition, this linkage would not only alter the fluorescent 
properties of the peptide but also due to different rotation barriers, could render novel 
fluorescent molecular rotors. Furthermore, the well-established ruthenium(II)-
catalyzed arylation of tryptophan moieties[120] enabled the stitching of the phenyl-
BODIPY fluorescent core to indole moiety of the tryptophan via a biaryl linkage, thus 
obtaining three different fluorescent probes (Scheme 3.6.1). Initial studies in 
collaboration with Professor M. Vendrell, demonstrated that among these three novel 
fluorescent probes 291, 292 and 293, molecule 292 featuring the alkenyl linkage 
between the indole moiety and phenyl-BODIPY core leads to high viscosity-dependent 
fluorescence. More accurately compound 292 displayed viscosity sensitivity coefficient 
of around 0.7, being among the most sensitive fluorescent rotors reported to date.[187] 
 
 
Scheme 3.6.1. Tryptophan-BODIPY conjugates with different linkages. 
 
3.6.1. Optimization Studies for Manganese(I)-Catalyzed Labeling of Tryptophan 
with BODIPY-Alkynes 
 
After initial optimization by Dr. J. Son for the manganese(I)-catalyzed labeling of 
tryptophan-containing peptides, the labeling of tryptophan derivative 153 with terminal 
BODIPY-alkyne 294a was further studied to establish a milder reaction manifold (Table 
3.6.1). Thus, under the optimized reaction conditions consisting of catalytic amounts 
of MnBr(CO)5, co-catalytic amounts of 1-adamantanecarboxylic acid, in 1,4-dioxane at 
100 °C for 24 h the desired fluorescent tryptophan derivative 292a was obtained in 
88% yield (entry 1). Gratifyingly, reducing the reaction temperature, even to 
physiological temperature of 37 °C, led to only slight decrease in the reaction efficacy 
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Table 3.6.1. Optimization of the manganese(I)-catalyzed labeling of tryptophan 153.  
 
Entry X Temperature (°C) Yield (%) 
1 20 100 88 a 
2 20 80 83 
3 20 60 80 
3 20 60 80 
4 20 37 52 
5 10 100 60 
Reaction conditions: 153 (0.10 mmol), 294a (0.10 mmol), MnBr(CO)5, 1-AdCO2H 
(40 mol %), 1,4-dioxane (1.0 mL), 24 h. Yields of isolated product. a Performed by 
Dr. J. Son. 
 
3.6.2. Scope of the Manganese(I)-Catalyzed Labeling of Tryptophan-Containing 
Peptides 
 
With the optimized reaction conditions in hand and taking into consideration the 
remarkable robustness of the manganese(I)-catalyzed C–H activation, we probed 
whether our regime could be conducted in a flow setup, thus, due to enhanced heat 
and mass transfer the reaction time could be significantly reduced.[188] Furthermore, 
flow setups allow facile incorporation of metal-scavenging techniques to remove trace-
metal impurities that might be detrimental for further biological applications. Therefore, 
using a standardized flow reactor the reaction time could be significantly reduced to 
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only 100 min. In addition, a cartridge filled with the metal scavenger, QuadraPure™ 
IDA could be connected after the reactor (Scheme 3.6.2). Thereby, the residual 
manganese level was reduced to 6.1 ppm, as determined by inductively coupled 
plasma mass spectrometry (ICP-MS) analysis. The analysis was conducted in 
collaboration with I. Maksso in the Ackermann group. 
 
 
Scheme 3.6.2. Manganese(I)-catalyzed tryptophan C–H labeling in flow. 
 
The modular nature of BODIPY dyes allows expedient access to distinct fluorescent 
dyes, since small changes in the substituents and/or substitution pattern on the pyrrole 
core result in significant changes at the fluorescent properties. Thus, BODIPY-alkynes 
featuring the 2,4-dimethyl-pyrrole core tethered with para- or meta-substituted 
aromatic linkage were efficiently incorporated into tryptophan-derived substrate 153 
leading to the fluorescent amino acid derivatives 292a and 292b with strong green 
fluorescence (Scheme 3.6.3). Furthermore, BODIPY-alkynes 294 derived from C2-
arylated pyrroles bathochromically shift the emission wavelength of obtained 
fluorescent amino acid derivatives 292c and 292d, thus leading to strong yellow 
fluorescence (Scheme 3.6.3). 




Scheme 3.6.3. Access to BODIPY-tryptophan derivatives with various fluorescent 
properties. 
 
Since our strategy enabled the modular and efficient synthesis of various fluorescent 
amino acid derivatives, we probed whether a designed modification to the tryptophan-
BOBIPY conjugates would lead to fluorogenic probes with translational impact. The 
fluorogenic properties of the alkenylated tryptophan derivative 294 led us to probe 
whether it can act as membrane viscosity probe. Thus, tryptophan derivatives 
containing lipophilic tails at the N-terminus were also subjected to the labeling process 
to afford modulated lipophilic rotors that could potentially be anchored on membranes. 
Thus, upon utilizing lauric, palmitic, stearic and cis-oleic acids attached to tryptophan, 
under our optimized reaction conditions we thus gained access to E-bent fluorogenic 
tryptophan derivatives 296a-296d (Scheme 3.6.4). 




Scheme 3.6.4. Manganese(I)-catalyzed labeling of lipopeptides. 
 
After establishing that our manganese(I)-catalyzed labeling regime tolerated a wide 
range of different BODIPY-alkynes 294 for the functionalization of tryptophan 
derivative 153 we probed the diversification of the more challenging dipeptides 
(Scheme 3.6.5). Thus, dipeptides containing phenylalanine, free tyrosine and free 
tryptophan were subjected to our hydroarylation manifold. Gratifyingly, the 
corresponding dipeptides were efficiently labeled in chemo- and site-selective fashion 
with the BODIPY-alkyne 294a. Furthermore, the labeling of dipeptide 243m was also 
conducted at 60 °C and the functionalized dipeptide 297a was obtained with equally 
high efficiency, being a strong testament to the mildness and robustness of our 
manganese(I)-catalyzed hydroarylation regime. 




Scheme 3.6.5. Manganese(I)-catalyzed labeling of tryptophan dipeptides 243 
containing aromatic amino acids. a 60 °C. b Performed by Dr. J. Son. 
 
An efficient method for late-stage functionalizations not only requires to be mild, but 
also needs to be extremely selective, guaranteeing that the desired transformation is 
not hindered by other structural motifs. Thus, polar functional groups, found in the side 
chains of some amino acids, can potentially hinder the functionalization of peptides 
featuring these amino acids in their unprotected form. In this context, it should be 
mentioned that the vast majority of large peptides are synthesized with their side-
chains protected. Hence, various dipeptides featuring free-alcohols, amines or 
carboxylic acids were subjected to our hydroarylation manifold (Scheme 3.6.6). 
Remarkably, serine- and threonine-containing dipeptides were efficiently labeled in a 
chemoselective fashion, without any sign of diminished efficacy caused by the 
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unprotected alcohol, leading to fluorescent dipeptides 297d and 297e. With regards to 
the more nucleophilic and coordinating amine group in lysine, orthogonally bis-
protected fluorescent dipeptide 297f was obtained by our manganese(I)-catalysis. This 
approach can enable the selective elongation of the peptidic chain, after judicious 
deprotection conditions. Moreover, free-lysine was tolerated when using stoichiometric 
amounts of MnBr(CO)5. Thus, the unprotected-lysine-containing fluorescent dipeptide 
297g was obtained in 66% yield, completely bypassing hydroamination regimes. 
Lastly, under the optimized reaction conditions fluorescent dipeptide 297h featuring 








Scheme 3.6.6. Manganese(I)-catalyzed C–H labeling of dipeptides featuring polar 
functional groups. a The reaction was performed with MnBr(CO)5 (1.0 equiv) and 1-
AdCO2H (1.4 equiv). 
 
The 2,5-diketopiperazine scaffold is found in many bioactive natural products. Thus 
the labeling of such moieties would potentially find application in deciphering their 
molecular mode of action. Encouraged by the robustness of our manganese(I)-
hydroarylation regime we choose Brevianamide F cyclo-[L-Trppy-L-Pro] and 
Fellutanine A cyclo-[L-Trppy-L-Trp] derivatives for applying our method. Remarkably, 
both natural products 276a and 276b were efficiently labeled with either 
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dimethylpyrrole- or arylated-pyrrole-based BODIPYs, thus having either strong green 
or yellow fluorescence (Scheme 3.6.7). 
 
Scheme 3.6.7. Manganese(I)-catalyzed labeling of 2,5-diketopiperazines 276. 
 
Inspired by the robustness of our hydroarylation regime we probed the functionalization 
of tripeptides 243 (Scheme 3.6.8). Hence, various labeled tripeptides featuring 
protected aspartic acid and threonine, among others, were efficiently obtained with 
high chemo- and site-selectivity. In addition, the labeling of tripeptide 297ac was 
efficiently conducted at 60 °C with similar efficiency. 




Scheme 3.6.8. Manganese(I)-catalyzed BODIPY-labeling of tripeptides. a 60 °C. 
 
Encouraged by the efficiency of our manganese(I)-catalyzed labeling of di- and 
tripeptides we examined the viability of larger peptides as suitable substrates. To our 
delight, labeled tetra- and pentapeptides 243 were obtained under mild and 
epimerization-free reaction conditions in a chemo- and site-selective manner (Scheme 
3.6.9). Remarkably, even in this complex setting, the manganese(I)-catalyzed 
hydroarylation regime tolerated unprotected serine and tryptophan, found in labeled 
pentapeptides 243ad and 243ae, respectively. In addition, the sensitive disulfide 
bridge, found in a plethora of naturally occurring peptides was fully tolerated, as it is 
evident from the expedient access to fluorescent tetrapeptide 297q. Furthermore, the 
labeled tetrapeptide 297m was also obtained, when the reaction was carried out at 60 
°C, albeit with slightly diminished efficiency. Thus, the efficient, chemo- and site-
selective labeling of large peptides, even at as low as 60 °C, demonstrated the mild 
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and robust nature of our manganese(I)-catalyzed C–H hydroarylation manifold, 
utilizing modular terminal BODIPY-alkynes. 
 
 
Scheme 3.6.9. Manganese(I)-catalyzed labeling of tetra- and pentapeptides 243. a 
60 °C. 
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Cyclic peptides hold a very prominent place among naturally occurring peptides, since 
they are generally more stable in terms of proteolytic degradation. Thus, they have 
favorable properties for medicinal purposes. The late-stage functionalization of cyclic 
peptides is hence of utmost importance, since a plethora of analogues would be readily 
available, without the need for step- and resource-intensive de novo peptide synthesis 
and finally a challenging macrocyclization. To our delight, our manganese(I)-catalyzed 
hydroarylation manifold provided expedient access to fluorescent cyclic peptides 300a 
and 300b (Scheme 3.6.10). 
 
 
Scheme 3.6.10. Late-stage BODIPY-labeling of tryptophan-containing cyclic 
peptides. 
 
3.6.3. Traceless Azine Removal: Access to NH-Free Fluorescent Tryptophan 
Derivative 
 
Having established a robust protocol for the chemo- and site-selective labeling of 
tryptophan-containing peptides we probed whether the 2-pyrydyl group could be 
removed, preferably without affecting the olefin. Gratifyingly, selective methylation of 
the pyridine moiety and subsequent hydrogenation with Pearlman’s catalyst cleanly 
cleaved the directing group and left the disubstituted olefin untouched (Scheme 
3.6.11). 





Scheme 3.6.11. Traceless removal of the 2-pyridyl group. 
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4. Summary and Outlook 
 
Organic synthesis has traditionally relied on step-, time- and resource-intensive 
strategies, namely the functional group interconversion and, more recently, on cross-
coupling reactions. These approaches have enabled the synthetic community to 
synthesize every imaginable molecule, given the necessary time and resources. Thus, 
the next major challenge in the field of organic synthesis is the efficiency, scalability, 
and sustainability.[2b, 189] In this context, transition metal-catalyzed C–H activation has 
emerged as a powerful tool, as the time- and resource-consuming 
prefunctionalizations of starting materials are minimized, since inert and omnipresent 
C–H bonds are utilized as latent functional groups. In this thesis, the primary focus was 
the development of novel strategies for increasing the molecular complexity of simple 
precursors via an one-pot difunctionalization approach and the late-stage 
diversification of peptides. Moreover, in order to address the need for more 
environmentally-benign C–H transformations we focused on the use of inexpensive 
Earth-abundant 3d transition metals, namely manganese and cobalt. 
Within the first project, a highly efficient meta-/ortho-difunctionalization of aryl-
oxazolines under ruthenium catalysis was developed (Scheme 4.1).[190] Mild and 
robust reaction conditions ensured ample substrate scope featuring a plethora of 
valuable functional groups. The synergy of the ruthenium(II)-biscarboxylate catalyst 
and of the  phosphine ligand allowed the site-selective meta-alkylation of various aryl-
oxazolines with α-bromo carbonyl compounds. The robust ruthenium catalyst allowed 
the sequential meta-alkylation/ortho-arylation of arenes by the simple addition of the 
arylating agent upon completion of the initial alkylation. Detailed mechanistic studies 








Scheme 4.1. Ruthenium-catalyzed double meta-/ortho-C–H difunctionalization. 
 
In the second project, we developed a versatile C(sp3)–H/C(sp2)–H glycosylation 
strategy of peptidomimetics, featuring the 1,4-disubstituted triazole moiety, an amide 
surrogate, as the essential bidentate directing group. (Scheme 4.2).[191] Consequently, 
the synthesis of structurally complex C-aryl glycosides, C-alkyl glycoamino acids, and 
glycopeptides was achieved by palladium-catalyzed C–H activation in a regio-, chemo- 
and diastereoselective fashion. The synthetic utility of our approach was reflected by 
the expedient assembly of BODIPY fluorescent labeled glycoamino acids and the 
epimerization-free late-stage diversification of structurally complex molecules. 
Considering the importance of C-aryl glycosides and glycopeptides in drug discovery, 
these studies are expected to inspire further developments in the field of transition 
metal-catalyzed C–H functionalization of saccharide scaffolds. 
 
 
Scheme 4.2. Palladium-catalyzed C(sp3)–H/C(sp2)–H glycosylation. 
 
In the third project, we realized a ruthenium(II)-catalyzed peptide C–H alkylation 
manifold for the epimerization-free diversification of complex peptides in a 
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bioorthogonal manner (Scheme 4.3).[192] Gratifyingly, the air- and water-tolerant 
[RuCl2(p-cymene)]2 catalyst set the stage for the chemo- and site-selective 
diversification of amino acids and peptides. The robustness of the ruthenium(II) 
catalysis was reflected by the C–H modification and ligation of structurally complex 
peptides with modular acrylates. This method provided facile access to hybrid 
architectures bearing natural products, drug scaffolds and even fluorescent tags. 
These findings should prove invaluable for applications to medicinal chemistry, 
illustrating the robust nature of the ruthenium(II)-catalyzed C–H activation. 
Furthermore, our approach demonstrated the outstanding synthetic utility of 
ruthenium(II)catalyzed C–H activation towards complex peptides bypassing the need 
for lengthy and resource-demanding de novo strategies. 
 
 
Scheme 4.3. Diversification of peptides by ruthenium(II)-catalyzed C–H alkylation. 
 
Thus far, the late-stage diversification of peptides via C–H activation has relied heavily 
on precious transition metals, mostly palladium. In this regard the use of expensive 
and potentially toxic 4d and 5d transition metal hinders the inherit sustainable nature 
of the C–H functionalization strategy. Hence, in the fourth project, we developed an 
unprecedented manganese(I)-catalyzed C–H allylation strategy towards decorated 
peptides, nucleotides, and drug molecules (Scheme 4.4).[193] The chemo- and site-
selective diversification of biomolecules was accomplished under exceedingly mild and 
epimerization-free reaction conditions. Consequently, a plethora of sensitive functional 
groups was fully tolerated, reflecting the robustness and mildness of the C–H activation 
regime. Our findings further highlight the user-friendly nature of manganese(I)-
catalyzed C–H activation for the late-stage peptide and drug diversification, as well as 
the bioorthogonal assembly of hybrid peptides and macrocycles. The C–H allylation of 
peptides with 3d transition metals was not restricted to manganese. Indeed cobalt(III) 
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catalysis enabled the position-selective allylation of tryptophan containing peptides.[194] 
The robust C–H allylation was elegantly combined with the ruthenium-catalyzed olefin 
metathesis leading to stapled peptides. 
 
 
Scheme 4.4. Manganese-catalyzed C–H allylation of peptides with MBH adducts. 
 
In the fifth project, we developed an unprecedented manganese(I)catalyzed C─H 
hydroarylation on complex peptides, that enabled the highly valuable C–H ligation 
(Scheme 4.5).[195] The chemo- and site-selective peptide stitching was characterized 
by an excellent functional group tolerance featuring a plethora of delicate functional 
groups, under mild and epimerization-free reaction conditions. We then focused on 
assembling hybrid molecules by stitching tryptophan-containing peptides with natural 
products, sugars, and fluorescent tags. The generality of our intermolecular regime 
prompted us to explore the more challenging intramolecular macrocyclization version. 
Gratifyingly, our robust method paved the way for a highly efficient access to cyclic 
peptides via a C–H macrocyclization regime. Furthermore, the modular nature of our 
approach with propiolates, allowed for the synthesis of stapled peptides via Trp→C 
terminus, Trp→N terminus, or Trp→Ser cyclization. Our general route towards 
tryptophan-containing peptides will enable the expedient discovery of constrained 
bioactive macrocyclic scaffolds. 
 




Scheme 4.5. Manganese-catalyzed C–H ligation and macrocyclization. 
 
Finally, a strategy for the late-stage manganese(I)-catalyzed C–H labeling of 
structurally complex peptides with BODIPY probes was established (Scheme 4.6).[196] 
The tunable nature of the BODIPY fluorophores allowed facile access to fluorescent 
peptides with distinct photophysical properties, enabling their potential use in various 
biological applications. Moreover, the manganese(I)-catalyzed carboxylate-assisted 
hydroarylation manifold gave access to a myriad of fluorescent complex peptides, 
cyclic peptides, and cyclic peptides, decorated with sensitive functional groups under 
mild, epimerization-free reaction conditions. The hindered rotation of the alknenyl 
linkage would favour the charge transfer between the indole and phenyl-BODIPY 
groups, showing excellent fluorogenic character. Remarkably, the alkenylated 
tryptophan-BODIPY conjugate exhibited high viscosity-dependent fluorescence. Thus, 
in collaboration with the Vendrell group in Edinburgh, we incorporated this scaffold into 
a lipophilic tail that enabled the anchoring of the viscosity-sensitive dye in cell 
membranes. Furthermore, we identified a fluidity-sensitive probe, which emits bright 
fluorescence in response to cholesterol found in cell membranes, and we utilized it to 
establish a fluorescence-based screening platform for the identification of small 
molecule modulators of CD8+ T cells. Overall, our manganese(I)-catalyzed C–H 
hydroarylation strategy will establish novel avenues in the development of functional 
fluorophores to image cell function and in the late-stage labeling peptides. 
 




Scheme 4.6. Manganese-catalyzed C–H labeling with BODIPY fluorophores 294. 
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5. Experimental Part 
 
5.1. General Remarks 
 
All reactions involving air- and/or moisture-sensitive compounds were conducted under 
a dry nitrogen atmosphere using pre-dried glassware and standard Schlenk 
techniques. If not otherwise noted, yields refer to isolated compounds, which were 
estimated to be >95% pure based on 1H-NMR. 
 
Vacuum 
The following average pressure was measured on the used rotary vane pump RD4 
from Vacuubrand®: 0.8∙10–1 mbar (uncorrected value). 
 
Melting Points  
Melting points were measured on a Stuart® Melting Point Apparatus SMP3 from 
Barloworld Scientific. Values are uncorrected. 
 
Chromatography  
Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 
aluminium sheets from Merck. Plates were either visualized under irradiation at 254 
nm or 365 nm or developed by treatment with a potassium permanganate solution 
followed by careful warming. Chromatographic purifications were accomplished by 
column chromatography on Merck Geduran® silica gel, grade 60 (40–63 μm, 70–230 
mesh ASTM). 
 
Gel permeation chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped 
with two sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, 
gradient rate: 20.000; internal diameter = 20 mm; length = 600 mm; Flush rate = 10.0 
mL/min and CHCl3 (HPLC-quality with 0.6% EtOH as stabilizer) was used as the 
eluent. 
 
Infrared Spectroscopy  
IR spectra were recorded using a Bruker® Alpha-P ATR spectrometer. Liquid samples 
were measured as film and solid samples neat. Spectra were recorded in the range 
from 4000 to 400 cm–1. Analysis of the spectral data was carried out using Opus 6. 
Absorption is given in wave numbers (cm–1). 
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Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were recorded on Mercury Plus 300, VNMRS 300, Inova 500 and 600 
from Varian®, or Avance 300, Avance III 300 and 400, Avance III HD 400 and 500 from 
Bruker®. Chemical shifts are reported in δ-values in ppm relative to the residual proton 
peak or carbon peak of the deuterated solvent. 
The coupling constants J are reported in hertz (Hz). Analysis of the recorded spectra 
was carried out using MestReNova 10.0 software. 
 1H-NMR 13C-NMR 
CDCl3 7.26 77.16 
CD2Cl2 5.32 54.00 
(CD3)2SO 2.50 39.51 
 
Gas Chromatography  
Monitoring of reaction process via gas chromatography or coupled gas 
chromatography-mass spectrometry was performed using a 7890 GC-system 
with/without mass detector 5975C (Triple-Axis-Detector) or a 7890B GC-system 
coupled with a 5977A mass detector, both from Agilent Technologies®. 
 
Mass Spectrometry  
Electron ionization (EI) and EI high resolution mass spectra (HR-MS) were measured 
on a time-of-flight mass spectrometer AccuTOF from JEOL. Electrospray ionization 
(ESI) mass spectra were recorded on an Io-Trap mass spectrometer LCQ from 
Finnigan, a quadrupole time-of-flight maXis from Bruker Daltonic or on a time-of-flight 
mass spectrometer microTOF from Bruker Daltonic. ESI-HR-MS spectra were 
recorded on a Bruker Apex IV or Bruker Daltonic 7T, Fourier transform ion cyclotron 
resonance (FTICR) mass spectrometer. The ratios of mass to charge (m/z) are 
indicated, intensities relative to the base peak (I = 100) are written in parentheses. 
 
Chiral HPLC  
Chiral HPLC chromatograms were recorded on an Agilent 1290 Infinity using 
CHIRALPAK® IA-3, IB-3, IC-3, ID-3, IE-3 and IF-3 columns (3.0 μm particle size; ø: 4.6 
mm and 250 mm length) at ambient temperature. 
  




All solvents for reactions involving air- and/or moisture-sensitive reagents were dried, 
distilled and stored under an N2 atmosphere according to the following standard 
procedures. 
1,2-Dichloroethane (DCE) and toluene (PhMe) were dried over CaH2 for 8 h, degassed 
and distilled under reduced pressure. 1,4-Dioxane and di-n-butylether (nBu2O) were 
dried over Na for 8 h, degassed and distilled under reduced pressure.  
CH2Cl2, DMF, THF, Et2O were obtained from a MBRAUN MB SPS-800 solvent 
purification system.  
 
Chemicals 
Chemicals obtained from commercial sources with a purity >95% were used as 
received without further purification. 
The following compounds were known from the literature and synthesized according 
to previously known methods: oxazolines 217,[197] indoles 270,[121], triazole-containing 
peptides 237 and 239,[131, 134] pyridylated peptides 243,[120] acrylates 22,[84] protected 
MBH adducts 253.[198] 
The following compounds were kindly synthesized and provided by the persons listed 
below:  
Karsten Rauch: [RuCl2(p-cymene)]2, [Ru(OCMes)2(p-cymene)], [Ru(OAc)2(p-
cymene)], dry and/or degassed solvents. 
Dr. Korkit Korvorapun: nucleotides 260. 
Dr. Cuiju Zhu: triazole-containing benzamides 234. 
Jun Wu: 1-iodo glucal 235. 
Adelina Kopp: BODIPY alkynes 294. 
Rongxin Yin: MBH-adducts 253f and 253i. 
Giedre Sirvinskaite: propiolates 211, peptides 284. 
Felix Kaltenhäuser: peptides 286.  
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5.2. General Procedures 
 
5.2.1. General Procedure A: Ruthenium(II)-Catalyzed meta-Alkylation of 
Oxazolines 
 
Oxazoline 217 or 220 (0.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), 
PPh3 (13.1 mg, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a Schlenk 
tube. The tube was evacuated and purged with N2 three times. 1,4-Dioxane (2.0 mL) 
and alkyl bromide 218 (1.50 mmol) were then added and the mixture was stirred at 60 
°C. After 20 h, the resulting mixture was filtered through silica gel pad and washed with 
EtOAc. The filtrate was concentrated in vacuo. Purification by column chromatography 
on silica gel (n-hexane/EtOAc) afforded the desired product. 
 
5.2.2. General Procedure B: Ruthenium(II)-Catalyzed meta-Alkylation/ortho-
Arylation of Oxazolines 
 
Oxazoline 217 or 220 (0.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), 
PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) were placed in a Schlenk 
tube. The tube was evacuated and purged with N2 three times. 1,4-Dioxane (2.0 mL) 
and alkyl bromide 218 (1.50 mmol) were then added and the mixture was stirred at 40 
°C. After 20 h, bromoarene 163 (1.50 mmol) was added to the reaction mixture at 
ambient temperature and the mixture was stirred at 120 °C for an additional 20 h. The 
resulting mixture was filtered through silica gel pad and washed with EtOAc. The filtrate 
was concentrated in vacuo. Purification by column chromatography on silica gel (n-
hexane/EtOAc) afforded desired product. 
 
5.2.3. General Procedure C: Palladium-Catalyzed C(sp2)–H Glycosylation with 
TAMBu 
 
Amide 234 (0.1 mmol), Pd(OAc)2 (2.2 mg, 10 mol %), Ag2CO3 (55 mg, 0.2 mmol), were 
added to Schlenk tube. The tube was evacuated and purged with N2 three times. Then, 
1-iodo glycal 235 (0.15 mmol) in 1,4-dioxane (0.50 mL) was added. The tube was 
sealed and heated at 80 °C for 10 h. After cooling to ambient temperature, the resulting 
reaction mixture was diluted with CH2Cl2 and concentrated in vacuo. Purification by 
column chromatography on silica gel (n-hexane/EtOAc) afforded the desired product. 
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5.2.4. General Procedure D: Palladium-Catalyzed Peptide C(sp3)–H Glycosylation 
with TAM 
 
Amide 237 or 239 (0.1 mmol), Pd(TFA)2 (3.3 mg, 10 mol %), Ag2CO3 (55 mg, 0.2 
mmol), 1-AdCO2H (5.4 mg, 30 mol %) were placed in an oven-dried Schlenk tube. The 
mixture was evacuated and purged with N2 three times. Then, 1-iodo glycal 235 (0.15 
mmol) in 1,4-dioxane (0.50 mL) was added. The tube was sealed and heated at 80 °C 
for 10 -16 h. After cooling to ambient temperature, the resulting reaction mixture was 
diluted with CH2Cl2 and concentrated in vacuo. Purification by column chromatography 
on silica gel (n-hexane/EtOAc) afforded the desired product. 
 
5.2.5. General Procedure E: Ruthenium(II)-Catalyzed C–H Alkylation of 
Tryptophan 
 
A test tube with a stir bar was charged with pyridylated tryptophane 241 (0.15 mmol, 
1.0 equiv) and [RuCl2(p-cymene)]2 (9.2 mg, 10mol %). AcOH (0.15 mL) and acrylate 
22 (1.1 – 3.0 equiv.) were added. The tube was fitted with a septum and the mixture 
was heated to 80 °C for 15 h. After cooling to ambient temperature, the resulting 
reaction mixture was diluted with PhMe and concentrated in vacuo. Purification by 
column chromatography on silica gel afforded the desired product. 
 
5.2.6. General Procedure F: Ruthenium(II)-Catalyzed C–H Alkylation of Peptides 
 
A test tube with a stir bar was charged with pyridylated peptide 243 (0.15 mmol, 
1.0 equiv) and [RuCl2(p-cymene)]2 (9.2 mg, 10mol %). AcOH (0.15 mL) and acrylate 
22 or vinyl ketone 245 (1.1 – 3.0 equiv.) were added. The tube was fitted with a septum 
and the mixture was heated to 80 °C for 15 h. After cooling to ambient temperature, 
the resulting reaction mixture was diluted with PhMe and concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired product. 
 
5.2.7. General Procedure G: Ruthenium(II)-Catalyzed C–H Ligation of Peptides 
 
A test tube with a stir bar was charged with pyridylated peptide 241 or 243 (0.15 mmol, 
1.0 equiv), acryloyl peptide 247 (0.17 mmol, 1.1 equiv.) and [RuCl2(p-cymene)]2 
(9.2 mg, 10mol %). AcOH (0.15 mL) were added. The tube was fitted with a septum 
and the mixture was heated to 80 °C for 15 h. After cooling to ambient temperature, 
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the resulting reaction mixture was diluted with PhMe and concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired product. 
 
5.2.8. General Procedure H: Traceless Removal of 2-Pyridyl Group from 
Alkylated Peptides 
 
To a stirred solution of peptide 242a or 244c or 248a (1.0 equiv) in CH2Cl2 (0.25 M) 
was added MeOTf (1.0 equiv) at 0 ˚C. After 30 min, the mixture was allowed to warm 
up to 25 °C and stirred for 18 h. The crude mixture was concentrated under reduced 
pressure to afford a bright yellow solid. In a sealed-tube, the crude product, Pd(OH)2/C 
(10 mol %, 20 wt%) and ammonium formate (10.0 equiv) were dissolved in ethanol 
(0.5 M) and stirred at 60 ˚C for 16 hours. The mixture was filtered through a short plug 
of celite, concentrated under reduced pressure and purified by column 
chromatography on silica gel afforded the desired product. 
 
5.2.9. General Procedure I: Manganese(I)-Catalyzed Late-Stage C–H Allylation on 
Peptides with MBH Adducts 
 
A suspension of pyridylated peptide 243 (1.0 equiv), MBH adduct 253 (2.0 equiv), 
MnBr(CO)5 (10 mol %) and NaOAc (30 mol %) in 1,4-dioxane (0.33 M) was stirred at 
80 °C for 16 h under N2. After cooling to ambient temperature, CH2Cl2 (10 mL) was 
added and the mixture concentrated in vacuo. Purification by column chromatography 
on silica gel afforded the desired product. 
 
5.2.10. General Procedure J: Manganese(I)-Catalyzed Late-Stage C–H Allylation 
on (Hetero)Arenes with MBH Adducts 
 
A suspension of (hetero)arenes 257 or 259 (0.20 mmol, 1.0 equiv), MBH adduct 2 
(0.40 mmol, 2.0 equiv), MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) 
in 1,4-dioxane (1.0 mL) was stirred at 80 °C for 16 h under N2. After cooling to ambient 
temperature, CH2Cl2 (10 mL) was added and the mixture concentrated in vacuo. 
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5.2.11. General Procedure K: Traceless Removal of 2-Pyridyl Group from 
Allylated Peptides 
 
To a stirred solution of 254a or 269b or 268 (1.0 equiv) in CH2Cl2 (0.25 M) was added 
methyl trifluoromethanesulfonate (1.0 equiv) at 0 ˚C. After 30 min, the mixture was 
allowed to warm up to 25 °C and stirred for 18 h. The crude mixture was concentrated 
under reduced pressure to afford a bright yellow solid. In a sealed-tube, the crude 
product, Pd(OH)2/C (10 mol %, 20 wt%), and ammonium formate (10.0 equiv) were 
dissolved in methanol (0.5 M), and stirred at 60 ˚C for 16 hours. The mixture was 
filtered through a short plug of celite, concentrated under reduced pressure and 
purified by column chromatography on silica gel afforded the desired product. 
 
5.2.12. General Procedure L: Cobalt(III)-Catalyzed Late-Stage C–H Allylation on 
Peptides 
 
A mixture of peptide 243 (1.00 equiv), allyl acetate 272 (30 µL, 2.00 equiv), 
[Cp*Co(MeCN)3](SbF6)2 (5.9 mg, 5.0 mol %) and PivOH (1.5 mg, 10 mol %) in TFE 
(1.0 mL) was stirred at 80 °C for 14 h under N2. After cooling to ambient temperature, 
EtOAc (15 mL) was added and the mixture concentrated in vacuo. Purification by 
column chromatography on silica gel afforded the desired product. 
 
5.2.13. General Procedure M: Manganese(I)-Catalyzed Late-Stage C–H 
Hydroarylation on Peptides 
 
A suspension of peptide 243 (0.15 mmol, 1.0 equiv), propiolate 211 (0.23 mmol, 1.5 
equiv), MnBr(CO)5 (10 mol %) and NaOAc (30 mol %) in 1,4-dioxane (0.25 M) was 
stirred at 100 °C for 16 h under N2. After cooling to ambient temperature, CH2Cl2 (10 
mL) was added and the mixture concentrated in vacuo. Purification by column 
chromatography on silica gel afforded the desired product. 
 
5.2.14. General Procedure N: Manganese(I)-Catalyzed C–H Macrocyclization of 
Peptides 
 
A suspension of peptide 284 or 286 or 288 (0.15 mmol, 1.0 equiv), MnBr(CO)5 (20 
mol %) and NaOAc (60 mol %) in 1,4-dioxane (30 mL) was stirred at 100 °C for 16 h 
under N2. After cooling to ambient temperature, CH2Cl2 (10 mL) was added and the 
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mixture concentrated in vacuo. Purification by column chromatography on silica gel 
afforded the desired product 10. 
 
5.2.15. General Procedure O: Manganese(I)-Catalyzed Late-Stage C–H Allylation 
on Peptides 
 
A suspension of peptide 243 or 299 (0.10 mmol, 1.0 equiv), BODIPY-alkyne 294 (0.11-
0.20 mmol, 1.1 -2.0 equiv), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 
mol %) in 1,4-dioxane (1.0 mL) was stirred at 100 °C for 24 h. After cooling to ambient 
temperature, CH2Cl2 (10 mL) was added and the mixture was concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired product. 
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5.3. Sequential meta-/ortho-C–H Functionalization of Oxazolines via Ruthenium 
Catalysis 
 
5.3.1. Characterization Data 
 
Methyl 2-[3-(4,5-dihydrooxazol-2-yl)phenyl]hexanoate (219aa) 
 
The general procedure A was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 3/1) yielded 219aa (104.7 mg, 76%) as a brown 
oil. Gram scale reaction: 2-phenyl-4,5-dihydrooxazole 217a (1.18 g, 8.00 mmol), 
[Ru(O2CMes)2(p-cymene)] (224 mg, 0.40 mmol, 5.0 mol %), PPh3 (105 mg, 0.40 mmol, 
5.0 mol %) and K2CO3 (2.20 mg, 16.0 mmol) were placed in a pre-dried 100 mL schlenk 
flask. The mixture was evacuated and purged with N2 for three times. Methyl 2-
bromohexanoate 218a (4.99 g, 24.0 mmol) and 1,4-dioxane (32.0 mL) were then 
added and the mixture was stirred at 60 °C. After 20 h, the resulting mixture was filtered 
over silica gel pad and washed with EtOAc. The filtrate was concentrated in vacuo. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 3/1) 
yielded 219aa (1.74 g, 79%). 
1H-NMR (300 MHz, CDCl3): δ 7.85 (td, J = 1.6, 0.9 Hz, 1H), 7.79 (dt, J = 7.6, 1.6 Hz, 
1H), 7.42–7.37 (m, 1H), 7.32 (td, J = 7.6, 0.7 Hz, 1H), 4.39 (t, J = 9.4 Hz, 2H), 4.02 (t, 
J = 9.4 Hz, 2H), 3.61 (s, 3H), 3.54 (t, J = 7.7 Hz, 1H), 2.06 (dddd, J = 13.3, 9.5, 7.9, 
5.7 Hz, 1H), 1.75 (dddd, J = 13.5, 9.3, 7.6, 5.9 Hz, 1H), 1.37–1.09 (m, 4H), 0.82 (t, J = 
7.1 Hz, 3H). 13C-NMR (126 MHz, CDCl3): δ 174.0 (Cq), 164.3 (Cq), 139.4 (Cq), 130.6 
(CH), 128.5 (CH), 127.9 (CH), 127.8 (Cq), 126.7 (CH), 67.6 (CH2), 54.9 (CH2), 51.9 
(CH3), 51.4 (CH), 33.2 (CH2), 29.7 (CH2), 22.4 (CH2), 13.9 (CH3). IR (ATR): 2952, 2872, 
1733, 1649, 1357, 1160, 950, 709 cm–1. MS (ESI): m/z (relative intensity): 298 (14) 
[M+Na] +, 276 (100) [M+H]+. HR-MS (ESI): m/z calcd for C16H22NO3+ [M+H]+: 276.1594, 
found: 276.1597. 
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Methyl 2-[5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl]hexanoate (219ba) 
 
The general procedure A was followed using 2-(4-methoxyphenyl)-4,5-dihydrooxazole 
217b (88.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 3/1) yielded 219ba (107.4 mg, 70%) as a pale 
yellow solid. 
M.p.: 79 – 80 °C. 1H-NMR (600 MHz, CDCl3): δ 7.81 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 
8.6, 2.2 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 4.34 (t, J = 9.5 Hz, 2H), 3.97 (t, J = 9.5 Hz, 
2H), 3.92 (t, J = 7.6 Hz, 1H), 3.81 (s, 3H), 3.59 (s, 3H), 2.11–1.95 (m, 1H), 1.71 (dddd, 
J = 13.2, 9.8, 7.6, 5.4 Hz, 1H), 1.35–1.08 (m, 4H), 0.81 (t, J = 7.2 Hz, 3H). 13C-NMR 
(126 MHz, CDCl3): δ 174.3 (Cq), 164.2 (Cq), 159.1 (Cq), 128.5 (CH), 128.4 (CH), 128.0 
(Cq), 120.2 (Cq), 110.1 (CH), 67.4 (CH2), 55.6 (CH3), 54.8 (CH2), 51.8 (CH3), 44.1 (CH), 
31.8 (CH2), 29.7 (CH2), 22.5 (CH2), 13.9 (CH3). IR (ATR): 2953, 2872, 1733, 1648, 
1607, 1459, 1433, 1249, 1107, 952 cm–1. MS (ESI): m/z (relative intensity): 306 (100) 
[M+H] +. HR-MS (ESI): m/z calcd for C17H24NO4+ [M+H]+: 306.1700, found: 306.1701. 
 
Methyl 2-[5-(4,5-dihydrooxazol-2-yl)-2-methylphenyl]hexanoate (219ca) 
 
The general procedure A was followed using 2-(p-tolyl)-4,5-dihydrooxazole 217c (80.6 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 4/1) yielded 219ca (112.7 mg, 78%) as a white 
solid.  
M.p.: 73 – 74 °C. 1H-NMR (600 MHz, CDCl3): δ 7.86 (d, J = 1.8 Hz, 1H), 7.69 (dd, J = 
8.0, 1.8 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 4.42–4.33 (m, 2H), 4.01 (t, J = 9.5 Hz, 2H), 
3.79 (dd, J = 8.0, 7.1 Hz, 1H), 3.61 (s, 3H), 2.37 (s, 3H), 2.12 (dddd, J = 13.4, 10.2, 
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8.0, 5.1 Hz, 1H), 1.74 (dddd, J = 13.4, 9.9, 7.1, 5.5 Hz, 1H), 1.36–1.11 (m, 4H), 0.84 
(t, J = 7.2 Hz, 3H). 13C-NMR (126 MHz, CDCl3): δ 174.1 (Cq), 164.4 (Cq), 139.7 (Cq), 
137.9 (Cq), 130.4 (CH), 126.7 (CH), 126.6 (CH), 125.9 (Cq), 67.5 (CH2), 54.9 (CH2), 
51.9 (CH3), 47.0 (CH), 32.6 (CH2), 29.9 (CH2), 22.6 (CH2), 20.0 (CH3), 14.0 (CH3). IR 
(ATR): 2952, 2929, 2871, 1733, 1649, 1215, 1160, 723 cm–1. MS (ESI) m/z (relative 
intensity): 290 (100) [M+H]+. HR-MS (ESI): m/z calcd for C17H24NO3+ [M+H]+: 
290.1751, found: 290.1752. 
 
Methyl 2-[5-(4,5-dihydrooxazol-2-yl)-2-fluorophenyl]hexanoate (219da) 
 
The general procedure A was followed using 2-(4-fluorophenyl)-4,5-dihydrooxazole 
217d (82.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 4/1) yielded 219da (89.5 mg, 61%) as a colorless 
oil. 
1H-NMR (300 MHz, CDCl3): δ 7.94 (dd, J = 7.1, 2.2 Hz, 1H), 7.83 (ddd, J = 8.6, 5.1, 
2.2 Hz, 1H), 7.07 (dd, J = 9.6, 8.6 Hz, 1H), 4.42 (t, J = 9.4 Hz, 2H), 4.04 (t, J = 9.4 Hz, 
2H), 3.90 (t, J = 7.5 Hz, 1H), 3.66 (s, 3H), 2.11 (dddd, J = 12.8, 9.8, 7.5, 5.5 Hz, 1H), 
1.87–1.67 (m, 1H), 1.41–1.10 (m, 4H), 0.85 (t, J = 7.0 Hz, 3H). 13C-NMR (126 MHz, 
CDCl3): δ 173.5 (Cq), 163.7 (Cq), 162.3 (d, 1JC-F = 252 Hz, Cq), 129.5 (d, 3JC-F = 5 Hz, 
CH), 128.9 (d, 3JC-F = 9 Hz, CH), 126.7 (d, 2JC-F = 16 Hz, Cq), 124.2 (d, 4JC-F = 3 Hz, 
Cq), 115.6 (d, 2JC-F = 24 Hz, CH), 67.7 (CH2), 54.9 (CH2), 52.1 (CH3), 43.6 (d, 3JC-F = 2 
Hz, CH), 32.0 (CH2), 29.6 (CH2), 22.4 (CH2), 13.7 (CH3). 19F-NMR (471 MHz, CDCl3): 
δ –113.35 (ddd, J = 9.6, 7.1, 5.1 Hz). IR (ATR): 2954, 2873, 1736, 1651, 1997, 1359, 
1228, 1169, 1104, 979 cm–1. MS (EI): m/z (relative intensity): 293 (25) [M] +, 234 (100) 
[M–CO2Me]+, 178 (90). HR-MS (EI): m/z calcd for C16H20FNO3+ [M]+: 293.1422, found: 
293.1422. 
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Methyl 2-[2-chloro-5-(4,5-dihydrooxazol-2-yl)phenyl]hexanoate (219ea) 
 
The general procedure A was followed using 2-(4-chlorophenyl)-4,5-dihydrooxazole 
217e (90.8 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 3/1) yielded 219ea (110.3 mg, 71%) as a white 
solid. 
M.p.: 62 – 64 °C. 1H-NMR (300 MHz, CDCl3): δ 7.91 (d, J = 2.1 Hz, 1H), 7.72 (dd, J = 
8.4, 2.1 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 4.38 (t, J = 9.2 Hz, 2H), 4.10 (t, J = 7.6 Hz, 
1H), 4.01 (t, J = 9.2 Hz, 2H), 3.63 (s, 3H), 2.19–2.01 (m, 1H), 1.76 (dddd, J = 13.4, 9.7, 
7.5, 5.6 Hz, 1H), 1.41–1.10 (m, 4H), 0.83 (t, J = 7.0 Hz, 3H). 13C-NMR (126 MHz, 
CDCl3): δ 173.3 (Cq), 163.5 (Cq), 137.2 (Cq), 137.0 (Cq), 129.5 (CH), 128.5 (CH), 127.7 
(CH), 126.7 (Cq), 67.7 (CH2), 55.0 (CH2), 52.1 (CH3), 47.2 (CH), 32.4 (CH2), 29.6 (CH2), 
22.4 (CH2), 13.9 (CH3). IR (ATR): 2954, 2872, 1735, 1651, 1358, 1251, 1166, 731 cm–
1. MS (ESI): m/z (relative intensity) 332 (15) [M+Na]+, 310 (100) [M+H]+. HR-MS (ESI): 
m/z calcd for C16H2135ClNO3+ [M+H]+: 310.1204, found: 310.1207. 
 
Methyl 2-[2-bromo-5-(4,5-dihydrooxazol-2-yl)phenyl]hexanoate (219fa) 
 
The general procedure A was followed using 2-(4-bromophenyl)-4,5-dihydrooxazole 
217f (113.0 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 3/1) yielded 219fa (119.2 mg, 67%) as a white 
solid. 
M.p.: 66 – 68 °C. 1H-NMR (400 MHz, CDCl3): δ 7.88 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 
8.3, 2.1 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 4.35 (t, J = 9.6 Hz, 2H), 4.10 (t, J = 7.6 Hz, 
1H), 3.97 (t, J = 9.6 Hz, 2H), 3.61 (s, 3H), 2.05 (dddd, J = 13.4, 10.1, 7.6, 5.0 Hz, 1H), 
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1.74 (dddd, J = 13.2, 9.9, 7.5, 5.5 Hz, 1H), 1.35–1.09 (m, 4H), 0.81 (t, J = 7.1 Hz, 3H). 
13C-NMR (126 MHz, CDCl3): δ 173.2 (Cq), 163.5 (Cq), 138.9 (Cq), 132.8 (CH), 128.2 
(CH), 128.0 (Cq), 127.8 (CH), 127.3 (Cq), 67.6 (CH2), 54.9 (CH2), 52.0 (CH3), 49.8 (CH), 
32.7 (CH2), 29.5 (CH2), 22.4 (CH2), 13.8 (CH3). IR (ATR): 2953, 2872, 1743, 1650, 
1193, 1166, 1078, 909, 731 cm−1. MS (ESI): m/z (relative intensity) 354 (100) [M+H]+. 





The general procedure A was followed using 2-[4-(trifluoromethyl)phenyl]-4,5-
dihydrooxazole 217g (108.1 mg, 0.50 mmol),methyl 2-bromohexanoate 218a (314 mg, 
1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol 
%) and K2CO3 (138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1 → 4/1) yielded 219ga (90.9 mg, 
53%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ 8.16 (dd, J = 1.7, 0.8 Hz, 1H), 7.90 (ddd, J = 8.2, 1.7, 
0.9 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 4.48–4.37 (m, 2H), 4.13–3.96 (m, 3H), 3.64 (s, 
3H), 2.22–2.05 (m, 1H), 1.84–1.67 (m, 1H), 1.41–1.09 (m, 4H), 0.84 (t, J = 7.0 Hz, 3H). 
13C-NMR (126 MHz, CDCl3): δ 173.3 (Cq), 163.2 (Cq), 138.5 (m, Cq), 131.3 (Cq), 130.7 
(q, 2JC-F = 30 Hz, Cq), 128.6 (CH), 126.6 (CH), 125.9 (q, 3JC-F = 6 Hz, CH), 123.8 (q, 
1JC-F = 274 Hz, Cq), 67.8 (CH2), 55.1 (CH2), 52.2 (CH3), 46.4 (CH), 34.2 (CH2), 29.8 
(CH2), 22.4 (CH2), 13.8 (CH3). 19F-NMR (282 MHz, CDCl3): δ –58.7 (s). IR (ATR):  
2955, 1737, 1652, 1310, 1160, 1123, 1038, 980 cm–1. MS (EI): m/z (relative intensity): 
343 (15) [M] +, 287 (100) [M–Bu]+, 284 (90) [M–CO2Me]+, 229 (67). HR-MS (EI): m/z 
calcd for C17H20F3NO3+ [M]+: 343.1390, found: 343.1393. 
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Methyl 2-[3-(4,5-dihydrooxazol-2-yl)-2-fluorophenyl]hexanoate (219ha) 
 
The general procedure A was followed using 2-(2-fluorophenyl)-4,5-dihydrooxazole 
217h (82.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 4/1) yielded 219ha (107.3 mg, 73%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ 7.76 (ddd, J = 7.8, 6.8, 1.8 Hz, 1H), 7.46 (ddd, J = 8.1, 
6.6, 1.8 Hz, 1H), 7.16 (td, J = 7.8, 0.8 Hz, 1H), 4.41 (td, J = 9.4, 1.0 Hz, 2H), 4.17–4.05 
(m, 2H), 3.98 (t, J = 7.6 Hz, 1H), 3.66 (s, 3H), 2.17–1.99 (m, 1H), 1.86–1.67 (m, 1H), 
1.39–1.11 (m, 4H), 0.85 (t, J = 7.1 Hz, 3H). 13C-NMR (125 MHz, CDCl3): δ 173.5 (Cq), 
161.2 (d, 3JC-F = 6 Hz, Cq), 158.7 (d, 1JC-F = 258 Hz, Cq), 131.8 (d, 3JC-F = 5 Hz, CH), 
129.6 (d, 4JC-F = 2 Hz, CH), 127.6 (d, 2JC-F = 15 Hz, Cq), 123.8 (d, 3JC-F = 4 Hz, CH), 
116.1 (d, 2JC-F = 12 Hz, Cq), 67.1 (CH2), 55.3 (CH2), 52.1 (CH3), 43.3 (d, 3JC-F = 4 Hz, 
CH), 32.3 (CH2), 29.6 (CH2), 22.4 (CH2), 13.9 (CH3). 19F-NMR (282 MHz, CDCl3): δ –
115.3 (t, J = 6.7 Hz). IR (ATR): 2956, 1738, 1651, 1455, 1217, 1163, 743 cm–1. MS 
(EI): m/z (relative intensity) 293 (20) [M] +, 234 (100) [M–CO2Me]+. HR-MS (EI): m/z 
calcd for C16H20FNO3+ [M]+: 293.1422, found: 293.1427. 
 
Methyl 2-[3-(4,5-dihydrooxazol-2-yl)-2-ethoxyphenyl]hexanoate (219ia) 
 
The general procedure A was followed using 2-(2-ethoxyphenyl)-4,5-dihydrooxazole 
217i (95.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 1/1) yielded 219ia (79.8 mg, 50%) as a colorless 
oil. 
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1H-NMR (300 MHz, CDCl3): δ 7.64 (dd, J = 7.7, 1.8 Hz, 1H), 7.44 (dd, J = 7.8, 1.8 Hz, 
1H), 7.08 (dd, J = 7.8, 7.7 Hz, 1H), 4.46–4.32 (m, 2H), 4.16–3.85 (m, 5H), 3.62 (s, 3H), 
2.02 (dddd, J = 13.0, 10.2, 8.0, 5.0 Hz, 1H), 1.74–1.58 (m, 1H), 1.39 (t, J = 7.0 Hz, 3H), 
1.35–1.06 (m, 4H), 0.83 (t, J = 7.1 Hz, 3H). 13C-NMR (125 MHz, CDCl3): δ 174.5 (Cq), 
163.3 (Cq), 155.9 (Cq), 134.0 (Cq), 130.8 (CH), 129.9 (CH), 123.7 (CH), 121.8 (Cq), 
70.8 (CH2), 67.3 (CH2), 55.2 (CH2), 51.9 (CH3), 43.5 (CH), 33.4 (CH2), 29.9 (CH2), 22.5 
(CH2), 15.6 (CH3), 13.9 (CH3). IR (ATR): 2916, 2848, 1737, 1465, 1238, 1054, 719 cm–
1. MS (ESI): m/z (relative intensity): 342 (20) [M+Na]+, 320 (100) [M+H]+. HR-MS (ESI): 
m/z calcd for C18H26NO4+ [M+H]+: 320.1856, found: 320.1858. 
 
Methyl 2-[3-(5-methyl-4,5-dihydrooxazol-2-yl)phenyl]hexanoate (221aa) 
 
The general procedure A was followed using 5-methyl-2-phenyl-4,5-dihydrooxazole 
220a (80.5 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1 → 1/1) yielded 221aa (92.5 mg, 64%) as a colorless 
oil. 
1H-NMR (600 MHz, CDCl3, mixture of diastereoisomers, dr 1.0:1.0): δ 7.88–7.84 (m, 
2H), 7.83–7.78 (m, 2H), 7.44–7.39 (m, 2H), 7.36–7.31 (m, 2H), 4.90–4.76 (m, 2H), 
4.18–4.08 (m, 2H), 3.63 (s, 3H), 3.63 (s, 3H), 3.61–3.54 (m, 4H), 2.12–2.03 (m, 2H), 
1.82–1.72 (m, 2H), 1.42–1.39 (m, 6H), 1.35–1.11 (m, 8H), 0.87–0.77 (m, 6H). 13C-NMR 
(126 MHz, CDCl3, mixture of diastereoisomers, dr 1.0:1.0): δ 174.1 (Cq), 163.5 (Cq), 
139.4 (Cq), 130.5 (CH), 130.5 (CH), 128.4 (CH), 128.3 (Cq), 127.7 (CH), 127.7 (CH), 
126.8 (CH), 76.3 (CH), 61.6 (CH2), 51.9 (CH3), 51.5 (CH), 51.5 (CH), 33.2 (CH2), 33.1 
(CH2), 29.7 (CH2), 22.4 (CH2), 21.1 (CH3), 13.9 (CH3). IR (ATR): 2952, 2928, 2869, 
1735, 1646, 1434, 1260, 1068, 994, 712 cm–1. MS (ESI): m/z (relative intensity) 312 
(25) [M+Na]+, 290 (100) [M+H] +. HR-MS (ESI): m/z calcd for C17H24NO3+ [M+H]+: 
290.1751, found: 290.1746. 
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Methyl 2-[3-(5-phenyl-4,5-dihydrooxazol-2-yl)phenyl]hexanoate (221ba) 
 
The general procedure A was followed using 2,5-diphenyl-4,5-dihydrooxazole 220b 
(116.5 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 9/1 → 5/1) yielded 221ba (151.4 mg, 86%) as a 
colorless oil. 
1H-NMR (400 MHz, CDCl3, mixture of diastereoisomers, dr 1.0:1.0): δ 8.00–7.93 (m, 
2H), 7.95–7.87 (m, 2H), 7.51–7.43 (m, 2H), 7.41–7.29 (m, 12H), 5.69–5.60 (m, 2H), 
4.53–4.39 (m, 2H), 4.09–3.92 (m, 2H), 3.65 (s, 3H), 3.64 (s, 3H), 3.65–3.55 (m, 2H), 
2.16–2.04 (m, 2H), 1.87–1.73 (m, 2H), 1.36–1.17 (m, 8H), 0.92–0.81 (m, 6H). 13C-NMR 
(100 MHz, CDCl3, mixture of diastereoisomers, dr 1.0:1.0): δ 174.2 (Cq), 174.1 (Cq), 
163.8 (Cq), 140.9 (Cq), 139.6 (Cq), 130.8 (CH), 130.8 (CH), 128.7 (CH), 128.6 (CH), 
128.2 (CH), 128.0 (CH), 128.0 (CH), 127.9 (Cq), 127.1 (CH), 127.1 (CH), 125.7 (CH), 
125.7 (CH), 81.0 (CH), 63.1 (CH2), 51.9 (CH3), 51.4 (CH), 33.2 (CH2), 33.0 (CH2), 29.7 
(CH2), 29.6 (CH2), 22.3 (CH2), 22.3 (CH2), 13.8 (CH3). IR (ATR): 2953, 2871, 1731, 
1649, 1584, 1493, 1161, 697 cm–1. MS (ESI): m/z (relative intensity) 352 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C22H26NO3+ [M+H]+: 352.1907, found: 352.1908. 
 
Methyl 2-[3-(5,6-dihydro-4H-1,3-oxazin-2-yl)phenyl]hexanoate (221ca) 
 
The general procedure A was followed using 2-phenyl-5,6-dihydro-4H-1,3-oxazine 
220c (80.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1) yielded 221ca (85.4 mg, 59%) as a colorless oil. 
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1H-NMR (600 MHz, CDCl3): δ 7.81 (t, J = 1.6 Hz, 1H), 7.77 (dt, J = 7.6, 1.6 Hz, 1H), 
7.36 (dt, J = 7.8, 1.6 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 4.34 (t, J = 5.5 Hz, 2H), 3.62 (s, 
3H), 3.61–3.53 (m, 3H), 2.14–1.95 (m, 1H), 2.00–1.91 (m, 2H), 1.76 (dddd, J = 13.2, 
9.5, 7.4, 5.7 Hz, 1H), 1.35–1.11 (m, 4H), 0.84 (t, J = 7.2 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3): δ 174.4 (Cq), 155.4 (Cq), 139.1 (Cq), 134.3 (Cq), 129.6 (CH), 128.2 (CH), 126.6 
(CH), 125.7 (CH), 65.1 (CH2), 51.8 (CH3), 51.5 (CH), 42.6 (CH2) 33.2 (CH2), 29.7 (CH2), 
22.4 (CH2), 21.9 (CH2), 13.8 (CH3). IR (ATR): 2952, 2858, 1734, 1653, 1347, 1272, 
1160, 1130, 716 cm−1. MS (ESI): m/z (relative intensity)  290 (100) [M+H]+. HR-MS 
(ESI): m/z calcd for C17H24NO3 [M+H]+: 290.1751, found: 290.1753. 
 
Methyl 2-[3-(4,5-dihydrooxazol-2-yl)phenyl]propanoate (222ab) 
 
The general procedure A was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol) and methyl 2-bromopropanoate 218b (247 mg, 1.50 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 2/1) 
yielded 222ab (93.3 mg, 80%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ 7.85 (t, J = 1.7 Hz, 1H), 7.80 (dt, J = 7.5, 1.7 Hz, 1H), 
7.39 (dt, J = 7.5, 1.7 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 4.39 (t, J = 9.5 Hz, 2H), 4.02 (t, 
J = 9.5 Hz, 2H), 3.73 (q, J = 7.2 Hz, 1H), 3.62 (s, 3H), 1.48 (d, J = 7.2 Hz, 3H). 13C-
NMR (126 MHz, CDCl3): δ 174.4 (Cq), 164.3 (Cq), 140.6 (Cq), 130.2 (CH), 128.5 (CH), 
127.9 (Cq), 127.3 (CH), 126.8 (CH), 67.6 (CH2), 54.9 (CH2), 52.0 (CH3), 45.2 (CH), 
18.5 (CH3). IR (ATR): 2951, 2872, 1733, 1648, 1607, 1251, 1077, 947 cm–1. MS (EI): 
m/z (relative intensity) 233 (40) [M]+, 174 (100) [M–CO2Me]+. HR-MS (EI): m/z calcd 
for C13H15NO3+ [M]+: 233.1046, found: 233.1040. 
 
2,2,2-Trifluoroethyl 2-[3-(4,5-dihydrooxazol-2-yl)phenyl]propanoate (222ac) 
 
The general procedure A was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), 2,2,2-trifluoroethyl 2-bromopropanoate 218c (353 mg, 1.50 mmol), 
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[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5/1) yielded 222ac (116.2 mg, 77%) as a colorless oil. 
1H-NMR (500 MHz, CDCl3): δ 7.89 (t, J = 1.2 Hz, 1H), 7.85 (dt, J = 6.9, 1.2 Hz, 1H), 
7.44–7.33 (m, 2H), 4.60–4.29 (m, 4H), 4.05 (t, J = 9.5 Hz, 2H), 3.86 (q, J = 7.2 Hz, 1H), 
1.56 (d, J = 7.2 Hz, 3H). 13C-NMR (126 MHz, CDCl3): δ 172.4 (Cq), 164.1 (Cq), 139.4 
(Cq), 130.2 (CH), 128.7 (CH), 128.2 (Cq), 127.2 (CH), 127.2 (CH), 122.7 (q, 1JC-F = 277 
Hz, Cq), 67.6 (CH2), 60.5 (q, 2JC-F = 37 Hz, CH2), 54.9 (CH2), 44.9 (CH), 18.3 (CH3). 
19F-NMR (282 MHz, CDCl3): δ –73.9 (t, J = 8.4 Hz). IR (ATR): 2884, 1755, 1650, 1279, 
1163, 976, 949 cm–1. MS (ESI): m/z (relative intensity) 302 [M+H]+.HR-MS (ESI): m/z 
calcd for C14H15F3NO3+ [M+H]+: 302.0999, found: 302.1009. 
 
Methyl 5-bromo-2-[3-(4,5-dihydrooxazol-2-yl)phenyl]pentanoate (222ad) 
 
The general procedure A was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2,5-dibromopentanoate 218d (411 mg, 1.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 8/1 → 5/1) yielded 222ad (107.2 mg, 63%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ 7.91–7.83 (m, 1H), 7.84 (dt, J = 7.6, 1.7 Hz, 1H), 7.42 
(dt, J = 7.6, 1.7 Hz, 1H), 7.37 (dd, J = 7.6, 7.6 Hz, 1H), 4.43 (td, J = 9.5, 0.8 Hz, 2H), 
4.06 (td, J = 9.6, 0.8 Hz, 2H), 3.65 (s, 3H), 3.60 (t, J = 7.6 Hz, 1H), 3.44–3.28 (m, 2H), 
2.23 (dddd, J = 12.5, 9.7, 7.5, 5.0 Hz, 1H), 2.04–1.91 (m, 1H), 1.88–1.69 (m, 2H). 13C-
NMR (126 MHz, CDCl3): δ 173.4 (Cq), 164.2 (Cq), 138.7 (Cq), 130.5 (CH), 128.7 (CH), 
128.2 (Cq), 127.7 (CH), 127.2 (CH), 67.6 (CH2), 55.0 (CH2), 52.2 (CH3), 50.6 (CH), 
32.9 (CH2), 31.9 (CH2), 30.6 (CH2). IR (ATR): 2949, 1730, 1649, 1433, 1358, 1165, 
1068, 710 cm–1. MS (ESI): m/z (relative intensity) 340 (100) [M+H]+. HR-MS (ESI): m/z 
calcd for C15H1979BrNO3 [M+H]+: 340.0543, found: 340.0546. 
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Methyl 2-[2-(4,5-dihydrooxazol-2-yl)-[1,1'-biphenyl]-4-yl]hexanoate (223aa) 
 
The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), bromobenzene 
163a (236 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 50.0 μmol, 10.0 mol 
%), PPh3 (13.1 mg, 50.0 μmol, 10.0 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-
dioxane (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc 5/1: → 1/1) yielded 223aa (123.4 mg, 70%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ 7.68 (dd, J = 2.0, 0.5 Hz, 1H), 7.43 (ddd, J = 7.9, 2.0, 
0.5 Hz, 1H), 7.38–7.27 (m, 6H), 4.15–4.05 (m, 2H), 3.94–3.85 (m, 2H), 3.65 (s, 3H), 
3.58 (t, J = 8.0 Hz, 1H), 2.09 (dddd, J = 13.4, 9.5, 8.1, 5.7 Hz, 1H), 1.80 (dddd, J = 
13.4, 9.2, 8.0, 6.0 Hz, 1H), 1.37–1.16 (m, 4H), 0.86 (t, J = 7.1 Hz, 3H). 13C-NMR (100 
MHz, CDCl3): δ 174.2 (Cq), 165.9 (Cq), 140.8 (Cq), 140.7 (Cq), 138.3 (Cq), 130.6 (CH), 
129.9 (CH), 129.8 (CH), 128.2 (CH), 127.9 (CH), 127.6 (Cq), 127.1 (CH), 67.7 (CH2), 
54.9 (CH2), 51.9 (CH3), 51.1 (CH), 33.1 (CH2), 29.7 (CH2), 22.4 (CH2), 13.8 (CH3). IR 
(ATR): 2953, 2927, 2870, 1734, 1648, 1434, 1348, 1224, 749 cm–1. MS (ESI): m/z 
(relative intensity) 352 (100) [M+H]+. HR-MS (ESI): m/z calcd for C22H26NO3+ [M+H]+: 





The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
bromotoluene 163b (256 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 5/1: → 1/1) 
yielded 223ab (111.0 mg, 61%) as a colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ 7.66 (d, J = 2.0 Hz, 1H), 7.44–7.40 (m, 1H), 7.31 (d, J = 
8.0 Hz, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.16 (d, J = 8.1 Hz, 2H), 4.15–4.08 (m, 2H), 3.90 
(t, J = 9.5 Hz, 2H), 3.65 (s, 3H), 3.57 (t, J = 7.7 Hz, 1H), 2.36 (s, 3H), 2.09 (dddd, J = 
13.3, 9.4, 7.7, 5.7 Hz, 1H), 1.79 (dddd, J = 13.3, 9.2, 7.7, 6.0 Hz, 1H), 1.40–1.16 (m, 
4H), 0.86 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ 174.2 (Cq), 166.0 (Cq), 
140.6 (Cq), 138.0 (Cq), 137.9 (Cq), 136.8 (Cq), 130.6 (CH), 129.9 (CH), 129.8 (CH), 
128.7 (CH), 128.1 (CH), 127.6 (Cq), 67.8 (CH2), 54.9 (CH2), 51.9 (CH3), 51.1 (CH), 
33.1 (CH2), 29.7 (CH2), 22.4 (CH2), 21.1 (CH3), 13.8 (CH3). IR (ATR): 2952, 2871, 
1733, 1650, 1484, 1434, 1348, 1162, 817 cm–1. MS (ESI): m/z (relative intensity) 366 






The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 1-bromo-4-
tert-butylbenzene 163c (319 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 
mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 5/1 → 1/1) 
yielded 223ac (124.2 mg, 61%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): 7.67 (d, J = 1.9 Hz, 1H), 7.44 (dd, J = 8.0, 1.9 Hz, 1H), 
7.39 (d, J = 8.7 Hz, 2H), 7.34 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.7 Hz, 2H), 4.15–4.09 
(m, 2H), 3.96–3.89 (m, 2H), 3.67 (s, 3H), 3.59 (t, J = 7.7 Hz, 1H), 2.11 (dddd, J = 13.4, 
9.3, 8.1, 5.7 Hz, 1H), 1.81 (dddd, J = 13.4, 9.2, 7.3, 6.0 Hz, 1H), 1.35 (s, 9H), 1.34–
1.18 (m, 4H), 0.88 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3): 174.2 (Cq), 166.1 
(Cq), 150.0 (Cq), 140.6 (Cq), 138.0 (Cq), 137.8 (Cq), 130.6 (CH), 129.8 (CH), 129.7 
(CH), 127.8 (CH), 127.6 (Cq), 124.9 (CH), 67.8 (CH2), 54.9 (CH2), 51.9 (CH3), 51.1 
(CH), 34.5 (Cq), 33.2 (CH2), 31.3 (CH3), 29.7 (CH2), 22.4 (CH2), 13.8 (CH3). IR (ATR): 
2954, 2862, 1736, 1650, 1485, 1191, 1112, 827 cm−1. MS (ESI): m/z (relative intensity) 
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837 (15) [2M+Na]+, 815 (15) [2M+H]+, 408 (100) [M+H]+. HR-MS (ESI): m/z calcd for 





The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
bromoanisole 163d (280 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 1/1) 
yielded 223ad (139.4 mg, 73%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ 7.64 (d, J = 1.9 Hz, 1H), 7.41 (dd, J = 8.0, 1.9 Hz, 1H), 
7.35–7.19 (m, 3H), 6.89 (d, J = 8.8 Hz, 2H), 4.20–4.06 (m, 2H), 3.90 (td, J = 9.6, 1.3 
Hz, 2H), 3.81 (s, 3H), 3.64 (s, 3H), 3.57 (t, J = 7.7 Hz, 1H), 2.16–2.00 (m, 1H), 1.89–
1.71 (m, 1H), 1.38–1.15 (m, 4H), 0.86 (t, J = 7.0 Hz, 3H). 13C-NMR (126 MHz, CDCl3): 
δ 174.1 (Cq), 165.9 (Cq), 158.8 (Cq), 140.2 (Cq), 137.8 (Cq), 133.2 (Cq), 130.4 (CH), 
129.8 (CH), 129.8 (CH), 129.3 (CH), 127.5 (Cq), 113.4 (CH), 67.8 (CH2), 55.2 (CH3), 
55.0 (CH2), 52.0 (CH3), 51.1 (CH), 33.2 (CH2), 29.8 (CH2), 22.5 (CH2), 13.9 (CH3). IR 
(ATR): 2952, 2871, 1732, 1649, 1608, 1246, 1177, 1162, 828 cm−1. MS (ESI): m/z 
(relative intensity) 382 (100) [M+H]+. HR-MS (ESI): m/z calcd for C23H28NO4+ [M+H]+: 





The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 1-bromo-4-
fluorobenzene 163e (263 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
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%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 5:1 → 3:1) 
yielded 223ae (120.2 mg, 65%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ 7.68 (d, J = 2.0 Hz, 1H), 7.43 (dd, J = 8.0, 2.0 Hz, 1H), 
7.34–7.22 (m, 3H), 7.08–6.99 (m, 2H), 4.17–4.07 (m, 2H), 3.94–3.83 (m, 2H), 3.65 (s, 
3H), 3.58 (t, J = 7.7 Hz, 1H), 2.16–2.01 (m, 1H), 1.90–1.71 (m, 1H), 1.39–1.14 (m, 4H), 
0.86 (t, J = 7.0 Hz, 3H). 13C-NMR (126 MHz, CDCl3): δ 174.0 (Cq), 165.5 (Cq), 162.1 
(d, 1JC-F = 246 Hz, Cq), 139.6 (Cq), 138.4 (Cq), 136.8 (d, 4JC-F = 3 Hz, Cq), 130.5 (CH), 
129.8 (d, 3JC-F = 8 Hz, CH), 129.8 (CH), 129.8 (CH), 127.6 (Cq), 114.8 (d, 2JC-F = 22 
Hz, CH), 67.7 (CH2), 55.0 (CH2), 52.0 (CH3), 51.1 (CH), 33.2 (CH2), 29.8 (CH2), 22.5 
(CH2), 13.9 (CH3). 19F-NMR (282 MHz, CDCl3): δ – 115.6 (tt, J = 8.8, 5.4 Hz). IR (ATR): 
2954, 2873, 1734, 1650, 1485, 1350, 1221, 1192, 830 cm−1. MS (ESI): m/z (relative 
intensity): 392 (5) [M+Na]+, 370 (100) [M+H]+. HR-MS (ESI): m/z calcd for C22H25FNO3+ 





The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 1-bromo-3,5-
difluorobenzene 163f (289 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 
mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 3/1) 
yielded 223af (114.3 mg, 59%) as a colorless oil. 
M.p.: 99 – 100 °C. 1H-NMR (400 MHz, CDCl3): δ 7.71 (d, J = 1.9 Hz, 1H), 7.45 (dd, J 
= 8.0, 2.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 6.98–6.81 (m, 2H), 6.76 (tt, J = 9.0, 2.3 Hz, 
1H), 4.21–4.11 (m, 2H), 3.92 (td, J = 9.5, 0.9 Hz, 2H), 3.65 (s, 3H), 3.58 (t, J = 7.7 Hz, 
1H), 2.09 (dddd, J = 13.1, 9.4, 7.8, 5.5 Hz, 1H), 1.79 (dddd, J = 13.4, 9.1, 7.4, 5.9 Hz, 
1H), 1.40–1.12 (m, 4H), 0.86 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ 174.0 
(Cq), 165.0 (Cq), 162.6 (dd, 1,3JC-F = 248, 13 Hz, Cq), 144.2 (t, 3,3JC-F J = 10 Hz, Cq), 
139.4 (Cq), 138.4 (t, 4,4JC-F J = 2 Hz, Cq), 130.3 (CH), 130.1 (CH), 130.0 (CH), 127.6 
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(Cq), 111.4 (dd, 2,4JC-F = 18.7, 6.9 Hz, CH), 102.6 (t, 2,2JC-F = 25 Hz, CH), 67.9 (CH2), 
55.1 (CH2), 52.1 (CH3), 51.1 (CH), 33.2 (CH2), 29.7 (CH2), 22.4 (CH2), 13.8 (CH3). 19F-
NMR (376 MHz, CDCl3): δ (– 110.5) – (– 110.6) (m). IR (ATR): 2955, 2930, 1736, 1623, 
1594, 1162, 1045, 987 cm−1. MS (ESI): m/z (relative intensity) 410 (15) [M+Na]+, 388 






The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
iodobenzotrifluoride 163g (408 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 
10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane 
(2.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 
3/1) yielded 223ag (134.2 mg, 64%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ 7.75 (d, J = 1.9 Hz, 1H), 7.62 (dt, J = 8.0, 0.7 Hz, 2H), 
7.52 – 7.42 (m, 3H), 7.30 (d, J = 8.0 Hz, 1H), 4.12 (t, J = 9.7 Hz, 2H), 3.90 (t, J = 9.7 
Hz, 2H), 3.67 (s, 3H), 3.61 (t, J = 7.7 Hz, 1H), 2.12 (dtd, J = 10.0, 8.1, 5.2 Hz, 1H), 
1.88–1.76 (m, 1H), 1.43–1.20 (m, 4H), 0.87 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3): δ 174.1 (Cq), 165.2 (Cq), 144.6 (Cq), 139.3 (Cq), 139.1 (Cq), 130.5 (CH), 130.1 
(CH), 129.9 (CH), 129.2 (q, 2JC-F J = 33 Hz, Cq), 128.6 (CH), 127.5 (Cq), 124.8 (q, 3JC-
F = 4 Hz, CH), 124.2 (q, 1JC-F = 272 Hz, Cq), 67.8 (CH2), 55.0 (CH2), 52.0 (CH3), 51.1 
(CH), 33.2 (CH2), 29.7 (CH2), 22.4 (CH2), 13.8 (CH3). 19F-NMR (376 MHz, CDCl3): δ – 
62.4 (s). IR (ATR): 2953, 2872, 1734, 1647, 1323, 1160, 1122, 1084, 1021, 831 cm−1. 
MS (ESI): m/z (relative intensity) 442 (12) [M+Na]+, 420 [M+H]+. HR-MS (ESI): m/z 
calcd for C23H25F3NO3+ [M+H]+: 420.1781, found: 420.1781. 
  






The general procedure B was followed using 2-phenyl-4,5-dihydrooxazole 217a (73.5 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 1,3-
bis(trifluoromethyl)-5-bromobenzene 163h (439 mg, 1.50 mmol), [Ru(O2CMes)2(p-
cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 
mmol) in 1,4-dioxane (2.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 5/1 → 4/1) yielded 223ah (122.2 mg, 50%) as a white solid. 
M.p.: 96 – 98 °C. 1H-NMR (300 MHz, CDCl3): δ 7.84 (s, 1H), 7.83–7.80 (m, 3H), 7.52 
(dd, J = 8.0, 2.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 4.22–4.10 (m, 2H), 3.99–3.85 (m, 
2H), 3.68 (s, 3H), 3.63 (t, J = 7.7 Hz, 1H), 2.13 (dddd, J = 13.3, 9.3, 7.7, 5.8 Hz, 1H), 
1.83 (dddd, J = 13.5, 9.1, 7.7, 6.0 Hz, 1H), 1.41–1.16 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ 173.8 (Cq), 164.4 (Cq), 142.8 (Cq), 140.0 (Cq), 137.5 
(Cq), 131.1 (q, 2JC-F = 33 Hz, Cq), 130.5 (CH), 130.4 (CH), 130.2 (Cq), 123.3 (q, 1JC-F = 
272 Hz, Cq), 128.7 (CH), 127.6 (CH),  120.8 (sept, 3JC-F = 3.9 Hz, CH),  67.8 (CH2), 
55.1 (CH2), 52.1 (CH3), 51.2 (CH), 33.2 (CH2), 29.8 (CH2), 22.5 (CH2), 13.9 (CH3). 19F-
NMR (282 MHz, CDCl3): δ – 62.8 (s). IR (ATR): 2957, 2932, 1737, 1380, 1277, 1169, 
1131, 898, 681 cm−1. MS (ESI): m/z (relative intensity) 510 (38) [M+Na]+, 488 (100) 





The general procedure B was followed using 5-methyl-2-phenyl-4,5-dihydrooxazole 
220a (80.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
bromoanisole 163d (280 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
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mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 3/1) 
yielded 224aa (150.3 mg, 76%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3, mixture of diastereoisomers, dr 1.0:1.0): δ 7.66–7.63 (m, 
2H), 7.45–7.39 (m, 2H), 7.32–7.27 (m, 6H), 6.92–6.88 (m, 4H), 4.62–4.53 (m, 2H), 
4.05–3.97 (m, 2H), 3.86–3.81 (m, 6H), 3.68–3.64 (m, 6H), 3.61–3.56 (m, 2H), 3.51–
3.43 (m, 2H), 2.20–2.00 (m, 2H), 1.85–1.75 (m, 2H), 1.44–1.20 (m, 8H), 1.17 (d, J = 
6.0 Hz, 3H), 1.16 (d, J = 5.9 Hz, 3H), 0.91–0.84 (m, 6H). 13C-NMR (126 MHz, CDCl3, 
mixture of diastereoisomers, dr 1.0:1.0): δ 174.1 (Cq), 174.1 (Cq), 165.1 (Cq), 158.8 
(Cq), 140.2 (Cq), 137.8 (Cq), 133.2 (Cq), 130.5 (CH), 130.5 (CH), 129.7 (CH), 129.7 
(CH), 129.6 (CH), 129.5 (CH), 129.5 (CH), 128.0 (Cq), 127.9 (Cq), 113.3 (CH), 76.3 
(CH), 61.7 (CH2), 55.3 (CH3), 52.0 (CH3), 51.1 (CH), 33.2 (CH2), 33.2 (CH2), 29.8 
(CH2), 22.5 (CH2), 20.8 (CH3), 13.9 (CH3). IR (ATR): 2928, 1733, 1650, 1608, 1519, 
1245, 1176, 1162, 1037, 827 cm−1. MS (ESI): m/z (relative intensity) 813 (21) 
[2M+Na]+, 791 (18) [2M+H]+, 418 (17) [M+Na]+, 396 (100) [M+H]+. HR-MS (ESI): m/z 





The general procedure B was followed using 2-phenyl-5,6-dihydro-4H-1,3-oxazine 
220c (80.6 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
bromoanisole 163d (280 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 2/1) 
yielded 224ca (104.4 mg, 57%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ 7.46 (d, J = 2.0 Hz, 1H), 7.39–7.30 (m, 2H), 7.25 (d, J = 
8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 3.94–3.85 (m, 2H), 3.81 (s, 3H), 3.62 (s, 3H), 
3.54 (t, J = 7.7 Hz, 1H), 3.47 (t, J = 5.9 Hz, 2H), 2.07 (dddd, J = 13.3, 9.3, 8.2, 5.6 Hz, 
1H), 1.88–1.72 (m, 3H), 1.37–1.16 (m, 4H), 0.85 (t, J = 7.1 Hz, 3H). 13C-NMR (101 
MHz, CDCl3): δ 174.4 (Cq), 158.6 (Cq), 158.4 (Cq), 139.1 (Cq), 137.8 (Cq), 134.6 (Cq), 
133.8 (Cq), 130.1 (CH), 129.2 (CH), 129.0 (CH), 128.7 (CH), 113.4 (CH), 65.0 (CH2), 
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55.2 (CH3), 51.9 (CH3), 51.1 (CH), 42.7 (CH2), 33.2 (CH2), 29.8 (CH2), 22.4 (CH2), 21.5 
(CH2), 13.8 (CH3). IR (ATR): 2952, 2857, 1732, 1656, 1464, 1246, 1176, 827, 731 
cm−1. MS (ESI): m/z (relative intensity) 813 (12) [2M+Na]+, 791 (30) [2M+H]+, 396 (100) 





The general procedure B was followed using 2-(4-methoxyphenyl)-4,5-dihydrooxazole 
217c (88.5 mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
bromoanisole 163d (280 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). The first step was performed at 60 °C Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 5/1 → 2/1) yielded 225ca (156.2 mg, 76%) as a colorless 
oil. 
1H-NMR (300 MHz, CDCl3): δ 7.66 (s, 1H), 7.29 (dm, J = 8.9 Hz, 2H), 6.90 (dm, J = 
8.9 Hz, 2H), 6.79 (s, 1H), 4.16–4.04 (m, 2H), 3.98 (t, J = 7.5 Hz, 1H), 3.92–3.84 (m, 
5H), 3.82 (s, 3H), 3.64 (s, 3H), 2.08 (dddd, J = 13.4, 9.1, 7.5, 3.0 Hz, 1H), 1.76 (dddd, 
J = 13.4, 9.3, 7.5, 5.7 Hz, 1H), 1.40–1.19 (m, 4H), 0.87 (t, J = 7.0 Hz, 3H). 13C-NMR 
(126 MHz, CDCl3): δ 174.3 (Cq), 165.6 (Cq), 158.8 (Cq), 158.0 (Cq), 141.7 (Cq), 133.7 
(Cq), 130.4 (CH), 129.2 (CH), 126.6 (Cq), 119.6 (Cq), 113.3 (CH), 112.3 (CH), 67.4 
(CH2), 55.7 (CH3), 55.1 (CH3), 54.9 (CH2), 51.8 (CH3), 43.7 (CH), 32.0 (CH2), 29.7 
(CH2), 22.5 (CH2), 13.9 (CH3). IR (ATR): 2956, 2853, 1733, 1608, 1494, 1245, 1225, 
1173, 908, 728 cm−1. MS (ESI): m/z (relative intensity) 412 (100) [M+H]+. HR-MS (ESI): 
m/z calcd for C24H30NO5+ [M+H]+ 412.2118, found 412.2119. 
  






The general procedure B was followed using 2-(p-tolyl)-4,5-dihydrooxazole 217b (80.6 
mg, 0.50 mmol), methyl 2-bromohexanoate 218a (314 mg, 1.50 mmol), 4-
bromoanisole 163a (280 mg, 1.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol 
%), PPh3 (13.1 mg, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) in 1,4-dioxane (2.0 
mL). The first step was performed at 60 °C. Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 5/1 → 2/1) yielded 225ba (103.2 mg, 52%) as a colorless 
oil. 
1H-NMR (600 MHz, CDCl3): δ 7.68 (s, 1H), 7.29 (d, J = 8.8 Hz, 2H), 7.16 (s, 1H), 6.90 
(d, J = 8.8 Hz, 2H), 4.18–4.09 (m, 2H), 3.91 (ddd, J = 10.3, 9.1, 1.9 Hz, 2H), 3.86–3.79 
(m, 4H), 3.66 (s, 3H), 2.41 (s, 3H), 2.23–2.09 (m, 1H), 1.77 (dddd, J = 13.4, 9.6, 6.9, 
5.5 Hz, 1H), 1.41–1.21 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). 13C-NMR (126 MHz, CDCl3): 
δ 174.2 (Cq), 165.9 (Cq), 158.7 (Cq), 139.8 (Cq), 138.6 (Cq), 136.4 (Cq), 133.4 (Cq), 
132.3 (CH), 129.3 (CH), 128.7 (CH), 125.4 (Cq), 113.4 (CH), 67.6 (CH2), 55.2 (CH3), 
55.0 (CH2), 52.0 (CH3), 46.7 (CH), 32.8 (CH2), 30.0 (CH2), 22.6 (CH2), 19.9 (CH3), 14.0 
(CH3). IR (ATR): 2953, 2872, 1733, 1609, 1457, 1244, 1174, 1032, 832 cm−1. MS (ESI): 
m/z (relative intensity) 396 [M+H]+. HR-MS (ESI): m/z calcd for C24H30NO4+ [M+H]+: 
396.2169, found: 396.2171. 
 
3-(1-Carboxypentyl)benzoic acid (226) 
 
Methyl 2-[3-(4,5-dihydrooxazol-2-yl)phenyl]hexanoate 219aa (412.5 mg, 1.50 mmol) 
was placed in a round bottom flask and aqueous HCl (6M, 10 mL) was added. The 
resulting solution was stirred at 105 °C for 20 h. At ambient temperature, the solution 
was extracted with Et2O (3 × 20 mL). The combined organic layers were washed with 
brine (20 ml), dried over Na2SO4 and the filtrate was concentrated in vacuo to afford 
226 (315.0 mg, 89%) as a white solid. 
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M.p.: 117 – 121 °C. 1H-NMR (400 MHz, DMSO-d6): δ 12.61 (br s, 2H), 7.87 (t, J = 1.6 
Hz, 1H), 7.83 (dt, J = 7.6, 1.6 Hz, 1H), 7.54 (dt, J = 7.6, 1.6 Hz, 1H), 7.45 (t, J = 7.6 
Hz, 1H), 3.59 (t, J = 7.6 Hz, 1H), 1.96 (dddd, J = 13.0, 9.9, 7.6, 5.1 Hz, 1H), 1.65 (dddd, 
J = 13.0, 9.5, 7.6, 5.5 Hz, 1H), 1.35–1.05 (m, 4H), 0.82 (t, J = 7.2 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6): δ 174.6 (Cq), 167.3 (Cq), 140.3 (Cq), 132.4 (CH), 131.0 
(Cq), 128.8 (CH), 128.6 (CH), 127.9 (CH), 50.6 (CH), 32.7 (CH2), 29.2 (CH2), 21.9 
(CH2), 13.8 (CH3). IR (ATR): 2957, 1691, 1606, 1587, 1282, 1195, 1109, 929, 733 
cm−1. MS (ESI): m/z (relative intensity) 471 (35) [2M–H]–, 235 (25) [M–H]–, 191 (100) 
[M–CO2H]– HR-MS (ESI): m/z calcd for C13H15O4- [M–H]–: 235.0976, found: 235.0977. 
 
5.3.2. Mechanistic Studies 
 
5.3.2.1. Intermolecular Competition Experiments 
 
 
Oxazoline 217d (82.6 mg, 0.50 mmol), oxazoline 217b (88.6 mg, 0.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) were placed in a Schlenk tube. The tube was evacuated and 
purged with N2 for three times. 1,4-Dioxane (2.0 mL) and alkyl bromide 218a (104 mg, 
0.50 mmol) were then added and the mixture was stirred at 60 °C. After 20 h, the 
resulting mixture was filtered through silica gel pad and washed with EtOAc. The filtrate 
was concentrated in vacuo. Yields of products were determined by 1H-NMR 
spectroscopy using CH2Br2 (86.9 mg, 0.50 mmol) as internal standard. 






Oxazoline 217g (107.6 mg, 0.50 mmol), oxazoline 217c (80.6 mg, 0.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 1.00 mmol) were placed in a Schlenk tube. The tube was evacuated and 
purged with N2 for three times. 1,4-Dioxane (2.0 mL) and alkyl bromide 218a (104 mg, 
0.50 mmol) were then added and the mixture was stirred at 60 °C. After 20 h, the 
resulting mixture was filtered through silica gel pad and washed with EtOAc. The filtrate 
was concentrated in vacuo. Yields of products were determined by 1H-NMR 
spectroscopy using CH2Br2 (86.9 mg, 0.50 mmol) as internal standard. 
CH2Br2 219da 
219ba 





5.3.2.2. H/D Exchange Study 
 
Oxazoline 217a (73.5 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 50.0 μmol, 
10.0 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed 
in a pre-dried 25 mL schlenk tube. were placed in a Schlenk tube. The tube was 
evacuated and purged with N2 for three times. 1,4-Dioxane (2.0 mL), alkyl bromide 
218a (314 mg, 1.50 mmol) and CD3OD (90.1 mg, 2.50 mmol) were then added and 
the mixture was stirred at 60 °C. After 4 h, Purification by column chromatography on 
silica gel (n-hexane/EtOAc 10:1) yielded [D]n-217a (31.5 mg, 42%) and [D]n-219aa 
(73.5 mg, 53%). The H/D exchange result was determined by 1H-NMR spectroscopy. 
219ca 219ga 
CH2Br2 
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5.3.2.3. Intermolecular KIE by One-Pot Procedure 
 
 
Oxazoline 217a (73.6 mg, 0.50 mmol), [D]5-219aa (76.1 mg, 0.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), PPh3 (13.1 mg, 10 mol %) and K2CO3 
(138 mg, 2.00 mmol) were placed in a Schlenk tube. The tube was evacuated and 
purged with N2 for three times. 1,4-Dioxane (2.0 mL) and alkyl bromide 218a (314 mg, 
1.50 mmol) were then added and the mixture was stirred at 60 °C. After 20 h, the 
resulting mixture was filtered through silica gel pad and washed with EtOAc. The filtrate 
was concentrated in vacuo. Purification by column chromatography on silica gel (n-
hexane/EtOAc 5:1 to 3:1) yielded 219aa and [D]4-219aa. (191.4 mg, 69%). The kinetic 
isotope effect of this reaction was determined to be kH/kD = 1.27 as estimated by 1H-
NMR spectroscopy. 




5.3.2.4. Intermolecular KIE by Independent Experiments 
 
 
Two parallel reactions of 218a with 217aa or [D]5-217aa were performed to determine 
the corresponding KIE value. The general procedure A was followed using 217a (147.1 
mg, 1.00 mmol) or [D]5-217aa (152.2 mg, 1.00 mmol), 218a (630 mg, 3.00 mmol), 
[Ru(O2CMes)2(p-cymene)] (56.2 mg, 10 mol %), PPh3 (26.2 mg, 10 mol %), K2CO3 
(276 mg, 2.0 mmol), 1,3,5-trimethoxybenzene (168.2 mg, 1.00 mmol) as internal 
standard and 1,4-dioxane (4.0 mL). The mixture was stirred at 60 °C, and a periodic 
aliquot (0.10 mL) was removed by syringe and analyzed by 1H-NMR to determine the 
following conversions: 
5. Experimental Part 
 
178 
             t 
(min)     
yield (%) 
10 20 30 40 50 
219aa 5 16 23 29 36 
[D]4-219aa 6 14 23 29 34 
 
  
  5. Experimental Part 
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5.4. Palladium-Catalyzed C(sp2)–H and C(sp3)–H Late-Stage Glycosylation 
 






The general procedure C was followed using N-[2-(1-butyl-1H-1,2,3-triazol-4-
yl)propan-2-yl]-2-methylbenzamide 234a (30 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(OAc)2 (2.2 mg, 10 mol 
%), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 9:1 → 8:2) yielded 236a (87 mg, 95%) 
as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 7.57 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.21 (dd, J = 7.7, 
7.7 Hz, 1H), 7.10 (d, J = 7.7 Hz, 1H), 6.22 (s, 1H), 5.44 (d, J = 4.4 Hz, 1H), 4.42 (dd, J 
= 8.2, 4.4 Hz, 1H), 4.32 (t, J = 7.3 Hz, 2H), 4.23 – 4.06 (m, 3H), 3.84 (dd, J = 11.2, 4.3 
Hz, 1H), 2.20 (s, 3H), 1.94 – 1.81 (m, 5H), 1.73 (s, 3H), 1.43 – 1.30 (m, 2H), 1.11 – 
1.01 (m, 63H), 0.95 (t, J = 7.4 Hz, 3H).13C NMR (101 MHz, CDCl3): δ 169.2 (Cq), 153.0 
(Cq), 148.1 (Cq), 135.7 (Cq), 135.0 (Cq), 133.4 (Cq), 130.1 (CH), 128.1 (CH), 126.3 
(CH), 120.5 (CH), 101.7 (CH), 81.0 (CH), 71.1 (CH), 67.1 (CH), 60.9 (CH2), 51.6 (Cq), 
50.0 (CH2), 32.3 (CH2), 28.4 (CH3), 26.9 (CH3), 19.7 (CH2), 18.9 (CH3), 18.2 (CH3), 
18.2 (CH3), 18.1 (CH3), 18.1 (CH3), 18.0 (CH3), 13.5 (CH3), 12.5 (CH), 12.3 (CH), 12.0 
(CH). (One CH3 resonance of the TIPS group is missing due to overlap, the overlap 
was verified by analysis of the HSQC spectrum). IR (ATR): 2942, 2865, 1660, 1462, 
1383, 1050, 1012, 881, 680 cm–1. MS (ESI): m/z (relative intensity) 936 (100) [M+Na]+, 
913 (62) [M+H]+. HR-MS (ESI): m/z calcd for C50H93N4O5Si3+ [M+H]+: 913.6448 found: 
913.6441. 
  







The general procedure C was followed using N-[2-(1-butyl-1H-1,2,3-triazol-4-
yl)propan-2-yl]-2-fluorobenzamide 234b (30 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(OAc)2 (2.2 mg, 10 mol 
%), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 9:1) yielded 236b (85 mg, 92%) as a 
colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.32 (ddd, J = 7.9, 
7.4, 5.8 Hz, 1H), 7.05 (dd, J = 9.1, 7.4 Hz, 1H), 6.26 (s, 1H), 5.52 (d, J = 4.6 Hz, 1H), 
4.45 (dd, J = 7.9, 4.6 Hz, 1H), 4.34 (t, J = 7.4 Hz, 2H), 4.22 – 4.10 (m, 3H), 3.87 (dd, J 
= 11.3, 4.4 Hz, 1H), 1.96 – 1.85 (m, 5H), 1.74 (s, 3H), 1.40 (tq, J = 7.9, 7.4 Hz, 2H), 
1.14 – 1.02 (m, 63H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 164.3 
(Cq), 159.3 (d, 1JC-F = 245.5 Hz, Cq), 153.0 (Cq), 147.2 (d, 4JC-F = 3.0 Hz, Cq), 135.8 (d, 
3JC-F = 3.8 Hz, Cq), 129.8 (d, 3JC-F = 8.8 Hz, CH) 124.4 (d, 2JC-F = 19.9 Hz, Cq), 124.4 
(d, 4JC-F = 3.0 Hz, CH), 120.3 (d, 7JC-F = 2.9 Hz, CH), 115.4 (d, 2JC-F = 22.1 Hz, CH), 
102.3 (CH), 81.2 (CH), 70.6 (CH), 66.8 (CH), 60.9 (CH2), 52.7 (Cq), 50.0 (CH2), 32.2, 
(CH2) 29.1 (CH3), 27.3 (CH3), 19.7 (CH2), 18.2 (CH3), 18.2 (CH3), 18.1 (CH3), 18.1 
(CH3), 18.0 (CH3), 18.0 (CH3), 13.5 (CH3), 12.5 (CH), 12.4 (CH), 12.0 (CH).19F NMR 
(282 MHz, CDCl3): δ – 117.5 (s). IR (ATR): 2942, 2865, 1673, 1508, 1461, 1082, 1052, 
881, 758, 679 cm–1. MS (ESI): m/z (relative intensity) 940 (100) [M+Na]+, 917 (55) 
[M+H]+. HR-MS (ESI): m/z calcd for C49H90N4O5Si3F+ [M+H]+: 917.6198 found: 
917.6188. 
  







The general procedure C was followed using N-[2-(1-butyl-1H-1,2,3-triazol-4-
yl)propan-2-yl]-2-(trifluoromethyl)benzamide 234c (35 mg, 0.10 mmol), [({2R,3R,4R}-
6-iodo-2-{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(OAc)2 (2.2 mg, 10 mol 
%), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 9:1) yielded 236c (91 mg, 94%) as a 
colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.99 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.59 
(s, 1H), 7.46 (dd, J = 7.9, 7.9 Hz, 1H), 6.45 (s, 1H), 5.55 (d, J = 4.6 Hz, 1H), 4.47 – 
4.41 (m, 1H), 4.40 – 4.22 (m, 3H), 4.17 (d, J = 4.7 Hz, 1H), 4.08 (s, 1H), 3.81 (d, J = 
11.3 Hz, 1H), 1.94 – 1.85 (m, 5H), 1.79 (s, 3H), 1.39 (tq, J = 7.5, 7.5 Hz, 2H), 1.14 – 
1.07 (m, 63H), 0.98 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 165.6 (Cq), 152.7 
(Cq), 146.5 (Cq), 135.8 (Cq), 133.9 (q, 3JC-F = 1.6 Hz, Cq), 133.5 (CH), 128.5 (CH), 127.4 
(q, 2JC-F = 31.3 Hz, Cq), 126.0 (q, 3JC-F = 4.9 Hz, CH), 123.7 (q, 1JC-F = 274.4 Hz, Cq), 
120.2 (CH), 103.4 (CH), 81.2 (CH), 71.1 (CH), 66.9 (CH), 60.6 (CH2), 52.7 (Cq), 50.0 
(CH2), 32.2 (CH2), 28.2 (CH3), 27.2 (CH3), 19.7 (CH2), 18.2 (CH3), 18.1 (CH3), 18.1 
(CH3), 18.1 (CH3), 18.0 (CH3), 18.0 (CH3), 13.4 (CH3), 12.4 (CH), 12.3 (CH), 11.9 (CH). 
19F NMR (376 MHz, CDCl3): δ – 58.5 (s). IR (ATR): 2942, 2865, 1664, 1320, 1133, 
1075, 1058, 881, 734, 673 cm–1. MS (ESI): m/z (relative intensity) 990 (100) [M+Na]+, 
967 (34) [M+H]+. HR-MS (ESI): m/z calcd for C50H90N4O5Si3F3+ [M+H]+: 967.6166 
found: 967.6150. 
  







The general procedure C was followed using N-[2-(1-butyl-1H-1,2,3-triazol-4-
yl)propan-2-yl]thiophene-2-carboxamide 234e (29 mg, 0.10 mmol), [({2R,3R,4R}-6-
iodo-2-{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(OAc)2 (2.2 mg, 10 mol 
%), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 8:1 → 8:2) yielded 236e (79 mg, 87%) 
as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.33 (s, 1H), 7.54 (s, 1H), 7.34 (d, J = 5.1 Hz, 1H), 7.11 
(d, J = 5.1 Hz, 1H), 5.38 (d, J = 5.0 Hz, 1H), 4.58 – 4.49 (m, 1H), 4.28 (t, J = 7.4 Hz, 
2H), 4.24 – 4.12 (m, 3H), 3.91 (dd, J = 11.4, 3.8 Hz, 1H), 1.94 – 1.76 (m, 8H), 1.37 (q, 
J = 7.6 Hz, 2H), 1.15 – 0.96 (m, 63H), 0.95 (t, J = 7.6 Hz, 3H). 13C NMR (101 MHz, 
CDCl3): δ = 161.0 (Cq), 152.5 (Cq), 146.6 (Cq), 138.7 (Cq), 134.6 (Cq), 130.3 (CH), 128.2 
(CH), 121.0 (CH), 102.7 (CH), 82.2 (CH), 69.5 (CH), 65.8 (CH), 61.7 (CH2), 51.8 (Cq), 
49.9 (CH2), 32.2 (CH2), 28.8 (CH3), 28.6 (CH3), 19.8 (CH2), 18.1 (CH3), 18.1 (CH3), 
17.9 (CH3), 17.9 (CH3), 13.5 (CH3), 12.5 (CH), 12.4 (CH), 11.9 (CH). (2 CH3 
resonances of the TIPS groups are missing due to overlap, the overlap was verified by 
analysis of the HSQC spectrum). IR (ATR): 2942, 2865, 1649, 1462, 1300, 1060, 1012, 
881, 680 cm–1. MS (ESI): m/z (relative intensity) 928 (100) [M+Na]+, 905 (23) [M+H]+. 
HR-MS (ESI): m/z calcd for C47H89N4O5Si3S+ [M+H]+: 905.5856 found: 905.5857. 
  







The general procedure C was followed using N-[2-(1-butyl-1H-1,2,3-triazol-4-
yl)propan-2-yl]furan-2-carboxamide 234f (28 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(OAc)2 (2.2 mg, 10 mol 
%), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 9:1 → 8:2) yielded 26f (48 mg, 54%) 
as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.44 (s, 1H), 7.56 (s, 1H), 7.40 (d, J = 1.8 Hz, 1H), 6.52 
(d, J = 1.8 Hz, 1H), 5.57 (dd, J = 5.4, 1.5 Hz, 1H), 4.57 – 4.43 (m, 1H), 4.26 (t, J = 7.4 
Hz, 2H), 4.20 – 4.07 (m, 3H), 3.85 (dd, J = 11.5, 3.5 Hz, 1H), 1.92 – 1.77 (m, 8H), 1.35 
(tq, J = 7.4, 7.4 Hz, 2H), 1.10 – 0.96 (m, 63H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ 157.8 (Cq), 152.7 (Cq), 143.6 (Cq), 143.4 (Cq), 143.0 (CH), 122.8 (Cq), 
121.2 (CH), 111.8 (CH), 102.2 (CH), 82.3 (CH), 69.3 (CH), 65.6 (CH), 61.8 (CH2), 51.6 
(Cq), 49.9 (CH2), 32.3 (CH2), 28.6 (CH3), 28.5 (CH3), 19.8 (CH2), 18.2 (CH3), 18.1 
(CH3), 18.1 (CH3), 18.0 (CH3), 17.9 (CH3), 17.9 (CH3), 13.5 (CH3), 12.5 (CH), 12.4 
(CH), 11.9 (CH). IR (ATR): 2942, 2865, 1670, 1462, 1095, 1058, 881, 755, 679 cm–1. 
MS (ESI): m/z (relative intensity) 912 (100) [M+Na]+, 889 (22) [M+H]+. HR-MS (ESI): 
m/z calcd for C47H89N4O6Si3+ [M+H]+: 889.6084 found: 889.6089. 
  








The general procedure D was followed using methyl [4-({S}-3-{[2-(1-benzyl-1H-1,2,3-
triazol-4-yl)propan-2-yl]amino}-2-{1,3-dioxoisoindolin-2-yl}-3-oxopropyl)benzoyl]-L-
valinate 237a (65 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 
238a (78 mg, 62%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.71 – 7.57 (m, 4H), 7.52 (d, J = 8.0 Hz, 2H), 7.42 (s, 
1H), 7.36 (d, J = 8.0 Hz, 2H), 7.34 – 7.27 (m, 3H), 7.24 – 7.17 (m, 2H), 6.96 (s, 1H), 
6.41 (d, J = 8.6 Hz, 1H), 5.56 (d, J = 11.8 Hz, 1H), 5.42 (s, 2H), 5.10 (d, J = 5.3 Hz, 
1H), 4.79 – 4.60 (m, 2H), 4.45 – 4.26 (m, 1H), 4.15 – 3.93 (m, 4H), 3.74 (s, 3H), 2.28 
– 2.17 (m, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 1.14 – 1.05 (m, 42H), 0.93 (t, J = 7.2 Hz, 
6H), 0.88 – 0.83 (m, 21H). 13C NMR (101 MHz, CDCl3): δ 172.5 (Cq), 167.8 (Cq), 166.8 
(Cq), 166.4 (Cq), 153.0 (Cq), 150.6 (Cq), 142.8 (Cq), 134.9 (Cq), 133.9 (CH), 132.5 (Cq), 
131.3 (Cq), 128.9 (CH), 128.4 (CH), 128.4 (CH), 127.9 (CH), 126.8 (CH), 123.4 (CH), 
120.9 (CH), 99.2 (CH), 81.1 (CH), 69.3 (CH), 66.6 (CH), 61.2 (CH2), 57.2 (CH), 54.8 
(CH), 53.9 (CH2), 52.2 (Cq), 52.2 (CH3), 50.0 (CH), 31.6 (CH), 28.4 (CH3), 28.2 (CH3), 
18.9 (CH3), 18.2 (CH3), 18.2 (CH3), 18.1 (CH3), 18.0 (CH3), 18.0 (CH3), 17.9 (CH3), 
17.8 (CH3), 12.4 (CH), 12.3 (CH), 12.2 (CH). IR (ATR): 2943, 2865, 2197, 1717, 1464, 
1383, 1102, 1060, 681 cm–1. MS (ESI): m/z (relative intensity) 1286 (81) [M+Na]+, 
1263(92) [M+H]+. HR-MS (ESI): m/z calcd for C69H107N6O10Si3+ [M+H]+: 1263.7351 
found: 1263.7335. 
  








The general procedure D was followed using methyl [4-({S}-3-{[2-(1-benzyl-1H-1,2,3-
triazol-4-yl)propan-2-yl]amino}-2-{1,3-dioxoisoindolin-2-yl}-3-oxopropyl)benzoyl]-L-
isoleucinate 237b (67 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 
238b (65 mg, 51%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.72 – 7.56 (m, 4H), 7.52 (d, J = 8.0 Hz, 2H), 7.42 (s, 
1H), 7.36 (d, J = 8.0 Hz, 2H), 7.33 – 7.27 (m, 3H), 7.25 – 7.17 (m, 2H), 6.96 (s, 1H), 
6.44 (d, J = 8.4 Hz, 1H), 5.56 (d, J = 11.9 Hz, 1H), 5.42 (s, 2H), 5.10 (d, J = 5.4 Hz, 
1H), 4.79 – 4.64 (m, 2H), 4.43 – 4.28 (m, 1H), 4.14 – 3.92 (m, 4H), 3.74 (s, 3H), 1.99 
– 1.90 (m, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 1.52 – 1.42 (m, 1H), 1.24 – 1.16 (m, 1H), 
1.15 – 1.03 (m, 42H), 0.97 – 0.88 (m, 6H), 0.88 – 0.80 (m, 21H). 13C NMR (101 MHz, 
CDCl3): δ 172.4 (Cq), 167.7 (Cq), 166.6 (Cq), 166.4 (Cq), 153.0 (Cq), 150.6 (Cq), 142.7 
(Cq), 134.9 (Cq), 133.9 (CH), 132.4 (Cq), 131.2 (Cq), 128.9 (CH), 128.4 (CH), 128.3 
(CH), 127.9 (CH), 126.8 (CH), 123.4 (CH), 120.8 (CH), 99.1 (CH), 81.0 (CH), 69.3 
(CH), 66.6 (CH), 61.2 (CH2), 56.5 (CH), 54.8 (CH), 53.9 (CH2), 52.2 (Cq), 52.1 (CH3), 
50.0 (CH), 38.2 (CH), 28.4 (CH3), 28.2 (CH3), 25.2 (CH2), 18.2 (CH3), 18.2 (CH3), 18.1 
(CH3), 18.0 (CH3), 17.9 (CH3), 17.9 (CH3), 15.4 (CH3), 12.3 (CH), 12.2 (CH), 12.1 (CH), 
11.5 (CH3). IR (ATR): 2942, 2865, 1717, 16651, 1462, 1382, 1095, 1052, 882, 682 cm–
1. MS (ESI): m/z (relative intensity) 1300 (84) [M+Na]+, 1277 (100) [M+H]+. HR-MS 
(ESI): m/z calcd for C70H109N6O10Si3+ [M+H]+: 1277.7507 found: 1277.7483. 
  








The general procedure D was followed using benzyl [4-({S}-3-{[2-(1-benzyl-1H-1,2,3-
triazol-4-yl)propan-2-yl]amino}-2-{1,3-dioxoisoindolin-2-yl}-3-oxopropyl)benzoyl]-L-
phenylalaninate 237c (77 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 2/1 → 1/1) 
yielded 238c (69 mg, 50%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.72 – 7.54 (m, 4H), 7.47 – 7.40 (m, 3H), 7.39 – 7.27 (m, 
10H), 7.25 – 7.14 (m, 5H), 7.01 – 6.92 (m, 3H), 6.42 – 6.31 (m, 1H), 5.54 (d, J = 12.1 
Hz, 1H), 5.42 (s, 2H), 5.27 – 4.97 (m, 4H), 4.72 (dd, J = 12.1, 1.9 Hz, 1H), 4.41 – 4.30 
(m, 1H), 4.17 – 3.91 (m, 4H), 3.34 – 3.03 (m, 2H), 1.78 (s, 3H), 1.74 (s, 3H), 1.14 – 
1.06 (m, 42H), 0.87 – 0.83 (m, 21H).13C NMR (101 MHz, CDCl3): δ 171.3 (Cq), 167.7 
(Cq), 166.4 (Cq), 166.3 (Cq), 153.0 (Cq), 150.5 (Cq), 142.7 (Cq), 135.6 (Cq), 135.0 (Cq), 
134.9 (Cq), 133.9 (CH), 132.2 (Cq), 131.2 (Cq), 129.2 (CH), 128.9 (CH), 128.6 (CH), 
128.6 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 127.9 (CH), 127.0 (CH), 
126.7 (CH), 123.3 (CH), 120.8 (CH), 99.2 (CH), 81.0 (CH), 69.3 (CH), 67.3 (CH2), 66.6 
(CH), 61.1 (CH2), 54.9 (CH), 53.9 (CH2), 53.3 (CH), 52.2 (Cq), 50.0 (CH), 37.8 (CH2), 
28.3 (CH3), 28.2 (CH3), 18.2 (CH3), 18.2 (CH3), 18.1 (CH3), 18.0 (CH3), 17.9 (CH3), 
17.9 (CH3), 12.3 (CH), 12.2 (CH), 12.1 (CH). IR (ATR): 2942, 2865, 1715, 1664, 1461, 
1050, 881, 718, 681 cm–1. MS (ESI): m/z (relative intensity) 1411 (100) [M+Na]+, 1387 
(33) [M+H]+. HR-MS (ESI): m/z calcd for C79H111N6O10Si3+ [M+H]+: 1387.7664 found: 
1387.7636. 
  









The general procedure D was followed using tert-butyl (S)-2-{[4-({S}-3-{[2-(1-benzyl-
1H-1,2,3-triazol-4-yl)propan-2-yl]amino}-2-{1,3-dioxoisoindolin-2-yl}-3-
oxopropyl)phenyl]carbamoyl}pyrrolidine-1-carboxylate 237d (71 mg, 0.10 mmol), 
[({2R,3R,4R}-6-iodo-2-{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (hexane/EtOAc 2:1 → 1:1) 
yielded 238d (106 mg, 80%) as a colorless oil. 
1H NMR (600 MHz, DMSO-d6, 100 °C): δ 9.27 (s, 1H), 7.74 – 7.71 (m, 3H), 7.70 – 7.66 
(m, 2H), 7.37 (s, 1H), 7.35 – 7.27 (m, 3H), 7.25 (d, J = 8.6 Hz, 2H), 7.24 – 7.21 (m, 
2H), 7.06 – 7.03 (m, 2H), 5.48 (s, 2H), 5.28 (d, J = 11.4 Hz, 1H), 5.01 (dd, J = 5.2, 1.5 
Hz, 1H), 4.52 (d, J = 11.4 Hz, 1H), 4.24 (ddt, J = 7.6, 6.0, 1.8 Hz, 1H), 4.18 (dd, J = 
1.8, 1.8 Hz, 1H), 4.13 (dd, J = 8.4, 4.1 Hz, 1H), 4.11 – 4.05 (m, 1H), 4.04 (dt, J = 4.4, 
1.8 Hz, 1H), 3.74 (dd, J = 10.7, 5.6 Hz, 1H), 3.38 (ddd, J = 10.2, 7.5, 5.6 Hz, 1H), 3.32 
(dt, J = 10.2, 6.7 Hz, 1H), 2.14 – 2.05 (m, 1H), 1.89 – 1.71 (m, 3H), 1.66 (s, 3H), 1.61 
(s, 3H), 1.24 (s, 9H), 1.10 – 1.07 (m, 21H), 1.05 – 1.01 (m, 21H), 0.98 – 0.94 (m, 21H). 
13C NMR (151 MHz, DMSO-d6, 100 °C): δ 170.2 (Cq), 166.5 (Cq), 164.9 (Cq), 152.9 
(Cq), 152.6 (Cq), 151.6 (Cq), 137.3 (Cq), 135.3 (Cq), 133.8 (CH), 132.8 (Cq), 130.4 (Cq), 
128.0 (CH), 127.6 (CH), 127.3 (CH), 127.2 (CH), 122.3 (CH), 120.3 (CH), 117.9 (CH), 
96.9 (CH), 80.2 (CH), 78.0 (Cq), 69.3 (CH), 66.2 (CH), 60.9 (CH2), 59.8 (CH), 54.5 
(CH), 52.4 (CH2), 51.1 (Cq), 47.8 (CH), 46.0 (CH2), 29.9 (CH2), 27.6 (CH3), 27.5 (CH3), 
27.3 (CH3), 22.8 (CH2), 17.4 (CH3), 17.4 (CH3), 17.2 (CH3), 17.2 (CH3), 17.2 (CH3), 
17.2 (CH3), 11.5 (CH), 11.5 (CH), 11.1 (CH). IR (ATR): 2943, 2865, 1708, 1526, 1383, 
1098, 1052, 1026, 882, 715, 679 cm–1. MS (ESI): m/z (relative intensity) 1341 (100) 
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[M+Na]+, 1318 (7) [M+H]+. HR-MS (ESI): m/z calcd for C72H112N7O10Si3+ [M+H]+: 







The general procedure D was followed using (1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl 4-({S}-3-{[2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl]amino}-2-
{1,3-dioxoisoindolin-2-yl}-3-oxopropyl)benzoate 237e (68 mg, 0.10 mmol), 
[({2R,3R,4R}-6-iodo-2-{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) yielded 
238e (82 mg, 64%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 8.2 Hz, 2H), 7.69 – 7.64 (m, 2H), 7.64 – 7.58 
(m, 2H), 7.42 (s, 1H), 7.37 – 7.29 (m, 5H), 7.24 – 7.19 (m, 2H), 6.97 (s, 1H), 5.56 (d, J 
= 11.9 Hz, 1H), 5.42 (s, 2H), 5.10 (dd, J = 5.5, 1.4 Hz, 1H), 4.81 (ddd, J = 10.8, 10.8, 
4.3 Hz, 1H), 4.72 (d, J = 11.9 Hz, 1H), 4.36 (ddd, J = 7.8, 4.9, 3.1 Hz, 1H), 4.13 – 4.05 
(m, 2H), 4.02 (dd, J = 11.2, 6.1 Hz, 1H), 3.97 (dd, J = 4.9, 2.5 Hz, 1H), 2.03 (dd, J = 
12.0, 4.2 Hz, 1H), 1.90 (dtd, J = 13.9, 7.2, 2.8 Hz, 1H), 1.78 (s, 3H), 1.75 – 1.65 (m, 
5H), 1.57 – 1.42 (m, 2H), 1.13 – 1.06 (m, 42H), 1.03 – 0.98 (m, 1H), 0.93 – 0.82 (m, 
29H), 0.72 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 167.7 (Cq), 166.4 (Cq), 
165.9 (Cq), 153.0 (Cq), 150.6 (Cq), 143.7 (Cq), 134.9 (Cq), 133.8 (CH), 131.3 (Cq), 129.3 
(Cq), 129.3 (CH), 128.9 (CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 123.3 (CH), 120.8 
(CH), 99.1 (CH), 81.0 (CH), 74.5 (CH), 69.3 (CH), 66.6 (CH), 61.2 (CH2), 54.8 (CH), 
53.9 (CH2), 52.2 (Cq), 50.1 (CH), 47.1 (CH), 40.9 (CH2), 34.2 (CH2), 31.3 (CH), 28.4 
(CH3), 28.2 (CH3), 26.2 (CH), 23.4 (CH2), 22.0 (CH3), 20.8 (CH3), 18.2 (CH3), 18.2 
(CH3), 18.1 (CH3), 18.0 (CH3), 17.9 (CH3), 17.9 (CH3), 16.3 (CH3), 12.3 (CH), 12.2 
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(CH), 12.1 (CH). IR (ATR): 2942, 2865, 1714, 1462, 1382, 1274, 1107, 1049, 882, 717, 
657 cm–1. MS (ESI): m/z (relative intensity) 1311 (100) [M+Na]+, 1288 (7) [M+H]+. HR-













237f(91 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-{[(triisopropylsilyl)oxy]methyl}-3,4-
dihydro-2H-pyran-3,4-diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), 
Pd(TFA)2 (3.3 mg, 10 mol %), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 
mmol), in 1,4-dioxane (0.50 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc 7:3) yielded 238f (101 mg, 67%,) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 8.4 Hz, 2H), 7.69 – 7.63 (m, 2H), 7.60 (dd, 
J = 5.5, 3.0 Hz, 2H), 7.43 (s, 1H), 7.36 – 7.29 (m, 5H), 7.25 – 7.19 (m, 2H), 6.98 (s, 
1H), 5.55 (d, J = 11.9 Hz, 1H), 5.43 (s, 2H), 5.40 – 5.36 (m, 1H), 5.10 (dd, J = 5.6, 1.5 
Hz, 1H), 4.81 – 4.67 (m, 2H), 4.35 (dddd, J = 7.1, 6.7, 3.2, 3.2 Hz, 1H), 4.14 – 4.06 (m, 
1H), 4.06 – 3.93 (m, 1H), 2.38 (d, J = 8.2 Hz, 2H), 2.03 (dt, J = 12.7, 3.2 Hz, 2H), 1.98 
– 1.82 (m, 5H), 1.78 (s, 3H), 1.74 (s, 3H), 1.66 – 1.43 (m, 8H), 1.43 – 1.32 (m, 4H), 
1.25 – 1.14 (m, 5H), 1.11 – 1.07 (m, 43H), 1.05 (s, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.91 
– 0.85 (m, 28H), 0.70 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 167.7 (Cq), 166.4 (Cq), 
165.8 (Cq), 153.0 (Cq), 150.7 (Cq), 143.8 (Cq), 139.6 (Cq), 135.0 (Cq), 133.9 (CH), 131.3 
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(Cq), 129.4 (CH), 129.4 (Cq), 128.9 (CH), 128.4 (CH), 128.1 (CH), 127.9 (CH), 123.3 
(CH), 122.7 (CH), 120.9 (CH), 99.1 (CH), 81.1 (CH), 74.2 (CH), 69.4 (CH), 66.6 (CH), 
61.2 (CH2), 56.7 (CH), 56.1 (CH), 54.8 (CH), 53.9 (CH2), 52.2 (Cq), 50.1 (CH), 50.0 
(CH), 42.3 (Cq), 39.7 (CH2), 39.5 (CH2), 38.2 (CH2), 37.0 (CH2), 36.6 (Cq), 36.2 (CH2), 
35.8 (CH), 31.9 (CH), 31.9 (CH2), 28.4 (CH3), 28.2 (CH2), 28.2 (CH3), 28.0 (CH2), 27.8 
(CH), 24.3 (CH2), 23.8 (CH2), 22.8 (CH3), 22.6 (CH3), 21.0 (CH2), 19.3 (CH3), 18.7 
(CH3), 18.2 (CH3), 18.2 (CH3), 18.1 (CH3), 18.0 (CH3), 18.0 (CH3), 17.9 (CH3), 12.4 
(CH), 12.3 (CH), 12.1 (CH), 11.9 (CH3). IR (ATR): 2941, 2865, 1716, 1464, 1272, 1050, 
882, 717, 681 cm–1. MS (ESI): m/z (relative intensity) 1542 (100) [M+Na]+, 1519 (30) 








The general procedure D was followed using methyl {2-[2-(4-{2-[(S)-2-(1,3-
dioxoisoindolin-2-yl)propanamido]propan-2-yl}-1H-1,2,3-triazol-1-yl)acetyl]-1-
isobutylhydrazine-1-carbonyl}-L-phenylalaninate 239c (66 mg, 0.10 mmol), 
[({2R,3R,4R}-6-iodo-2-{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 1:1 → 1:2) 
yielded 239c (79 mg, 62%) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 7.78 (dd, J = 5.4, 3.0 Hz, 2H), 7.68 – 7.64 (m, 2H), 7.58 
(s, 1H), 7.28 – 7.22 (m, 2H), 7.22 – 7.16 (m, 1H), 7.11 – 7.05 (m, 2H), 6.98 (s, 1H), 
6.48 (d, J = 7.9 Hz, 1H), 6.43 (d, J = 7.8 Hz, 1H), 4.98 (dd, J = 8.2, 5.8 Hz, 1H), 4.89 
(s, 2H), 4.78 (ddd, J = 8.0, 6.7, 5.7 Hz, 1H), 4.73 (dd, J = 5.3, 1.4 Hz, 1H), 4.32 (td, J 
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= 8.5, 6.0 Hz, 1H), 4.22 (ddt, J = 7.2, 5.6, 1.9 Hz, 1H), 4.02 – 3.97 (m, 1H), 3.91 – 3.81 
(m, 3H), 3.68 (s, 3H), 3.11 (dd, J = 13.9, 5.7 Hz, 1H), 3.07 – 2.98 (m, 2H), 2.93 (dd, J 
= 14.8, 5.8 Hz, 1H), 1.71 (s, 3H), 1.70 (s, 3H), 1.54 (ddd, J = 13.5, s7.4, 5.8 Hz, 1H), 
1.48 – 1.37 (m, 2H), 1.03 – 1.00 (m, 21H), 0.98 – 0.97 (m, 21H), 0.95 – 0.91 (m,  21H), 
0.80 (d, J = 6.4 Hz, 3H), 0.77 (d, J = 6.4 Hz, 3H). 13C NMR (151 MHz, CDCl3): δ 171.7 
(Cq), 170.8 (Cq), 167.9 (Cq), 167.7 (Cq), 165.4 (Cq), 153.2 (Cq), 149.1 (Cq), 135.7 (Cq), 
133.9 (CH), 131.9 (Cq), 129.2 (CH), 128.5 (CH), 127.1 (CH), 123.4 (CH), 122.7 (CH), 
99.2 (CH), 81.4 (CH), 69.1 (CH), 66.0 (CH), 61.8 (CH2), 53.1 (CH), 53.0 (CH), 52.6 
(CH2), 52.3 (CH), 52.2 (CH3), 51.7 (Cq), 40.2 (CH2), 37.7 (CH2), 34.8 (CH2), 28.3 (CH3), 
27.8 (CH3), 24.6 (CH), 22.6 (CH3), 21.9 (CH3), 18.1 (CH3), 18.1 (CH3), 18.0 (CH3), 18.0 
(CH3), 18.0 (CH3), 12.3 (CH), 11.9 (CH) (1 CH3 and 1 CH resonances of the TIPS 
groups are missing due to overlap, the overlap was verified by analysis of the HSQC 
spectrum). IR (ATR): 3263, 2942, 2865, 1718, 1660, 1556, 1381, 1051, 881, 679 cm–
1. MS (ESI): m/z (relative intensity) 1295 (100) [M+Na]+, 1272 (2) [M+H]+. HR-MS (ESI): 







The general procedure D was followed using benzyl [2-(4-{2-[(S)-2-(1,3-
dioxoisoindolin-2-yl)propanamido]propan-2-yl}-1H-1,2,3-triazol-1-yl)acetyl]-L-
phenylalanyl-L-leucinate 239d (74 mg, 0.10 mmol), [({2R,3R,4R}-6-iodo-2-
{[(triisopropylsilyl)oxy]methyl}-3,4-dihydro-2H-pyran-3,4-
diyl)bis(oxy)]bis(triisopropylsilane) 235 (111 mg, 0.15 mmol), Pd(TFA)2 (3.3 mg, 10 mol 
%), 1-AdCO2H (5.4 mg, 30 mol %), Ag2CO3 (55 mg, 0.20 mmol), in 1,4-dioxane (0.50 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc 3:2 → 2:3) 
yielded 240d (68 mg, 50%) as a colorless oil. 
5. Experimental Part 
 
192 
1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 5.5 Hz, 2H), 7.66 (dd, J = 5.5 Hz, 2H), 7.54 
(s, 1H), 7.40 – 7.28 (m, 5H), 7.24 – 7.14 (m, 3H), 7.06 (d, J = 7.1 Hz, 2H), 7.01 (s, 1H), 
6.60 (d, J = 7.6 Hz, 1H), 6.22 (d, J = 8.1 Hz, 1H), 5.12 (s, 2H), 5.01 (dd, J = 8.2, 5.8 
Hz, 1H), 4.92 (d, J = 16.8 Hz, 1H), 4.87 (d, J = 16.8 Hz, 1H), 4.75 (d, J = 5.1 Hz, 1H), 
4.65 – 4.42 (m, 2H), 4.25 (t, J = 6.2 Hz, 1H), 4.02 (s, 1H), 3.95 – 3.81 (m, 3H), 3.08 
(dd, J = 14.8, 8.3 Hz, 1H), 3.02 – 2.88 (m, 3H), 1.76 – 1.68 (s, 6H), 1.61 – 1.51 (m, 
1H), 1.51 – 1.40 (m, 2H), 1.06 – 1.02 (m, 21H), 1.00 (s, 21H), 0.96 – 0.91 (m, 21H), 
0.88 – 0.78 (m, 6H). 13C NMR (101 MHz, CDCl3): δ 172.1 (Cq), 169.7 (Cq), 167.8 (Cq), 
167.7 (Cq), 165.2 (Cq), 153.2 (Cq), 149.1 (Cq), 136.0 (Cq), 135.3 (Cq), 133.9 (CH), 131.9 
(Cq), 129.2 (CH), 128.6 (CH), 128.6 (CH), 128.4 (CH), 128.2 (CH), 127.0 (CH), 123.4 
(CH), 122.5 (CH), 99.2 (CH), 81.4 (CH), 69.1 (CH), 67.0 (CH2), 66.0 (CH), 61.8 (CH2), 
54.9 (CH), 53.0 (CH), 52.6 (CH2), 51.7 (Cq), 51.0 (CH), 41.2 (CH2), 37.6 (CH2), 34.9 
(CH2), 28.4 (CH3), 27.7 (CH3), 24.7 (CH), 22.6 (CH3), 21.8 (CH3), 18.1 (CH3), 18.1 
(CH3), 18.0 (CH3), 18.0 (CH3), 12.3 (CH), 11.9 (CH). (2 CH3 and 1 CH resonances of 
the TIPS groups are missing due to overlap, the overlap was verified by analysis of the 
HSQC spectrum). IR (ATR): 3307, 2942, 2866, 1716, 1651, 1463, 1383, 881, 730, 680 
cm–1. MS (ESI): m/z (relative intensity) 1371 (100) [M+Na]+, 1348 (2) [M+H]+. HR-MS 
(ESI): m/z calcd for C73H114N7O11Si3+ [M+H]+: 1348.7879 found: 1348.7852.  
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5.5. Ruthenium(II)-Catalyzed Peptide C–H Functionalization via Hydroarylation 
Manifold 
 
5.5.1. Characterization Data 
 
Methyl acetyl-1-(2-pyridyl)-2-(ethyl propionate-3-yl)-L-tryptophanate (242aa) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), ethyl acrylate 22a (45 mg, 0.45 mmol), 
[RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). Purification by column 
chromatography on silica gel (EtOAc) yielded 242aa(59 mg, 90%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ 8.63 (dd, J = 4.9, 1.8 Hz, 1H), 7.91 (ddd, J = 7.7, 7.7, 
1.9 Hz, 1H), 7.59–7.51 (m, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.34 (dd, J = 7.2, 5.1 Hz, 1H), 
7.30–7.24 (m, 1H), 7.18–7.09 (m, 2H), 6.36 (d, J = 7.6 Hz, 1H), 4.96 (ddd, J = 7.7, 6.0, 
6.0 Hz, 1H), 4.02 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 3.38 (dd, J = 14.7, 6.0 Hz, 1H), 3.31 
(dd, J = 14.7, 6.0 Hz, 1H), 3.27–3.13 (m, 2H), 2.29 (ddd, J = 9.0, 7.1, 2.5 Hz, 2H), 1.95 
(s, 3H), 1.16 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 172.4 (Cq), 172.2 (Cq), 
169.7 (Cq), 150.9 (Cq), 149.4 (CH), 138.7 (CH), 136.8 (Cq), 136.6 (Cq), 128.5 (Cq), 
122.4 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 118.5 (CH), 109.8 (CH), 109.4 (Cq), 
60.5 (CH2), 52.8 (CH), 52.3 (CH3), 33.7 (CH2), 27.1 (CH2), 23.1 (CH3), 20.3 (CH2), 14.1 
(CH3). IR (ATR): 2954, 2927, 1731, 1655, 1470, 1459, 1436, 1369, 1176, 742 cm‒1. 
MS (ESI): m/z (relative intensity) 897 (24) [2M+Na]+, 460 (79) [M+Na]+, 438 (100) 
[M+H]+. HR-MS (ESI): m/z calcd for C24H28N3O5+ [M+H]+: 438.2023, found: 438.2026. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-bromophenyl propionate-3-yl)-L-tryptophanate 
(242ab) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 242ab (50.6 mg, 0.15 mmol), 4-bromophenyl acrylate 22b (41 mg, 
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0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). 
Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/3) 
yielded 242ab (61 mg, 72%) as a white solid. 
M.p.: 126 – 129 °C. 1H NMR (300 MHz, CDCl3): δ 8.65 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.93 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.60–7.53 (m, 1H), 7.50 (ddd, J = 8.0, 1.0, 1.0 Hz, 
1H), 7.43 (d, J = 8.9 Hz, 2H), 7.38–7.28 (m, 2H), 7.22–7.13 (m, 2H), 6.83 (d, J = 8.9 Hz, 
2H), 6.25 (d, J = 7.8 Hz, 1H), 4.97 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 3.69 (s, 3H), 3.55–
3.18 (m, 4H), 2.65–2.57 (m, 2H), 1.92 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 172.4 
(Cq), 170.5 (Cq), 169.6 (Cq), 151.1 (Cq), 149.6 (CH), 149.4 (Cq), 138.5 (CH), 136.6 (Cq), 
136.3 (Cq), 132.3 (CH), 128.5 (Cq), 123.1 (CH), 122.6 (CH), 122.3 (CH), 120.8 (CH), 
120.8 (CH), 118.8 (Cq), 118.5 (CH), 110.0 (CH), 109.6 (Cq), 52.9 (CH), 52.4 (CH3), 
33.9 (CH2), 27.2 (CH2), 23.1 (CH3), 20.3 (CH2). IR (ATR): 2928, 1745, 1654, 1585, 
1471, 1437, 1199, 1134, 744 cm‒1. MS (ESI): m/z (relative intensity) 586 (100) 
[M+Na]+, 564 (50) [M+H]+. HR-MS (ESI): m/z calcd for C28H2779BrN3O5+ [M+H]+: 
564.1129, found: 564.1130. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-cyanophenyl propionate-3-yl)-L-tryptophanate 
(242ac) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 4-cyanophenyl acrylate 22c (40 mg, 
0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). 
Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/3) 
yielded 242ac (47 mg, 61%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.94 (ddd, J = 8.0, 
7.5, 2.0 Hz, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.58–7.48 (m, 2H), 7.42–7.28 (m, 2H), 7.23–
7.13 (m, 2H), 7.10 (d, J = 8.8 Hz, 2H), 6.20 (d, J = 7.9 Hz, 1H), 4.96 (ddd, J = 7.9, 6.0, 
6.0 Hz, 1H), 3.68 (s, 3H), 3.40–3.25 (m, 4H), 2.69 (dd, J = 8.0, 7.0 Hz, 2H), 1.94 (s, 
3H). 13C NMR (126 MHz, CDCl3): δ 172.4 (Cq), 170.0 (Cq), 169.6 (Cq), 153.6 (Cq), 
151.0 (Cq), 149.6 (CH), 138.6 (CH), 136.6 (Cq), 136.1 (Cq), 133.5 (CH), 128.6 (Cq), 
122.7 (CH), 122.5 (CH), 122.3 (CH), 120.9 (CH), 120.8 (CH), 118.5 (CH), 118.1 (Cq), 
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110.0 (CH), 109.7 (Cq), 109.7 (Cq), 52.9 (CH), 52.4 (CH3), 34.0 (CH2), 27.3 (CH2), 23.2 
(CH3), 20.3 (CH2). IR (ATR): 2930, 2228, 1743, 1653, 1586, 1472, 1438, 1209, 1121, 
744 cm‒1. MS (ESI): m/z (relative intensity) 533 (100) [M+Na]+, 511 (69) [M+H]+. HR-
MS (ESI): m/z calcd for C29H27N4O5+ [M+H]+:511.1976, found: 511.1982. 
 
Methyl acetyl-1-(2-pyridyl)-2-(4-nitrophenyl propionate-3-yl)-L-tryptophanate 
(242ad) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 4-nitrophenyl acrylate 22d (44 mg, 
0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). 
Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/3) 
yielded 242ad (42 mg, 53%) as a white solid. 
M.p.: 102 – 104 °C. 1H NMR (300 MHz, CDCl3): δ 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
8.21 (d, J = 9.3 Hz, 2H), 7.94 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.57–7.48 (m, 2H), 7.39–
7.30 (m, 2H), 7.23–7.12 (m, 4H), 6.20 (d, J = 7.9 Hz, 1H), 4.96 (ddd, J = 7.9, 6.0, 
6.0 Hz, 1H), 3.68 (s, 3H), 3.44–3.24 (m, 4H), 2.72 (dd, J = 8.2, 7.0 Hz, 2H), 1.95 (s, 
3H). 13C NMR (126 MHz, CDCl3): δ 172.4 (Cq), 170.0 (Cq), 169.6 (Cq), 155.1 (Cq), 
151.1 (Cq), 149.7 (CH), 145.2 (Cq), 138.5 (CH), 136.6 (Cq), 136.1 (Cq), 128.6 (Cq), 
125.0 (CH), 122.7 (CH), 122.3 (CH), 122.2 (CH), 120.9 (CH), 120.8 (CH), 118.5 (CH), 
110.1 (CH), 109.7 (Cq), 53.0 (CH), 52.4 (CH3), 34.1 (CH2), 27.3 (CH2), 23.2 (CH3), 20.3 
(CH2). IR (ATR): 2923, 1743, 1653, 1589, 1522, 1458, 1437, 1370, 1347, 1156, 
745 cm‒1. MS (ESI): m/z (relative intensity) 553 (100) [M+Na]+, 531 (68) [M+H]+. HR-
MS (ESI): m/z calcd for C28H27N4O7+ [M+H]+: 531.1874, found: 531.1881. 
 
Methyl acetyl-1-(2-pyridyl)-2-(3-methoxyphenyl propionate-3-yl)-L-tryptophanate 
(242ae) 
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The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 3-methoxyphenyl acrylate 22e (41 mg, 
0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). 
Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/3) 
yielded 242ae (56 mg, 72%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.67 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.93 (ddd, J = 8.0, 
7.5, 2.0 Hz, 1H), 7.61–7.54 (m, 1H), 7.51 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.40–7.29 (m, 
2H), 7.24–7.13 (m, 3H), 6.73 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H), 6.53 (ddd, J = 8.2, 2.4, 
0.9 Hz, 1H), 6.42 (dd, J = 2.4, 2.4 Hz, 1H), 6.24 (d, J = 7.7 Hz, 1H), 4.98 (ddd, J = 7.7, 
6.0, 6.0 Hz, 1H), 3.71 (s, 3H), 3.70 (s, 3H), 3.48–3.21 (m, 4H), 2.70–2.45 (m, 2H), 1.89 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ 172.5 (Cq), 170.8 (Cq), 169.7 (Cq), 160.3 (Cq), 
151.3 (Cq), 151.1 (Cq), 149.7 (CH), 138.5 (CH), 136.7 (Cq), 136.3 (Cq), 129.6 (CH), 
128.6 (Cq), 122.6 (CH), 122.3 (CH), 120.8 (CH), 120.8 (CH), 118.6 (CH), 113.5 (CH), 
111.8 (CH), 110.0 (CH), 109.6 (Cq), 107.2 (CH), 55.4 (CH3), 52.8 (CH), 52.4 (CH3), 
33.8 (CH2), 27.2 (CH2), 23.1 (CH3), 20.4 (CH2). IR (ATR): 2950, 1745, 1655, 1588, 
1489, 1471, 1458, 1437, 1139, 744 cm‒1. MS (ESI): m/z (relative intensity) 538 (65) 
[M+Na]+, 516 (100) [M+H]+. HR-MS (ESI): m/z calcd for C29H30N3O6+ [M+H]+: 
516.2129, found: 516.2134. 
 
Methyl acetyl-1-(2-pyridyl)-2-(2-phenylphenyl propionate-3-yl)-L-tryptophanate 
(242af) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 2-phenylphenyl acrylate 22f (52 mg, 
0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). 
Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/2) 
yielded 242af (66 mg, 79%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ 8.57–8.52 (m, 1H), 7.87 (ddd, J = 7.8, 7.8, 1.9 Hz, 1H), 
7.61–7.48 (m, 1H), 7.41–7.20 (m, 11H), 7.18–7.11 (m, 2H), 7.01–6.95 (m, 1H), 6.15 
(d, J = 7.8 Hz, 1H), 4.93 (ddd, J = 7.8, 5.9, 5.9 Hz, 1H), 3.65 (s, 3H), 3.33 (dd, J = 14.8, 
6.1 Hz, 1H), 3.23 (dd, J = 14.8, 5.9 Hz, 1H), 3.15–3.02 (m, 2H), 2.39 (t, J = 7.7 Hz, 
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2H), 1.85 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 172.4 (Cq), 170.8 (Cq), 169.7 (Cq), 
151.0 (Cq), 149.6 (CH), 147.5 (Cq), 138.4 (CH), 137.4 (Cq), 136.6 (Cq), 136.4 (Cq), 
134.7 (Cq), 130.7 (CH), 128.7 (CH), 128.6, (Cq) 128.4 (CH), 128.1 (CH), 127.3 (CH), 
126.3 (CH), 122.6 (CH), 122.5 (CH), 122.2 (CH), 120.8 (CH), 120.7 (CH), 118.5 (CH), 
110.0 (CH), 109.4 (Cq), 52.8 (CH), 52.4 (CH3), 33.7 (CH2), 27.1 (CH2), 23.1 (CH3), 20.2 
(CH2). IR (ATR): 3056, 2925, 1749, 1654, 1584, 1541, 1136, 701 cm‒1. MS (ESI): m/z 
(relative intensity) 584 (49) [M+Na]+, 562 (100) [M+H]+. HR-MS (ESI): m/z calcd for 





The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 2-(trifluoromethyl)phenyl acrylate 22g 
(50 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 
mL). Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/2) 
yielded 242ag (62 mg, 75%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.93 (ddd, J = 8.0, 
7.5, 2.0 Hz, 1H), 7.68–7.46 (m, 4H), 7.39–7.27 (m, 3H), 7.20–7.14 (m, 2H), 7.11 (d, 
J = 8.2 Hz, 1H), 6.24 (d, J = 7.9 Hz, 1H), 5.00 (ddd, J = 7.9, 5.9, 5.9 Hz, 1H), 3.70 (s, 
3H), 3.49–3.21 (m, 4H), 2.70 (dd, J = 8.5, 7.3 Hz, 2H), 1.91 (s, 3H). 13C NMR 
(126 MHz, CDCl3): δ 172.4 (Cq), 170.2 (Cq), 169.6 (Cq), 151.0 (Cq), 149.7 (CH), 147.8 
(q, 3JC-F = 2.2 Hz, Cq), 138.5 (CH), 136.6 (Cq), 136.2 (Cq), 132.9 (CH), 128.6 (Cq), 126.7 
(q, 3JC-F = 4.8 Hz, CH), 125.7 (CH), 124.3 (CH), 122.8 (q, 1JC-F = 272.3 Hz, Cq), 122.5 
(CH), 122.4 (q, 2JC-F = 33.9 Hz, Cq), 122.3 (CH), 120.8 (CH), 120.7 (CH), 118.5 (CH), 
110.0 (CH), 109.5 (Cq), 52.8 (CH3), 52.4 (CH), 33.7 (CH2), 27.2 (CH2), 23.1 (CH3), 20.3 
(CH2). 19F NMR (282 MHz, CDCl3): δ –61.8 (s). IR (ATR): 3055, 2952, 1745, 1655, 
1588, 1472, 1438 1371, 1131, 744 cm‒1. MS (ESI): m/z (relative intensity) 576 (78) 
[M+Na]+, 554 (100) [M+H]+. HR-MS (ESI): m/z calcd for C29H27F3N3O5+ [M+H]+: 
554.1897, found: 554.1903. 
  




indol-3-yl}propanoic acid (242be) 
 
The general procedure E was followed using Na-acetyl-1-(pyridin-2-yl)-L-tryptophan 
242be (48.5 mg, 0.15 mmol), 3-methoxyphenyl acrylate 22e (41 mg, 0.23 mmol), and 
[RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in acetic acid (0.15 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 30/1 → 20/1) yielded 242be (42 mg, 
84 µmol, 56%) as a white solid. 
M.p.: 116 – 118 °C. 1H NMR (400 MHz, CDCl3): δ 8.73 (d, J = 4.9 Hz, 1H), 7.99 (dd, J 
= 7.7, 7.7 Hz, 1H), 7.59 (d, J = 7.4 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.45 (dd, J = 7.4, 
4.9 Hz, 1H), 7.22–7.11 (m, 2H), 7.11–6.98 (m, 2H), 6.93–6.83 (m, 1H), 6.70 (dd, J = 
8.1, 2.2 Hz, 1H), 6.43 (dd, J = 8.1, 2.2 Hz, 1H), 6.31 (d, J = 2.2 Hz, 1H), 5.08–4.99 (m, 
1H), 3.64 (s, 3H), 3.39–3.16 (m, 3H), 3.16 – 2.96 (m, 1H), 2.45-2.28 (m, 2H), 1.81 (s, 
3H). 13C NMR (101 MHz, CDCl3): δ 174.0 (Cq), 171.3 (Cq), 170.7 (Cq), 160.4 (Cq), 151.2 
(Cq), 150.6 (Cq), 149.2 (CH) , 139.7 (CH), 136.9 (Cq), 136.4 (Cq), 129.7 (CH), 128.6 
(Cq), 123.1 (CH), 122.6 (CH), 122.1 (CH), 120.8 (CH), 119.0 (CH), 113.4 (CH), 112.0 
(CH), 110.1 (Cq), 109.6 (CH), 107.1 (CH), 55.3 (CH3), 52.2 (CH), 33.5 (CH2), 26.5 
(CH2), 22.7 (CH3), 20.2 (CH2). IR (ATR): 3341, 3053, 2932, 1731, 1586, 1471, 1437, 
1163, 742 cm–1. MS (ESI): m/z (relative intensity) 1003 (26) [2M+H]+, 524 (34) [M+Na]+, 




yl}propanoic acid (242bh) 
 
The general procedure E was followed using Na-acetyl-1-(pyridin-2-yl)-L-tryptophan 
241b (48.5 mg, 0.15 mmol), benzyl acrylate 22h (37 mg, 0.23 mmol) and [RuCl2(p-
cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). Purification by column 
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chromatography on silica gel (CH2Cl2/MeOH: 30/1 → 20/1) yielded 242bh (40 mg, 
83 µmol, 55%) as a white solid.  
M.p.: 110 – 112 °C. 1H NMR (400 MHz, CDCl3): δ 8.67 (dd, J = 5.0, 1.7 Hz, 1H), 8.03–
7.90 (m, 1H), 7.56 (dd, J = 6.9, 1.8 Hz, 1H), 7.46–7.33 (m, 2H), 7.31–7.21 (m, 3H), 
7.20–7.11 (m, 2H), 7.13–6.95 (m, 4H), 5.11–4.84 (m, 3H), 3.27–2.85 (m, 4H), 2.34–
2.21 (m, 2H), 1.85 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 174.2 (Cq), 173.2 (Cq), 170.8 
(Cq), 150.9 (Cq), 149.4 (CH), 139.7 (CH), 137.0 (Cq), 136.9 (Cq), 135.5 (Cq), 128.7 
(CH), 128.6 (Cq), 128.5 (CH), 128.3 (CH), 123.1 (CH), 122.6 (CH), 122.2 (CH), 120.8 
(CH), 119.0 (CH), 109.9 (Cq), 109.8 (CH), 66.8 (CH2), 52.1 (CH), 33.8 (CH2), 26.5 
(CH2), 23.0 (CH3), 20.4 (CH2). IR (ATR): 3366, 3056, 2929, 1752, 1608, 1589, 1471, 
1438, 1138, 742 cm–1. MS (ESI) m/z (relative intensity) 993 (16) [2M+Na]+, 971 (20) 
[2M+H]+, 508 (33) [M+Na]+, 486 (100) [M+H]+. HR-MS (ESI): m/z calcd for C28H28N3O5+ 





The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 4-allyl-2-methoxyphenyl acrylate 22i 
(50 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in toluene/AcOH (1:1, 
0.15 mL). Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 
1/2) yielded 242ai (73 mg, 88%) as a pale yellow solid.  
M.p.: 77 – 79 °C. 1H NMR (600 MHz, CDCl3): δ 8.66 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 
7.93 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.62–7.56 (m, 1H), 7.52 (dd, J = 8.0, 0.9 Hz, 1H), 
7.35 (dd, J = 7.5, 4.9 Hz, 1H), 7.33–7.29 (m, 1H), 7.20–7.14 (m, 2H), 6.78 (dd, J = 8.0, 
0.7 Hz, 1H), 6.73–6.63 (m, 2H), 6.32 (d, J = 7.6 Hz, 1H), 5.92 (ddtd, J = 16.9, 10.2, 
6.7, 0.7 Hz, 1H), 5.08 (ddd, J = 9.2, 1.2, 0.8 Hz, 1H), 5.06 (q, J = 1.2 Hz, 1H), 4.99 
(ddd, J = 7.6, 6.1, 6.1 Hz, 1H) 3.72 (s, 3H), 3.63 (s, 3H), 3.46–3.26 (m, 6H), 2.60 (ddd, 
J = 16.7, 8.6, 6.0 Hz, 1H), 2.54 (ddd, J = 16.3, 8.7, 7.3 Hz, 1H), 1.85 (s, 3H). 13C NMR 
(126 MHz, CDCl3): δ 172.5 (Cq), 170.7 (Cq), 169.9 (Cq), 151.1 (Cq), 150.5 (Cq), 149.7 
(CH), 138.9 (Cq), 138.5 (CH), 137.6 (Cq), 136.8 (CH), 136.7 (Cq), 136.5 (Cq), 128.5 
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(Cq), 122.5 (CH), 122.2 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 120.5 (CH), 118.6 
(CH), 116.0 (CH2), 112.6 (CH), 109.9 (CH), 109.6 (Cq), 55.6 (CH3), 52.8 (CH), 52.4 
(CH3), 40.0 (CH2), 33.3 (CH2), 27.1 (CH2), 23.0 (CH3), 20.4 (CH2). IR (ATR): 2951, 
1745, 1656, 1507, 1437, 1137, 1123, 742 cm‒1. MS (ESI): m/z (relative intensity) 578 
(62) [M+Na]+, 556 (100) [M+H]+. HR-MS (ESI): m/z calcd for C32H34N3O6+ [M+H]+: 
556.2442, found: 556.2438. 
 
Methyl acetyl-1-(2-pyridyl)-2-(1-pyrenyl propionate-3-yl)-L-tryptophanate (242aj) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), pyren-1-yl acrylate 22j (62 mg, 0.23 mmol) 
and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). Purification by column 
chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/2) yielded 242aj (62 mg, 68%) 
as a white solid. 
M.p.: 205 – 207 °C. 1H NMR (300 MHz, CDCl3): δ 8.76 (dd, J = 4.9, 1.2 Hz, 1H), 8.26–
8.08 (m, 3H), 8.07–7.88 (m, 4H), 7.78 (d, J = 9.2 Hz, 1H), 7.70–7.57 (m, 4H), 7.48–
7.35 (m, 2H), 7.33–7.24 (m, 2H), 6.29 (d, J = 7.7 Hz, 1H), 5.04 (ddd, J = 7.7, 6.1, 
6.1 Hz, 1H), 3.72 (s, 3H), 3.64–3.33 (m, 4H), 2.98–2.84 (m, 2H), 1.81 (s, 3H). 13C NMR 
(126 MHz, CDCl3): δ 172.6 (Cq), 171.6 (Cq), 170.0 (Cq), 151.2 (Cq), 149.7 (CH), 144.0 
(Cq), 138.9 (CH), 136.9 (Cq), 136.3 (Cq), 131.0 (Cq), 130.8 (Cq), 129.3 (Cq), 128.8 (Cq), 
128.1 (CH), 127.1 (CH), 127.0 (CH), 126.3 (CH), 125.5 (CH), 125.4 (Cq), 125.3 (CH), 
124.9 (CH), 124.4 (Cq), 122.9 (Cq), 122.8 (CH), 122.5 (CH), 121.1 (CH), 121.0 (CH), 
119.9 (CH), 119.5 (CH), 118.8 (CH), 110.2 (Cq), 110.1 (CH), 52.8 (CH), 52.4 (CH3), 
33.8 (CH2), 27.1 (CH2), 22.9 (CH3), 20.6 (CH2). IR (ATR): 3276, 3074, 2962, 2930, 
1742, 1647, 1542, 1472, 1459, 1148, 743 cm‒1. MS (ESI): m/z (relative intensity) 1241 
(100) [2M+Na]+, 632 (59) [M+Na]+, 610 (33) [M+H]+. HR-MS (ESI): m/z calcd for 
C38H32N3O5+ [M+H]+: 610.2336, found: 610.2336. 
  




isobutylphenyl)propanamido]ethyl propionate-3-yl}-L-tryptophanate (242ak) 
 
The general procedure E was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), 2-[2-(4-isobutylphenyl)propanamido]ethyl 
acrylate 22k (69 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH 
(0.15 mL). Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 
→ 1/2) yielded 242ak (80 mg, 83%) as a white solid.  
M.p.: 123 – 126 °C. 1H NMR (600 MHz, CDCl3, mixture of diastereoisomers 1.0/1.0): 
δ 8.60 (dd, J = 4.7, 2.9 Hz, 1H), 7.94–7.85 (m, 1H), 7.49 (ddd, J = 5.8, 1.8, 1.8 Hz, 1H), 
7.41 (d, J = 7.7 Hz, 1H), 7.33 (dd, J = 7.3, 4.8 Hz, 1H), 7.17–7.09 (m, 4H), 7.04 (d, J = 
7.6 Hz, 2H), 6.41–6.35 (m, 2H), 4.91–4.81 (m, 1H), 4.15–3.90 (m, 2H), 3.64 (s, 1.5H), 
3.63 (s, 1.5H), 3.57–3.44 (m, 1H), 3.44–3.23 (m, 2H), 3.22–3.10 (m, 2H), 2.38 (d, J = 
7.2 Hz, 3H), 2.32–2.23 (m, 2H), 1.94 (s, 1.5H), 1.91 (s, 1.5H), 1.83–1.74 (m, 1H), 1.43 
(d, J = 7.1 Hz, 1.5H), 1.42 (d, J = 6.9 Hz, 1.5H), 0.84 (d, J = 6.6 Hz, 6H). 13C NMR 
(126 MHz, CDCl3): δ 174.5 (Cq), 172.4 (Cq), 172.4 (Cq), 171.9 (Cq), 169.8 (Cq), 151.0 
(Cq), 149.6 (CH), 140.3 (Cq), 138.6 (Cq), 138.5 (Cq), 138.5 (CH), 136.6 (Cq), 136.6 (Cq), 
136.5 (Cq), 129.3 (CH), 128.4 (Cq), 128.4 (Cq), 127.1 (CH), 122.4 (CH), 122.3 (CH), 
120.8 (CH), 120.7 (CH), 118.2 (CH), 118.2 (CH), 110.0 (CH), 109.3 (Cq), 63.5 (CH2), 
53.1 (CH), 53.1 (CH), 52.4 (CH3), 46.3 (CH), 46.3 (CH), 45.0 (CH2), 38.6 (CH2), 34.0 
(CH2), 33.9 (CH2), 30.1 (CH), 27.2 (CH2), 27.2 (CH2), 23.2 (CH3), 23.2 (CH3), 22.4, 
20.5 (CH2), 18.7 (CH3), 18.6 (CH3). IR (ATR): 3276, 3074, 2962, 1742, 1647, 1542, 
1472, 1459, 1148, 743 cm‒1. MS (ESI): m/z (relative intensity) 1304 (22) [2M+Na]+ 663 
(63) [M+Na]+, 641 (100) [M+H]+. HR-MS (ESI): m/z calcd for C37H45N4O6+ [M+H]+: 
641.3334, found: 641.1331. 
 
  






The general procedure F was followed using methyl N-acetyl-1-(2-pyridyl)-L-tryptophyl-
L-isoleucinate 243a (67.5 mg, 0.15 mmol), 2-phenylphenyl acrylate 22f (52 mg, 
0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). 
Purification by column chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 30/1 → 
20/1) yielded 244a (77 mg, 76%) as a white solid. 
M.p.: 102 – 105 °C. 1H NMR (600 MHz, CDCl3): δ 8.54 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 
7.87 (dd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.70–7.66 (m, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.34 
(dd, J = 7.3, 1.9 Hz, 1H), 7.32–7.28 (m, 6H), 7.29–7.26 (m, 2H), 7.26–7.24 (m, 1H), 
7.18–7.11 (m, 2H), 7.04 (dd, J = 7.9, 1.5 Hz, 1H), 6.50 (d, J = 7.5 Hz, 1H), 6.29 (d, J = 
8.1 Hz, 1H), 4.82 (ddd, J = 8.7, 7.5, 6.3 Hz, 1H), 4.34 (dd, J = 8.1, 4.9 Hz, 1H), 3.47 
(s, 3H), 3.31 (dd, J = 14.5, 6.2 Hz, 1H), 3.16 (dd, J = 8.0, 6.7 Hz, 2H), 3.10 (dd, J = 
14.5, 8.8 Hz, 1H), 2.57 (ddd, J = 17.1, 6.9, 6.9 Hz, 1H), 2.40 (ddd, J = 17.1, 7.8, 7.8 Hz, 
1H), 1.93 (s, 3H), 1.71–1.66 (m, 1H), 1.27–1.19 (m, 1H), 1.02–0.93 (m, 1H), 0.80 (t, 
J = 7.4 Hz, 3H), 0.70 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 171.2 (Cq), 
170.9 (Cq), 170.9 (Cq), 169.7 (Cq), 151.2 (Cq), 149.5 (CH), 147.5 (Cq), 138.3 (CH), 
137.4 (Cq), 136.7 (Cq), 136.4 (Cq), 134.6 (Cq), 130.6 (CH), 128.7 (CH), 128.3 (CH), 
128.3 (Cq), 128.1 (CH), 127.3 (CH), 126.2 (CH), 122.8 (CH), 122.3 (CH), 122.1 (CH), 
120.9 (CH), 120.8 (CH), 118.7 (CH), 110.1 (Cq), 109.9 (CH), 56.6 (CH), 53.6 (CH), 
51.8 (CH3), 38.1 (CH), 33.5 (CH2), 28.1 (CH2), 25.1 (CH2), 23.2 (CH3), 20.1 (CH2), 15.2 
(CH3), 11.6 (CH3). IR (ATR): 2961, 2923, 1747, 1646, 1472, 1436, 743 cm‒1. MS (ESI): 
m/z (relative intensity) 697 (100) [M+Na]+, 675 (36) [M+H]+. HR-MS (ESI): m/z calcd 
for C40H43N4O6+ [M+H]+: 675.3177, found: 675.3165. 
  






The general procedure F was followed using methyl Na-acetyl-1-(pyridin-2-yl)-L-
tryptophyl-L-methioninate 243b (70.2 mg, 0.15 Mmol), 3-methoxyphenyl acrylate 22e 
(40 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.45 mL). 
Purification by column chromatography on silica gel (EtOAc) yielded 244b (55.2 mg, 
57%) as a white solid.  
M.p.: 88 – 89 °C. 1H NMR (600 MHz, CDCl3): δ 8.66 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 
7.93 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.68–7.62 (m, 1H), 7.58 (ddd, J = 7.8, 0.9, 0.9 Hz, 
1H), 7.36 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 7.32–7.27 (m, 1H), 7.18 (dd, J =8.2, 8.2 Hz, 
1H), 7.16–7.12 (m, 2H), 6.72 (ddd, J = 8.2, 2.2, 0.8 Hz, 1H), 6.55 (ddd, J = 8.2, 2.2, 
0.8 Hz, 1H), 6.52 (d, J = 7.4 Hz, 1H), 6.47 (dd, J = 2.2 Hz, 1H), 6.42 (d, J = 7.1 Hz, 
1H), 4.84 (ddd, J = 9.1, 7.4, 6.0 Hz, 1H), 4.44 (ddd, J = 7.1, 7.1, 5.1 Hz, 1H), 3.70 (s, 
3H), 3.51 (s, 3H), 3.43–3.34 (m, 3H), 3.15 (dd, J = 14.4, 9.1 Hz, 1H), 2.75 (ddd, J = 
16.7, 6.7, 6.7 Hz, 1H), 2.56 (ddd, J = 16.7, 7.8, 7.8 Hz, 1H), 2.29 (ddd, J = 13.3, 9.1, 
6.1 Hz, 1H), 2.23 (ddd, J = 13.3, 9.1, 6.1 Hz, 1H), 1.96 (s, 3H), 1.94 (s, 3H), 1.83–1.66 
(m, 2H). 13C NMR (126 MHz, CDCl3): δ 171.2 (Cq), 171.0 (Cq), 170.9 (Cq), 169.8 (Cq), 
160.3 (Cq), 151.3 (Cq), 151.3 (Cq), 149.6 (CH), 138.5 (CH), 136.8 (Cq), 136.3 (Cq), 
129.5 (CH), 128.3 (Cq), 122.4 (CH), 122.2 (CH), 121.0 (CH), 120.8 (CH), 118.6 (CH), 
113.6 (CH), 111.7 (CH), 110.2 (Cq), 109.9 (CH), 107.4 (CH), 55.4 (CH3), 53.7 (CH), 
52.3 (CH3), 51.6 (CH), 33.5 (CH2), 31.9 (CH2), 29.6 (CH2), 28.1 (CH2), 23.2 (CH3), 20.4 
(CH2), 15.4 (CH3). IR (ATR): 3277, 2921, 1744, 1645, 1459, 1436, 1137, 741 cm–1. MS 
(ESI): m/z (relative intensity) 1316 (58) [2M+Na]+, 669 (100) [M+Na]+, 647 (82) [M+H]+. 
HR-MS (ESI): m/z calcd for C34H39N4O7S+ [M+H]+: 647.2534, found: 647.2527. 
  






The general procedure F was followed using 3-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 243c (54 mg, 150 µmol), ethyl 
acrylate 22a (45 mg, 0.45 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH 
(0.45 mL). Purification by column chromatography on silica gel (EtOAc) yielded 244c 
(57 mg, 82%) as a pale yellow solid. 
M.p.: 97 – 98 °C. 1H NMR (600 MHz, CDCl3): δ 8.62 (ddd, J = 4.8, 2.0, 1.0 Hz, 1H), 
7.91 (ddd, J = 7.5, 7.5, 1.8 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.47 (dd, J = 7.9, 1.0 Hz, 1H), 
7.37 – 7.31 (m, 1H), 7.29 (ddd, J = 7.5, 1.0, 1.0 Hz, 1H), 7.22 – 7.08 (m, 2H), 5.86 (s, 
1H), 4.47 (dd, J = 11.5, 3.8 Hz, 1H), 4.10 – 3.97 (m, 3H), 3.74 (dd, J = 15.2, 3.8 Hz, 
1H), 3.67 (ddd, J = 11.7, 7.9, 7.9 Hz, 1H), 3.57 (ddd, J = 11.7, 8.8, 3.1 Hz, 1H), 3.26 – 
3.15 (m, 2H), 3.06 (ddd, J = 15.2, 11.7, 1.0 Hz, 1H), 2.43 (ddd, J = 15.9, 8.8, 7.1 Hz, 
1H), 2.39 – 2.28 (m, 2H), 2.09 – 1.97 (m, 2H), 1.93 – 1.83 (m, 1H), 1.15 (t, J = 7.2 Hz, 
3H). 13C NMR (126 MHz, CDCl3): δ 172.1 (Cq), 169.3 (Cq), 165.5 (Cq), 150.8 (Cq), 149.7 
(CH), 138.4 (CH), 137.3 (Cq), 136.8 (Cq), 127.6 (Cq), 122.8 (CH), 122.4 (CH), 121.0 
(CH), 120.9 (CH), 118.1 (CH), 110.3 (CH), 108.5 (Cq), 60.6 (CH2), 59.3 (CH), 54.5 
(CH), 45.5 (CH2), 34.0 (CH2), 28.4 (CH2), 25.7 (CH2), 22.7 (CH2), 20.6 (CH2), 14.2 
(CH3). IR (ATR): 2979, 2930, 1718, 1585, 1469, 1436, 1164, 782, 732 cm–1. MS (ESI): 
m/z (relative intensity) 943 (50) [2M+Na]+,483 (100) [M+Na]+, 461 (93) [M+H]+. HR-MS 
(ESI): m/z calcd for C26H29N4O4+ [M+H]+: 461.2183, found: 461.2186. 
  






The general procedure F was followed using methyl Na-(acetyl-L-glutaminyl)-1-(pyridin-
2-yl)-L-tryptophanate 243d (70 mg, 0:15 mmol), ethyl acrylate 22a (45 mg, 0.45 mmol) 
and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 20/1) yielded 244d (54 mg, 64%) as a 
white solid.  
M.p.: 206 – 209 °C. 1H NMR (300 MHz, CDCl3): δ 8.65 (d, J = 4.7 Hz, 1H), 7.95 (dd, J 
= 7.9, 7.4 Hz, 1H), 7.61–7.58 (m, 2H), 7.52 (d, J = 7.9 Hz, 1H), 7.39–7.35 (dd, J = 7.4, 
4.7 Hz, 1H), 7.30–7.25 (m, 1H), 7.18–7.15 (m, 2H), 6.64 (d, J = 6.7 Hz, 1H), 6.32 (s, 
1H), 5.61 (s, 1H), 4.95 (ddd, J = 6.4, 6.4, 6.4 Hz, 1H), 4.48 (ddd, J = 6.7, 6.7, 6.7 Hz, 
1H), 4.07 (q, J = 7.0, 2H), 3.76 (s, 3H), 3.42 (dd, J = 6.4 Hz, 5.5 Hz, 1H), 3.33–3.18 
(m, 3H), 2.40–2.22 (m, 4H), 2.11–2.04 (m, 1H), 2.01–1.96 (m, 1H), 1.94 (s, 3H), 1.18 
(t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 175.2 (Cq), 172.9 (Cq), 172.6 (Cq), 
171.3 (Cq), 170.1 (Cq), 151.2 (Cq), 149.8 (CH), 138.7 (CH), 136.91 (Cq), 136.90 (Cq), 
128.2 (Cq), 122.5 (CH), 122.4 (CH), 121.1 (CH), 120.8 (CH), 118.5 (CH), 110.0 (CH), 
109.3 (Cq), 60.8 (CH2), 52.9 (CH), 52.5 (CH3), 52.2 (CH), 33.4 (CH2), 31.6 (CH2), 29.0 
(CH2), 26.8 (CH2), 23.1 (CH3), 20.1 (CH2), 14.1 (CH3). IR (ATR): 3394, 3280, 3226, 
3064, 2952, 1734, 1687, 1633, 1585, 1539. MS (ESI): m/z (relative intensity) 588 (100) 
[M+Na]+, 566 (20) [M+H]+. HR-MS (ESI) m/z calcd for C29H35N5O7Na+ [M+Na]+: 
588.2434, found: 588.2431. 
  






The general procedure F was followed using methyl N-acetyl-1-(2-pyridyl)-L-tryptophyl-
L-alaninyl-L-phenylalaninate 243e (84.6 mg, 0.15 mmol), 3-methoxyphenyl acrylate 
22e (41 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 
mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 30/1 
→ 20/1) yielded 244e (58 mg, 53%) as a white solid.  
M.p.: 202 – 204 °C..1H NMR (300 MHz, CDCl3): δ 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.90 (ddd, J = 8.0, 7.4, 2.0 Hz, 1H), 7.72–7.63 (m, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.37–
7.08 (m, 8H), 7.07–7.00 (m, 2H), 6.70 (ddd, J = 8.2, 2.2, 0.9 Hz, 1H), 6.64–6.53 (m, 
3H), 6.51 (ddd, J = 8.2, 2.2, 0.9 Hz, 1H), 6.41 (dd, J = 2.2, 2.2 Hz, 1H), 4.80 (ddd, J = 
7.1, 7.1, 7.1 Hz, 1H), 4.65 (ddd, J = 7.8, 6.2, 6.2 Hz, 1H), 4.33 (dq, J = 7.0, 7.0 Hz, 
1H), 3.65 (s, 3H), 3.64 (s, 3H), 3.42–3.12 (m, 4H), 2.98 (d, J = 6.2 Hz, 2H), 2.69 (ddd, 
J = 16.6, 7.2, 6.1 Hz, 1H), 2.56 (ddd, J = 16.6, 7.7, 7.7 Hz, 1H), 1.83 (s, 3H), 1.17 (d, 
J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 171.5 (Cq), 171.4 (Cq), 171.0 (Cq), 
170.2 (Cq), 160.3 (Cq), 151.3 (Cq), 151.2 (Cq), 149.6 (CH), 138.5 (CH), 136.8 (Cq), 
136.3 (Cq), 135.8 (Cq), 129.6 (CH), 129.1 (CH), 128.5 (CH), 128.3 (Cq), 127.0 (CH), 
122.6 (CH), 122.3 (CH), 121.1 (CH), 120.8 (CH), 118.8 (CH), 113.6 (CH), 111.9 (CH), 
110.2 (Cq), 110.0 (CH), 107.3 (CH), 55.4 (CH3), 53.7 (CH), 53.4 (CH), 52.3 (CH3), 49.0 
(CH), 37.8 (CH2), 33.7 (CH2), 27.6 (CH2), 23.0 (CH3), 20.4 (CH2), 18.2 (CH3). IR (ATR): 
2919, 1748, 1628, 1541, 1521, 1472, 1141, 744 cm‒1. MS (ESI): m/z (relative intensity) 
756 (100) [M+Na]+, 734 (76) [M+H]+. HR-MS (ESI): m/z calcd for C41H44N5O8+ [M+H]+: 
734.3184, found: 734.3178. 
  






The general procedure F was followed using methyl N-acetyl-1-(2-pyridyl)-L-tryptophyl-
L-alaninyl-L-phenylalaninate 243e (84.6 mg, 0.15 mmol), 2-phenylphenyl acrylate 22f 
(52 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). 
Purification by column chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 30/1 → 
20/1) yielded 244f (69 mg, 59%) as a white solid.  
M.p.: 206 – 209 °C. 1H NMR (300 MHz, CDCl3): δ 8.52 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.85 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.71–7.60 (m, 1H), 7.43 (ddd, J = 8.0, 1.0, 1.0 Hz, 
1H), 7.35–7.22 (m, 10H), 7.22–7.17 (m, 3H), 7.16–7.08 (m, 2H), 7.07–6.90 (m, 3H), 
6.71–6.59 (m, 3H), 4.78 (ddd, J = 7.0, 7.0, 7.0 Hz, 1H), 4.64 (ddd, J = 7.7, 6.3, 6.3 Hz, 
1H), 4.35 (dq, J = 7.0, 7.0 Hz, 1H), 3.62 (s, 3H), 3.41–3.01 (m, 4H), 3.02–2.95 (m, 2H), 
2.54–2.33 (m, 2H), 1.82 (s, 3H), 1.17 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): 
δ 171.5 (Cq), 171.3 (Cq), 171.1 (Cq), 171.0 (Cq), 170.2 (Cq), 151.1 (Cq), 149.5 (CH), 
147.4 (Cq), 138.4 (CH), 137.3 (Cq), 136.8 (Cq), 136.3 (Cq), 135.8 (Cq), 134.6 (Cq), 130.7 
(CH), 129.1 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.2 (Cq), 128.1 (CH), 127.3 
(CH), 127.0 (CH), 126.3 (CH), 122.7 (CH), 122.5 (CH), 122.1 (CH), 121.0 (CH), 120.8 
(CH), 118.8 (CH), 110.0 (Cq), 109.9 (CH), 53.6 (CH), 53.4 (CH), 52.2 (CH3), 49.0 (CH), 
37.8 (CH2), 33.6 (CH2), 27.6 (CH2), 23.0 (CH3), 20.1 (CH2), 18.3 (CH3). IR (ATR): 2923, 
2853, 1748, 1683, 1637, 1507, 1473, 1188, 742 cm‒1. MS (ESI): m/z (relative intensity) 
1582 (19) [2M+Na] +, 802 (100) [M+Na]+, 780 (66) [M+H]+. HR-MS (ESI): m/z calcd for 
C46H46N5O7+ [M+H]+:780.3392, found: 780.3380. 
  






The general procedure F was followed using methyl N-acetyl-1-(2-pyridyl)-L-tryptophyl-
L-alaninyl-L-phenylalaninate 243e (84.6 mg, 0.15 mmol), pyren-1-yl acrylate 22j 
(62 mg, 0.23 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). 
Purification by column chromatography on silica gel (hexanes/EtOAc: 1/1 → 1/2) 
yielded 244h (66 mg, 53%) as a white solid.  
M.p.: 237 °C (decompotition). 1H NMR (300 MHz, CDCl3): δ 8.73 (dd, J = 5.2, 1.8 Hz, 
1H), 8.23–7.92 (m, 7H), 7.84–7.71 (m, 2H), 7.71–7.58 (m, 3H), 7.45–7.35 (m, 2H), 
7.27–7.15 (m, 5H), 7.06–6.91 (m, 2H), 6.69–6.53 (m, 3H), 4.87 (ddd, J = 7.0,7.0, 
7.0 Hz, 1H), 4.66 (ddd, J = 6.7, 6.7, 6.7 Hz, 1H), 4.35 (dq, J = 7.0, 7.0 Hz, 1H), 3.64 
(s, 3H), 3.58–3.45 (m, 2H), 3.43–3.18 (m, 2H), 3.09–2.83 (m, 4H), 1.66 (s, 3H), 1.14 
(d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 172.2 (Cq), 171.7 (Cq), 171.3 (Cq), 
171.2 (Cq), 170.5 (Cq) 151.5 (Cq), 149.8 (CH), 144.1 (Cq), 138.7 (CH), 137.1 (Cq), 136.4 
(Cq), 135.8 (Cq), 131.1 (Cq), 130.9 (Cq), 129.4 (Cq), 129.1 (CH), 128.5 (Cq), 128.5 (CH), 
128.2 (CH), 127.2 (CH), 127.1 (CH), 127.0 (CH), 126.4 (CH), 125.5 (CH), 125.5 (Cq), 
125.3 (CH), 124.9 (CH), 124.4 (Cq), 123.0 (Cq), 122.8 (CH), 122.5 (CH), 121.3 (CH), 
121.1 (CH), 120.0 (CH), 119.6 (CH), 119.1 (CH), 110.7 (Cq), 110.2 (CH), 53.7 (CH), 
53.3 (CH), 52.2 (CH3), 49.0 (CH), 37.7 (CH2), 33.7 (CH2), 27.6 (CH2), 22.8 (CH3), 20.5 
(CH2), 18.1 (CH3). IR (ATR): 3050, 2949, 2929, 1760, 1748, 1625, 1472, 1210, 848, 
741 cm‒1. MS (ESI): m/z (relative intensity) 1677 (54) [2M+Na]+, 850 (100) [M+Na]+, 
828 (86) [M+H]+. HR-MS (ESI): m/z calcd for C50H46N5O7+ [M+H]+: 828.3392, found: 
828.3393. 
  






The general procedure F was followed using benzyl Na-{N2-acetyl-N6-
[(benzyloxy)carbonyl]-L-lysyl}1-(pyridin-2-yl)-L-tryptophanate 243g (99 mg, 0.15 
mmol), but-3-en-2-one 245 (32 mg, 0.45 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 
mol %) in AcOH (0.45 mL). Purification by column chromatography on silica gel 
(CH2Cl2/MeOH: 40/1) yielded 246a (82 mg, 73%) as a white solid.  
M.p.: 178 – 180 °C. 1H NMR (600 MHz, CDCl3): δ 8.60 (dd, J = 5.0, 1.9 Hz, 1H), 7.89 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.57–7.50 (m, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.35–7.16 
(m, 12H), 7.15–7.07 (m, 2H), 7.02–6.96 (m, 1H), 6.21 (d, J = 7.1 Hz, 1H), 5.16–5.00 
(m, 5H), 4.95 (ddd, J = 7.0, 7.0, 7.0 Hz, 1H), 4.39 (ddd, J = 7.1, 7.1, 7.1 Hz, 1H), 3.34 
(dd, J = 14.8, 6.1 Hz, 1H), 3.27 (dd, J = 14.8, 7.6 Hz, 1H), 3.15–3.06 (m, 4H), 2.57–
2.34 (m, 2H), 1.96 (s, 3H), 1.87 (s, 3H), 1.79–1.69 (m, 1H), 1.60–1.51 (m, 1H), 1.48–
1.35 (m, 2H), 1.32–1.24 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 208.0 (Cq), 171.7 (Cq), 
171.5 (Cq), 169.7 (Cq), 156.4 (Cq), 151.1 (Cq), 149.6 (CH), 138.5 (CH), 137.2 (Cq), 
136.8 (Cq), 136.6 (Cq), 135.1 (Cq), 128.4 (CH), 128.4 (CH), 128.2 (CH), 128.2 (CH), 
128.2 (Cq), 127.9 (CH), 127.9 (CH), 122.4 (CH), 122.3 (CH), 121.0 (CH), 120.8 (CH), 
118.4 (CH), 109.9 (CH), 109.0 (Cq), 67.4 (CH2), 66.5 (CH2), 52.9 (CH), 52.5 (CH), 42.7 
(CH2), 40.4 (CH2), 32.2 (CH2), 30.0 (CH3), 29.3 (CH2), 27.1 (CH2), 23.2 (CH3), 22.0 
(CH2), 19.0 (CH2). IR (ATR): 3297, 2934, 1712, 1649, 1530, 1471, 1438, 1264, 1246, 
735 cm‒1. MS (ESI): m/z (relative intensity): 784 (65) [M+K]+, 769 (96) [M+Na]+, 746 
(100) [M+H]+. HR-MS (ESI): m/z calcd for C43H48N5O7+ [M+H]+: 746.3548, found: 
746.3540. 
  






The general procedure F was followed using methyl methyl N-[Na-acetyl-1-(pyridin-2-
yl)-L-tryptophyl]-S-(4-methylbenzyl)-L-cysteinyl-L-leucinate 243h (97 mg, 150 µmol), 
but-3-en-2-one 245 (32 mg, 0.45 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in 
AcOH (0.30 mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 
40/1 → 30/1) yielded 246b (96 mg, 88%) as a white solid.  
M.p.: 143 – 145 °C. 1H NMR (600 MHz, CDCl3): δ 8.64–8.51 (m, 1H), 7.89 (ddd, J = 
7.7, 7.7, 1.9 Hz, 1H), 7.69–7.60 (m, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.33 (ddd, J = 7.5, 
4.8, 1.0 Hz, 1H), 7.23–7.19 (m, 1H), 7.17 (d, J = 7.8 Hz, 2H), 7.12–7.06 (m, 2H), 7.06 
(d, J = 7.8 Hz, 2H), 6.94–6.89 (m, 2H), 6.79 (d, J = 6.5 Hz, 1H), 4.79 (ddd, J = 6.5, 6.5, 
6.5 Hz, 1H), 4.49–4.35 (m, 2H), 3.68–3.65 (m, 5H), 3.30 (dd, J = 14.7, 7.0 Hz, 1H), 
3.23 (dd, J = 14.7, 6.9 Hz, 1H), 3.10 (dd, J = 7.1, 7.1 Hz, 2H), 2.89 (dd, J = 14.1, 4.9 
Hz, 1H), 2.63–2.43 (m, 3H), 2.28 (s, 3H), 1.98 (s, 3H), 1.94 (s, 3H), 1.71–1.47 (m, 3H), 
0.90 (d, J = 5.9 Hz, 3H), 0.85 (d, J = 5.9 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 207.9 
(Cq), 172.5 (Cq), 171.2 (Cq), 170.5 (Cq), 169.5 (Cq), 151.3 (Cq), 149.5 (CH), 138.4 (CH), 
137.1 (Cq), 136.8 (Cq), 136.6 (Cq), 134.9 (Cq), 129.1 (CH), 128.8 (CH), 128.2 (Cq), 
122.3 (CH), 122.2 (CH), 121.3 (CH), 120.7 (CH), 118.5 (CH), 109.9 (CH), 109.4 (Cq), 
54.1 (CH), 52.3 (CH), 52.2 (CH), 51.3 (CH3), 42.7 (CH2), 40.8 (CH2), 36.4 (CH2), 33.7 
(CH2), 30.0 (CH3), 27.5 (CH2), 24.8 (CH), 23.1 (CH3), 22.8 (CH3), 21.9 (CH3), 21.1 
(CH3), 19.1 (CH2). IR (ATR): 3283, 2955, 1743, 1713, 1640, 1542, 1460, 1437, 1204, 
738 cm–1. MS (ESI): m/z (relative intensity): 1477 (12) [2M+Na]+, 750 (89) [M+Na]+, 
728 (100) [M+H]+. HR-MS (ESI): m/z calcd for C40H50N5O6S+ [M+H]+: 728.3476, found: 
728.3473. 
  







The general procedure F was followed using benzyl (S)-3-{[S]-2-acetamido-3-[1-
(pyridin-2-yl)-1H-indol-3-yl]propanamido}-4-{[(S)-1-methoxy-1-oxo-3-phenylpropan-2-
yl]amino}-4-oxobutanoate 243i (99 mg, 0.15 mmol), but-3-en-2-one 245 (32 mg, 
0.45 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.60mL). Purification 
by column chromatography on silica gel (CH2Cl2/MeOH: 40/1) yielded 246c (93 mg, 
82%) as a white solid.  
M.p.: 96 – 98 °C. 1H NMR (600 MHz, CDCl3): δ 8.60 (d, J = 3.2 Hz, 1H), 7.88 (ddd, J 
= 7.7, 7.7, 1.8 Hz, 1H), 7.61 (dd, J = 7.2, 1.6 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.35–
7.25 (m, 8H), 7.23–7.18 (m, 2H), 7.13–7.05 (m, 5H), 7.03 (d, J = 7.5 Hz, 1H), 6.63 (d, 
J = 6.5 Hz, 1H), 5.03 (d, J = 12.3 Hz, 1H), 4.99 (d, J = 12.3 Hz, 1H), 4.76–4.66 (m, 2H), 
4.61 (ddd, J = 7.5, 7.5, 5.9 Hz, 1H), 3.61 (s, 3H), 3.27 (dd, J = 14.7, 7.1 Hz, 1H), 3.18 
(dd, J = 14.7, 6.9 Hz, 1H), 3.11 (t, J = 7.2 Hz, 2H), 3.04 (dd, J = 14.0, 5.9 Hz, 1H), 2.98 
(dd, J = 14.0, 7.5 Hz, 1H), 2.90 (dd, J = 17.3, 4.1 Hz, 1H), 2.61–2.42 (m, 3H), 1.98 (s, 
3H), 1.89 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 207.7 (Cq), 171.4 (Cq), 171.2 (Cq), 
171.2 (Cq), 170.5 (Cq), 169.4 (Cq), 151.2 (Cq), 149.5 (CH), 138.4 (CH), 137.1 (Cq), 
136.8 (Cq), 136.0 (Cq), 135.2 (Cq), 129.1 (CH), 128.4 (CH), 128.4 (CH), 128.2 (Cq), 
128.2 (CH), 128.0 (CH), 126.9 (CH), 122.4 (CH), 122.3 (CH), 121.2 (CH), 120.8 (CH), 
118.5 (CH), 109.9 (CH), 109.4 (Cq), 66.7 (CH2), 54.1 (CH), 53.8 (CH), 52.2 (CH3), 49.1 
(CH), 42.7 (CH2), 37.5 (CH2), 35.8 (CH2), 30.0 (CH3), 27.2 (CH2), 23.0 (CH3), 19.0 
(CH2). IR (ATR): 3296, 3061, 2950, 1738, 1715, 1643, 1526, 1471, 1169, 742 cm–1. 
MS (ESI): m/z (relative intensity) 1542 (29) [2M+Na]+, 782 (100) [M+Na]+, 760 (82) 
[M+H]+. HR-MS (ESI): m/z calcd for C43H46N5O8+ [M+H]+: 760.3341, found: 760.3338. 
  




yl] propionate-3-yl}-L-tryptophanate (248a) 
 
The general procedure G was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), N-acetyl-L-phenylalaninyl-2-aminoethane-
1-yl acrylate 247a (46 mg, 0.17 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in 
AcOH (0.15 mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 
40/1 → 30/1) yielded 248a (64 mg, 67%) as a white solid.  
M.p.: 145 – 146 °C. 1H NMR (400 MHz, CDCl3): δ 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.94–7.84 (m, 1H), 7.53–7.45 (m, 1H), 7.43 (dd, J = 8.0, 0.9 Hz, 1H), 7.33 (ddd, J = 
7.5, 4.9, 1.0 Hz, 1H), 7.30–7.26 (m, 1H), 7.24–7.18 (m, 2H), 7.18–7.09 (m, 6H), 6.70 
(d, J = 8.0 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 4.84 (ddd, J = 7.8, 6.4, 6.4 Hz, 1H), 4.69 
(ddd, J = 8.0, 6.9, 6.9 Hz, 1H), 4.11–3.82 (m, 2H), 3.62 (s, 3H), 3.40 (dddd, J = 14.4, 
6.2, 6.2, 3.2 Hz, 1H), 3.34–3.26 (m, 2H), 3.25–3.10 (m, 3H), 3.09–2.93 (m, 2H), 2.43–
2.21 (m, 2H), 1.97 (s, 3H), 1.94 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 172.7 (Cq), 
171.9 (Cq), 171.2 (Cq), 170.1 (Cq), 169.7 (Cq), 151.0 (Cq), 149.7 (CH), 138.5 (CH), 
136.6 (Cq), 136.6 (Cq), 136.5 (Cq), 129.1 (CH), 128.3 (Cq), 128.3 (CH), 126.7 (CH), 
122.4 (CH), 122.3 (CH), 120.7 (CH), 118.2 (CH), 110.0 (CH), 109.4 (Cq), 63.4 (CH2), 
54.4 (CH), 53.3 (CH), 52.5 (CH3), 38.8 (CH2), 38.5 (CH2), 34.3 (CH2), 27.5 (CH2), 23.1 
(CH3), 23.1 (CH3), 20.7 (CH2). IR (ATR): 3062, 2951, 1735, 1650, 1541, 1471, 1458, 
1225, 1174, 745 cm‒1. MS (ESI): m/z (relative intensity) 664 (74) [M+Na]+, 642 (100) 
[M+H]+, 341 (31). HR-MS (ESI): m/z calcd for C35H40N5O7+ [M+H]+: 642.2922, found: 
642.2917. 
  







The general procedure G was followed using methyl (S)-2-(1,3-dioxoisoindolin-2-yl)-3-
[1-(pyridin-2-yl)-1H-indol-3-yl]propanoate 241c (64 mg, 0.15 mmol), methyl acryloyl-L-
phenylalaninate 247b (70 mg, 0.30 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) 
in AcOH (0.45 mL). Purification by column chromatography on silica gel (EtOAc) 
yielded 248b (52.3 mg, 53%) as a white solid.  
M.p.: 178 – 180 °C. 1H NMR (400 MHz, CDCl3): δ 8.55 (dd, J = 5.0, 1.8 Hz, 1H), 7.86 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.76–7.68 (m, 2H), 7.69–7.62 (m, 2H), 7.61–7.55 (m, 
1H), 7.35–7.30 (m, 2H), 7.26–7.18 (m, 4H), 7.10–7.02  (m, 4H), 6.29 (d, J = 7.8 Hz, 
1H), 5.32 (dd, J = 9.7, 5.9 Hz, 1H), 4.84 (ddd, J = 7.8, 6.0, 6.0 Hz, 1H), 3.82 (s, 3H), 
3.79–3.68 (m, 2H), 3.65 (s, 3H), 3.24–3.16 (m, 2H), 3.12 (dd, J = 13.9, 5.9 Hz, 1H), 
3.05 (dd, J = 13.9, 6.1 Hz, 1H), 2.37–2.27 (m, 1H), 2.27–2.16  (m, 1H). 13C NMR (101 
MHz, CDCl3): δ 172.0 (Cq), 171.3 (Cq), 169.5 (Cq), 167.6 (Cq), 151.2 (Cq), 149.6 (CH), 
138.5 (CH), 137.0 (Cq), 136.7 (Cq), 136.0 (Cq), 134.0 (CH), 131.7 (Cq), 129.2 (CH), 
128.4 (CH), 128.2 (Cq), 126.9 (CH), 123.4 (CH), 122.3 (CH), 122.2 (CH), 121.0 (CH), 
120.6 (CH), 118.3 (CH), 110.0 (CH), 109.7 (Cq), 53.0 (CH), 52.9 (CH3), 52.4 (CH3), 
52.1 (CH), 37.9 (CH2), 36.3 (CH2), 24.5 (CH2), 21.4 (CH2). IR (ATR): 3057, 2952, 1742, 
1713, 1672, 1436, 1388, 1368, 1204, 731 cm–1. MS (ESI): m/z (relative intensity) 681 
(100) [M+Na]+, 659 (59) [M+H]+. HR-MS (ESI): m/z calcd for C38H35N4O7+ [M+H]+: 
659.2500, found: 659.2508. 
  




yl] propionate-3-yl}-L-tryptophanate) (248c) 
 
The general procedure G was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), [methyl (N-acetyl-L-phenylalaninyl)-L-
alaninate-3-yl] acrylate 247c (60 mg, 0.17 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 
mol %) in AcOH (0.15 mL). Purification by column chromatography on silica gel 
(CH2Cl2/MeOH: 40/1 → 30/1 → 20/1) yielded 248c (67 mg, 64%) as a white solid. 
M.p.: 116 – 118 °C. 1H NMR (600 MHz, CDCl3): δ 8.67–8.56 (m, 1H), 7.89 (ddd, J = 
7.7, 7.7, 1.9 Hz, 1H), 7.53–7.47 (m, 1H), 7.43 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.39 (d, 
J = 7.5 Hz, 1H), 7.33 (ddd, J = 7.4, 4.9, 0.9 Hz, 1H), 7.28–7.25 (m, 1H), 7.26–7.21 (m, 
2H), 7.20–7.10 (m, 5H), 6.59 (d, J = 7.9 Hz, 1H), 6.49 (d, J = 8.0 Hz, 1H), 4.89 (ddd, 
J = 7.9, 6.5, 6.5 Hz, 1H), 4.80 (ddd, J = 8.0, 6.7, 6.7 Hz, 1H), 4.75 (ddd, J = 7.5, 3.6, 
3.6 Hz, 1H), 4.35 (dd, J = 8.2, 3.7 Hz, 1H) 4.33 (dd, J = 8.2, 3.7 Hz, 1H), 3.69 (s, 3H), 
3.62 (s, 3H), 3.36–3.25 (m, 2H), 3.19–3.11 (m, 3H), 2.99 (dd, J = 14.0, 7.1 Hz, 1H), 
2.50–2.28 (m, 2H), 1.97 (s, 3H), 1.92 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 172.8 
(Cq), 171.6 (Cq), 171.0 (Cq), 170.1 (Cq), 170.0 (Cq), 169.2 (Cq), 150.9 (Cq), 149.6 (CH), 
138.5 (CH), 136.7 (Cq), 136.5 (Cq), 136.4 (Cq), 129.2 (CH), 128.4 (Cq), 128.4 (CH), 
126.7 (CH), 122.5 (CH), 122.3 (CH), 120.8 (CH), 120.8 (CH), 118.3 (CH), 110.0 (CH), 
109.3 (Cq), 63.7 (CH2), 54.0 (CH), 53.0 (CH), 52.8 (CH3), 52.5 (CH3), 51.8 (CH), 38.1 
(CH2), 34.3 (CH2), 27.4 (CH2), 23.2 (CH3), 23.1 (CH3), 20.6 (CH2). IR (ATR): 3054, 
2953, 1742, 1653, 1541, 1458, 1222, 744 cm‒1. MS (ESI): m/z (relative intensity) 722 
(100) [M+Na]+, 700 (49) [M+H]+, 426 (30). HR-MS (ESI): m/z calcd for C37H42N5O9+ 
[M+H]+: 700.2977, found: 700.2971. 
  




yl}methylcarbonyl [L-phenylalaninyl-L-leucinate]) (248d) 
 
The general procedure G was followed using methyl acetyl-1-(2-pyridyl)-L-
tryptophanate 241a (50.6 mg, 0.15 mmol), methyl [2-(acryloyloxy)acetyl]-L-
phenylalanyl-L-leucinate 247d (67 mg, 0.17 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 
10 mol %) in AcOH (0.15 mL). Purification by column chromatography on silica gel 
(CH2Cl2/MeOH: 40/1 → 20/1) yielded 248d (68 mg, 61%) as a white solid.  
M.p.: 179 – 180 °C. 1H NMR (600 MHz, CDCl3): δ 8.65–8.62 (m, 1H), 7.91 (ddd, J = 
7.7, 7.7, 1.7 Hz, 1H), 7.54–7.49 (m, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.34 (dd, J = 7.4, 
4.9 Hz, 1H), 7.28–7.25 (m, 1H), 7.25–7.20 (m, 2H), 7.19–7.11 (m, 5H), 7.08 (d, J = 
7.6 Hz, 1H), 6.41 (d, J = 7.8 Hz, 1H), 6.31 (d, J = 7.8 Hz, 1H), 4.91 (ddd, J = 7.6, 7.6, 
7.6 Hz, 1H), 4.63 (ddd, J = 7.8, 7.8, 7.8 Hz, 1H), 4.51–4.37 (m, 3H), 3.67 (s, 3H), 3.63 
(s, 3H), 3.33 (dd, J = 14.7, 6.9 Hz, 1H), 3.28 (dd, J = 14.7, 5.6 Hz, 1H), 3.25–3.13 (m, 
2H), 3.09–2.97 (m, 2H), 2.54–2.40 (m, 2H), 1.94 (s, 3H), 1.60–1.39 (m, 3H), 0.85 (d, 
J = 6.3 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ 172.5 (Cq), 172.4 (Cq), 170.9 (Cq), 
170.0 (Cq), 169.9 (Cq), 166.8 (Cq), 150.9 (Cq), 149.7 (CH), 138.6 (CH), 136.6 (Cq), 
136.3 (Cq), 136.3 (Cq), 129.2 (CH), 128.5 (Cq), 128.5 (CH), 126.9 (CH), 122.5 (CH), 
122.4 (CH), 120.8 (CH), 120.8 (CH), 118.4 (CH), 110.1 (CH), 109.6 (Cq), 62.8 (CH2), 
54.2 (CH), 53.0 (CH), 52.4 (CH3), 52.2 (CH3), 51.0 (CH), 41.3 (CH2), 37.7 (CH2), 33.8 
(CH2), 27.5 (CH2), 24.8 (CH), 23.2 (CH3), 22.7 (CH3), 22.0 (CH3), 20.4 (CH2). IR (ATR): 
2956, 1743, 1654, 1541, 1472, 1478, 1159, 745 cm‒1. MS (ESI): m/z (relative intensity) 
764 (100) [M+Na]+, 742 (78) [M+H]+. HR-MS (ESI): m/z calcd for C40H48N5O9+ 
[M+H]+:742.3447, found: 742.3437. 
  




yl] propionate-3-yl}-L-tryptophyl-L-isoleucinate) (249a) 
 
The general procedure G was followed using methyl N-acetyl-1-(2-pyridyl)-L-
tryptophyl-L-isoleucinate 243a (67.5 mg, 0.15 mmol), [methyl (N-acetyl-L-
phenylalaninyl)-L-alaninate-3-yl] acrylate 247c (60 mg, 0.17 mmol) and [RuCl2(p-
cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.30 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 30/1 → 20/1) yielded 249a 
(68 mg, 56%) as a white solid.  
M.p.: 135 – 137 °C. 1H NMR (600 MHz, CDCl3): δ 8.63 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.89 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.58–7.55 (m, 1H), 7.49 
(dd, J = 8.0, 1.0 Hz, 1H), 7.32 (ddd, J = 7.7, 4.8, 1.0 Hz, 1H), 7.30–7.27 (m, 1H), 7.25–
7.17 (m, 3H), 7.17–7.10 (m, 4H), 6.88 (d, J = 8.0 Hz, 1H), 6.61–6.54 (m, 2H), 4.90 
(ddd, J = 6.9, 6.9, 6.9 Hz, 1H), 4.88–4.79 (m, 2H), 4.42 (dd, J = 11.3, 4.4 Hz, 1H), 4.38 
(dd, J = 8.4, 5.0 Hz, 1H), 4.34 (dd, J = 11.3, 3.2 Hz, 1H), 3.74 (s, 3H), 3.44 (s, 3H), 
3.30–3.09 (m, 5H), 3.00 (dd, J = 14.0, 6.8 Hz, 1H), 2.48 (ddd, J = 15.6, 9.2, 6.0 Hz, 
1H), 2.37 (ddd, J = 15.6, 9.1, 6.5 Hz, 1H), 1.97 (s, 3H), 1.94 (s, 3H), 1.77–1.69 (m, 1H), 
1.37–1.24 (m, 1H), 1.05 (ddq, J = 14.4, 9.3, 7.4 Hz, 1H), 0.82 (t, J = 7.4 Hz, 3H), 0.77 
(d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 171.9 (Cq), 171.2 (Cq), 171.1 (Cq), 
171.0 (Cq), 169.9 (Cq), 169.8 (Cq), 169.6 (Cq), 151.1 (Cq), 149.6 (CH), 138.4 (CH), 
136.6 (Cq), 136.6 (Cq), 136.4 (Cq), 129.2 (CH), 128.5 (Cq), 128.3 (CH), 126.7 (CH), 
122.3 (CH), 122.1 (CH), 120.9 (CH), 120.8 (CH), 118.2 (CH), 110.0 (CH), 109.7 (Cq), 
63.7 (CH2), 56.6 (CH), 53.9 (CH), 53.8 (CH), 52.8 (CH3), 51.9 (CH), 51.8 (CH3), 38.3 
(CH), 38.2 (CH2), 34.3 (CH2), 28.0 (CH2), 25.2 (CH2), 23.3 (CH3), 23.1 (CH3), 20.6 
(CH2), 15.2 (CH3), 11.6 (CH3). IR (ATR): 3050, 2949, 2929, 1744, 1656, 1584, 1458, 
1335, 1120, 736 cm‒1. MS (ESI): m/z (relative intensity) 835 (100) [M+Na]+, 813 (29) 
[M+H]+, 426 (30). HR-MS (ESI): m/z calcd for C43H53N6O10+ [M+H]+:813.3818, found 
813.3816. 
  




yl] propionate-3-yl}-L-tryptophyl-L-alaninyl-L-phenylalaninate (249b) 
 
The general procedure G was followed using methyl N-acetyl-1-(2-pyridyl)-L-
tryptophyl-L-alaninyl-L-phenylalaninate 243e (84.6 mg, 0.15 mmol), N-acetyl-L-
phenylalaninyl-2-aminoethane-1-yl acrylate 247a (46 mg, 0.17 mmol) and [RuCl2(p-
cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 20/1) yielded 249b (67 mg, 52%) 
as a white solid. 
M.p.: 192 °C (decomposition). 1H NMR (600 MHz, CDCl3): δ 8.59 (dd, J = 4.8, 1.6 Hz, 
1H), 7.85 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.70–7.60 (m, 1H), 7.49 (dd, J = 8.0, 1.0 Hz, 
1H), 7.39 (dd, J = 6.0, 6.0 Hz, 1H), 7.30 (ddd, J = 7.5, 4.8, 1.0 Hz, 1H), 7.26–7.23 (m, 
2H), 7.22–7.19 (m, 4H), 7.18–7.16 (m, 1H), 7.15–7.10 (m, 5H), 7.04–7.01 (m, 2H), 6.92 
(d, J = 7.3 Hz, 1H), 6.83–6.77 (m, 2H), 4.80–4.68 (m, 2H), 4.57 (ddd, J = 7.7, 6.4, 
6.4 Hz, 1H), 4.50 (dq, J = 7.0, 7.0 Hz, 1H), 4.05 (ddd, J = 11.4, 6.8, 2.9 Hz, 1H), 3.95 
(ddd, J = 11.4, 6.6, 2.9 Hz, 1H), 3.61 (s, 3H), 3.48–3.39 (m, 1H), 3.37–3.31 (m, 1H), 
3.27 (dd, J = 14.5, 6.3 Hz, 1H), 3.16–3.00 (m, 4H), 2.99–2.92 (m, 3H), 2.45–2.24 (m, 
2H), 1.96 (s, 3H), 1.88 (s, 3H), 1.23 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 
172.0 (Cq), 171.6 (Cq), 171.5 (Cq), 171.3 (Cq), 171.0 (Cq), 170.1 (Cq), 170.1 (Cq), 151.1 
(Cq), 149.6 (CH), 138.4 (CH), 136.8 (Cq), 136.6 (Cq), 136.6 (Cq), 136.5 (Cq), 135.8 (Cq), 
129.2 (CH), 129.0 (CH), 128.4 (CH), 128.3 (CH), 127.0 (CH), 126.7 (CH), 122.5 (CH), 
122.2 (CH), 121.1 (CH), 120.9 (CH), 118.4 (CH), 110.1 (CH), 109.6 (Cq), 63.5 (CH2), 
54.5 (CH), 54.4 (CH), 53.6 (CH), 52.2 (CH3), 48.8 (CH), 38.7 (CH2), 38.5 (CH2), 37.8 
(CH2), 34.7 (CH2), 28.0 (CH2), 23.3 (CH3), 23.1 (CH3), 20.7 (CH2), 19.1 (CH3). IR 
(ATR): 2957, 2921, 2851, 1734, 1647, 1541, 1457, 1438, 744 cm‒1. MS (ESI): m/z 
(relative intensity) 882 (100) [M+Na]+, 860 (46) [M+H]+. HR-MS (ESI): m/z calcd for 
C47H54N7O9+ [M+H]+: 860.3978, found: 860.3968. 
  







The general procedure G was followed using methyl N-acetyl-1-(2-pyridyl)-L-
tryptophyl-L-alaninyl-L-phenylalaninate 243e (84.6 mg, 0.15 mmol), methyl (2-
(acryloyloxy)acetyl)-L-phenylalanyl-L-leucinate 247d (67 mg, 0.17 mmol) and 
[RuCl2(p-cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.30 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 30/1 → 20/1) yielded 
249c(75 mg, 52%) as a white solid.  
M.p.: 152 – 154 °C. 1H NMR (600 MHz, CDCl3): δ 8.60 (dd, J = 5.0, 1.9 Hz, 1H), 7.88 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.64–7.61 (m, 1H), 7.54–7.49 (m, 1H), 7.35–7.29 (m, 
2H), 7.27–7.23 (m, 3H), 7.23–7.16 (m, 7H), 7.12–7.08 (m, 2H), 7.04–6.97 (m, 2H), 6.73 
(d, J = 7.3 Hz, 1H), 6.66-6.61 (m, 2H), 4.79 (ddd, J = 8.0, 8.0, 5.3 Hz, 1H), 4.63 (ddd, 
J = 7.4, 7.4, 7.4 Hz, 1H), 4.60 (ddd, J = 7.7, 7.7 Hz, 1H), 4.52–4.43 (m, 2H), 4.41–4.32 
(m, 2H), 3.66 (s, 3H), 3.61 (s, 3H), 3.34–3.10 (m, 4H), 3.06 (d, J = 7.2 Hz, 2H), 2.94 
(d, J = 6.2 Hz, 2H), 2.43 (t, J = 7.8 Hz, 2H), 1.93 (s, 3H), 1.59–1.48 (m, 2H), 1.45 (ddd, 
J = 12.5, 8.8, 5.1 Hz, 1H), 1.21 (d, J = 7.0 Hz, 3H), 0.85 (d, J = 6.4 Hz, 6H). 13C NMR 
(126 MHz, CDCl3): δ 172.5 (Cq), 171.5 (Cq), 171.2 (Cq), 171.1 (Cq), 170.8 (Cq), 170.3 
(Cq), 169.9 (Cq), 167.0 (Cq), 151.1 (Cq), 149.6 (CH), 138.4 (CH), 136.7 (Cq), 136.5 (Cq), 
136.3 (Cq), 135.7 (Cq), 129.2 (CH), 129.0 (CH), 128.5 (CH), 128.5 (CH), 128.4 (Cq), 
127.1 (CH), 126.9 (CH), 122.5 (CH), 122.2 (CH), 121.1 (CH), 120.8 (CH), 118.6 (CH), 
110.1 (CH), 109.8 (Cq), 63.0 (CH2), 54.5 (CH), 53.8 (CH), 53.4 (CH), 52.3 (CH3), 52.2 
(CH3), 51.1 (CH), 48.8 (CH), 41.2 (CH2), 37.8 (CH2), 37.8 (CH2), 33.9 (CH2), 27.8 
(CH2), 24.8 (CH3), 23.3 (CH3), 22.7 (CH3), 22.0 (CH), 20.4 (CH2), 18.8 (CH3). IR (ATR): 
2921, 1745, 1652, 1541, 1473, 1457, 1158, 745 cm‒1. MS (ESI): m/z (relative intensity) 
982 (100) [M+Na]+, 961 (14) [M+H]+. HR-MS (ESI): m/z calcd for C52H62N7O11+ [M+H]+: 
961.4502, found: 961.4502. 
  







The general procedure G was followed using methyl N-acetyl-1-(2-pyridyl)-L-
tryptophyl-L-alaninyl-L-phenylalaninate 243c (84.6 mg, 0.15 mmol), 2-[2-(4-
isobutylphenyl)propanamido]ethyl acrylate 22k (69 mg, 0.23 mmol) and RuCl2(p-
cymene)]2 (9.2 mg, 10 mol %) in AcOH (0.15 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 40/1 → 20/1) yielded 249d (82 mg, 
95 µmol, 63%) as a white solid. 
M.p.: 135 – 139 °C. 1H NMR (600 MHz, CDCl3, mixture of diastereoisomers): δ 8.60 
(ddd, J = 4.6, 2.1, 2.1 Hz, 1H), 7.95–7.82 (m, 1H), 7.67–7.60 (m, 1H), 7.50 (dd, J = 8.0, 
3.4 Hz, 1H), 7.33 (ddd, J = 5.1, 5.1, 2.4 Hz, 1H), 7.26 (s, 3H), 7.25–7.18 (m, 1H), 7.19–
7.14 (m, 2H), 7.12–7.07 (m, 4H), 7.05 (d, J = 6.6 Hz, 2H), 6.88–6.67 (m, 3H), 6.53–
6.47 (m, 1H), 4.76 (ddd, J = 7.2,7.2, 7.2 Hz, 1H), 4.67 (dq, J = 6.7, 6.7 Hz, 1H), 4.42–
4.32 (m, 1H), 4.12–3.92 (m, 2H), 3.65 (s, 3H), 3.54–3.35 (m, 2H), 3.31–3.08 (m, 5H), 
3.02 (dd, J = 6.3, 4.7 Hz, 2H), 2.42–2.27 (m, 4H), 1.94-1.91 (m, 3H), 1.83–1.74 (m, 
1H), 1.44 (d, J = 7.1 Hz, 1.5H), 1.41 (d, J = 7.1 Hz, 1.5H), 1.25 (t, J = 6.9 Hz, 3H), 0.86 
(d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3, mixture of diastereoisomers): δ 174.6 
(Cq), 172.5 (Cq), 172.4 (Cq), 171.6 (Cq), 171.0 (Cq), 171.0 (Cq), 170.9 (Cq), 170.0 (Cq), 
151.1 (Cq), 151.1 (Cq), 149.5 (CH), 140.3 (Cq), 140.2 (Cq), 138.6 (Cq), 138.6 (Cq), 138.5 
(Cq), 136.7 (Cq), 136.7 (Cq), 136.5 (Cq), 136.4 (Cq), 135.7 (Cq), 129.3 (CH), 129.2 (CH), 
129.1 (CH), 128.5 (CH), 128.3 (Cq), 128.3 (Cq), 127.1 (CH), 127.1 (CH), 122.4 (CH), 
122.3 (CH), 122.3 (CH), 121.2 (CH), 121.1 (CH), 120.7 (CH), 118.5 (CH), 118.4 (CH), 
110.0 (CH), 109.9 (Cq), 63.4 (CH2), 54.1 (CH), 53.5 (CH), 52.2 (CH3), 49.0 (CH), 46.3 
(CH), 46.3 (CH), 45.0 (CH2), 38.5 (CH2), 37.9 (CH2), 33.9 (CH2), 33.8 (CH2), 30.2 
(CH3), 28.0 (CH2), 27.9 (CH2), 23.2 (CH), 22.4 (CH3), 20.5 (CH2), 20.5 (CH2), 18.7 
(CH3), 18.7 (CH3), 18.6 (CH3). IR (ATR): 2950, 2923, 1734, 1683, 1647, 1637, 1541, 
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1523, 1508 cm‒1. MS (ESI): m/z (relative intensity) 882 (100) [M+Na]+, 859 (35) 





The general procedure H was followed using methyl (S)-2-acetamido-3-[2-(3-ethoxy-
3-oxopropyl)-1-(pyridin-2-yl)-1H-indol-3-yl]propanoate 242a (87.4 mg, 0.20 mmol). 
Purification by column chromatography on silica gel (EtOAc) yielded 250a (46.8 mg, 
65%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.82 (s, 1H), 7.42 (dd, J = 7.5, 1.1 Hz, 1H), 7.28–7.22 
(m, 1H), 7.10 (ddd, J = 8.1, 7.1, 1.3 Hz, 1H), 7.04 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 6.18 
(d, J = 7.8 Hz, 1H), 4.86 (ddd, J = 7.8, 5.7, 5.7 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.64 
(s, 3H), 3.30–3.24 (m, 1H), 3.24–3.18 (m, 1H), 3.00–2.91 (m, 2H), 2.68–2.60 (m, 2H), 
1.91 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 174.1 (Cq), 172.6 
(Cq), 169.8 (Cq), 135.8 (Cq), 135.3 (Cq), 128.4 (Cq), 121.5 (CH), 119.4 (CH), 118.0 
(CH), 110.7 (CH), 105.6 (Cq), 61.0 (CH2), 53.1 (CH), 52.3 (CH3), 34.0 (CH2), 26.7 
(CH2), 23.1 (CH3), 20.3 (CH2), 14.1 (CH3). IR (ATR): 3333, 2969, 1734, 1655, 1528, 
1438, 1374, 1202, 745 cm–1. MS (ESI): m/z (relative intensity) 743 (17) [2M+Na]+, 383 
(100) [M+Na]+, 361 (28) [M+H]+. HR-MS (ESI): m/z calcd for C19H25N2O5+ [M+H]+: 





The general procedure H was followed using ethyl 3-{3-[(1,4-
dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methyl]-1-[pyridin-2-yl]-1H-indol-2-
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yl}propanoate 244c (92.1 mg, 0.20 mmol). Purification by column chromatography on 
silica gel (EtOAc) yielded 250b (48.9 mg, 64%) as a pale yellow solid. 
M.p.: 92 – 94 °C. 1H NMR (400 MHz, CDCl3): δ 8.86 (s, 1H), 7.48–7.41 (m, 1H), 7.29 
(dd, J = 8.1, 0.9 Hz, 1H), 7.14 (ddd, J = 8.0, 7.1, 0.9 Hz, 1H), 7.06 (ddd, J = 8.0, 7.1, 
0.9 Hz, 1H), 5.73 (s, 1H), 4.36 (ddd, J = 11.3, 4.3, 1.5 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 
4.03 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 3.74 – 3.48 (m, 3H), 3.09–2.88 (m, 3H), 2.77–2.55 
(m, 2H), 2.38–2.23 (m, 1H), 2.07–1.94 (m, 2H), 1.93–1.79 (m, 1H), 1.22 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3): δ 173.8 (Cq), 169.4 (Cq), 165.7 (Cq), 136.2 (Cq), 135.6 
(Cq), 127.4 (Cq), 122.1 (CH), 119.8 (CH), 117.8 (CH), 111.0 (CH), 105.2 (Cq), 61.1 
(CH2), 59.2 (CH), 54.6 (CH), 45.4 (CH2), 34.0 (CH2), 28.3 (CH2), 25.6 (CH2), 22.6 
(CH2), 20.5 (CH2), 14.1 (CH3). IR (ATR): 3282, 2979, 2925, 1726, 1655, 1460, 1419, 
1188, 733 cm–1. MS (ESI): m/z (relative intensity) 789 (46) [2M+Na]+, 406 (100) 






The general procedure H was followed using (S)-methyl 2-acetamido-3-[2-(3-{2-[(S)-
2-acetamido-3-phenylpropanamido]ethoxy}-3-oxopropyl)-1-(pyridin-2-yl)-1H-indol-3-
yl]propanoate 248a (128.3 mg, 0.20 mmol). Purification by column chromatography on 
silica gel (CH2Cl2/MeOH: 40/1 → 20/1) yielded 250c (59.8 mg, 53%) as a pale yellow 
solid.  
M. p.: 107 – 109 °C. 1H NMR (400 MHz, CDCl3): δ 9.19 (s, 1H), 7.45 (d, J = 7.6 Hz, 
1H), 7.29–7.03 (m, 8H), 6.95–6.86 (m, 1H), 6.66 (d, J = 7.2 Hz, 1H), 6.51 (d, J = 7.7 
Hz, 1H), 4.86 (ddd, J = 6.7, 6.7, 6.7 Hz, 1H), 4.74–4.64 (m, 1H), 4.21–3.94 (m, 2H), 
3.67 (s, 3H), 3.45–3.35 (s, 2H), 3.33–3.17 (m, 2H), 3.10–2.95 (m, 4H), 2.74–2.60 (m, 
2H), 1.95–1.90 (m, 6H). 13C NMR (126 MHz, CDCl3): δ 173.3 (Cq), 172.8 (Cq), 171.6 
(Cq), 170.5 (Cq), 170.1 (Cq), 136.5 (Cq), 135.5 (Cq), 135.4 (Cq), 129.1 (CH), 128.5 (CH), 
128.4 (Cq), 126.9 (CH), 121.5 (CH), 119.4 (CH), 117.9 (CH), 110.7 (CH), 105.7 (Cq), 
63.3 (CH2), 54.5 (CH), 53.2 (CH), 52.4 (CH3), 38.4 (CH2), 38.3 (CH2), 33.8 (CH2), 26.9 
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(CH2), 23.0 (CH3), 22.9 (CH3), 20.8 (CH2). IR (ATR): 3296, 3062, 2952, 1731, 1648, 
1531, 1178, 731, 699 cm-1. MS (ESI): m/z (relative intensity) 587 (100) [M+Na]+, 565 
(26) [M+H]+. HR-MS (ESI): m/z calcd for C30H37N4O7+ [M+H]+: 565.2657, found: 
565.2651. 
 
5.5.1. Mechanistic Studies 
 
5.5.1.2. H/D Exchange Study 
 
 
A 10 mL conical-bottom test tube with a stir bar was charged with pyridylated 
tryptophan 241a (0.15 mmol) and [RuCl2(p-cymene)]2 (9.2 mg, 10 mol %). Toluene/D4-
acetic acid (1:1, 150 µL) were added. The tube was fitted with a septum and the 
mixture was heated to 80 °C for 1 h. After cooling to ambient temperature, the reaction 
mixture was diluted with toluene (5.0 mL). Purification by column chromatography 
(hexanes/EtOAc 1:1→1:2) yielded [D]1-241a (45 mg, 89%) as a white solid. The H/D 
exchange result was determined by 1H-NMR spectroscopy.  
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5.6. 3d-Transtion Metal-Catalyzed Allylation of Drug Scaffolds and Peptides 
 





The general procedure I was followed using (S)-methyl 2-acetamido-3-[1-(pyridin-2-
yl)-1H-indol-3-yl]propanoate 241a (67.5 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) yielded 254a (85.3 
mg, 98%) as a white foam. 
M. p. 52 – 56 ºC. 1H NMR (300 MHz, CDCl3): δ 8.56 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.82 (ddd, J = 7.9, 7.4, 2.0 Hz, 1H), 7.64 – 7.47 (m, 1H), 7.34 (ddd, J = 8.0, 0.8, 0.8 
Hz, 1H), 7.32 – 7.21 (m, 2H), 7.19 – 7.07 (m, 2H), 6.32 (d, J = 7.5 Hz, 1H), 5.92 (td, J 
= 1.8, 1.1 Hz, 1H), 5.01 (td, J = 2.2, 1.1 Hz, 1H), 4.92 (dt, J = 7.5, 6.0 Hz, 1H), 3.94 
(dd, J = 2.2, 1.8 Hz, 2H), 3.67 (s, 3H), 3.65 (s, 3H), 3.38 – 3.24 (m, 2H), 1.92 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 172.4 (Cq), 169.6 (Cq), 166.5 (Cq), 151.1 (Cq), 149.4 
(CH), 138.2 (CH), 137.3 (Cq), 136.8 (Cq), 134.2 (Cq), 128.4 (Cq), 126.1 (CH2), 122.5 
(CH), 122.1 (CH), 120.9 (CH), 120.7 (CH), 118.5 (CH), 110.4 (Cq), 110.1 (CH), 52.8 
(CH), 52.4 (CH3), 51.9 (CH3), 27.2 (CH2), 27.1 (CH2), 23.1 (CH3). IR (ATR): 3054, 2951, 
1718, 1656, 1585, 1470, 1436, 1370, 1256, 1138, 737 cm-1. MS (ESI): m/z (relative 
intensity): 458 (62) [M+Na]+, 436 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C24H26N3O5+ [M+H]+: 436.1867, found: 436.1871. 
  






The general procedure I was followed using (S)-benzyl 2-[(tert-butoxycarbonyl)amino]-
3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanoate 153 (94.3 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate) 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 4/1 → 2/1) yielded 254b (108.2 
mg, 95%) as a white solid. 
M. p. 62 – 64 ºC. 1H NMR (300 MHz, CDCl3): δ 8.56 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 
7.80 (ddd, J = 8.1, 7.4, 2.0 Hz, 1H), 7.62 – 7.53 (m, 1H), 7.35 – 7.20 (m, 6H), 7.21 – 
7.09 (m, 4H), 5.93 (td, J = 2.1, 1.0 Hz, 1H), 5.19 (d, J = 7.0 Hz, 1H), 5.07 (d, J = 12.2 
Hz, 1H), 5.01 – 4.92 (m, 2H), 4.67 (dt, J = 7.0 Hz, 1H), 3.94 (dd, J = 1.6, 1.0 Hz, 2H), 
3.64 (s, 3H), 3.30 (d, J = 7.0 Hz, 2H), 1.39 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 172.1 
(Cq), 166.5 (Cq), 154.9 (Cq), 151.1 (Cq), 149.3 (CH), 138.1 (CH), 137.3 (Cq), 136.7 (Cq), 
135.1 (Cq), 134.2 (Cq), 128.4 (Cq), 128.3 (CH), 128.2 (CH), 128.1 (CH), 126.0 (CH2), 
122.4 (CH), 122.0 (CH), 120.8 (CH), 120.6 (CH), 118.6 (CH), 110.6 (Cq), 110.1 (CH), 
79.7 (Cq), 67.2 (CH2), 54.2 (CH), 51.8 (CH3), 28.3 (CH3), 27.7 (CH2), 27.0 (CH2). IR 
(ATR): 2976, 2951, 1708, 1585, 1498, 1470, 1437, 1254, 733 cm-1. MS (ESI): m/z 
(relative intensity): 592 (100) [M+Na]+, 570 (75) [M+H]+, 514 (38). HR-MS (ESI): m/z 





The general procedure I was followed using (S)-methyl 2-acetamido-3-[1-(pyridin-2-
yl)-1H-indol-3-yl]propanoate 241a (67.5 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy][phenyl]methyl}acrylate 253d (116.9 mg, 0.40 mmol), MnBr(CO)5 
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(5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) yielded 254c 
(98.2 mg, 96%, E/Z = 1.2) as a white solid. 
M. p.: 153 – 156 ºC. 1H NMR (400 MHz, CDCl3): δ 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 
0.55H), 8.06 (ddd, J = 4.9, 2.0, 0.8 Hz, 0.45H), 7.82 (ddd, J = 8.0, 7.5, 2.0 Hz, 0.55H), 
7.73 (ddd, J = 7.9, 7.5, 2.0 Hz, 0.45H), 7.62 – 7.49 (m, 1H), 7.39 (dt, J = 8.0, 1.0 Hz, 
0.58H), 7.35 – 7.22 (m, 4H), 7.21 – 7.04 (m, 5H), 6.92 – 6.84 (m, 1.5H), 6.35 (d, J = 
7.5 Hz, 0.55H), 6.15 (s, 0.55H), 5.02 – 4.88 (m, 1H), 4.39 (dd, J = 16.1, 1.2 Hz, 0.45H), 
4.22 (dd, J = 16.2, 1.7 Hz, 0.45H), 4.09 (dd, J = 1.7, 0.9 Hz, 1.1H), 3.72 (s, 1.35H), 
3.68 (s, 1.65H), 3.57 (s, 1.35H), 3.43 (s, 1.65H), 3.40 – 3.24 (m, 2H), 1.93 (s, 1.35H), 
1.92 (s, 1.65H). 13C NMR (101 MHz, CDCl3): Major diastereomer: δ 172.5 (Cq), 169.9 
(Cq), 168.8 (Cq), 151.1 (Cq), 149.5 (CH), 138.3 (CH), 136.9 (Cq), 135.6 (Cq), 135.3 
(CH), 133.8 (Cq), 130.8 (Cq), 129.5 (CH), 128.4 (Cq), 127.8 (CH), 122.7 (CH), 122.2 
(CH), 121.3 (CH), 121.0 (CH), 120.7 (CH), 118.7 (CH), 110.7 (Cq), 110.0 (CH), 52.8 
(CH), 52.4 (CH3), 51.5 (CH3), 30.1 (CH2), 26.9 (CH2), 23.0 (CH3). Minor diastereomer: 
δ 172.9 (Cq), 170.4 (Cq), 167.9 (Cq), 150.9 (Cq), 149.5 (CH), 139.8 (CH), 137.9 (CH), 
137.0 (Cq), 135.3 (Cq), 134.4 (Cq), 129.3 (Cq), 128.7 (CH), 128.2 (Cq), 127.8 (CH), 
127.8 (CH), 122.3 (CH), 122.0 (CH), 121.0 (CH), 120.5 (CH), 118.5 (CH), 109.6 (Cq), 
109.6 (CH), 52.8 (CH), 52.3 (CH3), 52.0 (CH3), 26.8 (CH2), 24.1 (CH2), 22.7 (CH3). IR 
(ATR): 3363, 3057, 2951, 1741, 1714, 1658, 1587, 1471, 1437, 1225, 743 cm-1. MS 
(ESI): m/z (relative intensity) 534 (100) [M+Na]+, 512 (83) [M+H]+. HR-MS (ESI): m/z 





The general procedure I was followed using (S)-methyl 2-acetamido-3-[1-(pyridin-2-
yl)-1H-indol-3-yl]propanoate 241a (67.5 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy][4-chlorophenyl]methyl}acrylate 253e (130.7 mg, 0.40 mmol), 
MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) 
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yielded 254e (104.8mg, 96%, E/Z = 1.2) as a white solid. 
M. p. 157 – 159 ºC. 1H NMR (300 MHz, CDCl3): δ 8.62 (dd, J = 5.1, 2.0 Hz, 0.56H), 
8.14 – 8.05 (m, 0.44H), 7.88 – 7.64 (m, 1H), 7.63 – 7.45 (m, 1H), 7.37 (dt, J = 8.0, 1.0 
Hz, 0.56H), 7.33 – 7.19 (m, 3H), 7.19 – 7.04 (m, 5H), 6.86 (d, J = 6.5 Hz, 0.44H), 6.84 
– 6.76 (m, 1H), 6.32 (d, J = 7.5 Hz, 0.56H), 6.09 (s, 0.56H), 5.02 – 4.86 (m, 1H), 4.35 
(dd, J = 16.2, 1.3 Hz, 0.44H), 4.19 (dd, J = 16.1, 1.7 Hz, 0.44H), 4.09 (s, 1.16H), 3.71 
(s, 1.32H), 3.67 (s, 1.68H), 3.57 (s, 1.32H), 3.45 (s, 1.68H), 3.41 – 3.22 (m, 2H), 1.93 
(s, 1.32H), 1.92 (s, 1.68H). 
13C NMR (126 MHz, CDCl3): Major diastereomer: δ 172.7 (Cq), 169.7 (Cq), 168.3 (Cq), 
151.0 (Cq), 149.4 (CH), 138.3 (CH), 136.7 (Cq), 134.8 (Cq), 134.1 (CH), 134.0 (Cq), 
133.5 (Cq), 131.3 (Cq), 129.1 (CH), 128.3 (CH), 128.0 (Cq), 122.6 (CH), 122.2 (CH), 
121.1 (CH), 120.6 (CH), 118.6 (CH), 110.7 (Cq), 110.0 (CH), 52.9 (CH), 52.4 (CH3), 
51.6 (CH3), 30.1 (CH2), 27.0 (CH2), 22.7 (CH3). Minor diastereomer: δ 172.3 (Cq), 170.1 
(Cq), 167.5 (Cq), 150.8 (Cq), 149.4 (CH), 138.2 (CH), 137.8 (CH), 136.8 (Cq), 134.5 
(Cq), 133.5 (Cq), 132.7 (Cq), 130.6 (CH), 129.9 (Cq), 128.3 (CH), 128.1 (Cq), 122.2 
(CH), 121.9 (CH), 120.9 (CH), 120.5 (CH), 118.4 (CH), 109.8 (Cq), 109.5 (CH), 52.8 
(CH), 52.3 (CH3), 52.0 (CH3), 26.9 (CH2), 24.2 (CH2), 23.1 (CH3). IR (ATR): 3352, 3056, 
2951, 1715, 1660, 1471, 1437, 1224, 740 cm-1. MS (ESI): m/z (relative intensity) 568 
(86) [M+Na]+, 546 (100) [M+H]+. HR-MS (ESI): m/z calcd for C30H29N3O535Cl+ [M+H]+: 






The general procedure I was followed using (S)-methyl 2-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-4-
methylpentanoate 243j (101.7 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
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10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 4/1) yielded 255a (112.8 mg, 
93%) as a white solid. 
M. p. 74 – 77 ºC. 1H NMR (600 MHz, CDCl3): δ 8.56 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.82 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.62 (d, J = 6.9 Hz, 1H), 7.38 (dt, J = 8.0, 1.0 Hz, 
1H), 7.27 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.25 – 7.22 (m, 1H), 7.14 – 7.08 (m, 2H), 6.38 
(d, J = 7.9 Hz, 1H), 5.89 (td, J = 1.9, 1.2 Hz, 1H), 5.32 (brs, 1H), 5.05 (s, 1H), 4.57 – 
4.49 (m, 1H), 4.43 (ddd, J = 8.4, 8.4, 5.3 Hz, 1H), 3.98 (s, 2H), 3.64 (s, 3H), 3.52 (s, 
3H), 3.34 – 3.25 (m, 1H), 3.19 – 3.10 (m, 1H), 1.55 – 1.44 (m, 2H), 1.42 – 1.36 (s, 
10H), 0.85 (d, J = 6.0 Hz, 3H), 0.82 (d, J = 6.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 
172.3 (Cq), 171.1 (Cq), 166.7 (Cq), 155.2 (Cq), 151.3 (Cq), 149.3 (CH), 138.1 (CH), 
137.3 (Cq), 136.9 (Cq), 134.2 (Cq), 128.3 (Cq), 126.2 (CH2), 122.3 (CH), 122.1 (CH), 
121.2 (CH), 120.7 (CH), 118.7 (CH), 110.8 (Cq), 109.9 (CH), 79.8 (Cq), 54.6 (CH), 52.1 
(CH3), 52.0 (CH3), 50.7 (CH), 42.1 (CH2), 28.3 (CH3), 27.9 (CH2), 27.5 (CH2), 24.7 
(CH), 22.7 (CH3), 22.2 (CH3). IR (ATR): 3352, 2954, 1714, 1672, 1471, 1437, 1367, 
1202, 784 cm-1. MS (ESI): m/z (relative intensity) 1235 (23) [2M+Na]+, 629 (73) 
[M+Na]+, 607 (100) [M+H]+, 507 (27). HR-MS (ESI): m/z calcd for C33H43N4O7+ [M+H]+: 






The general procedure I was followed using tert-butyl ({S}-1-{[(S)-1-amino-4-methyl-1-
oxopentan-2-yl]amino}-1-oxo-3-{1-[pyridin-2-yl]-1H-indol-3-yl}propan-2-yl)carbamate 
243k (98.7 mg, 0.20 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a 
(86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30mol %) 
in 1,4-dioxane (0.6 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/2→ 1/5) yielded 255b (79.2 mg, 67%) as a white solid. 
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M. p. 104 – 107 ºC. 1H NMR (600 MHz, CDCl3): δ 8.57 (dd, J = 4.8, 1.8 Hz, 1H), 7.83 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.70 – 7.62 (m, 1H), 7.33 (d, J = 7.9 Hz, 1H), 7.30 (ddd, 
J = 7.5, 4.9, 1.0 Hz, 1H), 7.19 (dd, J = 7.7, 1.5 Hz, 1H), 7.17 – 7.08 (m, 2H), 6.42 (d, J 
= 8.3 Hz, 1H), 5.87 (d, J = 1.3 Hz, 1H), 5.66 (brs, 1H), 5.43 (brs, 2H), 4.99 (d, J = 1.3 
Hz, 1H), 4.54 (ddd, J = 7.6, 7.6, 7.6 Hz, 1H), 4.34 (ddd, J = 10.0, 8.3, 4.8 Hz, 1H), 3.97 
(dt, J = 17.3, 1.7 Hz, 1H), 3.89 (d, J = 17.3 Hz, 1H), 3.62 (s, 3H), 3.30 – 3.15 (m, 2H), 
1.63 (ddd, J = 13.8, 9.1, 4.7 Hz, 1H), 1.57 – 1.50 (m, 1H), 1.39 (s, 9H), 1.31 (ddd, J = 
13.8, 10.0, 5.1 Hz, 1H), 0.83 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ 173.8 (Cq), 171.8 (Cq), 166.6 (Cq), 155.5 (Cq), 150.9 (Cq), 149.4 
(CH), 138.4 (CH), 137.0 (Cq), 136.9 (Cq), 134.3 (Cq), 127.8 (Cq), 126.4 (CH2), 122.7 
(CH), 122.5 (CH), 121.5 (CH), 120.9 (CH), 118.7 (CH), 110.2 (Cq), 110.0 (CH), 80.2 
(Cq), 55.1 (CH), 52.0 (CH3), 51.4 (CH), 40.2 (CH2), 28.3 (CH3), 27.7 (CH2), 27.5 (CH2), 
24.7 (CH), 23.0 (CH3), 21.6 (CH3). IR (ATR): 3318, 2954, 1664, 1586, 1508, 1437, 
1253, 738 cm-1. MS (ESI): m/z (relative intensity) 614 (100) [M+Na]+, 592 (96) [M+H]+. 






The general procedure I was followed using (S)-methyl 2-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-3-
phenylpropanoate 243m (108.5 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 4/1 → 2/1) yielded 255d (116.6 
mg, 91%) as a white solid. 
M. p.: 80 – 82 ºC. 1H NMR (600 MHz, CDCl3): δ 8.55 (dd, J = 5.1, 1.9 Hz, 1H), 7.79 
(ddd, J = 7.8, 7.8, 1.9 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.26 
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(ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.19 (dd, J = 7.1, 1.6 Hz, 1H), 7.16 – 7.05 (m, 5H), 6.91 
– 6.85 (m, 2H), 6.37 (d, J = 7.3 Hz, 1H), 5.80 (s, 1H), 5.38 (d, J = 5.9 Hz, 1H), 5.00 (s, 
1H), 4.66 – 4.45 (m, 2H), 4.01 (d, J = 17.0 Hz, 1H), 3.97 (d, J = 17.0 Hz, 1H), 3.47 – 
3.45 (m, 6H), 3.37 – 3.25 (m, 1H), 3.13 – 3.06 (m, 1H), 2.96 (dd, J = 13.7, 5.7 Hz, 1H), 
2.90 (dd, J = 13.7, 5.4 Hz, 1H), 1.41 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 171.0 (Cq), 
170.6 (Cq), 166.6 (Cq), 155.0 (Cq), 151.2 (Cq), 149.3 (CH), 138.1 (CH), 137.3 (Cq), 
136.9 (Cq), 135.7 (Cq), 134.2 (Cq), 129.2 (CH), 128.3 (Cq), 128.2 (CH), 126.7 (CH), 
126.1 (CH2), 122.3 (CH), 122.1 (CH), 121.2 (CH), 120.6 (CH), 118.7 (CH), 110.7 (Cq), 
109.7 (CH), 79.7 (Cq), 54.4 (CH), 53.4 (CH), 51.9 (CH3), 51.9 (CH3), 38.2 (CH2), 28.4 
(CH3), 27.8 (CH2). (One aliphatic CH2 is missing due to overlap, the overlap was 
verified by HSQC analysis, showing that the peak at 28.4 ppm corresponds to two 
carbons). IR (ATR): 3346, 2976, 2952, 1712, 1670, 1586, 1471, 1437, 1253, 734 cm-
1. MS (ESI): m/z (relative intensity): 1303 (30) [2M+Na]+, 663 (63) [M+Na]+, 641 (100) 





The general procedure I was followed using (3S,8aS)-3-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 243c (72.1 mg, 0.20 mmol), 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), 
MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1→ 1/2) 
yielded 255e (84.3 mg, 92%) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 8.59 (dd, J = 4.9, 1.8 Hz, 1H), 7.86 (ddd, J = 7.7, 7.7, 
2.0 Hz, 1H), 7.61 – 7.55 (m, 1H), 7.38 (dd, J = 8.0, 1.0 Hz, 1H), 7.34 – 7.29 (m, 2H), 
7.21 – 7.15 (m, 2H), 6.00 (s, 1H), 5.97 (d, J = 1.4 Hz, 1H), 5.05 (d, J = 1.4 Hz, 1H), 
4.51 – 4.37 (m, 1H), 4.10 – 4.01 (m, 2H), 3.94 (d, J = 17.7 Hz, 1H), 3.75 (dd, J = 15.3, 
3.8 Hz, 1H), 3.67 (s, 3H), 3.67 – 3.63 (m, 1H), 3.57 (ddd, J = 12.0, 8.9, 3.2 Hz, 1H), 
3.05 (dd, J = 15.3, 11.2 Hz, 1H), 2.32 (ddt, J = 11.2, 7.1, 3.7 Hz, 1H), 2.16 – 1.97 (m, 
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2H), 1.95 – 1.85 (m, 1H). 13C NMR (126 MHz, CDCl3): δ 169.3 (Cq), 166.5 (Cq), 165.5 
(Cq), 150.8 (Cq), 149.4 (CH), 138.3 (CH), 137.1 (Cq), 137.0 (Cq), 134.6 (Cq), 127.6 (Cq), 
126.2 (CH2), 122.9 (CH), 122.3 (CH), 121.0 (CH), 121.0 (CH), 118.1 (CH), 110.4 (CH), 
109.7 (Cq), 59.2 (CH), 54.7 (CH), 52.0 (CH3), 45.4 (CH2), 28.3 (CH2), 27.4 (CH2), 25.7 
(CH2), 22.7 (CH2). IR (ATR): 3053, 2951, 2879, 1716, 1661, 1470, 1458, 1436, 1142, 
786 cm-1. MS (ESI): m/z (relative intensity): 939 (19) [2M+Na]+, 481 (63) [M+Na]+, 459 







The general procedure I was followed using (S)-methyl 2-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-3-
hydroxypropanoate 243n (96.5 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/2) yielded 255f (97.5 
mg, 84%) as a white solid. 
M. p. 97 – 99 ºC. 1H NMR (300 MHz, CDCl3): δ 8.59 (dd, J = 5.0, 1.8 Hz, 1H), 7.90 (td, 
J = 7.7, 1.9 Hz, 1H), 7.72 – 7.60 (m, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.35 (ddd, J = 7.6, 
4.9, 1.0 Hz, 1H), 7.27 – 7.11 (m, 3H), 6.85 (d, J = 6.7 Hz, 1H), 5.92 (s, 1H), 5.43 (d, J 
= 7.4 Hz, 1H), 5.03 (s, 1H), 4.61 (ddd, J = 7.4, 7.4, 7.4 Hz, 1H), 4.42 (ddd, J = 6.7, 3.2, 
3.2 Hz, 1H), 4.10 – 3.74 (m, 4H), 3.69 – 3.62 (s, 6H), 3.53 – 3.39 (m, 1H), 3.22 (dd, J 
= 14.5, 7.4 Hz, 1H), 2.22 (brs, 1H), 1.45 (s, 9H). 13C NMR (76 MHz, CDCl3): δ 171.9 
(Cq), 170.2 (Cq), 166.8 (Cq), 155.4 (Cq), 151.1 (Cq), 149.5 (CH), 138.7 (CH), 137.3 (Cq), 
137.1 (Cq), 134.5 (Cq), 128.4 (Cq), 126.3 (CH2), 122.7 (CH), 122.6 (CH), 121.7 (CH), 
121.0 (CH), 118.6 (CH), 110.9 (Cq), 109.9 (CH), 80.2 (Cq), 62.5 (CH2), 55.1 (CH), 55.1 
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(CH), 52.5 (CH3), 52.0 (CH3), 28.4 (CH3), 28.3 (CH2), 27.6 (CH2). IR (ATR): 3337, 2951, 
1744, 1715, 1671, 1472, 1368, 1162, 740 cm-1. MS (ESI): m/z (relative intensity) 1183 
(24) [2M+Na]+, 603 (100) [M+Na]+, 581 (66) [M+H]+, 481 (38). HR-MS (ESI): m/z calcd 






The general procedure I was followed using (S)-methyl 2-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-3-(4-
hydroxyphenyl)propanoate 243o (111.7 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/2) yielded 255g (116.9 
mg, 89%) as a white solid. 
M. p. 97 – 100 ºC. 1H NMR (600 MHz, CDCl3): δ 8.55 (dd, J = 4.9, 1.8 Hz, 1H), 7.81 
(ddd, J = 7.8, 7.8, 1.9 Hz, 1H), 7.64 – 7.53 (m, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.28 (dd, 
J = 7.5, 4.9 Hz, 1H), 7.19 – 7.16 (m, 1H), 7.10 – 7.06 (m, 2H), 7.03 – 6.93 (m, 1H), 
6.63 – 6.56 (m, 2H), 6.54 – 6.41 (m, 3H), 5.82 (s, 1H), 5.33 (brs, 1H), 4.98 (s, 1H), 4.63 
– 4.57 (m, 1H), 4.54 – 4.43 (m, 1H), 3.93 (s, 2H), 3.49 (s, 3H), 3.47 (s, 3H), 3.40 – 3.28 
(m, 1H), 3.12 – 3.07 (m, 1H), 2.92 – 2.84 (m, 1H), 2.79 (dd, J = 14.0, 5.8 Hz, 1H), 1.39 
(s, 9H). 13C NMR (126 MHz, CDCl3): δ 171.2 (Cq), 170.8 (Cq), 166.7 (Cq), 155.2 (Cq), 
155.1 (Cq), 151.1 (Cq), 149.1 (CH), 138.4 (CH), 137.1 (Cq), 136.9 (Cq), 134.3 (Cq), 
130.1 (CH), 128.3 (Cq), 126.8 (CH2), 126.2 (Cq), 122.4 (CH), 121.6 (CH), 120.7 (CH), 
118.9 (CH), 115.3 (CH), 110.6 (Cq), 109.6 (CH), 79.9 (Cq), 54.3 (CH), 53.4 (CH), 52.0 
(CH3), 52.0 (CH3), 37.2 (CH2), 28.3 (CH3), 27.9 (CH2), 27.7 (CH2). (One aromatic CH 
is missing due to overlap, the overlap was verified by HSQC analysis, showing that the 
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peak at 122.4 ppm corresponds to two carbons). IR (ATR): 3342, 2974, 2954, 2926, 
1715, 1669, 1515, 1473, 1439, 1367, 1225, 1170, 745 cm-1. MS (ESI): m/z (relative 
intensity) 679 (100) [M+Na]+, 657 (84) [M+H]+, 320 (37). HR-MS (ESI): m/z calcd for 





The general procedure I was followed using (S)-methyl 2-{[S]-2-acetamido-3-[1-
(pyridin-2-yl)-1H-indol-3-yl]propanamido}-4-(methylthio)butanoate 243b (93.7 mg, 
0.20 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 
mmol), MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane 
(0.6 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 
1/2) yielded 255h (91.8 mg, 81%) as a white solid. 
M. p. 106 – 108 ºC. 1H NMR (600 MHz, CDCl3): δ 8.56 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 
7.82 (ddd, J = 7.6, 7.6, 2.0 Hz, 1H), 7.60 – 7.55 (m, 1H), 7.40 (ddd, J = 7.9, 1.0, 1.0 
Hz, 1H), 7.27 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.21 – 7.18 (m, 1H), 7.11 – 7.04 (m, 2H), 
6.65 – 6.58 (m, 2H), 5.83 (t, J = 1.3 Hz, 1H), 5.06 (t, J = 1.3 Hz, 1H), 4.88 (ddd, J = 
9.3, 7.3, 6.0 Hz, 1H), 4.37 (ddd, J = 6.9, 6.9, 5.2 Hz, 1H), 4.06 (dt, J = 16.9, 1.3 Hz, 
1H), 3.99 (dt, J = 16.9, 1.3 Hz, 1H), 3.61 (s, 3H), 3.48 (s, 3H), 3.37 (dd, J = 14.4, 6.1 
Hz, 1H), 3.08 (dd, J = 14.2, 9.2 Hz, 1H), 2.34 (ddd, J = 13.4, 9.2, 6.2 Hz, 1H), 2.27 
(ddd, J = 13.4, 9.2, 6.0 Hz, 1H), 2.02 – 1.99 (m, 1H), 1.98 (s, 3H), 1.97 (s, 3H), 1.81 
(dddd, J = 14.2, 9.1, 6.9, 6.0 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ 171.1 (Cq), 170.9 
(Cq), 169.7 (Cq), 166.7 (Cq), 151.2 (Cq), 149.3 (CH), 138.1 (CH), 137.1 (Cq), 136.9 (Cq), 
134.4 (Cq), 128.3 (Cq), 126.4 (CH2), 122.2 (CH), 122.2 (CH), 121.3 (CH), 120.6 (CH), 
118.4 (CH), 110.5 (Cq), 109.7 (CH), 53.5 (CH), 52.3 (CH3), 52.0 (CH3), 51.6 (CH), 32.0 
(CH2), 29.6 (CH2), 28.0 (CH2), 27.9 (CH2), 23.3(CH3), 15.4 (CH3). IR (ATR): 3282, 
3056, 2952, 2918, 1741, 1718, 1585, 1542, 1205, 732 cm-1. MS (ESI): m/z (relative 
intensity) 1155 (56) [2M+Na]+, 589 (63) [M+Na]+, 567 (100) [M+H]+. HR-MS (ESI): m/z 
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The general procedure I was followed using (6S,9S,12S)-ethyl 12-[(1H-indol-3-
yl)methyl]-9-isobutyl-2,2-dimethyl-4,7,10-trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}-3-oxa-5,8,11-triazatridecan-13-oate 243p (141.8 mg, 0.20 mmol), methyl 2-
{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 
mg, 10.0 mol %) and NaOAc (4.9 mg, 30.0 mol %) in 1,4-dioxane (0.6 mL). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/2) yielded 255i 
(154.8 mg, 96%) as a white solid. 
M. p.: 102 – 107 ºC. 1H NMR (600 MHz, CDCl3): δ 8.76 (brs, 1H), 8.58 (ddd, J = 4.8, 
2.0, 0.8 Hz, 1H), 7.81 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.67 – 7.62 (m, 1H), 7.50 (dd, J 
= 7.7, 1.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.29 – 7.25 (m, 3H), 7.15 – 7.10 (m, 3H), 
7.06 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 6.91 – 6.87 (m, 1H), 6.63 (d, J = 7.7 Hz, 1H), 6.48 
(d, J = 8.2 Hz, 1H), 5.93 (td, J = 2.0, 1.2 Hz, 1H), 5.24 (d, J = 7.6 Hz, 1H), 5.02 (td, J = 
2.3, 1.2 Hz, 1H), 4.75 (ddd, J = 7.7, 5.8, 5.8 Hz, 1H), 4.57 – 4.45 (m, 1H), 4.37 (ddd, J 
= 7.8, 7.8, 7.8 Hz, 1H), 4.14 – 4.03 (m, 2H), 4.00 (d, J = 17.5 Hz, 1H), 3.95 (d, J = 17.4 
Hz, 1H), 3.64 (s, 3H), 3.36 – 3.14 (m, 4H), 1.63 – 1.54 (m, 1H), 1.51 – 1.44 (m, 1H), 
1.37 (s, 9H), 1.33 – 1.25 (m, 1H), 1.18 (t, J = 7.1 Hz, 3H), 0.79 (t, J = 6.8 Hz, 6H). 13C 
NMR (126 MHz, CDCl3): δ 171.5 (Cq), 171.4 (Cq), 170.7 (Cq), 166.8 (Cq), 155.5 (Cq), 
151.1 (Cq), 149.3 (CH), 138.2 (CH), 137.2 (Cq), 136.9 (Cq), 136.0 (Cq), 134.3 (Cq), 
128.2 (Cq), 127.3 (Cq), 126.2 (CH2), 123.3 (CH), 122.5 (CH), 122.2 (CH), 121.7 (CH), 
121.2 (CH), 120.8 (CH), 119.2 (CH), 118.9 (CH), 118.3 (CH), 111.2 (CH), 110.7 (Cq), 
110.0 (CH), 109.3 (Cq), 80.3 (Cq), 61.4 (CH2), 54.8 (CH), 52.7 (CH), 52.0 (CH3), 51.6 
(CH), 40.7 (CH2), 28.3 (CH3), 27.5 (CH2), 27.3 (CH2), 27.1 (CH2), 24.5 (CH), 22.7 
(CH3), 22.3 (CH3), 14.1 (CH3). IR (ATR): 3309, 2956, 2929, 1716, 1650, 1520, 1459, 
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1438, 1367, 1165, 741 cm-1. MS (ESI): m/z (relative intensity) 829 (100) [M+Na]+, 807 







The general procedure I was followed using (6S,9S)-ethyl 9-[(1H-indol-3-yl)methyl]-
2,2-dimethyl-4,7,10-trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-
triazatridecan-13-oate 243q (130.5 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), [MnBr(CO)5] (5.5 mg, 
10.0 mol %) and NaOAc (4.9 mg, 30.0 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 1/2) yielded 255j (145.5 
mg, 97%) as a white solid. 
M. p.: 109 – 111 ºC. 1H NMR (600 MHz, CDCl3): δ 8.77 (brs, 1H), 8.60 (dd, J = 5.0, 1.9 
Hz, 1H), 7.83 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.65 – 7.59 (m, 1H), 7.35 (ddd, J = 8.1, 
1.0, 1.0 Hz, 1H), 7.33 – 7.25 (m, 2H), 7.22 (d, J = 8.1 Hz, 1H), 7.18 – 7.10 (m, 3H), 
7.05 (dd, J = 7.7, 7.7 Hz, 1H), 6.88 (t, J = 7.6 Hz, 1H), 6.74 (brs, 2H), 6.52 (d, J = 7.9 
Hz, 1H), 5.84 (d, J = 1.5 Hz, 1H), 5.03 (d, J = 6.2 Hz, 1H), 4.92 (d, J = 1.5 Hz, 1H), 
4.70 (ddd, J = 6.5, 6.5, 6.5 Hz, 1H), 4.38 (ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 4.09 (q, J = 
7.1 Hz, 2H), 3.97 (d, J = 17.5 Hz, 1H), 3.91 (d, J = 17.5, 1H), 3.85 (dd, J = 17.5, 5.3 
Hz, 1H), 3.72 (dd, J = 17.5, 5.6 Hz, 1H), 3.60 (s, 3H), 3.35 – 3.24 (m, 2H), 3.15 (dd, J 
= 14.8, 6.5 Hz, 1H), 3.01 (dd, J = 14.8, 6.1 Hz, 1H), 1.24 – 1.15 (m, 12H). 13C NMR 
(126 MHz, CDCl3): δ 171.7 (Cq), 171.2 (Cq), 169.0 (Cq), 166.4 (Cq), 155.6 (Cq), 150.9 
(Cq), 149.3 (CH), 138.4 (CH), 137.0 (Cq), 136.9 (Cq), 135.8 (Cq), 134.3 (Cq), 128.1 (Cq), 
127.4 (Cq), 126.3 (CH2), 123.5 (CH), 122.7 (CH), 122.4 (CH), 121.7 (CH), 121.2 (CH), 
120.9 (CH), 119.4 (CH), 118.9 (CH), 118.0 (CH), 111.1 (CH), 110.2 (Cq), 110.0 (CH), 
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109.2 (Cq), 80.1 (Cq), 61.0 (CH2), 55.3 (CH), 53.7 (CH), 51.9 (CH3), 41.3 (CH2), 28.0 
(CH3), 27.2 (CH2), 26.7 (CH2), 26.5 (CH2), 14.1 (CH3). IR (ATR): 3310, 2979, 2929, 
1716, 1686, 1507, 1472, 1368, 1368, 1198, 1163, 741 cm-1. MS (ESI): m/z (relative 
intensity) 1523 (48) [2M+Na]+, 773 (63) [M+Na]+, 751 (100) [M+H]+. HR-MS (ESI): m/z 






The general procedure I was followed using (6S,9S,12S)-ethyl 12-[(1H-indol-3-
yl)methyl]-9-(2-amino-2-oxoethyl)-2,2-dimethyl-4,7,10-trioxo-6-{[1-(pyridin-2-yl)-1H-
indol-3-yl]methyl}-3-oxa-5,8,11-triazatridecan-13-oate 243r (141.9 mg, 0.20 mmol), 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), 
MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (CH2Cl2/MeOH: 60/1 → 40/1) 
yielded 255k (134.4 mg, 83%) as a pale yellow solid. 
M. p.: 126 – 128 ºC. 1H NMR (600 MHz, DMSO-d6): δ 10.85 (s, 1H), 8.56 (dd, J = 5.0, 
1.9 Hz, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.98 (ddd, J = 7.7, 7.7, 
2.0 Hz, 1H), 7.74 – 7.70 (m, 1H), 7.49 – 7.45 (m, 2H), 7.41 (dd, J = 7.5, 4.9 Hz, 1H), 
7.39 – 7.37 (m, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.18 – 7.15 (m, 1H), 
7.10 (dt, J = 6.3, 3.8 Hz, 2H), 7.08 – 7.03 (m, 1H), 7.00 – 6.94 (m, 2H), 6.87 (d, J = 8.8 
Hz, 1H), 5.84 (s, 1H), 4.97 (s, 1H), 4.64 (q, J = 6.9 Hz, 1H), 4.46 (q, J = 7.0 Hz, 1H), 
4.25 (td, J = 9.2, 4.3 Hz, 1H), 4.08 – 3.83 (m, 4H), 3.58 (s, 3H), 3.18 (dd, J = 14.6, 4.3 
Hz, 1H), 3.13 (dd, J = 14.6, 6.8 Hz, 1H), 3.08 (dd, J = 14.6, 7.1 Hz, 1H), 2.95 (dd, J = 
14.6, 9.7 Hz, 1H), 1.24 (s, 9H), 1.03 (t, J = 7.1 Hz, 3H). (Two aliphatic protons are 
missing due to overlap, the overlap was verified by HMBC analysis, showing that the 
peaks are overlapping with the residual solvent peak). 13C NMR (126 MHz, DMSO-d6): 
δ 171.4 (Cq), 171.2 (Cq), 171.1 (Cq), 170.6 (Cq), 165.9 (Cq), 154.8 (Cq), 150.4 (Cq), 
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149.0 (CH), 138.8 (CH), 136.9 (Cq), 136.0 (Cq), 135.9 (Cq), 133.7 (Cq), 128.0 (Cq), 
126.9 (CH2), 125.4 (Cq), 123.6 (CH), 122.3 (CH), 121.9 (CH), 121.8 (CH), 120.7 (CH), 
119.9 (CH), 118.7 (CH), 118.2 (CH), 117.7 (CH), 111.7 (Cq), 111.2 (CH), 109.8 (Cq), 
108.9 (CH), 78.1 (Cq), 60.3 (CH2), 55.3 (CH), 53.3 (CH), 51.7 (CH3), 49.2 (CH), 37.3 
(CH2), 28.0 (CH3), 27.0 (CH2), 26.9 (CH2), 26.4 (CH2), 13.8 (CH3). IR (ATR): 3292, 
2975, 1715, 1676, 1498, 1465, 1431, 1243, 733 cm-1. MS (ESI): m/z (relative intensity) 
830 (100) [M+Na]+, 808 (73) [M+H]+. HR-MS (ESI): m/z calcd for C43H50N7O9+ [M+H]+: 





The general procedure I was followed using (S)-methyl 2,2-dimethyl-4,7,10-trioxo-9-
{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-triazatridecan-13-oate 243s 
(101.9 mg, 0.20 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 
mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-
dioxane (0.6 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1→ 1/3) yielded 255l (64.4 mg, 53%) as a white solid. 
M. p.: 100 – 102 ºC. 1H NMR (600 MHz, CDCl3): δ 8.56 (dd, J = 5.0, 1.8 Hz, 1H), 7.83 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.30 – 
7.26 (m, 1H), 7.24 – 7.21 (m, 1H), 7.15 – 7.07 (m, 2H), 6.98 (d, J = 7.4 Hz, 1H), 6.62 
(brs, 1H), 5.87 (d, J = 1.4 Hz, 1H), 5.26 (brs, 1H), 5.02 (d, J = 1.4 Hz, 1H), 4.87 (ddd, 
J = 8.3, 7.3, 6.3 Hz, 1H), 4.04 – 3.94 (m, 2H), 3.92 (dd, J = 18.1, 5.5 Hz, 1H), 3.77 – 
3.72 (m, 2H), 3.68 (dd, J = 18.1, 4.9 Hz, 1H), 3.63 (s, 3H), 3.60 (s, 3H), 3.36 (dd, J = 
14.6, 6.3 Hz, 1H), 3.19 (dd, J = 14.6, 8.3 Hz, 1H), 1.39 (s, 9H). 13C NMR (126 MHz, 
CDCl3): δ 171.1 (Cq), 169.3 (Cq), 169.1 (Cq), 166.7 (Cq), 155.9 (Cq), 151.1 (Cq), 149.3 
(CH), 138.2 (CH), 137.1 (Cq), 136.9 (Cq), 134.5 (Cq), 128.2 (Cq), 126.4 (CH2), 122.5 
(CH), 122.2 (CH), 121.2 (CH), 120.8 (CH), 118.5 (CH), 110.7 (Cq), 110.0 (CH), 80.1 
(Cq), 53.4 (CH), 52.2 (CH3), 52.0 (CH3), 44.2 (CH2), 41.3 (CH2), 28.3 (CH3), 27.7 (CH2), 
27.6 (CH2). IR (ATR): 3305, 2953, 2927, 1716, 1655, 1471, 1459, 1209, 1169, 739 cm-
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1. MS (ESI): m/z (relative intensity): 1237 (45) [2M+Na]+, 630 (100) [M+Na]+, 608 (50) 







The general procedure I was followed using (6S,12S)-ethyl 12-(4-iodobenzyl)-2,2-
dimethyl-4,7,10-trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-
triazatridecan-13-oate 243t (147.9 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/3→ 0/1) yielded 255m 
(155.8 mg, 93%) as a white solid. 
M. p.: 109 – 111 ºC. 1H NMR (500 MHz, CDCl3): δ 8.55 (dd, J = 4.8, 1.8 Hz, 1H), 7.81 
(ddd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.66 – 7.50 (m, 3H), 7.35 (d, J = 7.9 Hz, 1H), 7.30 – 
7.21 (m, 3H), 7.17 – 7.06 (m, 2H), 6.94 – 6.79 (m, 2H), 6.65 (t, J = 5.4 Hz, 1H), 5.91 
(s, 1H), 5.39 (d, J = 6.9 Hz, 1H), 5.03 (s, 1H), 4.68 (ddd, J = 6.8, 6.8, 6.8 Hz, 1H), 4.45 
(ddd, J = 7.1, 7.1, 7.1 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 4.00 – 3.87 (m, 3H), 3.62 (s, 
3H), 3.53 (dd, J = 16.9, 4.7 Hz, 1H), 3.34 – 3.10 (m, 2H), 3.00 (dd, J = 13.8, 6.1 Hz, 
1H), 2.94 (dd, J = 13.8, 6.4 Hz, 1H), 1.37 (s, 9H), 1.16 (t, J = 7.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ 172.2 (Cq), 170.9 (Cq), 168.2 (Cq), 166.7 (Cq), 155.4 (Cq), 151.1 
(Cq), 149.4 (CH), 138.3 (CH), 137.5 (CH), 137.2 (Cq), 136.8 (Cq), 135.7 (Cq), 134.3 
(Cq), 131.3 (CH), 128.2 (Cq), 126.4 (CH2), 122.6 (CH), 122.3 (CH), 121.1 (CH), 120.8 
(CH), 118.6 (CH), 110.7 (Cq), 110.0 (CH), 92.5 (Cq), 80.0 (Cq), 61.5 (CH2), 55.0 (CH), 
53.1 (CH), 52.0 (CH3), 43.1 (CH2), 37.3 (CH2), 28.2 (CH3), 27.5 (CH2), 27.3 (CH2), 14.0 
(CH3). IR (ATR): 3306, 2978, 1714, 1654, 1509, 1471, 1437, 1367, 1163, 735 cm-1. 
MS (ESI): m/z (relative intensity): 1697 (38) [2M+Na]+, 860 (65) [M+Na]+, 838 (100) 
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The general procedure I was followed using (6S,9S,12S)-benzyl 6-isobutyl-2,2,9-
trimethyl-4,7,10-trioxo-12-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-
triazatetradecan-14-oate 243u (133.9 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in  1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) yielded 255u (145.8 
mg, 95%) as a white solid. 
M. p.: 123 – 125 ºC. 1H NMR (600 MHz, CDCl3): δ 8.59 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.83 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.71 – 7.64 (m, 1H), 7.38 – 7.33 (m, 5H), 7.33 – 
7.26 (m, 3H), 7.17 – 7.10 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.66 (d, J = 7.3 Hz, 1H), 
5.91 (d, J = 1.4 Hz, 1H), 5.13 (d, J = 13.4 Hz, 1H), 5.11 (d, J = 13.4 Hz, 1H), 5.07 (d, J 
= 7.9 Hz, 1H), 4.99 (d, J = 1.4 Hz, 1H), 4.72 – 4.59 (m, 1H), 4.37 (dt, J = 7.0, 7.0 Hz, 
1H), 4.13 – 4.05 (m, 1H), 3.99 (d, J = 17.5 Hz, 1H), 3.95 (d, J = 17.5 Hz, 1H), 3.67 (s, 
3H), 3.13 (dd, J = 14.5, 6.6 Hz, 1H), 3.04 (dd, J = 14.5, 8.2 Hz, 1H), 2.68 (dd, J = 16.3, 
5.4 Hz, 1H), 2.63 (dd, J = 16.3, 5.7 Hz, 1H), 1.68 – 1.63 (m, 1H), 1.58 (ddd, J = 13.8, 
8.7, 5.1 Hz, 1H), 1.52 – 1.44 (m, 1H), 1.44 (s, 9H), 1.26 (d, J = 7.0 Hz, 3H), 0.90 (t, J 
= 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ 172.1 (Cq), 171.3 (Cq), 171.3 (Cq), 166.7 
(Cq), 155.6 (Cq), 151.1 (Cq), 149.3 (CH), 138.2 (CH), 137.2 (Cq), 136.8 (Cq), 135.5 (Cq), 
133.9 (Cq), 128.4 (CH), 128.3 (Cq), 128.3 (CH), 128.2 (CH), 126.2 (CH2), 122.4 (CH), 
122.1 (CH), 121.1 (CH), 120.7 (CH), 118.9 (CH), 111.8 (Cq), 110.0 (CH), 80.0 (Cq), 
66.5 (CH2), 53.2 (CH), 52.0 (CH3), 48.8 (CH), 47.0 (CH), 41.3 (CH2), 37.3 (CH2), 29.0 
(CH2), 28.4 (CH3), 27.3 (CH2), 24.8 (CH), 23.1 (CH3), 21.9 (CH3), 18.4 (CH3). IR (ATR): 
3292, 2955, 2930, 1717, 1646, 1519, 1471, 1437, 1366, 1253, 1161, 738 cm-1. MS 
(ESI): m/z (relative intensity) 1558 (28) [2M+Na]+, 790 (58) [M+Na]+, 768 (100) [M+H]+. 
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The general procedure I was followed using (6S,9S,15S)-benzyl 6-benzyl-9-isobutyl-
2,2-dimethyl-4,7,10,13-tetraoxo-15-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-
5,8,11,14-tetraazahexadecan-16-oate 243v (78.9 mg, 0.10 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (43.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1→ 1/4) yielded 255o (83.3 
mg, 94%) as a white solid. 
M. p.: 93 – 96 ºC. 1H NMR (600 MHz, CDCl3): δ 8.53 – 8.47 (m, 1H), 7.82 (ddd, J = 
7.7, 7.7, 2.0 Hz, 1H), 7.57 – 7.48 (m, 1H), 7.31 – 7.25 (m, 6H), 7.21 – 7.15 (m, 5H), 
7.15 – 7.11 (m, 2H), 7.11 – 7.09 (m, 2H), 7.00 – 6.95 (m, 1H), 6.75 (d, J = 4.6 Hz, 1H), 
6.38 (d, J = 7.7 Hz, 1H), 5.89 (td, J = 1.8, 1.1 Hz, 1H), 5.33 (s, 1H), 5.11 (d, J = 12.3 
Hz, 1H), 4.99 – 4.93 (m, 3H), 4.34 (ddd, J = 9.6, 7.7, 5.0 Hz, 1H), 4.07 (d, J = 7.6 Hz, 
1H), 4.02 (dd, J = 17.0, 6.2 Hz, 1H), 3.91 (d, J = 17.4 Hz, 1H), 3.85 (d, J = 17.4 Hz, 
1H), 3.77 – 3.69 (m, 1H), 3.62 (s, 3H), 3.33 (d, J = 6.6 Hz, 1H), 3.32 (d, J = 6.3 Hz, 
1H), 3.05 (dd, J = 13.8, 6.6 Hz, 1H), 2.99 (dd, J = 13.8, 6.6 Hz, 1H), 1.59 (ddd, J = 
13.8, 8.9, 5.0 Hz, 1H), 1.53 – 1.46 (m, 1H), 1.42 – 1.35 (m, 1H), 1.36 (s, 9H), 0.86 – 
0.79 (m, 6H). 13C NMR (126 MHz, CDCl3): δ 171.7 (Cq), 171.6 (Cq), 171.6 (Cq), 168.5 
(Cq), 166.6 (Cq), 155.4 (Cq), 150.8 (Cq), 149.1 (CH), 138.5 (CH), 136.9 (Cq), 136.7 (Cq), 
136.7 (Cq), 134.9 (Cq), 134.3 (Cq), 129.2 (CH), 128.4 (CH), 128.4 (CH), 128.3 (Cq), 
128.2 (CH), 128.2 (CH), 126.8 (CH), 126.4 (CH2), 122.5 (CH), 122.3 (CH), 121.2 (CH), 
121.0 (CH), 118.6 (CH), 110.3 (Cq), 110.1 (CH), 80.2 (Cq), 67.4 (CH2), 56.0 (CH), 52.8 
(CH), 52.1 (CH3), 51.7 (CH), 42.9 (CH2), 40.2 (CH2), 37.3 (CH2), 28.3 (CH3), 27.3 
(CH2), 27.2 (CH2), 24.5 (CH), 23.1 (CH3), 21.7 (CH3). IR (ATR): 3285, 2954, 2927, 
1717, 1639, 1521, 1471, 1438, 1252, 784 cm-1. MS (ESI): m/z (relative intensity) 1797 
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(20) [M+Na]+, 909 (100) [M+Na]+, 887 (95) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure I was followed using (6S,9S,15S)-benzyl 9-benzyl-2,2,6-
trimethyl-4,7,10,13-tetraoxo-15-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-
5,8,11,14-tetraazahexadecan-16-oate 243w (74.7 mg, 0.10 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (43.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 1/4) yielded 255p (79.4 
mg, 94%) as a white solid. 
M. p.: 104 – 106 ºC. 1H NMR (600 MHz, CDCl3): δ 8.53 – 8.48 (m, 1H), 7.81 (td, J = 
7.7, 2.0 Hz, 1H), 7.60 – 7.51 (m, 1H), 7.29 – 7.23 (m, 6H), 7.21 – 7.19 (m, 2H), 7.17 – 
7.15 (m, 1H), 7.13 – 7.07 (m, 7H), 6.95 – 6.88 (m, 2H), 5.86 (d, J = 1.3 Hz, 1H), 5.07 
– 5.01 (m, 2H), 4.97 – 4.91 (m, 2H), 4.87 (ddd, J = 7.0, 7.0, 7.0 Hz, 1H), 4.57 (ddd, J 
= 7.0, 7.0, 7.0 Hz, 1H), 4.05 – 3.99 (m, 1H), 3.97 – 3.84 (m, 3H), 3.80 (dd, J = 16.8, 
5.4 Hz, 1H), 3.61 (s, 3H), 3.32 (dd, J = 14.7, 6.9 Hz, 1H), 3.27 (dd, J = 14.7, 6.7 Hz, 
1H), 3.07 (dd, J = 13.9, 6.5 Hz, 1H), 3.02 (dd, J = 13.9, 7.2 Hz, 1H), 1.35 (s, 9H), 1.15 
(d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 172.7 (Cq), 171.5 (Cq), 170.9 (Cq), 
168.3 (Cq), 166.6 (Cq), 155.5 (Cq), 150.9 (Cq), 149.2 (CH), 138.4 (CH), 137.0 (Cq), 
136.8 (Cq), 136.4 (Cq), 135.0 (Cq), 134.3 (Cq), 129.1 (CH), 128.5 (CH), 128.3 (CH), 
128.2 (Cq), 128.2 (CH), 128.1 (CH), 126.9 (CH), 126.4 (CH2), 122.6 (CH), 122.2 (CH), 
121.2 (CH), 120.8 (CH), 118.5 (CH), 110.5 (Cq), 110.1 (CH), 80.2 (Cq), 67.3 (CH2), 
54.5 (CH), 53.0 (CH), 52.0 (CH3), 50.5 (CH), 43.0 (CH2), 37.6 (CH2), 28.3 (CH3), 27.3 
(CH2), 18.2 (CH3). (One aliphatic CH2 is missing due to overlap, the overlap was 
verified by HSQC analysis, showing that the peak at 27.3 ppm corresponds to two 
carbons). IR (ATR): 3288, 2928, 1714, 1640, 1519, 1471, 1252, 734 cm-1. MS (ESI): 
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m/z (relative intensity) 1712 (15) [2M+Na]+, 867 (100) [M+Na]+, 845 (95) [M+H]+. HR-






The general procedure I was followed using (6S,9S,12S)-ethyl 9,12-diisopropyl-2,2-
dimethyl-4,7,10,13-tetraoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14-
tetraazahexadecan-16-oate 243x (66.4 mg, 0.10 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (43.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 1/4) yielded 255q (74.9 
mg, 98%) as a white solid. 
M. p.: 217 – 220 ºC. 1H NMR (600 MHz, CDCl3): δ 8.56 (dd, J = 5.1, 1.5 Hz, 1H), 7.82 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.61 (ddd, J = 7.3, 3.6, 3.6 Hz, 1H), 7.41 – 7.31 (m, 2H), 
7.27 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.14 – 7.07 (m, 2H), 7.05 – 
6.93 (m, 2H), 5.91 (d, J = 1.5 Hz, 1H), 5.50 (brs, 1H), 4.99 (d, J = 1.5 Hz, 1H), 4.55 
(ddd, J = 6.2, 6.2, 6.2 Hz, 1H), 4.48 – 4.39 (m, 1H), 4.25 (dd, J = 5.9, 5.9 Hz, 1H), 4.15 
(q, J = 7.1 Hz, 2H), 4.04 – 3.92 (m, 4H), 3.63 (s, 3H), 3.31 (dd, J = 15.0, 5.1 Hz, 1H), 
3.27 – 3.20 (m, 1H), 2.32 – 2.24 (m, 1H), 2.22 – 2.14 (m, 1H), 1.33 (s, 9H), 1.22 (t, J = 
7.1 Hz, 3H), 0.93 (t, J = 6.2 Hz, 6H), 0.84 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 172.9 (Cq), 171.3 (Cq), 170.9 (Cq), 169.5 (Cq), 166.6 
(Cq), 155.8 (Cq), 151.0 (Cq), 149.3 (CH), 138.3 (CH), 137.2 (Cq), 136.9 (Cq), 134.3 (Cq), 
128.1 (Cq), 126.3 (CH2), 122.6 (CH), 122.2 (CH), 121.1 (CH), 120.8 (CH), 118.8 (CH), 
110.4 (Cq), 110.0 (CH), 80.4 (Cq), 61.2 (CH2), 59.5 (CH), 58.7 (CH), 55.6 (CH), 52.0 
(CH3), 41.3 (CH2), 30.0 (CH), 30.0 (CH), 28.2 (CH3), 27.2 (CH2), 27.0 (CH2), 19.3 
(CH3), 19.2 (CH3), 17.7 (CH3), 14.2 (CH3). (One aliphatic CH3 is missing due to overlap, 
the overlap was verified by HSQC analysis, showing that the peak at 17.7 ppm 
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corresponds to two carbons). IR (ATR): 3281, 2963, 2931, 1719, 1634, 1471, 1437, 
1253, 1195, 737 cm-1. MS (ESI): m/z (relative intensity): 785 (79) [M+Na]+, 763 (100) 







The general procedure I was followed using (6S,9S,15S)-benzyl 6-benzyl-9-[(S)-sec-
butyl]-2,2-dimethyl-4,7,10,13-tetraoxo-15-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-
oxa-5,8,11,14-tetraazahexadecan-16-oate 243y (78.9 mg, 0.10 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (43.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1→ 1/4) yielded 255r (74.5 
mg, 84%) as a white solid. 
M. p.: 108 – 111 ºC. 1H NMR (600 MHz, CDCl3): δ 8.55 (d, J = 3.6 Hz, 1H), 7.81 (ddd, 
J = 7.7, 7.7, 1.9 Hz, 1H), 7.60 – 7.50 (m, 1H), 7.29 – 7.23 (m, 6H), 7.22 – 7.20 (m, 2H), 
7.18 – 7.08 (m, 7H), 7.03 (d, J = 7.4 Hz, 1H), 6.66 (brs, 1H), 6.48 (d, J = 7.0 Hz, 1H), 
5.86 (td, J = 1.8, 1.1 Hz, 1H), 5.14 (d, J = 7.8 Hz, 1H), 5.09 (d, J = 12.2 Hz, 1H), 5.00 
– 4.90 (m, 3H), 4.28 – 4.15 (m, 2H), 4.00 – 3.85 (m, 4H), 3.62 (s, 3H), 3.35 (dd, J = 
14.7, 6.8 Hz, 1H), 3.31 (dd, J = 14.7, 6.5 Hz, 1H), 3.04 (dd, J = 13.9, 6.6 Hz, 1H), 3.00 
(dd, J = 13.9, 7.3 Hz, 1H), 1.84 – 1.79 (m, 1H), 1.37 (s, 9H), 1.36 – 1.32 (m, 1H), 0.97 
(ddd, J = 13.5, 9.6, 7.2 Hz, 1H), 0.82 – 0.71 (m, 6H). 13C NMR (126 MHz, CDCl3): δ 
171.5 (Cq), 171.3 (Cq), 170.7 (Cq), 168.2 (Cq), 166.7 (Cq), 155.5 (Cq), 151.0 (Cq), 149.4 
(CH), 138.3 (CH), 137.0 (Cq), 136.8 (Cq), 136.5 (Cq), 135.0 (Cq), 134.4 (Cq), 129.2 
(CH), 128.6 (CH), 128.4 (CH), 128.2 (CH), 128.2 (CH), 126.8 (CH), 126.5 (CH2), 122.5 
(CH), 122.2 (CH), 121.1 (CH), 120.8 (CH), 118.6 (CH), 110.3 (Cq), 110.1 (CH), 80.3 
(Cq), 67.4 (CH2), 58.0 (CH), 56.0 (CH), 52.9 (CH), 52.1 (CH3), 42.8 (CH2), 37.7 (CH2), 
5. Experimental Part 
 
244 
36.6 (CH), 28.3 (CH3), 27.4 (CH2), 27.3, (CH2) 24.7 (CH2), 15.5 (CH3), 11.4 (CH3). 
(One aromatic Cq is missing due to overlap, the overlap was verified by HSQC and 
HMBC analysis, showing that the peak at 128.2 ppm corresponds to two carbons). IR 
(ATR): 3288, 2960, 2925, 1716, 1635, 1520, 1470, 1366, 1252, 735, 697 cm-1. MS 
(ESI): m/z (relative intensity) 909 (73) [M+Na]+, 887 (100) [M+H]+. HR-MS (ESI): m/z 







The general procedure I was followed using (6S,9S,12S,15S)-ethyl 12-[(R)-1-
(benzyloxy)ethyl]-9-[(benzyloxy)methyl]-15-[(S)-sec-butyl]-2,2-dimethyl-4,7,10,13,16-
pentaoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14,17-
pentaazanonadecan-19-oate 243z (94.8 mg, 0.10 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (43.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/2 → 0/1) yielded 255s (86.8 
mg, 83%) as a white solid. 
M. p.: 140 – 144 ºC. 1H NMR (600 MHz, CDCl3): δ 8.57 (dd, J = 5.1, 1.9 Hz, 1H), 7.82 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.36 (dd, J = 7.7, 1.0 Hz, 1H), 
7.30 – 7.18 (m, 13H), 7.15 – 7.09 (m, 2H), 7.01 – 6.93 (m, 3H), 5.91 (d, J = 1.4 Hz, 
1H), 5.34 (d, J = 5.6 Hz, 1H), 5.01 (d J = 1.4 Hz, 1H), 4.55 (d, J = 11.7 Hz, 1H), 4.47 – 
4.35 (m, 7H), 4.21 (d, J = 7.0 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 4.05 – 3.98 (m, 1H), 
3.96 (dd, J = 6.8, 1.6 Hz, 2H), 3.87 (dd, J = 17.9, 5.3 Hz, 1H), 3.80 (dd, J = 10.3, 3.6 
Hz, 1H), 3.64 (s, 3H), 3.49 (dd, J = 9.7, 6.2 Hz, 1H), 3.23 (d, J = 6.7 Hz, 2H), 1.51 – 
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1.41 (m, 1H), 1.32 – 1.27 (m, 10H), 1.22 (t, J = 7.1 Hz, 3H), 1.14 (d, J = 6.4 Hz, 3H), 
1. 11 – 1.04 (m, 1H), 0.87 (d, J = 6.8 Hz, 3H), 0.78 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3): δ 172.6 (Cq), 171.1 (Cq), 170.2 (Cq), 169.8 (Cq), 169.5 (Cq), 166.6 (Cq), 
155.5 (Cq), 151.1 (Cq), 149.4 (CH), 138.3 (CH), 137.8 (Cq), 137.2 (Cq), 137.0 (Cq), 
136.9 (Cq), 134.3 (Cq), 128.3 (CH), 128.2 (CH), 128.1 (Cq), 127.8 (CH), 127.6 (CH), 
127.6 (CH), 127.5 (CH), 126.2 (CH2), 122.6 (CH), 122.3 (CH), 121.2 (CH), 120.7 (CH), 
118.7 (CH), 110.4 (Cq), 110.0 (CH), 80.3 (Cq), 73.7 (CH), 73.4 (CH2), 71.3 (CH2), 68.8 
(CH2), 61.2 (CH2), 58.6 (CH), 58.3 (CH), 55.4 (CH), 54.0 (CH), 52.0 (CH3), 41.3 (CH2), 
36.5 (CH), 28.1 (CH3), 27.3 (CH2), 24.6 (CH2), 16.2 (CH3), 15.6 (CH3), 14.2 (CH3), 11.6 
(CH3). (One aliphatic CH2 is missing due to overlap, the overlap was verified by HSQC 
analysis, showing that the peak at 27.3 ppm corresponds to two carbons). IR (ATR): 
3280, 2972, 2932, 1719, 1633, 1523, 1471, 1199, 783 cm-1.MS (ESI): m/z (relative 
intensity): 1068 (100) [M+Na]+, 1046 (74) [M+H]+. HR-MS (ESI): m/z calcd for 







The general procedure I was followed using (9S,12S,15S,21S)-benzyl 12-benzyl-9-
[(tert-butoxycarbonyl)amino]-15-isobutyl-3,10,13,16,19-pentaoxo-1-phenyl-21-{[1-
(pyridin-2-yl)-1H-indol-3-yl]methyl}-2-oxa-4,11,14,17,20-pentaazadocosan-22-oate 
243aa (105.1 mg, 0.10 mmol), methyl 2-{[tert-butoxycarbonyl)oxy]methyl}acrylate 
253a (43.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 10 mol %) and NaOAc (2.5 mg, 30 
mol %) in 1,4-dioxane (0.3 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 1/1 → 1/4) yielded 255t (80.4 mg, 70%) as a white solid. 
M. p.: 100 – 102 ºC. 1H NMR (600 MHz, CDCl3): δ 8.55 – 8.50 (m, 1H), 7.77 (ddd, J = 
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7.7, 7.7, 2.0 Hz, 1H), 7.56 (dd, J = 6.1, 3.1 Hz, 1H), 7.36 – 7.29 (m, 4H), 7.30 – 7.21 
(m, 6H), 7.21 – 7.15 (m, 6H), 7.14 – 7.06 (m, 5H), 6.95 – 6.89 (m, 2H), 6.78 (d, J = 6.6 
Hz, 1H), 5.85 (s, 1H), 5.57 (brs, 1H), 5.18 – 5.02 (m, 3H), 4.98 – 4.87 (m, 2H), 4.84 – 
4.75 (m, 2H), 4.60 – 4.54 (m, 1H), 4.52 – 4.44 (m, 1H), 4.06 – 3.98 (m, 2H), 3.93 (d, J 
= 17.7 Hz, 1H), 3.88 – 3.78 (m, 2H), 3.60 (s, 3H), 3.29 – 3.23 (m, 1H), 3.19 – 3.08 (m, 
3H), 3.04 (dd, J = 14.0, 5.9 Hz, 1H), 1.79 – 1.64 (m, 2H), 1.62 – 1.54 (m, 1H), 1.54 – 
1.33 (m, 7H), 1.29 (s, 9H), 0.88 (d, J = 6.4 Hz, 3H), 0.83 (d, J = 6.5 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ 173.3 (Cq), 172.3 (Cq), 171.8 (Cq), 170.9 (Cq), 168.9 (Cq), 166.7 
(Cq), 156.8 (Cq), 156.6 (Cq), 151.0 (Cq), 149.3 (CH), 138.2 (CH), 137.1 (Cq), 136.7 (Cq), 
136.4 (Cq), 135.8 (Cq), 135.0 (Cq), 134.1 (Cq), 129.0 (CH), 128.7 (CH), 128.4 (CH), 
128.3 (Cq), 128.2 (CH), 128.0 (CH), 128.0 (CH), 127.9 (CH), 127.2 (CH), 126.2 (CH2), 
122.4 (CH), 122.4 (CH), 122.1 (CH), 121.0 (CH), 120.7 (CH), 118.6 (CH), 110.6 (Cq), 
110.1 (CH), 80.7 (Cq), 67.2 (CH2), 66.7 (CH2), 55.7 (CH), 54.9 (CH), 53.1 (CH), 52.1 
(CH), 51.9 (CH3), 43.1 (CH2), 40.0 (CH2), 39.8 (CH2), 36.9 (CH2), 30.8 (CH2), 29.5 
(CH2), 28.3 (CH3), 27.5 (CH2), 27.1 (CH2), 24.5 (CH), 23.2 (CH3), 22.0 (CH2), 21.2 
(CH3). IR (ATR): 3281, 2952, 1702, 1633, 1520, 1438, 1248, 1168, 734 cm-1. MS (ESI): 
m/z (relative intensity): 1172 (41) [M+Na]+, 1150 (50) [M+H]+, 586 (100) 525 (100). HR-






The general procedure I was followed using 2-{[S]-2-[(tert-butoxycarbonyl)amino]-3-[1-
(pyridin-2-yl)-1H-indol-3-yl]propanamido}-3-methylpentanoate 243f (101.7 mg, 0.20 
mmol), (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253f (136.2 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 256a (130.9 mg, 
90%) as a white solid. 
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M.p.: 87 – 89°C. 1H NMR (600 MHz, CDCl3): δ 8.53 (dd, J = 5.0, 1.8 Hz, 1H), 7.78 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.56 (d, J = 6.7 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.26 
– 7.22 (m, 1H), 7.21 – 7.18 (m, 1H), 7.10 – 7.04 (m, 2H), 6.52 (d, J = 7.8 Hz, 1H), 5.84 
(d, J = 1.4 Hz, 1H), 5.38 (d, J = 8.2 Hz, 1H), 5.05 (td, J = 2.5, 1.4 Hz, 1H), 4.60 (ddd, J 
= 10.9, 10.9, 4.4 Hz, 1H), 4.50 (ddd, J = 7.8, 7.8, 7.8 Hz, 1H), 4.32 (d, J = 6.3 Hz, 1H), 
3.98 (s, 2H), 3.44 (s, 3H), 3.31 (s, 1H), 3.12 (dd, J = 14.4, 8.8 Hz, 1H), 1.94 – 1.87 (m, 
1H), 1.73 – 1.57 (m, 4H), 1.40 (s, 9H), 1.36 – 1.25 (m, 4H), 1.08 – 0.92 (m, 2H), 0.85 
– 0.80 (m, 7H), 0.79 (d, J = 7.0 Hz, 3H), 0.72 (d, J = 6.8 Hz, 3H), 0.65 (d, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3): δ 171.0 (Cq), 170.9 (Cq), 165.5 (Cq), 155.1 (Cq), 151.3 
(Cq), 149.2 (CH), 138.0 (CH), 137.7 (Cq), 136.8 (Cq), 134.5 (Cq), 128.4 (Cq), 125.9 
(CH2), 122.1 (CH), 122.0 (CH), 121.3 (CH), 120.5 (CH), 118.5 (CH), 110.6 (Cq), 109.7 
(CH), 79.7 (Cq), 74.5 (CH), 56.4 (CH), 54.8 (CH), 51.7 (CH3), 47.1 (CH), 40.7 (CH2), 
38.3 (CH), 34.2 (CH2), 31.4 (CH), 28.4 (CH3), 28.0 (CH2), 27.9 (CH2), 26.3 (CH), 25.2 
(CH2), 23.6 (CH2), 22.0 (CH3), 20.8 (CH3), 16.5 (CH3), 15.1 (CH3), 11.6 (CH3). IR 
(ATR): 2957, 2871, 1706, 1472, 1366, 1252, 737 cm-1. MS (ESI): m/z (relative 
intensity): 1484 (9) [2M+Na]+, 753 (100) [M+Na]+, 731 (61) [M+H]+. HR-MS (ESI): m/z 







The general procedure I was followed using (6S,9S,15S)-benzyl 9-benzyl-2,2,6-
trimethyl-4,7,10,13-tetraoxo-15-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-
5,8,11,14-tetraazahexadecan-16-oate 243v (74.7 mg, 0.10 mmol), (1R,2S,5R)-2-
isopropyl-5-methylcyclohexyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253g (68.1 
mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-
dioxane (0.3 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 2/1→ 1/2) yielded 256b (89.2 mg, 83%) as a white solid. 
5. Experimental Part 
 
248 
M. p.: 112 – 114 ºC. 1H NMR (600 MHz, CDCl3): δ 8.48 (dd, J = 5.0, 1.8 Hz, 1H), 7.78 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.53 (dd, J = 6.0, 3.1 Hz, 1H), 7.29 – 7.23 (m, 6H), 7.22 
– 7.20 (m, 2H), 7.19 – 7.15 (m, 1H), 7.15 – 7.09 (m, 6H), 7.06 (d, J = 7.0 Hz, 1H), 7.00 
(d, J = 7.7 Hz, 1H), 6.90 (brs, 1H), 5.84 (d, J = 1.3 Hz, 1H), 5.08 – 5.04 (m, 2H), 4.97 
– 4.91 (m, 2H), 4.88 (q, J = 6.9 Hz, 1H), 4.65 – 4.53 (m, 2H), 4.03 (d, J = 9.4 Hz, 1H), 
3.97 – 3.84 (m, 3H), 3.79 (dd, J = 16.8, 5.3 Hz, 1H), 3.34 (dd, J = 14.8, 7.0 Hz, 1H), 
3.30 (dd, J = 15.1, 6.9 Hz, 1H), 3.07 (dd, J = 14.0, 6.6 Hz, 1H), 3.02 (dd, J = 13.8, 7.2 
Hz, 1H), 1.91 – 1.75 (m, 1H), 1.69 – 1.50 (m, 3H), 1.47 – 1.38 (m, 1H), 1.36 (s, 9H), 
1.31 – 1.21 (m, 1H), 1.13 (d, J = 7.0 Hz, 3H), 1.06 – 0.94 (m, 1H), 0.91 – 0.78 (m, 5H), 
0.75 (d, J = 7.0 Hz, 3H), 0.62 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 172.7 
(Cq), 171.5 (Cq), 170.8 (Cq), 168.2 (Cq), 165.6 (Cq), 155.4 (Cq), 151.1 (Cq), 149.2 (CH), 
138.2 (CH), 137.5 (Cq), 136.7 (Cq), 136.4 (Cq), 135.0 (Cq), 134.7 (Cq), 129.1 (CH), 
128.5 (CH), 128.4 (Cq), 128.3 (CH), 128.2 (CH), 128.1 (CH), 126.8 (CH2), 125.8 (CH), 
122.5 (CH), 122.1 (CH), 121.1 (CH), 120.7 (CH), 118.5 (CH), 110.3 (Cq), 110.1 (CH), 
80.2 (Cq), 74.6 (CH), 67.4 (CH2), 54.4 (CH), 53.0 (CH), 50.5 (CH), 47.0 (CH), 43.0 
(CH2), 40.8 (CH2), 37.6 (CH2), 34.2 (CH2), 31.3 (CH), 28.3 (CH3), 27.3 (CH2), 27.2 
(CH2), 26.3 (CH), 23.5 (CH2), 22.0 (CH3), 20.7 (CH3), 18.2 (CH3), 16.5 (CH3). IR (ATR): 
3290, 2955, 2926, 2869, 1707, 1638, 1520, 1471, 1438, 1250, 737 cm-1. MS (ESI): m/z 
(relative intensity): 991 (100) [M+Na]+, 970 (83) [M+H]+, 504 (46). HR-MS (ESI): m/z 








The general procedure I was followed using (2S,3S)-methyl 2-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-3-
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methylpentanoate 243l (50.9 mg, 0.10 mmol), (3S,8S,9S,10R,13R,14S,17R)-10,13-
dimethyl-17-[(R)-6-methylheptan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253h (114.2 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1→ 1/2) yielded 256c (85.6 
mg, 89%) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 8.58 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.82 (td, J = 7.7, 1.9 
Hz, 1H), 7.57 (d, J = 7.0 Hz, 1H), 7.45 – 7.41 (m, 1H), 7.28 (ddd, J = 7.4, 4.8, 1.0 Hz, 
1H), 7.22 – 7.18 (m, 1H), 7.12 – 7.06 (m, 2H), 6.59 (d, J = 6.7 Hz, 1H), 5.83 (d, J = 1.3 
Hz, 1H), 5.52 – 5.34 (m, 1H), 5.28 (d, J = 5.6 Hz, 1H), 5.06 (s, 1H), 4.62 – 4.55 (m, 
2H), 4.32 (dd, J = 8.2, 4.9 Hz, 1H), 4.05 (d J = 17.0 Hz, 1H), 3.98 (d, J = 17.0 Hz, 1H), 
3.46 (s, 3H), 3.37 – 3.29 (m, 1H), 3.18 – 3.08 (m, 1H), 2.31 – 2.19 (m, 2H), 2.00 (dt, J 
= 12.7, 3.5 Hz, 1H), 1.97 – 1.90 (m, 1H), 1.86 – 1.76 (m, 3H), 1.70 (tddd, J = 8.3, 6.1, 
4.2, 1.7 Hz, 1H), 1.60 – 1.20 (m, 21H), 1.18 – 0.94 (m, 13H), 0.92 – 0.89 (m, 4H), 0.86 
(d, J = 2.7 Hz, 3H), 0.85 (d, J = 2.7 Hz, 3H), 0.83 (t, J = 7.4 Hz, 3H), 0.74 (d, J = 6.9 
Hz, 3H), 0.67 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 171.1 (Cq), 170.9 (Cq), 165.5 (Cq), 
155.1 (Cq), 151.4 (Cq), 149.2 (CH), 139.5 (Cq), 138.0 (CH), 137.8 (Cq), 136.9 (Cq), 
134.4 (Cq), 128.4 (Cq), 125.9 (CH2), 122.5 (CH), 122.1 (CH), 122.1 (CH), 121.4 (CH), 
120.5 (CH), 118.5 (CH), 110.5 (CH), 109.6 (Cq), 79.6 (Cq), 74.2 (CH), 56.7 (CH) , 56.4 
(CH), 56.1 (CH), 54.5 (CH), 51.7 (CH3), 50.1 (CH), 42.3 (Cq), 39.7 (CH2), 39.5 (CH2), 
38.4 (CH), 37.9 (CH2), 37.0 (CH2), 36.6 (CH2), 36.2 (Cq), 35.8 (CH), 31.9 (CH2), 31.9 
(CH), 28.4 (CH3), 28.3 (CH2), 28.1 (CH), 28.0 (CH2), 28.0 (CH2), 27.7 (CH2), 25.1 
(CH2), 24.3 (CH2), 23.9 (CH2), 22.9 (CH3), 22.6 (CH3), 21.1 (CH2), 19.4 (CH3), 18.8 
(CH3), 15.2 (CH3), 11.9 (CH3), 11.7 (CH3). IR (ATR): 3346, 2948, 2868, 1740, 1710, 
1675, 1472, 1437, 1366, 1159, 736 cm-1. MS (ESI): m/z (relative intensity): 984 (100) 
[M+Na]+, 962 (39) [M+H]+. HR-MS (ESI): m/z calcd for C59H85N4O7+ [M+H]+: 961.6413, 
found: 961.6391. 
  







The general procedure I was followed using 3(3S,8aS)-3-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 243c (36.1 mg, 0.10 mmol), 
(1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253i (67.7 mg, 0.20 mmol), MnBr(CO)5 (2.7 mg, 
10 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.3 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/2) yielded 256d (56.3 mg, 
97%) as a white solid. 
M. p.: 95 – 96 ºC. 1H NMR (600 MHz, CDCl3): δ 8.57 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 
7.86 – 7.80 (m, 1H), 7.60 – 7.53 (m, 1H), 7.36 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.33 – 
7.26 (m, 2H), 7.21 – 7.14 (m, 2H), 5.97 (s, 1H), 5.97 (s, 1H), 5.04 (s, 1H), 4.84 (ddd, J 
= 10.0, 3.5, 2.1 Hz, 1H), 4.47 – 4.39 (m, 1H), 4.08 – 4.00 (m, 2H), 3.92 (dt, J = 17.8, 
1.7 Hz, 1H), 3.74 (dd, J = 15.3, 3.8 Hz, 1H), 3.65 (dt, J = 12.1, 8.2 Hz, 1H), 3.57 (ddd, 
J = 12.0, 8.9, 3.2 Hz, 1H), 3.03 (dd, J = 15.3, 11.4 Hz, 1H), 2.35 – 2.27 (m, 2H) 2.11 – 
1.96 (m, 2H), 1.94 – 1.78 (m, 2H), 1.71 (tt, J = 12.1, 4.0 Hz, 1H), 1.64 (t, J = 4.5 Hz, 
1H), 1.26 (dddd, J = 17.8, 11.6, 6.0, 3.6 Hz, 1H), 1.18 (ddd, J = 12.0, 9.4, 4.4 Hz, 1H), 
0.92 – 0.88 (m, 1H), 0.87 (s, 3H), 0.84 (s, 3H), 0.76 (s, 3H). 13C NMR (126 MHz, 
CDCl3): δ 169.3 (Cq), 166.2 (Cq), 165.5 (Cq), 150.8 (Cq), 149.5 (CH), 138.2 (CH), 137.8 
(Cq), 137.0 (Cq), 134.9 (Cq), 127.7 (Cq), 125.5 (CH2), 122.9 (CH), 122.3 (CH), 121.1 
(CH), 120.9 (CH), 118.1 (CH), 110.5 (CH), 109.7 (Cq), 80.5 (CH), 59.3 (CH), 54.8 (CH), 
48.9 (Cq), 47.8 (Cq), 45.5 (CH2), 44.9 (CH), 36.7 (CH2), 28.4 (CH2), 28.0 (CH2), 27.3 
(CH2), 27.3 (CH2), 25.7 (CH2), 22.7 (CH2), 19.7 (CH3), 18.9 (CH3), 13.6 (CH3). IR 
(ATR): 3054, 2953, 2878, 1663, 1586, 1470, 1458, 1262, 1138, 784 cm-1. MS (ESI): 
m/z (relative intensity) 603 (100) [M+Na]+, 581 (82) [M+H]+, 117 (35). HR-MS (ESI): 
m/z calcd for C35H41N4O4+ [M+H]+: 581.3122, found: 581.3124. 
  






The general procedure J was followed using 7-chloro-1-methyl-5-phenyl-1H-
benzo[e][1,4]diazepin-2(3H)-one 257c (56.9 mg, 0.20 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (1.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 4/1 → 2/1) yielded 258c (49.8 
mg, 65%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 7.44 – 7.29 (m, 4H), 7.23 – 7.14 (m, 2H), 6.99 (dd, J = 
2.5, 0.3 Hz, 1H), 6.10 (td, J = 1.8, 1.2 Hz, 1H), 5.15 (td, J = 2.3, 1.2 Hz, 1H), 4.81 (d, J 
= 10.9 Hz, 1H), 3.75 (d, J = 10.9 Hz, 1H), 3.64 (s, 3H), 3.46 (d, J = 17.1 Hz, 1H), 3.35 
(s, 3H), 3.26 (d, J = 17.1 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ 170.2 (Cq), 169.4 
(Cq), 166.9 (Cq), 141.5 (Cq), 138.9 (Cq), 138.3 (Cq), 136.5 (Cq), 131.3 (CH), 131.2 (Cq), 
130.9 (CH), 130.3 (CH), 129.8 (CH), 129.3 (Cq), 129.3 (CH), 126.8 (CH), 126.5 (CH2), 
122.3 (CH), 56.8 (CH2), 51.9 (CH3), 35.1 (CH2), 34.7 (CH3). IR (ATR): 2950, 2917, 
2849, 1716, 1673, 1613, 1480, 1341, 1196, 946, 732 cm-1. MS (ESI): m/z (relative 
intensity) 405 (74) [M+Na]+, 383 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C21H2035ClN2O3+ [M+H]+: 383.1157, found: 383.1156. 
 
(2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-{2-[2-(methoxycarbonyl)allyl]phenyl}-9H-
purin-9-yl)tetrahydrofuran-3,4-diyl diacetate (260a) 
 
The general procedure J was followed using (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-
phenyl-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 259a (90.9 mg, 0.20 mmol), 
methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 mmol), 
MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (1.0 mL). 
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Purification by column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 2/1) 
yielded 260a (99.4 mg, 90%) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 9.00 (s, 1H), 8.22 (s, 1H), 7.74 (dd, J = 7.6, 1.5 Hz, 1H), 
7.47 – 7.37 (m, 2H), 7.37 – 7.34 (m, 1H), 6.28 (d, J = 5.1 Hz, 1H), 6.05 (ddd, J = 1.8, 
1.8, 1.3 Hz, 1H), 6.01 (t, J = 5.3 Hz, 1H), 5.71 (dd, J = 5.6, 4.7 Hz, 1H), 5.20 (ddd, J = 
2.3, 2.3, 1.3 Hz, 1H), 4.50 – 4.45 (m, 2H), 4.40 (dd, J = 13.0, 5.2 Hz, 1H), 3.96 (d, J = 
16.6 Hz, 1H), 3.93 (d, J = 16.6 Hz, 1H), 3.60 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 2.10 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ 170.1 (Cq), 169.4 (Cq), 169.2 (Cq), 167.1 (Cq), 
158.9 (Cq), 152.2 (CH), 151.3 (Cq), 142.8 (CH), 139.6 (Cq), 137.7 (Cq), 134.6 (Cq), 
132.6 (Cq), 131.2 (CH), 130.9 (CH), 129.9 (CH), 126.5 (CH), 126.2 (CH2), 86.5 (CH), 
80.3 (CH), 73.1 (CH), 70.6 (CH), 63.0 (CH2), 51.8 (CH3), 35.1 (CH2), 20.8 (CH3), 20.6 
(CH3), 20.5 (CH3). IR (ATR): 2952, 2926, 1746, 1718, 1583, 1372, 1214, 1046, 765 
cm-1. MS (ESI): m/z (relative intensity): 575 (15) [M+Na]+, 553 (100) [M+H]+. HR-MS 




diyl diacetate (260b) 
 
The general procedure J was followed using (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-
phenyl-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 259a (90.9 mg, 0.20 mmol), 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253f (136.2 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (1.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 5/1 → 3/1) yielded 260b (116.4 
mg, 86%) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 9.00 (s, 1H), 8.23 (s, 1H), 7.77 (dd, J = 7.6, 1.6 Hz, 1H), 
7.43 (ddd, J = 7.4, 7.4, 1.6 Hz, 1H), 7.39 (ddd, J = 7.6, 7.6, 1.4 Hz, 1H), 7.35 (dd, J = 
7.6, 1.4 Hz, 1H), 6.29 (d, J = 5.4 Hz, 1H), 6.07 (ddd, J = 1.9, 1.9, 1.4 Hz, 1H), 5.99 (dd, 
J = 5.4, 5.4 Hz, 1H), 5.70 (dd, J = 5.4, 4.6 Hz, 1H), 5.20 (ddd, J = 2.2, 2.2, 1.4 Hz, 1H), 
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4.61 (ddd, J = 10.9, 10.9, 4.4 Hz, 1H), 4.51 – 4.44 (m, 2H), 4.42 – 4.38 (m, 1H), 3.97 
(d, J = 17.0 Hz, 1H), 3.93 (d, J = 17.0 Hz, 1H), 2.16 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 
1.86 (dtd, J = 12.0, 3.8, 1.8 Hz, 1H), 1.66 – 1.57 (m, 3H), 1.42 (tdd, J = 12.0, 6.5, 3.3 
Hz, 1H), 1.27 (ddt, J = 12.4, 10.9, 3.2 Hz, 1H), 0.99 (qd, J = 13.5, 12.9, 3.8 Hz, 1H), 
0.87 – 0.83 (s, 4H), 0.81 (dd, J = 12.4, 1.5 Hz, 1H), 0.78 (d, J = 7.0 Hz, 3H), 0.64 (d, J 
= 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 170.1 (Cq), 169.4 (Cq), 169.1 (Cq), 166.2 
(Cq), 158.9 (Cq), 152.2 (CH), 151.3 (Cq), 142.6 (CH), 140.2 (Cq), 138.0 (Cq), 134.5 (Cq), 
132.6 (Cq), 131.3 (CH), 130.7 (CH), 129.8 (CH), 126.4 (CH), 125.8 (CH2), 86.3 (CH), 
80.4 (CH), 74.5 (CH), 73.1 (CH), 70.6 (CH), 63.1 (CH2), 46.9 (CH), 40.6 (CH2), 35.3 
(CH2), 34.2 (CH2), 31.4 (CH), 26.2 (CH), 23.5 (CH2), 22.0 (CH3), 20.8 (CH3), 20.8 
(CH3), 20.6 (CH3), 20.5 (CH3), 16.4 (CH3). IR (ATR): 2955, 2869, 1748, 1707, 1582, 
1456, 1210, 911, 729 cm-1. MS (ESI): m/z (relative intensity) 699 (12) [M+Na]+, 677 







The general procedure J was followed using [(3aR,4R,6R,6aR)-2,2-dimethyl-6-(6-
phenyl-9H-purin-9-yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methanol 259b (73.6 mg, 
0.20 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (86.5 mg, 0.40 
mmol), MnBr(CO)5 (5.5 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane 
(1.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 
1/2) yielded 260c (79.3 mg, 85%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.96 (s, 1H), 8.18 (s, 1H), 7.72 (dd, J = 7.0, 2.1 Hz, 1H), 
7.48 – 7.32 (m, 3H), 6.03 (ddd, J = 1.8, 1.8, 1.3 Hz, 1H), 5.99 (d, J = 4.7 Hz, 1H), 5.63 
(dd, J = 10.7, 2.2 Hz, 1H), 5.28 (dd, J = 5.9, 4.7 Hz, 1H), 5.18 (ddd, J = 2.3, 2.3, 1.3 
Hz, 1H), 5.13 (ddd, J = 6.0, 1.5, 0.4 Hz, 1H), 4.55 (q, J = 1.8 Hz, 1H), 4.02 – 3.89 (m, 
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3H), 3.78 (ddd, J = 12.7, 10.5, 2.1 Hz, 1H), 3.59 (s, 3H), 1.65 (s, 3H), 1.38 (s, 3H). 13C 
NMR (126 MHz, CDCl3): δ 167.0 (Cq), 159.5 (Cq), 151.4 (CH), 150.4 (Cq), 144.1 (CH), 
139.5 (Cq), 137.7 (Cq), 134.4 (Cq), 133.5 (Cq), 131.2 (CH), 131.0 (CH), 130.0 (CH), 
126.5 (CH), 126.2 (CH2), 114.2 (Cq), 93.9 (CH), 86.2 (CH), 83.0 (CH), 81.5 (CH), 63.2 
(CH2), 51.8 (CH3), 35.1 (CH2), 27.6 (CH3), 25.3 (CH3). IR (ATR): 2990, 2939, 2249, 
1715, 1584, 1329, 1208, 1108, 1076, 725 cm-1. MS (ESI): m/z (relative intensity)  956 
(38) [2M+Na]+, 489 (45) [M+Na]+, 467 (100) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure J was followed using [(3aR,4R,6R,6aR)-2,2-dimethyl-6-(6-
phenyl-9H-purin-9-yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methanol 259b (73.7 mg, 
0.20 mmol), (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253i (135.4 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 
10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane (1.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/2 → 0/1) yielded 260d (82.4 
mg, 70%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.97 (s, 1H), 8.15 (s, 1H), 7.77 (dd, J = 7.5, 1.5 Hz, 1H), 
7.50 – 7.34 (m, 3H), 6.08 (ddd, J = 1.8, 1.8, 1.4Hz, 1H), 5.98 (d, J = 4.8 Hz, 1H), 5.63 
(dd, J = 11.0, 2.1 Hz, 1H), 5.30 (dd, J = 5.9, 4.8 Hz, 1H), 5.18 (ddd, J = 2.4, 2.4, 1.4 
Hz, 1H), 5.15 (dd, J = 6.0, 1.4 Hz, 1H), 4.82 (ddd, J = 9.9, 3.5, 2.1 Hz, 1H), 4.57 (t, J = 
1.8 Hz, 1H), 4.09 – 3.91 (m, 3H), 3.82 (ddd, J = 12.9, 11.1, 2.1 Hz, 1H), 2.40 – 2.17 
(m, 1H), 1.82 – 1.55 (m, 7H), 1.39 (s, 3H), 1.29 – 1.04 (m, 2H), 0.86 (s, 3H), 0.83 (s, 
3H), 0.72 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 167.1 (Cq), 159.7 (Cq), 151.5 (CH), 
150.5 (Cq), 144.2 (CH), 140.1 (Cq), 138.1 (Cq), 134.4 (Cq), 133.8 (Cq), 131.4 (CH), 
130.9 (CH), 130.2 (CH), 126.6 (CH), 126.1 (CH2), 114.3 (Cq), 94.1 (CH), 86.2 (CH), 
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82.9 (CH), 81.6 (CH), 80.2 (CH), 63.3 (CH2), 48.8 (Cq), 47.7 (Cq), 44.8 (CH), 36.6 
(CH2), 35.3 (CH2) , 27.9 (CH2), 27.6 (CH3), 27.1 (CH2), 25.2 (CH3), 19.6 (CH3), 18.8 
(CH3), 13.4 (CH3). IR (ATR): 2983, 2953, 2875, 1710, 1583, 1455, 1328, 1266, 1209, 
946, 763 cm-1. MS (ESI): m/z (relative intensity) 611 (18) [M+Na]+, 590 (100) [M+H]+. 








The general procedure I was followed using (6S,9R,14R)-methyl 14-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-9-
[methoxycarbonyl]-2,2-dimethyl-4,7-dioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-
oxa-11,12-dithia-5,8-diazapentadecan-15-oate 261 (99.5 mg, 0.10 mmol), methyl 2-
{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253A (86.5 mg, 0.40 mmol), MnBr(CO)5 (4.9 
mg, 20 mol %) and NaOAc (2.5 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (CH2Cl2/EtOAc: 4/1→ 3/1) yielded S1 (115.6 mg, 
97%) as a white solid. 
M. p.: 136 – 138 ºC. 1H NMR (300 MHz, CDCl3): δ 8.54 (ddd, J = 4.9, 1.9, 0.8 Hz, 2H), 
7.80 (ddd, J = 7.7, 7.7, 1.9 Hz, 2H), 7.56 (ddd, J = 7.0, 3.5, 3.5 Hz, 2H), 7.36 (ddd, J = 
7.9, 0.9, 0.9 Hz, 2H), 7.28 – 7.22 (m, 2H), 7.22 – 7.16 (m, 2H), 7.12 – 7.00 (m, 4H), 
6.90 (t, J = 4.5 Hz, 2H), 5.85 (d, J = 1.3 Hz, 2H), 5.50 (d, J = 7.9 Hz, 2H), 5.04 (d, J = 
1.3 Hz, 2H), 4.73 – 4.46 (m, 4H), 4.02 (d, J = 17.3 Hz, 2H), 3.94 (d, J = 17.3 Hz, 2H), 
3.61 (s, 6H), 3.52 (s, 6H), 3.30 (dd, J = 14.3, 6.2 Hz, 2H), 3.15 (dd, J = 14.3, 7.9 Hz, 
2H), 2.99 – 2.84 (m, 4H), 1.37 (s, 18H). 13C NMR (126 MHz, CDCl3): δ 171.5 (Cq), 
169.7 (Cq), 166.7 (Cq), 155.1 (Cq), 151.2 (Cq), 149.2 (CH), 138.1 (CH), 137.2 (Cq), 
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136.8 (Cq), 134.2 (Cq), 128.3 (Cq), 126.2 (CH2), 122.2 (CH), 122.1 (CH), 121.2 (CH), 
120.5 (CH), 118.6 (CH), 110.7 (Cq), 109.8 (CH), 79.7 (Cq), 54.4 (CH), 52.4 (CH), 52.0 
(CH3), 51.6 (CH3), 40.5 (CH2), 28.3 (CH3), 28.1 (CH2), 27.7 (CH2). IR (ATR): 3355, 
2950, 1745, 1715, 1676, 1472, 1438, 1367, 1164, 738 cm-1. MS (ESI): m/z (relative 
intensity): 2404 (21) [2M+Na]+, 1213 (74) [M+Na]+, 1191 (100) [M+H]+, 607 (27). HR-






Following a modified literature procedure, the corresponding disulfide S1 (64.4 mg, 
0.054 mmol), PPh3 (14.1 mg, 0.054 mmol), NaOAc (1.7 mg, 0.022 mmol) and HOAc 
(5.5 μL, 0.097 mmol) were disolved in MeOH/H2O (9 mL, 10/1). The mixture was 
heated to 60 ˚C for 16 h under N2. After cooling to ambient temperature, H2O (10 mL) 
were added and the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification by 
column chromatography on silica gel (CH2Cl2/EtOAc: 4/1) yielded 262 (47.1 mg, 73%) 
as colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.56 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.82 (ddd, J = 8.1, 
7.5, 2.0 Hz, 1H), 7.62 – 7.52 (m, 1H), 7.39 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 7.27 (ddd, J 
= 7.5, 4.9, 1.0 Hz, 1H), 7.23 – 7.17 (m, 1H), 7.14 – 7.06 (m, 2H), 6.77 (d, J = 6.7 Hz, 
1H), 5.85 (td, J = 1.9, 1.3 Hz, 1H), 5.40 (d, J = 6.3 Hz, 1H), 5.05 (td, J = 2.5, 1.3 Hz, 
1H), 4.62 (ddd, J = 7.6, 7.6, 7.6 Hz, 1H), 4.53 (ddd, J = 6.8, 4.2 Hz, 1H), 4.03 (d, J = 
17.1 Hz, 1H), 3.98 (d, J = 17.1 Hz, 1H), 3.63 (s, 3H), 3.55 (s, 3H), 3.43 – 3.31 (m, 1H), 
3.14 (dd, J = 14.4, 8.3 Hz, 1H), 2.90 (ddd, J = 13.0, 8.5, 4.2 Hz, 1H), 2.76 (ddd, J = 
13.0, 8.5, 4.2 Hz, 1H), 1.42 (s, 9H), 1.23 (t, J = 8.5, 1H). 13C NMR (101 MHz, CDCl3): 
δ 171.6 (Cq), 169.5 (Cq), 166.8 (Cq), 155.2 (Cq), 151.3 (Cq) , 149.4 (CH), 138.2 (CH), 
137.3 (Cq), 137.0 (Cq), 134.3 (Cq), 128.4 (Cq), 126.4 (CH2), 122.4 (CH), 122.3 (CH), 
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121.3 (CH), 120.7 (CH), 118.6 (CH), 110.6 (Cq), 109.8 (CH), 79.9 (Cq), 54.5 (CH), 53.8 
(CH), 52.4 (CH3), 52.0 (CH3), 28.3 (CH3), 27.9 (CH2), 27.8 (CH2), 26.8 (CH2). IR (ATR): 
3338, 2952, 2925, 1743, 1711, 1670, 1471, 1437, 1366, 1210, 1159, 736 cm-1. MS 
(ESI): m/z (relative intensity) 619 (100) [M+Na]+, 597 (75) [M+H]+, 290 (38). HR-MS 






Following a modified literature procedure, a mixture of methyl (S)-2-{[3-(2-acetamido-
3-methoxy-3-oxopropyl)-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate 254a (156.6 mg, 
0.36 mmol), Boc-Cys-OMe 263 (127.1 mg, 0.54 mmol), Et3N (54.6 mg, 0.54 mmol) in 
dry DMF (4.5 mL) was stirred at 60 °C under N2 for 16 h. After cooling to ambient 
temperature, EtOAc (30 mL) was added and the mixture was washed with brine three 
times. The organic layer was dried over Na2SO4 and concentrated in vacuo. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1→ 1/2) 
yielded 264 (172.3 mg, 71%, d.r. 1.6) as a white solid. 
M. p.: 71 – 75 ºC. 1H NMR (300 MHz, CDCl3): δ 8.73 – 8.47 (m, 1H), 8.00 – 7.81 (m, 
1H), 7.60 – 7.47 (m, 1H), 7.50 – 7.39 (m, 1H), 7.39 – 7.27 (m, 1H), 7.28 – 7.22 (m, 
1H), 7.18 – 7.06 (m, 2H), 6.32 (d, J = 7.5 Hz, 0.62H), 6.21 (d, J = 7.8 Hz, .38H), 5.37 
(d, J = 8.2 Hz, 0.32H), 5.28 (d, J = 8.0 Hz, 0.62H), 5.00 – 4.81 (m, 1H), 4.46 – 4.28 (m, 
1H), 3.67 – 3.65 (m, 4.13H), 3.64 (s, 1.87H), 3.47 (s, 1.87H), 3.46 (s, 1.13H), 3.38 – 
3.12 (m, 4H), 2.82 – 2.29 (m, 5H), 1.94 (s, 3H), 1.40 (s, 5.61H), 1.39 (s, 3.39H). 13C 
NMR (126 MHz, CDCl3): Major diastereoisomer: δ 173.6 (Cq), 172.4 (Cq), 171.0 (Cq), 
169.7 (Cq), 154.9 (Cq), 151.0 (Cq), 149.7 (CH), 138.5 (CH), 136.7 (Cq), 134.5 (Cq), 
128.2 (Cq), 122.6 (CH), 122.2 (CH), 120.9 (CH), 120.7 (CH), 118.6 (CH), 110.5 (Cq), 
110.0 (CH), 80.1 (Cq), 53.0 (CH), 52.7 (CH), 52.4 (CH3), 52.3 (CH3), 51.9 (CH3), 45.2 
(CH), 34.8 (CH2), 34.3 (CH2), 28.3 (CH3), 27.0 (CH2), 26.9 (CH2), 23.0 (CH3). Minor 
diastereoisomer: δ 173.5 (Cq), 172.2 (Cq), 171.1 (Cq), 169.6 (Cq), 154.9 (Cq), 151.0 
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(Cq), 149.6 (CH), 138.5 (CH), 136.7 (Cq), 134.6 (Cq), 128.4 (Cq), 122.5 (CH), 122.2 
(CH), 121.0 (CH), 120.7 (CH), 118.5 (CH), 110.4 (Cq), 109.9 (CH), 80.0 (Cq), 53.3 (CH), 
52.9 (CH), 52.4 (CH3), 52.3 (CH3), 51.8 (CH3), 45.5 (CH), 34.8 (CH2), 34.4 (CH2), 28.3 
(CH3), 27.0 (CH2), 26.9 (CH2), 23.2 (CH3). IR (ATR): 3368, 2977, 2952, 1735, 1663, 
1471, 1458, 1437, 1367, 1215, 1163, 729cm-1. MS (ESI): m/z (relative intensity) 693 
(100) [M+Na]+, 671 (76) [M+H]+, 571 (24). HR-MS (ESI): m/z calcd for C33H43N4O9S+ 





Following a modified literature procedure, a suspension of 1,3-dioxoisoindolin-2-yl 
cyclohexanecarboxylate (54.6 mg, 0.20 mmol), methyl (S)-2-{{3-{3-[benzyloxy]-2-[(tert-
butoxycarbonyl)amino]-3-oxopropyl}-1-[pyridin-2-yl]-1H-indol-2-yl}methyl}acrylate 
254b (227.5 mg, 0.40 mmol), Ni(acac)2 (20.5 mg, 40.0 mol %), LiCl (25.4 mg, 0.60 
mmol), Zn (26.1 mg, 0.40 mmol) in MeCN (1.0 mL) was stirred at 25 °C under N2. After 
16 h the mixture was diluted with CH2Cl2 (20 mL), filtered through a pad of Celite and 
concentrated in vacuo. Purification by column chromatography on silica gel afforded 
the desired product 265 (73.2 mg, 56%, d.r. 1.5) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 8.65 – 8.60 (m, 1H), 7.94 – 7.83 (m, 1H), 7.62 – 7.49 (m, 
1H), 7.41 – 7.36 (m, 1H), 7.34 – 7.30 (m, 1H), 7.29 – 7.22 (m, 4H), 7.20 – 7.13 (m, 
2H), 7.15 – 7.09 (m, 2H), 5.29 (d, J = 8.1 Hz, 0.60H), 5.13 (d, J = 8.1 Hz, 0.40H), 5.11 
– 4.95 (m, 2H), 4.73 (ddd, J = 8.1, 7.0, 7.0 Hz, 0.60H), 4.66 (ddd, J = 8.1, 6.8, 6.8 Hz, 
0.40H), 3.40 (s, 1.80H), 3.38 (s, 1.18H), 3.36 – 3.21 (m, 2H), 3.18 – 3.04 (m, 2H), 2.26 
– 2.17 (m, 1H), 1.60 – 1.51 (m, 3H), 1.45 – 1.36 (m, 9H), 1.36 – 1.30 (m, 2H), 1.28 – 
1.19 (m, 2H), 1.13 – 0.87 (m, 4H), 0.69 – 0.48 (m, 2H). 13C NMR (126 MHz, CDCl3): 
Major diastereoisomer: δ 175.8 (Cq), 172.3 (Cq), 155.1 (Cq), 151.4 (Cq), 149.6 (CH), 
138.3 (CH), 136.8 (Cq), 135.8 (Cq), 135.2 (Cq), 128.6 (Cq), 128.3 (CH), 128.1 (CH), 
128.1 (CH), 122.6 (CH), 122.1 (CH), 121.2 (CH), 120.5 (CH), 118.8 (CH), 110.1 (Cq), 
109.7 (CH), 79.6 (Cq), 67.1 (CH2), 54.0 (CH), 51.5 (CH3), 42.4 (CH), 40.4 (CH2), 35.2 
(CH), 33.2 (CH2), 32.7 (CH2), 28.4 (CH3), 28.0 (CH2), 27.5 (CH2), 26.4 (CH2), 26.2 
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(CH2), 26.1 (CH2). Minor diastereoisomer: δ 175.6 (Cq), 172.1 (Cq), 155.0 (Cq), 151.3 
(Cq), 149.6 (CH), 138.3 (CH), 136.8 (Cq), 135.8 (Cq), 135.2 (Cq), 128.6 (Cq), 128.3 
(CH), 128.1 (CH), 128.0 (CH), 122.3 (CH), 122.0 (CH), 121.1 (CH), 120.5 (CH), 118. 
(CH), 110.1 (Cq), 109.8 (CH), 79.7 (Cq), 67.2 (CH2), 54.4 (CH), 51.4 (CH3), 42.5 (CH), 
40.1 (CH2), 35.3 (CH), 33.3 (CH2), 32.6 (CH2), 28.4 (CH3), 28.1 (CH2), 27.4 (CH2), 26.4 
(CH2), 26.2 (CH2), 26.1 (CH2). IR (ATR): 2923, 2851, 1731, 1710, 1586, 1471, 1458, 
1437, 1367, 1164, 735 cm-1. MS (ESI): m/z (relative intensity) 676 (49) [M+Na]+, 654 






Following a modified literature procedure, a suspension of 1,3-dioxoisoindolin-2-yl 
cyclohexanecarboxylate (54.6 mg, 0.20 mmol), methyl (S)-2-{[3-(2-acetamido-3-
methoxy-3-oxopropyl)-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate 254a (174.2 mg, 
0.40 mmol), Ni(acac)2 (20.5 mg, 40.0 mol %), LiCl (25.4 mg, 0.60 mmol), Zn (26.1 mg, 
0.40 mmol) in MeCN (1.0 mL) was stirred at 25 °C under N2. After 16 h the mixture was 
diluted with CH2Cl2 (20 mL), filtered through a pad of Celite and concentrated in vacuo. 
Purification by column chromatography on silica gel afforded the desired product 266 
(53.9 mg, 52%, d.r. 1.3) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.70 – 8.63 (m, 1H), 8.04 – 7.89 (m, 1H), 7.68 – 7.44 (m, 
2H), 7.42 – 7.34 (m, 1H), 7.32 – 7.25 (m, 1H), 7.20 – 7.11 (m, 2H), 6.45 (d, J = 7.2 Hz, 
0.56H), 6.18 (d, J = 7.9 Hz, 0.44H), 5.05 – 4.90 (m, 1H), 3.74 (s, 1.68H), 3.71 (s, 
1.32H), 3.68 – 3.61 (m, 1H), 3.47 (s, 1.68H), 3.45 (s, 1.32H), 3.42 – 3.06 (m, 4H), 1.99 
(s, 1.68H), 1.97 (s, 1.32H), 1.67 – 1.38 (m, 5H), 1.35 – 0.89 (m, 6H), 0.79 – 0.50 (m, 
2H). 13C NMR (101 MHz, CDCl3): Major diastereoisomer: δ 176.2 (Cq), 172.9 (Cq), 
170.1 (Cq), 151.7 (Cq), 149.7 (CH), 138.6 (CH), 136.9 (Cq), 135.8 (Cq), 128.7 (Cq), 
122.5 (CH), 122.3 (CH), 121.2 (CH), 120.7 (CH), 118.7 (CH), 110.1 (Cq), 109.7 (CH), 
52.7 (CH), 52.3 (CH3), 51.6 (CH3), 42.1 (CH), 40.5 (CH2), 35.2 (CH), 33.2 (CH2), 32.7 
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(CH2), 27.8 (CH2), 26.9 (CH2), 26.1 (CH2), 23.0 (CH3). Minor diastereoisomer: δ 175.8 
(Cq), 172.5 (Cq), 169.8 (Cq), 151.4 (Cq), 149.7 (CH), 138.5 (CH), 136.8 (Cq), 135.9 (Cq), 
128.3 (Cq), 122.4 (CH), 122.3 (CH), 121.2 (CH), 120.6 (CH), 118.6 (CH), 109.9 (Cq), 
109.9 (CH), 52.9 (CH), 52.3 (CH3), 51.5 (CH3), 42.3 (CH), 40.3 (CH2), 35.2 (CH), 33.3 
(CH2), 32.6 (CH2), 28.0 (CH2), 26.7 (CH2), 26.1 (CH2), 23.2 (CH3). IR (ATR): 3355, 
3292, 2924, 2851, 1734, 1656, 1471, 1437, 1212, 1174, 748 cm-1. MS (ESI): m/z 
(relative intensity) 1062 (7) [2M+Na]+, 542 (100) [M+Na]+,520 (60) [M+H]+. HR-MS 






A suspension of peptide 267 (650.7 mg, 1.0 mmol), MnBr(CO)5 (27.5 mg, 10 mol %) 
and NaOAc (24.6 mg, 30 mol %) in 1,4-dioxane (25 mL, 40 mM) was stirred at 80 °C 
for 16 h under N2. After cooling to ambient temperature, CH2Cl2 (50 mL) was added 
and the mixture concentrated in vacuo. Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 268 (330.0 mg, 62%) as a white solid. 
M. p.: 245 ºC (decomposition). 1H NMR (600 MHz, CDCl3): δ 8.57 (dd, J = 5.2, 1.9 Hz, 
1H), 7.85 (td, J = 7.7, 2.0 Hz, 1H), 7.59 – 7.54 (m, 1H), 7.32 – 7.26 (m, 2H), 7.24 (d, J 
= 7.5 Hz, 1H), 7.14 – 7.05 (m, 2H), 6.19 (brs, 1H), 5.57 – 5.48 (m, 2H), 5.13 (s, 1H), 
4.70 – 4.60 (m, 2H), 4.22 (d, J = 16.2 Hz, 1H), 3.98 (d, J = 16.2 Hz, 1H), 3.81 – 4.67 
(m, 1H), 3.33 – 3.23 (m, 1H), 3.08 (dd, J = 14.2, 9.8 Hz, 2H), 2.42 – 2.32 (m, 1H), 1.68 
(tdd, J = 11.5, 6.0, 3.0 Hz, 1H), 1.42 (s, 9H), 1.40 – 1.20 (m, 4H), 0.87 – 0.76 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 171.1 (Cq), 168.6 (Cq), 155.0 (Cq), 151.2 (Cq), 149.2 
(CH), 138.4 (Cq), 137.9 (CH), 136.6 (Cq), 133.7 (Cq), 129.0 (Cq), 124.8 (CH2), 122.4 
(CH), 121.9 (CH), 120.8 (CH), 120.7 (CH), 119.2 (CH), 111.9 (Cq), 109.2 (CH), 79.4 
(Cq), 62.1 (CH2), 53.9 (CH), 38.4 (CH2), 29.6 (CH2), 29.1 (CH2), 28.5 (CH2), 28.4 (CH3), 
25.4 (CH2), 20.1 (CH2). IR (ATR): 3344, 3325, 3052, 2926, 2868, 1710, 1654, 1470, 
1457, 1438, 1249, 733 cm-1 MS (ESI): m/z (relative intensity) 555 (67) [M+Na]+, 533 
(100) [M+H]+, 433 (29). HR-MS (ESI): m/z calcd for C30H37N4O5+ [M+H]+: 533.2758, 








General procedure K was followed using 254a (87.1 mg, 0.20 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/2) yielded 269a (43.2 mg, 
60%, d.r. 1.1) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.69 – 8.60 (m, 1H), 7.48 – 7.38 (m, 1H), 7.30 – 7.20 (m, 
1H), 7.14 – 6.99 (m, 2H), 6.20 (d, J = 7.1 Hz, 0.48 H), 6.15 (d, J = 7.1 Hz, 0.52H), 4.94 
– 4.73 (m, 1H), 3.73 – 3.57 (m, 6H), 3.29 – 3.15 (m, 2H), 3.13 – 2.93 (m, 1H), 2.89 – 
2.74 (m, 2H), 1.92 (s, 1.55H), 1.91 (s, 1.45H), 1.29 – 1.13 (m, 3H). 13C NMR (101 MHz, 
CDCl3): Major diastereoisomer: δ 177.2 (Cq), 172.5 (Cq), 169.7 (Cq), 135.3 (Cq), 134.4 
(Cq), 128.3 (Cq), 121.5 (CH), 119.3 (CH), 118.0 (CH), 110.7 (CH), 106.6 (Cq), 53.0 
(CH), 52.3 (CH3), 52.1 (CH3), 39.9 (CH), 28.8 (CH2), 26.8 (CH2), 23.1 (CH3), 17.4 
(CH3). Minor diastereoisomer: δ 177.2 (Cq), 172.6 (Cq), 169.8 (Cq), 135.3 (Cq), 134.3 
(Cq), 128.2 (Cq), 121.5 (CH), 119.3 (CH), 118.0 (CH), 110.7 (CH), 106.6 (Cq), 53.0 
(CH), 52.3 (CH3), 52.1 (CH3), 39.7 (CH), 28.7 (CH2), 26.8 (CH2), 23.0 (CH3), 17.5 
(CH3). IR (ATR): 3374, 3297, 2953, 1732, 1655, 1529, 1436, 1208, 1177, 738 cm-1. 
MS (ESI): m/z (relative intensity) 743 (11) [2M+Na]+, 383 (100) [M+Na]+,361 (73) 





General procedure K was followed using 266 (103.8 mg, 0.20 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 269b (46.8 mg, 
53%, d.r. 1.3) as a colorless oil. 
1H NMR (600 MHz, CDCl3): δ 8.49 – 8.43 (m, 1H), 7.44 (d, J = 7.9 Hz, 0.56H), 7.41 (d, 
J = 7.9 Hz, 0.44H), 7.28 – 7.21 (m, 1H), 7.14 – 7.06 (m, 1H), 7.08 – 7.01 (m, 1H), 6.18 
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– 6.06 (m, 1H), 4.88 – 4.80 (m, 1H), 3.67 – 3.58 (m, 6H), 3.28 – 3.13 (m, 2H), 2.99 – 
2.85 (m, 1H), 2.90 – 2.75 (m, 2H), 1.92 (s, 1.32H), 1.91 (s, 1.68H), 1.76 – 1.53 (m, 6H), 
1.38 – 1.07 (m, 5H), 0.93 – 0.78 (m, 2H). 13C NMR (126 MHz, CDCl3): Major 
diastereoisomer: δ 177.2 (Cq), 172.5 (Cq), 169.7 (Cq), 135.4 (Cq), 134.2 (Cq), 128.3 
(Cq), 121.5 (CH), 119.4 (CH), 118.1 (CH), 110.6 (CH), 106.6 (Cq), 53.0 (CH), 52.2 
(CH3), 52.0 (CH3), 43.0 (CH), 40.3 (CH2), 35.6 (CH), 33.3 (CH2), 33.1 (CH2), 27.9 
(CH2), 26.5 (CH2), 26.2 (CH2), 23.1(CH3). Minor diastereoisomer: δ 177.2 (Cq), 172.4 
(Cq), 169.5 (Cq), 135.3 (Cq), 134.2 (Cq), 128.4 (Cq), 121.5 (CH), 119.3 (CH), 118.0 
(CH), 110.6 (CH), 106.5 (Cq), 53.0 (CH), 52.2 (CH3), 52.0 (CH3), 43.0 (CH), 40.2 (CH2), 
35.6 (CH), 33.4 (CH2), 33.0 (CH2), 28.1 (CH2), 26.9 (CH2), 26.2 (CH2), 23.2(CH3). IR 
(ATR): 3363, 3291, 2922, 2850, 1729, 1655, 1460, 1436, 1212, 1197, 1170, 909, 730 
cm-1. MS (ESI): m/z (relative intensity) 908 (39) [2M+Na]+, 465 (100) [M+Na]+,443 (88) 





General procedure K was followed using 268 (53.2 mg, 0.10 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 269c (28.3 mg, 
62%, d.r. 1.1) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.13 (s, 0.47H), 8.05 (s, 0.53H), 7.61 – 7.47 (m, 1H), 
7.24 – 7.17 (m, 1H), 7.15 – 6.99 (m, 2H), 5.65 (d, J = 8.2 Hz, 0.47H), 5.50 (d, J = 8.1 
Hz, 0.53H), 5.18 (brs, 0.47H), 5.00 (t, J = 5.7 Hz, 0.53H), 4.68 – 4.44 (m, 1H), 4.44 – 
4.22 (m, 0.53H), 4.19 – 3.92 (m, 0.94H), 3.68 (ddt, J = 10.2, 5.5, 2.8 Hz, 0.53H), 3.34 
– 3.21 (m, 1H), 3.20 – 2.79 (m, 5H), 2.75 – 2.47 (m, 1H), 1.46 (s, 9H), 1.42 – 1.23 (m, 
6H), 1.06 – 0.38 (m, 3H). 13C NMR (126 MHz, CDCl3): Major diastereoisomer: δ 177.8 
(Cq), 171.0 (Cq), 155.2 (Cq), 135.1 (Cq), 133.2 (Cq), 128.0 (Cq), 121.7 (CH), 119.8 (CH), 
118.5 (CH), 110.3 (CH), 107.7 (Cq), 79.5 (Cq), 63.9 (CH2), 54.2 (CH), 41.1 (CH), 38.0 
(CH2), 31.3 (CH2), 30.3 (CH2), 29.2 (CH2), 28.4 (CH3), 25.6 (CH2), 20.0 (CH2), 18.6 
(CH3). Minor diastereoisomer: δ 177.0 (Cq), 170.9 (Cq), 155.2 (Cq), 135.3 (Cq), 133.4 
(Cq), 128.4 (Cq), 121.8 (CH), 119.7 (CH), 118.5 (CH), 110.3 (CH), 107.4 (Cq), 79.6 (Cq), 
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63.3 (CH2), 55.6 (CH), 40.4 (CH), 37.3 (CH2), 31.3 (CH2), 30.3 (CH2), 28.9 (CH2), 28.4 
(CH3), 25.7 (CH2), 21.0 (CH2), 18.2 (CH3). IR (ATR): 3300, 2931, 1712, 1659, 1496, 
1460, 1366, 1243, 1167, 733 cm-1. MS (ESI): m/z (relative intensity) 937 (19) [2M+Na]+, 
480 (100) [M+Na]+,458 (50) [M+H]+, 402 (26). HR-MS (ESI): m/z calcd for C25H36N3O5+ 
[M+H]+: 458.2649, found: 458.2652. 
 
Methyl 2-{[1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271a) 
 
The general procedure J was followed using 1-(pyridin-2-yl)-1H-indole 270a (48.6 mg, 
0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 mg, 0.38 
mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %), NaOAc (6.2 mg, 30 mol %) in 1,4-dioxane (1.0 
mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 20/1 → 
10/1) yielded 271a (69.4 mg, 95%) as a colorless oil.  
1H NMR (600 MHz, CDCl3): δ 8.62 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 7.84 (ddd, J = 7.7, 
7.7, 1.9 Hz, 1H), 7.65 – 7.51 (m, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.39 – 7.34 (m, 1H), 
7.31 – 7.26 (m, 1H), 7.18 – 7.10 (m, 2H), 6.47 (d, J = 0.9 Hz, 1H), 6.15 (dt, J = 0.9, 0.9 
Hz, 1H), 5.40 (dt, J = 1.6, 0.9 Hz, 1H), 3.99 – 3.86 (m, 2H), 3.69 (s, 3H). 13C NMR (126 
MHz, CDCl3): δ 166.8 (Cq), 151.1 (Cq), 149.4 (CH), 138.1 (CH), 137.7 (Cq), 137.4 (Cq), 
137.2 (Cq), 128.3 (Cq), 126.4 (CH2), 121.9 (CH), 121.9 (CH), 120.8 (CH), 120.6 (CH), 
120.1 (CH), 110.2 (CH), 104.2 (CH), 51.9 (CH3), 29.9 (CH2). IR (ATR): 3052, 2950, 
1716, 1586, 1468, 1435, 1325, 1205, 1143, 735 cm-1. MS (ESI): m/z (relative intensity) 
315 (36) [M+Na]+, 293 (100) [M+H]+. HR-MS (ESI) m/z calcd for C18H17N2O2+ [M+H]+: 
293.1285, found: 293.1285. 
 
Methyl 2-{[3-methyl-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271b) 
 
The general procedure J was followed using 3-methyl-1-(pyridin-2-yl)-1H-indole 270b 
(52.1 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 
1,4-dioxane (1.0 mL). The reaction was performed at 80 °C. Purification by column 
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chromatography on silica gel (n-hexane/EtOAc: 20/1 → 15/1) yielded 271b (73.5 mg, 
96%) as a white solid. 
M.p.: 59 – 60 °C. 1H NMR (400 MHz, CDCl3): δ  8.59 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 
7.81 (ddd, J = 8.1, 7.5, 2.0 Hz, 1H), 7.63 – 7.54 (m, 1H), 7.41 – 7.33 (m, 2H), 7.27 – 
7.22 (m, 1H), 7.21 – 7.13 (m, 2H), 6.06 (td, J = 1.7, 1.2 Hz, 1H), 5.13 (td, J = 1.7, 1.2 
Hz, 1H), 3.95 (dd, J = 1.7, 1.7 Hz, 2H), 3.70 (s, 3H), 2.30 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ 167.1 (Cq), 151.5 (Cq), 149.4 (CH), 138.1 (CH), 137.5 (Cq), 136.6 (Cq), 132.3 
(Cq), 129.2 (Cq), 125.7 (CH2), 122.2 (CH), 121.7 (CH), 120.6 (CH), 120.2 (CH), 118.4 
(CH), 112.0 (Cq), 110.1 (CH), 51.8 (CH3), 27.0 (CH2), 8.7 (CH3). IR (ATR): 3054, 2949, 
1711, 1585, 1469, 1455, 1436, 1214, 746 cm-1. MS (ESI): m/z (relative intensity) 635 
(12) [2M+Na]+, 329 (100) [M+Na]+, 307 (52) [M+H]+. HR-MS (ESI): m/z calcd for 
C19H19N2O2+ [M+H]+: 307.1441, found: 307.1440. 
 
Methyl 2-{[3-bromo-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271c) 
 
The general procedure J was followed using 3-bromo-1-(pyridin-2-yl)-1H-indole 270c 
(68.3 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.375 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 
1,4-dioxane (1.0 mL). The reaction was performed at 80 °C. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 271c (86.9 mg, 94%) as 
a pale yellow oil.  
1H NMR (400 MHz, CDCl3): δ 8.59 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.84 (ddd, J = 8.0, 
7.5, 2.0 Hz, 1H), 7.63 – 7.55 (m, 1H), 7.37 – 7.33 (m, 2H), 7.30 (ddd, J = 7.5, 4.9, 0.9 
Hz, 1H), 7.26 – 7.18 (m, 2H), 6.11 (td, J = 1.5, 1.0 Hz, 1H), 5.22 (td, J = 1.9, 1.0 Hz, 
1H), 4.00 (dd, J = 1.9, 1.5 Hz, 2H), 3.70 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 166.7 
(Cq), 150.7 (Cq), 149.6 (CH), 138.4 (CH), 136.2 (Cq), 136.1 (Cq), 134.0 (Cq), 127.4 (Cq), 
126.2 (CH2), 123.4 (CH), 122.5 (CH), 121.5 (CH), 120.7 (CH), 119.0 (CH), 110.6 (CH), 
95.8 (Cq), 51.9 (CH3), 27.8 (CH2). IR (ATR): 3056, 2949, 1717, 1632, 1587, 1498, 1452, 
1436, 1345, 946, 785 cm-1. MS (ESI): m/z (relative intensity) 393 (100) [M+Na]+, 371 
(86) [M+H]+. HR-MS (ESI): m/z calcd for C18H1679BrN2O2+ [M+H]+: 371.0390, found: 
371.0386. 
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Methyl 2-{[3-acetyl-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271d) 
 
The general procedure J was followed using 1-[1-(pyridin-2-yl)-1H-indol-3-yl]ethanone 
270d (59.1 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a 
(81.0 mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) 
in 1,4-dioxane (1.0 mL). The reaction was run at 80 °C. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1 → 2/1) yielded 271d (74.9 mg, 
90%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3): δ 8.65 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 8.08 (ddd, J = 8.1, 
1.1, 1.1 Hz, 1H), 7.90 (ddd, J = 7.6, 7.6 2.0 Hz, 1H), 7.42 (ddd, J = 7.6, 4.9, 1.0 Hz, 
1H), 7.36 (ddd J = 7.6 1.1, 1.1 Hz, 1H), 7.34 – 7.27 (m, 1H), 7.25 – 7.14 (m, 2H), 6.13 
(td, J = 1.6, 1.0 Hz, 1H), 5.23 (td, J = 1.8. 1.0 Hz, 1H), 4.17 (dd, J = 1.8, 1.6 Hz, 2H), 
3.69 (s, 3H), 2.71 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 194.3 (Cq), 166.6 (Cq), 150.0 
(CH), 149.6 (Cq), 143.6 (Cq), 138.6 (CH), 137.0 (Cq), 136.9 (Cq), 126.2 (Cq), 125.7 
(CH2), 123.7 (CH), 123.1 (CH), 122.7 (CH), 122.2 (CH), 121.0 (CH), 116.5 (Cq), 111.0 
(CH), 52.0 (CH3), 31.6 (CH3), 28.6 (CH2). IR (ATR): 2953, 2923, 2853, 1718, 1650, 
1588, 1518, 1467, 1198, 1138, 792 cm-1. MS (ESI): m/z (relative intensity) 691 (12) 
[2M+Na]+, 357 (100) [M+Na]+, 335 (11) [M+H]+. HR-MS (ESI): m/z calcd for 





The general procedure J was followed using 4-methyl-N-{2-[1-(pyridin-2-yl)-1H-indol-
3-yl]ethyl}benzenesulfonamide 270e (97.9 mg, 0.25 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 
5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 1,4-dioxane (1.0 mL). The reaction was 
performed at 80 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc: 2/1→1/2) yielded 271e (114.4 mg, 93%) as a white solid. 
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M.p.: 112 –114 °C. 1H NMR (500 MHz, CDCl3): δ 8.56 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.82 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.44 (ddd, J = 7.4, 0.9, 
0.9 Hz, 1H), 7.33 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.30 – 7.26 (m, 2H), 7.20 (d, J = 8.1 
Hz, 2H), 7.16 – 7.05 (m, 2H), 5.91 (td, J = 2.1, 1.2 Hz, 1H), 5.06 – 4.84 (m, 2H), 3.91 
– 3.89 (m, 2H), 3.65 (s, 3H), 3.22 (td, J = 7.0, 6.8 Hz, 2H), 2.96 (t, J = 7.0 Hz, 2H), 2.36 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ 166.6 (Cq), 151.0 (Cq), 149.4 (CH), 143.0 (Cq), 
138.2 (CH), 137.4 (Cq), 136.8 (Cq), 136.7 (Cq), 133.6 (Cq), 129.4 (CH), 127.9 (Cq), 
126.9 (CH), 125.9 (CH2), 122.4 (CH), 122.1 (CH), 120.9 (CH), 120.6 (CH), 118.2 (CH), 
111.8 (Cq), 110.1 (CH), 51.9 (CH3), 43.2 (CH2), 27.1 (CH2), 25.0 (CH2), 21.5 (CH3). IR 
(ATR): 3053, 2950, 1712, 1586, 1469, 1454, 1435, 1348, 1337, 1266, 734 cm-1. MS 
(ESI): m/z (relative intensity) 512 (78) [M+Na]+, 490 (100) [M+H]+. HR-MS (ESI): m/z 
calcd for C27H28N3O4S+ [M+H]+: 490.1795, found: 490.1796. 
 
Methyl 2-{[4-fluoro-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271f) 
 
The general procedure J was followed using 4-fluoro-1-(pyridin-2-yl)-1H-indole 270f 
(53.1 mg, 0.25 mmol), [(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 mg, 0.38 
mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 1,4-dioxane 
(1.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 20/1 
→ 10/1) yielded 271f (66.7 mg, 86%) as a pale yellow oil.  
1H NMR (400 MHz, CDCl3): δ 8.64 (ddd, J = 4.9, 2.0, 1.0 Hz, 1H), 7.88 (td, J = 7.7, 2.0 
Hz, 1H), 7.45 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.33 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.12 
(dd, J = 8.3, 0.8 Hz, 1H), 7.05 (ddd, J = 8.0, 8.0, 5.1 Hz, 1H), 6.81 (ddd, J = 10.1, 7.7, 
0.9 Hz, 1H), 6.55 (td, J = 1.4, 1.1 Hz, 1H), 6.18 (td, J = 1.9, 1.1 Hz, 1H), 5.43 (dd, J = 
1.9, 1.4 Hz, 1H), 3.91 (t, J = 1.2 Hz, 2H), 3.70 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 
166.9 (Cq), 155.8 (d, J = 246.5 Hz, Cq), 151.0 (Cq), 149.6 (CH), 139.8 (d, J = 11.1 Hz, 
Cq), 138.4 (CH), 137.7 (Cq), 137.5 (Cq), 126.9 (CH2), 122.4 (CH), 122.4 (d, J = 7.7 Hz, 
CH), 121.0 (CH), 117.34 (d, J = 22.7 Hz, Cq), 106.40 (d, J = 3.5 Hz, CH),  105.64 (d, 
J = 19.0 Hz, CH), 99.8 (CH) 51.9 (CH3), 29.8 (CH2). 19F NMR (376 MHz, CDCl3): δ – 
122.7 (dd, J = 10.0, 5.1 Hz). IR (ATR): 2951, 1716, 1584, 1469, 1436, 1388, 1329, 
1203,1175, 853, 745 cm-1. MS (ESI): m/z (relative intensity) 333 (39) [M+Na]+, 311 
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The general procedure J was followed using methyl 1-(pyridin-2-yl)-1H-indole-4-
carboxylate 270g (63.1 mg, 0.25 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 
5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 1,4-dioxane (1.0 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 271g (86.3 mg, 
98%) as a colorless oil.  
1H NMR (400 MHz, CDCl3): δ δ 8.62 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.91 – 7.83 (m, 
2H), 7.50 (ddd, J = 8.2, 0.9, 0.9 Hz, 1H), 7.39 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.31 (ddd, 
J = 7.5, 4.9, 0.9 Hz, 1H), 7.15 (dd, J = 8.2, 7.5 Hz, 1H), 7.11 (d, J = 0.8 Hz, 1H), 6.17 
(td, J = 1.4, 1.2 Hz, 1H), 5.43 (td, J = 2.0, 1.2 Hz, 1H), 3.96 (s, 3H), 3.93 – 3.88 (m, 
2H), 3.67 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 167.8 (Cq), 166.8 (Cq), 150.7 (Cq), 
149.6 (CH), 139.9 (Cq), 138.4 (CH), 138.2 (Cq), 137.3 (Cq), 128.1 (Cq), 127.0 (CH2), 
124.0 (CH), 122.5 (CH), 121.2 (CH), 121.1 (CH), 120.9 (Cq), 115.0 (CH), 105.1 (CH), 
51.9 (CH3), 51.7 (CH3), 29.8 (CH2). IR (ATR): 2951, 1710, 1633, 1585, 1469, 1437, 
1285, 1262, 1192, 1135, 786 cm-1. MS (ESI): m/z (relative intensity) 723 (9) [2M+Na]+, 
373 (100) [M+Na]+, 351 (87) [M+H]+. HR-MS (ESI): m/z calcd for C20H19N2O4 [M+H]+: 
351.1339, found: 351.1352. 
 
Methyl 2-{[5-methoxy-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271h) 
 
The general procedure J was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole 
270h (56.1 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a 
(81.0 mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) 
in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1→5/1) yielded 271h (76.1 mg, 94%) as a pale colorless oil.  
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1H NMR (300 MHz, CDCl3): δ 8.59 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.83 (ddd, J = 8.1, 
7.5, 2.5 Hz, 1H), 7.40 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.29 – 7.22 (m, 2H), 7.03 (dd, J 
= 2.5, 0.8 Hz, 1H), 6.78 (dd, J = 8.9, 2.5 Hz, 1H), 6.37 (d, J = 0.8 Hz, 1H), 6.13 (td, J = 
1.5, 1.1 Hz, 1H), 5.38 (td, J = 2.1, 1.1 Hz, 1H), 3.93 – 3.88 (m, 2H), 3.83 (s, 3H), 3.68 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ 166.9 (Cq), 154.7 (Cq), 151.3 (Cq), 149.4 (CH), 
138.2 (CH), 138.0 (Cq), 137.8 (Cq), 132.3 (Cq), 128.9 (Cq), 126.4 (CH2), 121.7 (CH), 
120.5 (CH), 111.6 (CH), 111.0 (CH), 104.1 (CH), 102.3 (CH), 55.9 (CH3), 51.9 (CH3), 
30.1 (CH2). IR (ATR): 2950, 2832, 1718, 1582, 1471, 1437, 1388, 1204, 1140, 1033, 
746 cm-1. MS (ESI): m/z (relative intensity) 345 (100) [M+Na]+, 323 (84) [M+H]+. HR-
MS (ESI): m/z calcd for C19H19N2O3+ [M+H]+: 323.1390, found: 323.1392. 
 
Methyl 2-{[5-chloro-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271i) 
 
The general procedure J was followed using 5-chloro-1-(pyridin-2-yl)-1H-indole 270i 
(57.2 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 
1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 20/1 → 10/1) yielded 271i (78.9 mg, 96%) as a white solid. 
M.p.: 82 – 83 °C. 1H NMR (400 MHz, CDCl3): δ 8.61 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 
7.86 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.51 (dd, J = 2.1, 0.5 Hz, 1H), 7.39 (ddd, J = 8.1, 
1.0, 0.9 Hz, 1H), 7.30 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.24 (ddd, J = 8.7, 0.7, 0.7 Hz, 
1H), 7.07 (dd, J = 8.8, 2.1 Hz, 1H), 6.38 (d, J = 0.9 Hz, 1H), 6.15 (d, J = 1.2 Hz, 1H), 
5.39 (d, J = 1.2 Hz, 1H), 3.89 – 3.86 (m, 2H), 3.67 (s, 3H). 13C NMR (101 MHz, CDCl3): 
δ 166.9 (Cq), 150.8 (Cq), 149.6 (CH), 139.0(Cq), 138.5 (CH), 137.5 (Cq), 135.7 (Cq), 
129.4 (Cq), 126.8 (CH2), 126.3 (Cq), 122.4 (CH), 122.1 (CH), 120.8 (CH), 119.5 (CH), 
111.3 (CH), 103.6 (CH), 51.9 (CH3), 29.9 (CH2). IR (ATR): 2950, 2924, 1716, 1587, 
1435, 1384, 1281, 1205, 1135, 783 cm-1. MS (ESI): m/z (relative intensity) 349 (52) 
[M+Na]+, 327 (100) [M+H]+. HR-MS (ESI): m/z calcd for C18H1535ClN2O2+ [M+H]+: 
327.0895, found: 327.0897. 
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Methyl 2-{[5-bromo-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271j) 
 
The general procedure J was followed using 5-bromo-1-(pyridin-2-yl)-1H-indole 270j 
(52.1 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 
1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 20/1 → 10/1) yielded 271j (87.3 mg, 94%) as a white solid.  
M.p.: 88 – 89 °C. 1H NMR (300 MHz, CDCl3): δ 8.61 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.92 – 7.80 (m, 1H), 7.67 (dd, J = 1.3, 1.3 Hz, 1H), 7.39 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 
7.31 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.21 – 7.18 (m, 2H), 6.37 (s, 1H), 6.15 (d, J = 1.2 
Hz, 1H), 5.38 (d, J = 1.2 Hz, 1H), 3.91 – 3.85 (m, 2H), 3.67 (s, 3H).13C NMR (126 MHz, 
CDCl3): δ 166.7 (Cq), 150.7 (Cq), 149.5 (CH), 138.9 (Cq), 138.4 (CH), 137.4 (Cq), 135.9 
(Cq), 130.0 (Cq), 126.7 (CH2), 124.7 (CH), 122.6 (CH), 122.3 (CH), 120.8 (CH), 113.8 
(Cq), 111.7 (CH), 103.4 (CH), 52.0 (CH3), 30.0 (CH2). IR (ATR): 2949, 2924, 1717, 
1632, 1470, 1438, 1281, 1205, 1146, 784 cm-1. MS (ESI): m/z (relative intensity) 393 
(59) [M+Na]+, 371 (100) [M+H]+. HR-MS (ESI): m/z calcd for C18H15 79BrN2O2+ [M+H]+: 
371.0390, found: 371.0395. 
 
Methyl 2-{[5-iodo-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271k) 
 
The general procedure J was followed using 5-iodo-1-(pyridin-2-yl)-1H-indole 270k 
(80.0 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 
1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 20/1 → 10/1) yielded 271k (94.1 mg, 90%) as a white solid. 
M.p.: 89 – 91 °C. 1H NMR (400 MHz, CDCl3): δ 8.61 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 
7.92 – 7.81 (m, 2H), 7.42 – 7.34 (m, 2H), 7.30 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.10 
(ddd, J = 8.6, 0.7, 0.7 Hz, 1H), 6.36 (d, J = 0.7 Hz, 1H), 6.14 (dt, J = 0.9, 0.9 Hz, 1H), 
5.37 (td, J = 1.4, 0.9 Hz, 1H), 3.88 (dd, J = 1.4, 0.9 Hz, 2H), 3.67 (s, 3H). 13C NMR 
(126 MHz, CDCl3): δ 166.7 (Cq), 150.6 (Cq), 149.5 (CH), 138.5 (Cq), 138.4 (CH), 137.4 
(Cq), 136.4 (Cq), 130.8 (Cq), 130.2 (CH), 128.8 (CH), 126.7 (CH2), 122.3 (CH), 120.8 
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(CH), 112.2 (CH), 103.1 (CH), 84.2 (Cq), 52.0 (CH3), 29.9 (CH2). IR (ATR): 2948, 2922, 
1718, 1632, 1586, 1470, 1438, 1280, 1205, 784 cm-1. MS (ESI): m/z (relative intensity) 
441 (48) [M+Na]+, 419 (100) [M+H]+. HR-MS (ESI): m/z calcd for C18H16IN2O2+ [M+H]+: 
419.0251, found: 419.0255. 
 
Methyl 2-{[5-nitro-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271l) 
 
The general procedure J was followed using 5-nitro-1-(pyridin-2-yl)-1H-indole 270l 
(59.8 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30.0 mol %) in 
1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1 → 2/1) yielded 271l (73.4 mg, 87%) as a pale yellow solid. 
M.p.: 125 – 126 °C. 1H NMR (300 MHz, CDCl3): δ  8.66 (ddd, J = 4.0, 2.0, 0.8 Hz, 1H), 
8.48 (d, J = 2.3 Hz, 1H), 8.01 (dd, J = 9.1, 2.3 Hz, 1H), 7.93 (ddd, J = 7.7, 7.7, 1.9 Hz, 
1H), 7.47 – 7.36 (m, 2H), 7.30 (d, J = 9.1 Hz, 1H), 6.58 (d, J = 0.9 Hz, 1H), 6.19 (td, J 
= 1.6, 1.2 Hz, 1H), 5.43 (td, J = 2.1, 1.2 Hz, 1H), 3.88 – 3.85 (m, 2H), 3.68 (s, 3H). 13C 
NMR (126 MHz, CDCl3): δ 166.5 (Cq), 150.0 (Cq), 149.8 (CH), 142.4 (Cq), 141.3 (Cq), 
140.1 (Cq), 138.7 (CH), 136.9, (Cq) 127.6 (Cq), 127.2 (CH2), 123.2 (CH), 121.2 (CH), 
117.6 (CH), 117.0 (CH), 110.2 (CH), 105.3 (CH), 52.1 (CH3), 30.0 (CH2). IR (ATR): 
2951, 1718, 1587, 1511, 1470, 1437, 1326, 1145, 785 cm-1. MS (ESI): m/z (relative 
intensity) 360 (55) [M+Na]+, 338 (100) [M+H]+. HR-MS (ESI): m/z calcd for C18H16N3O4+ 
[M+H]+: 338.1135, found: 338.1133. 
 
Methyl 2-{[6-chloro-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271m) 
 
The general procedure J was followed using 6-chloro-1-(pyridin-2-yl)-1H-indole 270m 
(57.2 mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 
mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 
1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 20/1 → 10/1) yielded 271m (79.2 mg, 97%) as a colorless oil.  
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1H NMR (400 MHz, CDCl3): δ 8.62 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.87 (ddd, J = 8.0, 
7.5, 2.0 Hz, 1H), 7.45 (dd, J = 8.4, 0.5 Hz, 1H), 7.40 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 
7.35 – 7.29 (m, 2H), 7.08 (dd, J = 8.4, 1.9 Hz, 1H), 6.41 (d, J = 0.9 Hz, 1H), 6.15 (dt, J 
= 1.4, 1.0 Hz, 1H), 5.38 (dt, J = 1.4, 1.4 Hz, 1H), 3.88 – 3.85 (m, 2H), 3.67 (s, 3H). 13C 
NMR (101 MHz, CDCl3): δ 166.9 (Cq), 150.7 (Cq), 149.7 (CH), 138.5 (CH), 138.4 (Cq), 
137.7 (Cq), 137.5 (Cq), 127.9 (Cq), 126.9 (Cq), 126.8 (CH2), 122.4 (CH), 121.3 (CH), 
120.9 (CH), 120.8 (CH), 110.4 (CH), 104.0 (CH), 51.9 (CH3), 29.9 (CH2). IR (ATR): 
2950, 2923, 1718, 1587, 1469, 1435, 1339, 1325, 1146, 814 cm-1. MS (ESI): m/z 
(relative intensity) 349 (81) [M+Na]+, 327 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C18H1635ClN2O2+ [M+H]+: 327.0895, found: 327.0899. 
 
Methyl 2-{[6-bromo-1-(pyridin-2-yl)-1H-indol-2-yl]methyl}acrylate (271n) 
 
The general procedure J was followed using 6-bromo-1-(pyridin-2-yl)-1H-indole 270n 
(68.3 mg, 0.25 mmol), [(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 mg, 0.38 
mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 1,4-dioxane 
(1.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 20/1 
→ 10/1) yielded 271n (89.1 mg, 96%) as a pale yellow oil.  
1H NMR (300 MHz, CDCl3): δ 8.62 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.86 (ddd, J = 8.0, 
7.5, 2.0 Hz, 1H), 7.48 (ddd, J = 1.5, 0.8 Hz, 1H), 7.43 – 7.36 (m, 2H), 7.31 (ddd, J = 
7.5, 4.9, 1.0 Hz, 1H), 7.22 (dd, J = 8.4, 1.7 Hz, 1H), 6.41 (d, J = 0.9 Hz, 1H), 6.14 (td, 
J = 1.4, 1.2 Hz, 1H), 5.38 (dd, J = 2.0, 1.2 Hz, 1H), 3.86 (dd, J = 2.0, 1.2 Hz, 2H), 3.67 
(s, 3H). 13C NMR (126 MHz, CDCl3): δ 166.7 (Cq), 150.5 (Cq), 149.6 (CH), 138.4 (CH), 
138.2 (Cq), 138.0 (Cq), 137.4 (Cq), 127.1 (Cq), 126.7 (CH2), 123.8 (CH), 122.4 (CH), 
121.2 (CH), 120.8 (CH), 115.5 (Cq), 113.2 (CH), 104.0 (CH), 51.9 (CH3), 29.9 (CH2). 
IR (ATR): 2950, 1718, 1632, 1587, 1460, 1435, 1338, 1146, 955, 784 cm-1. MS (ESI): 
m/z (relative intensity) 393 (44) [M+Na]+, 371 (100) [M+H]+. HR-MS (ESI): m/z calcd 
for C18H1679BrN2O2+ [M+H]+: 371.0390, found: 371.0396. 
  






The general procedure J was followed using 2-(1H-pyrrol-1-yl)pyrimidine 270o (36.3 
mg, 0.25 mmol), methyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (162.0 mg, 
0.75 mmol), MnBr(CO)5 (3.4 mg, 5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 1,4-
dioxane (1.0 mL). The reaction was performed at 80 °C. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 271o (70.0 mg, 82%) as 
a colorless oil.  
1H NMR (400 MHz, CDCl3): δ 8.64 (d, J = 4.8 Hz, 2H), 7.10 (t, J = 4.8 Hz, 1H), 5.99 
(td, J = 1.7, 1.4 Hz, 2H), 5.98 (s, 2H), 5.22 (td, J = 2.3, 1.4 Hz, 2H), 3.86 (dd, J = 2.3, 
1.7 Hz, 4H), 3.66 (s, 6H). 13C NMR (101 MHz, CDCl3): δ 167.3 (Cq), 158.1 (CH), 157.7 
(Cq), 139.1 (Cq) , 131.1 (Cq), 125.4 (CH2), 118.1 (CH), 110.3 (CH), 51.7 (CH3), 30.3 
(CH2). IR (ATR): 2953, 2923, 1718, 1632, 1571, 1430, 1278, 1256, 1155, 816 cm-1. 
MS (ESI): m/z (relative intensity) 364 (100) [M+Na]+, 342 (82) [M+H]+. HR-MS (ESI): 





The general procedure J was followed using 1-(pyridin-2-yl)-6,7-dihydro-1H-indol-
4(5H)-one 270p (53.1 mg, 0.25 mmol), methyl 2-{[(tert-
butoxycarbonyl)oxy]methyl}acrylate 253a (81.0 mg, 0.38 mmol), MnBr(CO)5 (3.4 mg, 
5.0 mol %) and NaOAc (6.2 mg, 30 mol %) in 1,4-dioxane (1.0 mL). The reaction was 
performed at 80 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc: 5/1 → 2/1) yielded 271p (76.3 mg, 96%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ  8.57 (ddd, J = 4.8, 1.9, 0.8 Hz, 1H), 7.87 – 7.80 (m, 1H), 
7.39 – 7.30 (m, 1H), 7.28 – 7.23 (m, 1H), 6.41 – 6.35 (m, 1H), 6.10 (d, J = 1.1 Hz, 1H), 
5.36 (td, J = 1.4, 1.1 Hz, 1H), 3.63 (s, 3H), 3.54 – 3.51 (m, 2H), 2.62 (t, J = 6.0 Hz, 2H), 
2.51 – 2.38 (m, 2H), 2.05 (tt, J = 7.4, 6.0 Hz, 2H).  13C NMR (75 MHz, CDCl3): δ 194.4 
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(Cq), 166.8 (Cq), 150.0 (Cq), 149.6 (CH), 144.5 (Cq), 138.5 (CH), 137.4 (Cq), 131.9 (Cq), 
126.7 (CH2), 123.4 (CH), 121.4 (CH), 120.8 (Cq), 105.6 (CH), 51.9 (CH3), 37.8 (CH2), 
29.0 (CH2), 23.8 (CH2), 22.9 (CH2). IR (ATR): 2948, 1717, 1655, 1588, 1459, 1438, 
1210, 1140, 1001, 783 cm-1. MS (ESI): m/z (relative intensity) 333 (45) [M+Na]+, 311 






The general procedure L was followed using benzyl N-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophanate 153 (70.7 mg, 0.15 mmol), allyl acetate 272 (30.0 mg, 
0.30 mmol), [Cp*Co(MeCN)3](SbF6)2 (5.9 mg, 5.0 mol %) and PivOH (1.5 mg, 10 mol 
%) in TFE (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) yielded 273a (55.3 mg, 72%) as a colorless oil. The reaction was 
also performed using H2O (27.0 mg, 1.5 mmol, 10 equiv), and yielded 273a (40.9 mg, 
53%). 
1H NMR (300 MHz, CDCl3): δ 8.63 (ddd, J = 4.9, 1.9, 0.6 Hz, 1H), 7.84 (ddd, J = 7.7, 
7.7, 1.9 Hz, 1H), 7.59 – 7.53 (m, 1H), 7.35 – 7.28 (m, 6H), 7.20 – 7.11 (m, 4H), 5.67 
(dddd, J = 16.3, 10.8, 5.8, 5.8 Hz, 1H), 5.19 (d, J = 8.1 Hz, 1H), 5.09 (d, J = 12.3 Hz, 
1H), 5.00 (d, J = 12.3 Hz, 1H), 4.79 (d, J = 10.8 Hz, 1H), 4.72 – 4.66 (m, 2H), 3.66 (d, 
J = 5.8 Hz, 2H), 3.31 (d, J = 6.3 Hz, 2H), 1.41 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 
172.3 (Cq), 151.4 (Cq), 149.5 (CH), 138.1 (CH), 136.9 (Cq), 135.9 (Cq), 135.3 (Cq), 
135.0 (CH), 133.7 (CH), 128.7 (Cq), 128.5 (CH), 128.3 (CH), 128.2 (CH), 122.3 (CH), 
122.1 (CH), 121.4 (CH), 118.6 (Cq), 116.1 (CH2), 113.9 (CH), 110.2 (CH), 109.4 (Cq), 
79.9 (Cq), 67.4 (CH2), 55.4 (CH), 29.3 (CH2), 28.5 (CH3), 27.8 (CH2). IR (ATR): 3377, 
3171, 2970, 1701, 1610, 1511, 1381, 1029, 710, 695 cm–1. MS (ESI): m/z (relative 
intensity) 1045 (85) [2M+Na]+, 534 (100) [M+Na]+. HR-MS (ESI): m/z calcd for 
C31H33N3O4Na+ [M+Na]+: 534.2363; found: 534.2366. 
  






The general procedure L was followed using methyl N-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophanate 153 (59.3 mg, 0.15 mmol), allyl acetate 272 (30.0 mg, 
0.30 mmol), [Cp*Co(MeCN)3](SbF6)2 (5.9 mg, 5.0 mol %) and PivOH (1.5 mg, 10 mol 
%) in TFE (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 2/1) yielded 273b (52.9 mg, 81%) as a colorless oil. The reaction was 
also performed using H2O (27.0 mg, 1.5 mmol, 10 equiv), and yielded 273b (40.9 mg, 
69%). 
1H NMR (500 MHz, CDCl3): δ 8.63 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H),7.85 (ddd, J = 7.9, 
7.5, 2.0 Hz, 1H), 7.56 – 7.54 (m, 1H), 7.41 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H), 7.33 – 7.28 
(m, 2H), 7.18 – 7.10 (m, 2H), 5.70 – 5.65 (m, 1H), 5.16 (d, J = 8.0 Hz, 2H), 4.81 (d, J 
= 10.0 Hz, 1H), 4.72 (d, J = 17.0 Hz, 1H), 4.64 (ddd, J = 8.0, 5.9, 5.9 Hz, 1H), 3.69 (d, 
J = 5.9 Hz, 1H), 3.68 (s, 3H), 3.34– 3.25 (m, 2H), 1.41 (s, 9H). 13C NMR (126 MHz, 
CDCl3): δ =173.0 (Cq), 155.2 (Cq), 151.5 (Cq), 149.6 (CH), 138.3 (CH), 136.9 (Cq), 
136.0 (Cq), 135.0 (CH), 128.7 (Cq), 122.4 (CH), 122.2 (CH), 121.4 (CH), 120.7 (CH), 
118.6 (CH), 116.1 (CH2), 110.2 (CH), 109.4 (Cq), 79.9 (Cq), 54.2 (CH), 52.4 (CH3), 29.2 
(CH2), 28.4 (CH3), 27.6 (CH2). IR (ATR): 3374, 2977, 1741, 1708, 1499, 1470, 1437, 
1366, 1017, 735 cm–1. MS (ESI): m/z (relative intensity) 893 (20) [2M+Na]+, 458 (100) 
[M+Na]+, 436 (35) [M+H]+. HR-MS (ESI): m/z calcd for C25H29N3O4Na+ [M+Na]+: 
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The general procedure L was followed using tert-butyl [(S)-1-{[(S)-1-amino-4-methyl-
1-oxopentan-2-yl]amino}-1-oxo-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propan-2-
yl}carbamate 243k (74.1 mg, 0.15 mmol), allyl acetate 272 (30.0 mg, 0.30 mmol), 
[Cp*Co(MeCN)3](SbF6)2 (5.9 mg, 5.0 mol %) and PivOH (1.5 mg, 10 mol %) in TFE 
(1.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 4/1) 
yielded 273c (48.1 mg, 60%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 8.70 – 8.58 (m, 1H), 7.90 (ddd, J = 7.6, 7.6, 1.9 Hz, 1H), 
7.74 – 7.68 (m, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.37 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.33 
– 7.24 (m, 1H), 7.23 – 7.14 (m, 2H), 6.02 (d, J = 8.3 Hz, 1H), 5.88 – 5.60 (m, 2H), 5.50 
(br s, 1H), 5.29 (d, J = 7.2 Hz, 1H), 4.88 (dd, J = 10.1, 1.6 Hz, 1H), 4.75 (dd, J = 17.1, 
1.6 Hz, 1H), 4.50 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 4.39 (ddd, J = 9.6, 8.3, 4.6 Hz, 1H), 
3.67 (d, J = 6.2 Hz, 2H), 3.36 – 3.15 (m, 2H), 1.69 (ddd, J = 13.6, 9.6, 4.5 Hz, 1H), 1.62 
– 1.50 (m, 1H), 1.45 (s, 9H), 1.38 – 1.25 (m, 1H), 0.88 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 
6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ = 173.6 (Cq), 171.7 (Cq), 155.6 (Cq), 150.9 
(Cq), 149.5 (CH), 138.4 (CH), 136.7 (Cq), 135.7 (Cq), 134.8 (CH), 127.7 (Cq), 122.6 
(CH), 122.5 (CH), 121.6 (CH), 120.9 (CH), 118.5 (CH), 116.0 (CH2), 110.3 (CH), 109.1 
(Cq), 80.4 (Cq), 55.4 (CH), 51.5 (CH), 40.1 (CH2), 28.9 (CH2), 28.3 (CH3), 27.6 (CH2), 
24.7 (CH), 23.1 (CH3), 21.6 (CH3). IR (ATR): 3284, 3056, 2957, 1650, 1586, 1471, 
1366, 1166, 782 cm-1. MS (ESI): m/z (relative intensity) 556 (96) [M+Na]+, 534 (100) 





The general procedure Lwas followed using (3S,8aS)-3-{[1-(pyridin-2-yl)-1H-indol-3-
yl] methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 243c (51.1 mg, 0.15 mmol), allyl 
acetate 272 (30.0 mg, 0.30 mmol), [Cp*Co(MeCN)3](SbF6)2 (5.9 mg, 5.0 mol %) and 
PivOH (1.5 mg, 10 mol %) in TFE (1.0 mL). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 4/1) yielded 273d (46.4 mg, 77%) as a white solid.  
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M.p.: 89 – 91 °C. 1H NMR (400 MHz, CDCl3): δ 8.62 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 
7.87 (ddd, J = 8.0, 7.5, 2.0 Hz, 1H), 7.57 – 7.51 (m, 1H), 7.43 (ddd, J = 8.0, 1.0, 1.0 
Hz, 1H), 7.36 – 7.28 (m, 2H), 7.20 – 7.12 (m, 2H), 5.81 – 5.58 (m, 2H), 4.87 (dd, J = 
10.1, 1.5 Hz, 1H), 4.75 (dtd, J = 17.1, 1.7, 1.5  Hz, 1H), 4.41 (ddd, J = 11.3, 3.8, 1.5 
Hz, 1H), 4.04 (dd, J = 9.0, 6.9 Hz, 1H), 3.78 – 3.51 (m, 5H), 3.01 (dd, J = 15.1, 11.5 
Hz, 1H), 2.40 – 2.24 (m, 1H), 2.12 – 1.96 (m, 2H), 1.94 – 1.81 (m, 1H). 13C NMR (101 
MHz, CDCl3): δ 169.3 (Cq), 165.6 (Cq), 151.0 (Cq), 149.6 (CH), 138.3 (CH), 136.9 (Cq), 
136.2 (Cq), 134.8 (CH), 127.8 (Cq), 122.8 (CH), 122.3 (CH), 121.2 (CH), 121.0 (CH), 
118.0 (CH), 116.4 (CH2), 110.5 (CH), 108.6 (Cq), 59.2 (CH), 54.7 (CH), 45.4 (CH2), 
29.1 (CH2), 28.3 (CH2), 25.7 (CH2), 22.6 (CH2). IR (ATR): 3056, 2953, 2924, 1659, 
1587, 1469, 1458, 1436, 1370, 731 cm-1. MS (ESI): m/z (relative intensity) 423 (100) 






The general procedure L was followed using ethyl N-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-tryptophylglycinate 243q (97.9 mg, 0.15 mmol), allyl acetate 272 
(30.0 mg, 0.30 mmol), [Cp*Co(MeCN)3](SbF6)2 (5.9 mg, 5.0 mol %) and PivOH (1.5 
mg, 10 mol %) in TFE (1.0 mL). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 4/1) yielded 273e (78.6 mg, 76%) as a white solid. 
M.p.: 100 – 102 °C. 1H NMR (300 MHz, CDCl3): δ 8.70 (s, 1H), 8.68 – 8.64 (m, 1H), 
7.88 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.70 – 7.50 (m, 1H), 7.43 (ddd, J = 8.0, 1.0, 1.0 
Hz, 1H), 7.38 – 7.28 (m, 2H), 7.22 – 7.12 (m, 2H), 7.10 – 6.99 (m, 2H), 6.95 – 6.78 (m, 
2H), 6.70 (d, J = 2.4 Hz, 1H), 6.38 (d, J = 7.8 Hz, 1H), 5.66 (ddt, J = 17.1, 10.0, 5.8 Hz, 
1H), 4.93 (d, J = 5.9 Hz, 1H), 4.81 – 4.56 (m, 3H), 4.29 (ddd J = 5.9, 5.9, 5.9 Hz, 1H), 
4.10 (q, J = 7.1Hz, 2H), 3.88 (dd, J = 17.7, 5.7 Hz, 1H), 3.80 – 3.54 (m, 3H), 3.38 – 
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3.23 (m, 2H), 3.14 (dd, J = 14.8, 6.3 Hz, 1H), 2.92 (dd, J = 14.8, 6.0 Hz, 1H), 1.22 (t, J 
= 7.1 Hz, 3H), 1.16 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 171.8 (Cq), 171.4 (Cq), 169.2 
(Cq), 155.7 (Cq), 151.0 (Cq), 149.3 (CH), 138.4 (CH), 136.8 (Cq), 135.9 (Cq), 135.9 (Cq), 
134.7 (CH), 128.3 (Cq), 127.4 (Cq), 123.6 (CH), 122.6 (CH), 122.4 (CH), 121.8 (CH), 
121.5 (CH), 120.9 (CH), 119.5 (CH), 118.7 (CH), 117.9 (CH), 116.3 (CH2), 111.2 (CH), 
110.1 (CH), 109.0 (Cq), 109.0 (Cq), 80.2 (Cq), 61.1 (CH2), 55.7 (CH), 53.8 (CH), 41.4 
(CH2), 29.0 (CH2), 28.0 (CH3), 26.5 (CH2), 26.3 (CH2), 14.2 (CH3). IR (ATR): 3315, 
3056, 2977, 2867, 1744, 1655, 1508, 1471, 1438, 1200, 1166, 742 cm-1.  MS (ESI): 
m/z (relative intensity) 716 (100) [M+Na]+, 693 (40) [M+H]+. HR-MS (ESI): m/z calcd 
for C39H45N6O6+ [M+H]+: 693.3395, found: 693.3399. 
 
(S)-2-{[S]-3-[2-allyl-1-(pyridin-2-yl)-1H-indol-3-yl]-2-[(tert-butoxycarbonyl)amino] 
propanamido}-3-phenylpropanoic acid (273f) 
 
The general procedure L was followed using (S)-2-{[S]-2-[(tert-butoxycarbonyl)amino]-
3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-3-phenylpropanoic acid 243ab (79.2 
mg, 0.15 mmol), allyl acetate 272 (30.0 mg, 0.30 mmol), [Cp*Co(MeCN)3](SbF6)2 (11.8 
mg, 10 mol %) and PivOH (1.5 mg, 10 mol %) in TFE (1.0 mL) Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 9/1, + 1% AcOH) yielded 273f (52.0 mg, 
61%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 10.10 (br s, 1H), 8.71 – 8.61 (m, 1H) 8.01 (ddd, J = 7.8, 
7.8, 2.0 Hz, 1H), 7.93 – 7.81 (m, 1H), 7.54 – 7.44 (m, 2H), 7.39 – 6.83 (m, 9H), 5.66 – 
5.43 (m, 2H), 4.92 – 4.70 (m, 2H), 4.68 – 4.45 (m, 2H), 3.77 – 3.26 (m, 3H), 3.10 – 
2.64 (m, 3H), 1.49 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 172.1 (Cq), 171.0 (Cq), 155.1 
(Cq), 150.6 (Cq), 148.5 (CH), 139.8 (CH), 137.3 (Cq), 136.1 (Cq), 135.9 (Cq), 134.5 
(CH), 129.0 (CH), 128.4 (CH), 127.7 (Cq), 126.7 (CH), 123.3 (CH),123.3 (CH), 122.6 
(CH), 121.0 (CH), 118.8 (CH), 115.9 (CH2), 109.8 (CH), 109.6 (Cq), 79.8 (Cq), 54.6 
(CH), 53.7 (CH), 37.6 (CH2), 28.8 (CH2), 28.6 (CH2), 28.3 (CH3). IR (ATR): 3406, 3309, 
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2977, 2930, 1712, 1693, 1497, 1472, 1438, 1367, 1166, 733 cm-1. MS (ESI): m/z 
(relative intensity) 1159 (40) [2M+Na]+, 1137 (40) [2M+H]+, 583 (50) [M+Na]+, 569 




dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oic acid (273g) 
 
The general procedure L was followed using (6S,9S)-9-[(S)-sec-butyl]-2,2-dimethyl-
4,7,10-trioxo-6-[(1-(pyridin-2-yl)-1H-indol-3-yl]methyl-3-oxa-5,8,11-triazatridecan-13-
oic acid 243ac (82.7 mg, 0.15 mmol), allyl acetate 272 (30.0 mg, 0.30 mmol), 
[Cp*Co(MeCN)3](SbF6)2 (11.8 mg, 10 mol %) and PivOH (1.5 mg, 10 mol %) in TFE 
(1.0 mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 85/15, 
+ 1% AcOH) yielded 273g (47.0 mg, 53%) as a white solid. 
M.p.: 166 – 168 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.64 (d, J = 4.7 Hz, 1H), 8.08 – 
7.81 (m, 3H), 7.74 – 7.62 (m, 1H), 7.56 – 7.37 (m, 2H), 7.30 – 7.17 (m, 1H), 7.18 – 
6.97 (m, 2H), 5.64 (dddd, J = 14.4, 10.8, 5.5, 4.7 Hz, 1H), 4.73 (d, J = 10.0 Hz, 1H), 
4.63 (d, J = 17.1 Hz, 1H), 4.40 – 4.15 (m, 2H), 3.79 – 3.40 (m, 5H), 3.16 (dd, J = 13.8, 
4.4 Hz, 1H), 2.99 (dd, J = 13.8, 9.3 Hz, 1H), 1.82 – 1.65 (m, 1H), 1.57 – 1.38 (m, 1H), 
1.25 (s, 9H), 1.14 – 1.06 (m, 1H), 0.92 – 0.78 (m, 6H).13C NMR (101 MHz, DMSO-d6): 
δ 171.8 (Cq), 171.7 (Cq), 170.7 (Cq), 155.5 (Cq), 151.1 (Cq), 149.7 (CH), 139.4 (CH), 
136.6 (Cq), 135.8 (Cq), 135.8 (CH), 128.7 (Cq), 123.0 (CH), 122.2 (CH), 121.7 (CH), 
120.5 (CH), 119.2 (CH), 115.9 (CH2), 111.0 (Cq), 110.3 (CH), 78.6 (Cq), 70.2 (CH2), 
57.2 (CH), 56.2 (CH), 37.8 (CH), 29.1 (CH2), 28.5 (CH3), 27.3 (CH2), 24.7 (CH2), 15.7 
(CH3), 11.6 (CH3). IR (ATR): 3306, 2967, 2931, 1692, 1645, 1526, 1473, 1438, 1367, 
1222, 1169, 742 cm-1. MS (ESI): m/z (relative intensity) 614 (100) [M+Na]+, 592 (85) 
[M+H]+, 287 (83). HR-MS (ESI): m/z calcd for C32H42N5O6+ [M+H]+: 592.3130, found: 
592.3124.  
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5.7. Manganese(I)-Catalyzed Peptide C–H Ligation and Macrocyclization 
 






The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (59.3 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 6/1 → 3/1) 
yielded 274b (95.0 mg, 95%, E/Z = 97:3) as a white solid. 
M. p.: 83 – 85 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 5.0, 1.8 Hz, 1H), 8.10 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 16.2 Hz, 1H), 7.56 
(dd, J = 7.5, 4.9 Hz, 1H), 7.50 – 7.42 (m, 2H), 7.38 (d, J = 7.5 Hz, 1H), 7.31 – 7.23 (m, 
2H), 7.23 – 7.16 (m, 1H), 5.59 (d, J = 16.2 Hz, 1H), 4.51 – 4.11 (m, 4H), 3.63 (s, 3H), 
3.59 (s, 3H), 3.45 – 3.34 (m, 2H), 1.37 (s, 9H), 1.30 (s, 9H). 13C NMR (101 MHz, DMSO-
d6): δ 172.5 (Cq), 170.7 (Cq), 166.0 (Cq), 155.7 (Cq), 150.9 (Cq), 150.3 (CH), 140.0 
(CH), 139.0 (Cq), 133.1 (CH), 131.5 (Cq), 128.4 (Cq), 125.8 (CH), 124.0 (CH), 122.6 
(CH), 121.7 (CH), 120.7 (CH), 119.9 (Cq), 117.7 (CH), 111.2 (CH), 79.0 (Cq), 78.8 (Cq), 
63.5 (CH2), 54.9 (CH), 53.0 (CH), 52.6 (CH3), 52.4 (CH3), 28.6 (CH3), 28.5 (CH3), 27.0 
(CH2). (One Cq of the Boc group is missing due to overlap, the overlap was verified by 
HSQC and HMBC analysis, showing that the peaks at 155.7 ppm correspond to two 
carbons). IR (ATR): 2978, 1706, 1625, 1588, 1503, 1470, 1366, 1212, 1158, 1060, 
852, 731 cm-1. MS (ESI) m/z (relative intensity): 689 (100) [M+Na]+, 667 (12) [M+H]+. 
HR-MS (ESI): m/z calcd for C34H43N4O10+ [M+H]+: 667.2974, found: 667.2960. 
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Ethyl (E)-3-[1-(pyridin-2-yl)-1H-indol-2-yl]acrylate (S2) 
 
The general procedure M was followed using 1-(pyridin-2-yl)-1H-indole (48.6 mg, 0.25 
mmol), ethyl propiolate (1a) (36.8 mg, 0.38 mmol), MnBr(CO)5 (6.9 mg, 10 mol %) and 
NaOAc (6.1 mg, 30 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 20/1) yielded S3 (70.8 mg, 97%) as 
colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.69 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.90 (ddd, J = 7.7, 
7.7, 1.9 Hz, 1H), 7.68 (dd, J = 15.9, 0.7 Hz, 1H), 7.66 – 7.62 (m, 1H), 7.45 (d, J = 8.2 
Hz, 1H), 7.40 – 7.32 (m, 2H), 7.27 – 7.20 (m, 1H), 7.17 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 
7.11 (d, J = 0.7 Hz, 1H), 6.34 (d, J = 15.9 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 
7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 166.8 (Cq), 150.5 (Cq), 149.9 (CH), 138.6 
(Cq), 138.5 (CH), 134.8 (Cq), 133.8 (CH), 128.0 (Cq), 124.5 (CH), 122.5 (CH), 121.7 
(CH), 121.4 (CH), 121.4 (CH), 118.5 (CH), 111.0 (CH), 106.5 (CH), 60.4 (CH2), 14.3 
(CH3). IR (ATR): 3053, 2979, 1703, 1627, 1467, 1214, 1170, 738 cm-1. MS (ESI) m/z 
(relative intensity): 315 (60) [M+Na]+, 293 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C18H17N2O2+ [M+H]+: 293.1285, found: 293.1285. 






The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-phenylalaninate 243m (81.3 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
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Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) 
yielded 275b (106.2 mg, 87%, E/Z = 95:5) as a white solid. 
M. p. 89 – 93 ºC. 1H NMR (400 MHz, CDCl3): δ 8.64 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 
7.87 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.77 – 7.67 (m, 2H), 7.39 – 7.31 (m, 2H), 7.27 (d, 
J = 8.2 Hz, 1H), 7.26 – 7.21 (m, 1H), 7.20 – 7.11 (m, 4H), 6.98 – 6.84 (m, 2H), 6.10 
(brs, 1H), 5.92 (d, J = 10.4 Hz, 1H), 5.43 (d, J = 16.3 Hz, 1H), 5.35 (brs, 1H), 4.66 – 
4.58 (m, 2H), 4.52 (dd, J = 11.2, 3.6 Hz, 1H), 4.47 – 4.36 (m, 1H), 4.33 (dd, J = 11.2, 
3.3 Hz, 1H), 3.74 (s, 3H), 3.58 – 3.40 (m, 4H), 3.32 (dd, J = 14.0, 8.5 Hz, 1H), 3.00 (dd, 
J = 13.7, 5.9 Hz, 1H), 2.93 (dd, J = 13.7, 5.0 Hz, 1H), 1.43 (s, 9H), 1.40 (s, 9H). 13C 
NMR (101 MHz, CDCl3): δ 170.9 (Cq), 170.5 (Cq), 170.3 (Cq), 165.9 (Cq), 155.4 (Cq), 
155.0 (Cq), 151.1 (Cq), 149.9 (CH), 139.4 (Cq), 138.6 (CH), 135.5 (Cq), 132.9 (CH), 
131.5 (Cq), 129.2 (CH), 128.4 (CH), 128.0 (Cq), 127.0 (CH), 125.7 (CH), 123.0 (CH), 
122.1 (CH), 121.7 (CH), 120.1 (CH), 119.4 (Cq), 117.1 (CH), 110.8 (CH), 80.1 (Cq), 
80.0 (Cq), 64.6 (CH2), 55.0 (CH), 53.5 (CH), 53.0 (CH), 52.7 (CH3), 52.1 (CH3), 38.0 
(CH2), 28.7 (CH2), 28.3 (CH3), 28.3 (CH3). IR (ATR): 3345, 2976, 2927, 1744, 1711, 
1510, 1454, 1438, 1214, 1164, 745 cm-1. MS (ESI) m/z (relative intensity): 836 (100) 







The general procedure M was followed using dimethyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-aspartate 243ab (78.6 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) 
yielded 275c (100.2 mg, 84%, E/Z = 95:5) as a white solid. 
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M. p. 70 – 73 ºC. 1H NMR (400 MHz, CDCl3): δ 8.70 (d, J = 5.4 Hz, 1H), 7.93 (ddd, J 
= 7.7, 7.7, 1.9 Hz, 1H), 7.83 – 7.71 (m, 2H), 7.47 – 7.39 (m, 2H), 7.35 (d, J = 8.2 Hz, 
1H), 7.32 – 7.29 (m, 1H),7.26 – 7.19 (m, 1H), 6.61 (brs, 1H), 5.90 (d, J = 8.6 Hz, 1H), 
5.51 (d, J = 16.2 Hz, 1H), 5.34 (brs, 1H), 4.79 – 4.44 (m, 4H), 4.36 (dd, J = 11.3, 3.2 
Hz, 1H), 3.89 – 3.73 (m, 3H), 3.71 – 3.32 (m, 8H), 2.93 (dd, J = 17.3, 3.7 Hz, 1H), 2.83 
(dd, J = 17.3, 4.6 Hz, 1H), 1.48 (s, 9H), 1.43 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 
171.0 (Cq), 170.7 (Cq), 170.5 (Cq), 170.3 (Cq), 166.0 (Cq), 155.4 (Cq), 155.0 (Cq), 151.2 
(Cq), 149.9 (CH), 139.5 (Cq), 138.6 (CH), 133.0 (CH), 131.6 (Cq), 128.1 (Cq), 125.8 
(CH), 123.0 (CH), 122.2 (CH), 121.8 (CH), 120.1 (CH), 119.3 (Cq), 117.2 (CH), 110.9 
(CH), 80.2 (Cq), 80.1 (Cq), 64.6 (CH2), 55.0 (CH), 53.0 (CH), 52.7 (CH3), 52.6 (CH3), 
51.9 (CH3), 48.9 (CH), 36.1 (CH2), 28.6 (CH2), 28.3 (CH3), 28.3 (CH3). IR (ATR): 3344, 
2954, 2926, 1711, 1503, 1454, 1366, 1246, 1213, 1160, 744 cm-1. MS (ESI) m/z 
(relative intensity): 818 (100) [M+Na]+, 796 (23) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-serinate 243n (72.3 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (1.0 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/2) yielded 
275d (78.1 mg, 69%, E/Z = 98:2) as a white solid. 
M. p. 82 – 86 ºC. 1H NMR (400 MHz, CDCl3): δ 8.62 (d, J = 4.2 Hz, 1H), 8.08 – 7.89 
(m, 2H), 7.73 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.50 – 7.41 (m, 1H), 7.36 – 
7.29 (m, 2H), 7.26 – 7.21 (m, 2H), 6.96 – 6.80 (m, 1H), 6.48 (d, J = 8.9 Hz, 1H), 5.22 
– 5.06 (m, 2H), 4.70 – 4.55 (d, J = 11.3 Hz, 1H), 4.63 (d, J = 9.2 Hz, 3H), 4.34 – 4.19 
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(m, 1H), 4.14 (s, 1H), 3.89 – 3.80 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.40 (dd, J = 14.6, 
6.5 Hz, 1H), 1.47 (s, 9H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 170.8 (Cq), 170.6 
(Cq), 170.5 (Cq), 165.6 (Cq), 155.8 (Cq), 155.1 (Cq), 150.7 (Cq), 150.0 (CH), 139.7 (Cq), 
139.4 (CH), 133.2 (CH), 131.8 (Cq), 128.4 (Cq), 126.1 (CH), 123.5 (CH), 122.1 (CH), 
122.1 (CH), 119.8 (CH), 119.6 (Cq), 117.4 (CH), 110.7 (CH), 80.5 (Cq), 80.0 (Cq), 64.3 
(CH2), 62.3 (CH2), 55.4 (CH), 54.9 (CH), 53.2 (CH), 52.7 (CH3), 52.6 (CH3), 28.3 (CH3), 
28.3 (CH3), 27.0 (CH2). IR (ATR): 3344, 2977, 2954, 1743, 1708, 1505, 1454, 1366, 
1214, 1160, 731 cm-1. MS (ESI) m/z (relative intensity): 776 (100) [M+Na]+, 754 (16) 






The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-tyrosinate 243o (83.9 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 1/2) 
yielded 275e (83.4 mg, 67%, E/Z = 98:2) as a white solid. 
M. p. 90 – 92 ºC. 1H NMR (400 MHz, CDCl3): δ 8.69 (dd, J = 5.0, 1.9 Hz, 1H), 7.92 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.83 – 7.70 (m, 2H), 7.42 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 
7.34 (d, J = 8.0 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.19 (ddd, J = 8.0, 6.1, 1.9 Hz, 1H), 6.90 
– 6.71 (m, 3H), 6.62 (d, J = 7.8 Hz, 2H), 6.30 (brs, 1H), 5.94 (brs, 1H), 5.38 (d, J = 16.2 
Hz, 1H), 5.22 (brs, 1H), 4.81 – 4.44 (m, 4H), 4.34 (dd, J = 11.2, 3.3 Hz, 1H), 3.72 (s, 
3H), 3.59 (s, 3H), 3.51 – 3.34 (s, 2H), 3.10 – 2.97 (m, 1H), 2.88 (dd, J = 14.0, 6.0 Hz, 
1H), 1.47 (s, 9H), 1.40 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 171.3 (Cq), 170.6 (Cq), 
170.5 (Cq), 166.0 (Cq), 155.6 (Cq), 155.4 (Cq), 155.1 (Cq), 151.2 (Cq), 149.8 (CH), 139.7 
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(Cq), 138.9 (CH), 133.0 (CH), 131.6 (Cq), 130.3 (CH), 128.0 (Cq), 126.9 (Cq), 125.9 
(CH), 123.1 (CH), 122.4 (CH), 121.8 (CH), 120.2 (CH), 120.0 (Cq), 117.0 (CH), 115.6 
(CH), 110.8 (CH), 80.4 (Cq), 80.2 (Cq), 64.5 (CH2), 55.0 (CH), 53.4 (CH), 53.0 (CH), 
52.8 (CH3), 52.2 (CH3), 37.0 (CH2), 28.3 (CH3), 28.2 (CH3), 28.1 (CH2). IR (ATR): 3337, 
2976, 1741, 1710, 1515, 1366, 1246, 1215, 1163, 744 cm-1. MS (ESI) m/z (relative 
intensity): 852 (100) [M+Na]+, 830 (55) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-methioninate 243ac (78.9 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.9 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 
275f (105.6 mg, 88%, E/Z = 97:3) as a pale yellow solid. 
M. p. 131 – 133 ºC. 1H NMR (400 MHz, CDCl3): δ 8.70 (d, J = 4.7 Hz, 1H), 7.93 (t, J = 
7.6 Hz, 1H), 7.83 – 7.71 (m, 2H), 7.45 – 7.38 (m, 2H), 7.32 (d, J = 9.9 Hz, 1H), 7.26– 
7.22 (m, 1H), 7.22 (t, J = 7.4 Hz, 1H), 6.30 (d, J = 7.5 Hz, 1H), 5.89 (d, J = 8.6 Hz, 1H), 
5.52 (d, J = 16.2 Hz, 1H), 5.38 (d, J = 8.2 Hz, 1H), 4.72 – 4.44 (m, 4H), 4.41 – 4.33 (m, 
1H), 3.78 (s, 3H), 3.67 – 3.48 (m, 4H), 3.38 (dd, J = 11.4, 8.5 Hz, 1H), 2.47 – 2.27 (m, 
2H), 2.10 – 1.98 (m, 4H), 1.94 – 1.79 (m, 1H), 1.47 (s, 9H), 1.44 (s, 9H). 13C NMR (101 
MHz, CDCl3): δ 171.4 (Cq), 170.7 (Cq), 170.5 (Cq), 165.9 (Cq), 155.4 (Cq), 155.1 (Cq), 
151.1 (Cq), 149.9 (CH), 139.4 (Cq), 138.6 (CH), 132.9 (CH), 131.5 (Cq), 128.1 (Cq), 
125.8 (CH), 123.0 (CH), 122.2 (CH), 121.8 (CH), 120.0 (CH), 119.2 (Cq), 117.3 (CH), 
110.9 (CH), 80.1 (Cq), 64.6 (CH2), 55.1 (CH), 53.1 (CH), 52.7 (CH), 52.4 (CH3), 51.7 
(CH3), 31.9 (CH2), 29.5 (CH2), 28.5 (CH2), 28.3 (CH3), 28.3 (CH3), 15.3 (CH3). (One Cq 
  5. Experimental Part 
 
285 
of the Boc group is missing due to overlap, the overlap was verified by HMBC and 
HSQC analysis, showing that the peak at 80.1 ppm corresponds to two carbons). IR 
(ATR): 3335, 2976, 2927, 1741, 1708, 1524, 1366, 1247, 1214, 1163, 739 cm-1. MS 
(ESI) m/z (relative intensity): 820 (100) [M+Na]+. HR-MS (ESI): m/z calcd for 






The general procedure M was followed using methyl Na-(N2-(tert-butoxycarbonyl)-Nω-
tosyl-L-arginyl)-1-(pyridin-2-yl)-L-tryptophanate 243ad (105.9 mg, 0.15 mmol), (S)-2-
[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 
mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane 
(0.6 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 
1/2) yielded 275g (124.5 mg, 85%, E/Z = 86:14) as a yellow solid. 
M. p. 98 – 101 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.70 (dd, J = 4.8, 1.9 Hz, 1H), 8.46 
(d, J = 7.7 Hz, 1H), 8.09 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.71 
– 7.61 (m, 3H), 7.57 (dd, J = 7.4, 4.8 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 8.2 
Hz, 1H), 7.32 – 6.94 (m, 6H), 6.83 – 6.69 (m, 2H), 6.56 (s, 1H), 5.48 (d, J = 16.3 Hz, 
1H), 4.62 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 4.42 – 4.17 (m, 3H), 3.98 – 3.90 (m, 1H), 3.62 
(s, 3H), 3.54 – 3.50 (m, 5H), 3.08 – 2.90 (m, 2H), 2.33 (s, 3H), 1.49 – 1.15 (m, 22H). 
13C NMR (101 MHz, DMSO-d6): δ 172.3 (Cq), 171.6 (Cq), 170.3 (Cq), 165.6 (Cq), 156.7 
(Cq), 155.4 (Cq), 155.3 (Cq), 155.3 (Cq), 150.5 (Cq), 149.9 (CH), 141.2 (Cq), 139.7 (CH), 
138.8 (Cq), 132.6 (CH), 131.3 (Cq), 129.1 (CH), 127.7 (Cq), 125.7 (CH), 125.6 (CH), 
123.7 (CH), 122.3 (CH), 121.5 (CH), 120.2 (CH), 119.0 (Cq), 117.4 (CH), 110.9 (CH), 
78.8 (Cq), 78.3 (Cq), 63.1 (CH2), 53.9 (CH), 52.8 (CH), 52.6 (CH), 52.3 (CH3), 52.1 
(CH3), 40.1 (CH2), 29.5 (CH2), 28.2 (CH3), 28.2 (CH3), 28.0 (CH2), 26.9 (CH2), 21.0 
(CH3). IR (ATR): 3336, 2967, 2929, 1738, 1709, 1547, 1228, 1160, 1131, 729 cm-1. 
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MS (ESI) m/z (relative intensity): 999 (100) [M+Na]+, 977 (67) [M+H]+. HR-MS (ESI): 






The general procedure M was followed using (3S,6S)-3-[(1H-indol-3-yl)methyl]-6-{[1-
(pyridin-2-yl)-1H-indol-3-yl]methyl}piperazine-2,5-dione 276b (67.4 mg, 0.15 mmol), 
(S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 
0.23 mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-
dioxane (0.9 mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 
95/5 → 90/10) yielded 277b (77.7 mg, 72%) as a white solid. 
M. p. 151 – 154 ºC. 1H NMR (400 MHz, CDCl3): δ  8.65 (dd, J = 4.9, 2.1 Hz, 1H), 8.22 
(brs, 1H), 7.91 – 7.82 (m, 2H), 7.74 (dd, J = 16.3 Hz, 1H), 7.54 (d, J = 3.0 Hz, 1H), 7.43 
– 7.28 (m, 5H), 7.26 – 7.23 (m, J = 9.2 Hz, 2H), 7.23 – 7.12 (m, 2H), 7.02 (t, J = 7.5 
Hz, 1H), 5.84 (brs, 1H), 5.57 (brs, 1H), 5.11 (d, J = 16.3 Hz, 1H), 4.76 – 4.65 (m, 2H), 
4.59 – 4.42 (m, 2H), 4.34 (dd, J = 11.4, 3.5 Hz, 1H), 3.94 (d, J = 10.8 Hz, 1H), 3.88 (s, 
3H), 3.70 (dd, J = 14.8, 4.5 Hz, 1H), 3.32 – 3.17 (m, 2H), 1.45 (s, 9H). 13C NMR (101 
MHz, CDCl3): δ 173.1 (Cq), 166.4 (Cq), 166.0 (Cq), 165.0 (Cq), 156.2 (Cq), 150.9 (Cq), 
150.3 (CH), 139.9 (Cq), 139.0 (CH), 136.3 (Cq), 132.7 (Cq), 131.9 (CH), 128.2 (Cq), 
126.4 (Cq), 126.1 (CH), 123.6 (CH), 123.6 (CH), 122.3 (CH), 122.1 (CH), 121.9 (CH), 
121.2 (CH), 119.8 (CH), 118.4 (Cq), 118.3 (CH), 117.4 (CH), 111.2 (CH), 110.6 (CH), 
109.1 (Cq), 79.8 (Cq), 64.5 (CH2), 55.9 (CH), 55.4 (CH), 53.5 (CH), 53.0 (CH3), 30.4 
(CH2), 29.7 (CH2), 28.3 (CH3). IR (ATR): 3288, 2954, 2925, 1706, 16721454, 1438, 
1163, 741 cm-1. MS (ESI): m/z (relative intensity): 743 (100) [M+Na]+, 721 (24) [M+H]+. 
HR-MS (ESI): m/z calcd for C39H41N6O8+ [M+H]+: 721.2980, found: 721.2965. 
  







The general procedure M was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-isoleucylglycinate 243ae (86.9 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (1.2 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 
276h (110.9 mg, 87%, E/Z = 98:2) as a white solid. 
M. p. 146 – 148 ºC. 1H NMR (400 MHz, CDCl3): δ 8.70 (dd, J = 5.0, 1.9 Hz, 1H), 8.01 
– 7.91 (m, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 16.4 Hz, 1H), 7.52 (d, J = 8.0 Hz, 
1H), 7.42 (dd, J = 7.5, 4.9 Hz, 1H), 7.33 – 7.26 (m, 2H), 7.23 (ddd, J = 8.0, 6.3, 1.9 Hz, 
1H), 6.72 (d, J = 5.7 Hz, 1H), 6.19 (d, J = 8.5 Hz, 1H), 6.04 (d, J = 8.0 Hz, 1H), 5.52 
(d, J = 16.4 Hz, 1H), 5.44 (d, J = 7.7 Hz, 1H), 4.68 – 4.56 (m, 2H), 4.54 – 4.34 (m, 3H), 
4.29 (t, J = 7.5 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 3.78 (dd, J = 18.0, 5.3 
Hz, 1H), 3.55 (dd, J = 14.2, 4.8 Hz, 1H), 3.35 (dd, J = 14.2, 9.2 Hz, 1H), 1.80 – 1.65 
(m, 1H), 1.50 – 1.39 (m, 18H), 1.32 – 1.23 (m, 4H), 1.12 – 0.95 (m, 1H), 0.92 – 0.76 
(m, 6H). 13C NMR (101 MHz, CDCl3): δ 171.1 (Cq), 170.7 (Cq), 170.5 (Cq), 169.5 (Cq), 
166.4 (Cq), 155.4 (Cq), 155.2 (Cq), 151.1 (Cq), 149.8 (CH), 139.3 (Cq), 138.6 (CH), 
133.3 (CH), 131.6 (Cq), 128.0 (Cq), 125.8 (CH), 123.0 (CH), 122.6 (CH), 121.8 (CH), 
120.2 (CH), 118.9 (Cq), 116.8 (CH), 111.0 (CH), 80.2 (Cq), 80.1 (Cq), 64.3 (CH2), 61.4 
(CH2), 57.4 (CH), 55.3 (CH), 53.6 (CH), 53.0 (CH3), 41.2 (CH2), 37.9 (CH), 28.6 (CH2), 
28.3 (CH3), 24.6 (CH2), 15.0 (CH3), 14.1 (CH3), 11.4 (CH3). (One CH3 of the Boc group 
is missing due to overlap, the overlap was verified by HSQC, showing that the peaks 
at 28.3 ppm corresponds to two carbons). IR (ATR): 3314, 2969, 2931, 1708, 1651, 
1521, 1366, 1247, 1161, 1022, 739 cm-1. MS (ESI) m/z (relative intensity): 873 (100) 
[M+Na]+, 851 (8) [M+H]+. HR-MS (ESI): m/z calcd for C43H59N6O12+ [M+H]+: 851.1485, 
found: 851.4165.  







The general procedure M was followed using methyl N-[Na-acetyl-1-(pyridin-2-yl)-L-
tryptophyl]-S-(4-methylbenzyl)-L-cysteinyl-L-leucinate 243h (98.6 mg, 0.15 mmol), 
methyl propioloyl-L-tryptophanate 211c (60.8 mg, 0.23 mmol), MnBr(CO)5 (4.1 mg, 10 
mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/4 → 1/9) yielded 276i (109.9 mg, 
79%) as a pale yellow solid. 
M. p. 117 – 119 ºC. 1H NMR (300 MHz, CDCl3): δ 8.68 (dd, J = 5.0, 1.8 Hz, 1H), 8.41 
(brs, 1H), 7.89 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.63 – 7.50 (m, 3H), 7.44 (d, J = 8.0 Hz, 
1H), 7.42 – 7.31 (m, 3H), 7.27 – 7.06 (m, 10H), 6.78 (d, J = 16.2 Hz, 1H), 6.59 (d, J = 
7.5 Hz, 1H), 6.55 – 6.46 (m, 2H), 4.98 (ddd, J = 6.4, 6.4, 6.4 Hz, 1H), 4.59 (ddd, J = 
7.5, 7.5, 6.1 Hz, 1H), 4.31 – 3.97 (m, 2H), 3.78 – 3.70 (m, 2H), 3.69 (s, 3H), 3.64 (s, 
3H), 3.55 – 3.43 (m, 1H), 3.42 – 3.27 (m, 3H), 2.85 (dd, J = 14.0, 4.6 Hz, 1H), 2.57 (dd, 
J = 14.0, 8.0 Hz, 1H), 2.36 (s, 3H), 1.99 (s, 3H), 1.55 – 1.41 (m, 2H), 1.39 – 1.30 (m, 
1H), 0.90 (d, J = 5.6 Hz, 3H), 0.85 (d, J = 5.6 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 
172.8 (Cq), 172.8 (Cq), 170.7 (Cq), 170.3 (Cq), 169.3 (Cq), 165.8 (Cq), 150.8 (Cq), 149.9 
(CH), 138.7 (CH), 137.8 (Cq), 137.1 (Cq), 136.3 (Cq), 135.3 (Cq), 132.6 (Cq), 129.5 
(CH), 129.0 (CH), 129.0 (Cq), 128.9 (CH), 127.7 (Cq), 124.6 (CH), 123.6 (CH), 123.5 
(CH), 122.8 (CH), 122.4 (CH), 122.1 (CH), 121.5 (CH), 119.5 (CH), 118.8 (CH), 118.7 
(CH), 114.5 (Cq), 111.5 (CH), 111.3 (CH), 110.2 (Cq), 54.5 (CH), 53.2 (CH), 52.6 (CH), 
52.4 (CH), 52.3 (CH3), 51.5 (CH3), 40.8 (CH2), 36.6 (CH2), 34.2 (CH2), 29.3 (CH2), 27.8 
(CH2), 24.9 (CH), 23.4 (CH3), 22.7 (CH3), 22.2 (CH3), 21.3 (CH3). IR (ATR): 3282, 2955, 
1740, 1645, 1532, 1514, 1437, 1206, 735 cm-1. MS (ESI) m/z (relative intensity): 950 
(85) [M+Na]+, 928 (35) [M+H]+. HR-MS (ESI): m/z calcd for C51H58N7O8S+ [M+H]+: 
928.4062, found: 928.4070. 
  








The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-isoleucyl-L-tyrosinate 243af (100.8 mg, 0.15 mmol), (S)-2-
[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 
mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane 
(0.6 mL). Purification by column chromatography on silica gel (CH2Cl2/acetone: 7/3 → 
6/4) yielded 276j (96.7 mg, 68%) as a white solid. 
M. p. 155 – 157 ºC. 1H NMR (400 MHz, DMSO-d6): δ 9.22 (s, 1H), 8.79 – 8.65 (m, 1H), 
8.50 (d, J = 6.7 Hz, 1H), 8.08 (ddd, J = 8.0, 8.0 1.9 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 
7.72 (d, J = 16.2 Hz, 1H), 7.65 – 7.53 (m, 2H), 7.47 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 7.5 
Hz, 1H), 7.31 – 7.13 (m, 4H), 6.97 (d, J = 7.9 Hz, 2H), 6.72 – 6.62 (m, 2H), 5.55 (d, J 
= 16.2 Hz, 1H), 4.45 – 4.26 (m, 5H), 4.26 – 4.15 (m, 1H), 3.62 (s, 3H), 3.51 (s, 3H), 
3.43 – 3.37 (m, 1H), 3.21 (dd, J = 14.4, 9.4 Hz, 1H), 2.84 (d, J = 7.4 Hz, 2H), 1.79 – 
1.65 (m, 1H), 1.37 (s, 9H), 1.21 (s, 9H), 1.14 – 0.97 (m, 2H), 0.91 – 0.74 (m, 6H). 13C 
NMR (101 MHz, DMSO-d6): δ 171.8 (Cq), 170.9 (Cq), 170.6 (Cq), 170.3 (Cq), 165.7 
(Cq), 156.0 (Cq), 155.3 (Cq), 154.9 (Cq), 150.6 (Cq), 149.8 (CH), 139.4 (CH), 138.7 (Cq), 
133.0 (CH), 131.1 (Cq), 129.9 (CH), 128.1(Cq), 126.8 (Cq), 125.3 (CH), 123.5 (CH), 
122.3 (CH), 121.0 (CH), 120.5 (CH), 120.2 (Cq), 117.0 (CH), 115.1 (CH), 110.7 (CH), 
78.6 (Cq), 78.4 (Cq), 62.9 (CH2), 56.1 (CH), 55.6 (CH), 54.2 (CH), 52.6 (CH), 52.1 
(CH3), 51.5 (CH3), 37.6 (CH), 35.9 (CH2), 28.1 (CH3), 27.9 (CH3), 27.6 (CH2), 23.9 
(CH2), 15.0 (CH3), 11.1 (CH3). IR (ATR): 3310, 2965, 2930, 1744, 1712, 1650, 1516, 
1367, 1248, 1165, 747 cm-1. MS (ESI) m/z (relative intensity): 965 (95) [M+Na]+, 944 
(35) [M+H]+, 772 (65). HR-MS (ESI): m/z calcd for C49H63N6O13+ [M+H]+: 943.4448, 
found: 943.4426. 
  







The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-tryptophanate 243ag (87.2 mg, 0.15 mmol), ethyl 
propioloyl-L-phenylalanyl-L-valylglycinate 211e (90.3 mg, 0.23 mmol), MnBr(CO)5 (4.1 
mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/3 → 0/1) yielded 276k (129.7 
mg, 88%) as a pale yellow solid. 
M. p. 147 – 148 ºC. 1H NMR (400 MHz, CDCl3): δ 8.61 (dd, J = 4.8, 1.8 Hz, 1H), 8.43 
(s, 1H), 7.79 (dd, J = 7.9, 7.9 Hz, 1H), 7.54 – 7.38 (m, 3H), 7.36 – 7.30 (m, 2H), 7.30 
– 7.25 (m, 2H), 7.24 – 7.20 (m, 4H), 7.18 – 7.05 (m, 5H), 6.98 (t, J = 7.5 Hz, 1H), 6.91 
(d, J = 16.2 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 6.62 (d, J = 2.4 Hz, 1H), 6.39 (t, J = 5.5 
Hz, 1H), 5.89 – 5.73 (m, 2H), 4.69 (ddd, J = 7.6, 7.6, 7.2 Hz, 1H), 4.46 (ddd, J = 6.6. 
5.4, 5.4 Hz, 1H), 4.33 – 4.19 (m, 2H), 4.11 (q, J = 7.1 Hz, 2H), 3.89 (dd, J = 18.2, 5.4 
Hz, 1H), 3.82 (dd, J = 18.2, 5.4 Hz, 1H), 3.43 – 3.24 (m, 3H), 3.23 – 3.13 (m, 4H), 3.12 
– 2.93 (m, 2H), 2.17 (hept, J = 6.8 Hz, 1H), 1.51 (s, 9H), 1.21 (t, J = 7.1 Hz, 3H), 0.83 
(d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 171.4 (Cq), 
170.9 (Cq), 170.3 (Cq), 170.0 (Cq), 169.4 (Cq), 166.8 (Cq), 155.4 (Cq), 150.5 (Cq), 149.7 
(CH), 138.6 (CH), 137.3 (Cq), 137.1 (Cq), 136.0 (Cq), 132.2 (Cq), 129.3 (CH), 129.1 
(CH), 129.1 (CH), 128.7 (Cq), 128.6 (CH), 127.4 (Cq), 126.7 (CH), 124.4 (CH), 122.9 
(CH), 122.5 (CH), 121.9 (CH), 121.7 (CH), 121.5 (CH), 119.3 (CH), 118.4 (CH), 114.7 
(Cq), 111.2 (CH), 110.8 (CH), 109.3 (Cq), 80.3 (Cq), 61.4 (CH2), 58.4 (CH), 55.4 (CH), 
54.5 (CH), 53.4 (CH), 52.1 (CH3), 41.2 (CH2), 37.0 (CH2), 30.7 (CH2), 30.1 (CH), 28.5 
(CH3), 27.6 (CH2), 19.1 (CH3), 17.3 (CH3), 14.0 (CH3). (One aromatic CH is missing 
due to overlap, the overlap was verified by HSQC, showing that the peak at 122.8 ppm 
corresponds to two carbons). IR (ATR): 3287, 2967, 2929, 1738/, 1650, 1521, 1469, 
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1436, 1199, 1165, 741 cm-1. MS (ESI) m/z (relative intensity): 1006 (100) [M+Na]+, 983 








The general procedure M was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-alanyl-L-leucylglycinate 243ah (97.6 mg, 0.15 mmol), (S)-2-[(tert-
butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (61.0 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (1.2 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/3) yielded 
276l (110.8 mg, 80%) as a white solid.  
M. p. 137 – 141 ºC. 1H NMR (400 MHz, CDCl3): δ 8.66 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 
7.90 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.79 – 7.66 (m, 2H), 7.38 (ddd, J = 7.7, 4.9, 1.0 
Hz, 1H), 7.30 (dt, J = 8.0, 1.0 Hz, 1H), 7.28 – 7.25 (m, 1H), 7.25 – 7.21 (m, 1H), 7.17 
(ddd, J = 8.0, 6.6, 1.5 Hz, 1H), 7.08 (brs, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 6.3 
Hz, 1H), 5.81 (d, J = 7.9 Hz, 1H), 5.42 (d, J = 16.2 Hz, 1H), 5.15 (d, J = 6.6 Hz, 1H), 
4.66 – 4.47 (m, 3H), 4.42 (m, 1H), 4.38 – 4.29 (m, 2H), 4.14 (q, J = 7.2 Hz, 2H), 4.07 
– 3.88 (m, 2H), 3.74 (s, 3H), 3.50 – 3.32 (m, 2H), 1.84 – 1.67 (m, 1H), 1.64 – 1.45 (m, 
2H), 1.42 (s, 9H), 1.32 (s, 9H), 1.26 (d, J = 7.2 Hz, 3H), 1.22 (t, J = 7.2 Hz, 3H), 0.87 
(d, J = 6.5 Hz, 3H), 0.84 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 172.3 (Cq), 
172.1 (Cq), 171.7 (Cq), 170.9 (Cq), 169.8 (Cq), 166.1 (Cq), 155.7 (Cq), 155.5 (Cq), 151.2 
(Cq), 150.1 (CH), 139.6 (Cq), 139.0 (CH), 132.9 (CH), 131.8 (Cq), 128.3 (Cq), 126.1 
(CH), 123.3 (CH), 122.3 (CH), 122.0 (CH), 120.1 (CH), 119.2 (Cq), 117.6 (CH), 111.1 
(CH), 80.7 (Cq), 80.4 (Cq), 64.7 (CH2), 61.4 (CH2), 55.5 (CH), 53.2 (CH), 53.0 (CH), 
51.9 (CH3), 49.9 (CH), 41.4 (CH2), 40.5 (CH2), 28.4 (CH3), 28.3 (CH3), 27.7 (CH2), 24.9 
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(CH), 22.9 (CH3), 22.0 (CH3), 18.3 (CH3), 14.3 (CH3). IR (ATR): 3295, 2958, 2926, 
1742, 1707, 1645, 1523, 1366, 1197, 1158, 1022, 734 cm-1. MS (ESI) m/z (relative 
intensity): 944 (100) [M+Na]+, 922 (18) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure M was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-valyl-L-valylglycinate 243x (99.7 mg, 0.15 mmol), methyl propioloyl-
L-leucylglycinate 211f (57.2 mg, 0.23 mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and 
NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by column 
chromatography on silica gel (EtOAc) yielded 276m (91.0 mg, 66%, E/Z = 97:3) as a 
pale yellow solid. 
M. p. 146 – 148 ºC. 1H NMR (400 MHz, CDCl3): δ 8.67 (dd, J = 4.9, 1.9 Hz, 1H), 7.89 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 16.1 Hz, 1H), 7.41 
– 7.27 (m, 4H), 7.22 – 7.05 (m, 3H), 6.84 (brs, 1H), 6.74 (brs, 1H), 6.60 (brs, 1H), 6.48 
(d, J = 16.1 Hz, 1H), 5.64 (d, J = 7.6 Hz, 1H), 4.55 (ddd, J = 8.5, 6.9, 5.3 Hz, 1H), 4.46 
(dd, J = 7.6, 7.6 Hz, 1H), 4.24 – 4.13 (m, 3H), 4.13 – 4.00 (m, 1H), 4.01 – 3.86 (m, 4H), 
3.69 (s, 3H), 3.39 (d, J = 6.9 Hz, 2H), 2.00 – 1.91 (m, 2H), 1.84 – 1.68 (m, 2H), 1.69 – 
1.60 (m, 1H), 1.37 (s, 9H), 1.23 (t, J = 7.1 Hz, 3H), 0.99 – 0.70 (m, 18H). 13C NMR (101 
MHz, CDCl3): δ 172.8 (Cq), 171.7 (Cq), 171.2 (Cq), 170.6 (Cq), 170.4 (Cq), 169.7 (Cq), 
166.7 (Cq), 155.6 (Cq), 151.0 (Cq), 150.0 (CH), 138.8 (CH), 138.0 (Cq), 132.1 (Cq), 
129.6 (CH), 129.1 (Cq), 125.0 (CH), 122.8 (CH), 122.3 (CH), 122.1 (CH), 121.6 (CH), 
119.7 (CH), 116.1 (Cq), 111.1 (CH), 80.3 (Cq), 61.6 (CH2), 58.9 (CH), 58.9 (CH), 55.1 
(CH), 52.5 (CH3), 52.1 (CH), 41.4 (CH2), 41.3 (CH2), 40.2 (CH2), 31.5 (CH), 30.7 (CH), 
29.4 (CH2), 28.4 (CH3), 24.9 (CH), 23.1 (CH3), 22.1 (CH3), 19.1 (CH3), 19.0 (CH3), 18.5 
(CH3), 18.1 (CH3), 14.3 (CH3). IR (ATR): 3292, 2960, 1748, 1642, 1523, 1438, 1201, 
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1166, 1020, 736 cm-1. MS (ESI) m/z (relative intensity): 941 (85) [M+Na]+, 920 (100) 





The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (59.3 mg, 0.15 mmol), 1,2-diphenylethyne 82a (40.1 
mg, 0.23 mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-
dioxane (0.6 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 277a (79.1 mg, 92%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.41 (dd, J = 4.9, 1.9 Hz, 1H), 7.69 (ddd, J = 6.8, 3.4, 
3.4 Hz, 1H), 7.56 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.41 (dd, J = 6.2, 3.1 Hz, 1H), 7.24 – 
7.19 (m, 2H), 7.19 – 7.10 (m, 6H), 7.08 – 7.03 (m, 2H), 7.02 – 6.96 (m, 4H), 6.89 (s, 
1H), 5.08 (d, J = 8.3 Hz, 1H), 4.62 (ddd, J = 8.3, 7.7, 5.5 Hz, 1H), 3.62 (s, 3H), 3.31 
(dd, J = 14.5, 5.5 Hz, 1H), 3.24 (dd, J = 14.5, 7.7 Hz, 1H), 1.36 (s, 9H). 13C NMR (101 
MHz, CDCl3): δ 173.0 (Cq), 155.2 (Cq), 151.4 (Cq), 149.0 (CH), 139.9 (Cq), 138.3 (Cq), 
137.5 (CH), 137.0 (Cq), 136.5 (Cq), 133.3 (CH), 132.9 (Cq), 130.1 (CH), 129.4 (CH), 
128.4 (Cq), 128.0 (CH), 127.8 (CH), 127.3 (CH), 127.2 (CH), 123.5 (CH), 121.4 (CH), 
121.4 (CH), 121.0 (CH), 119.2 (CH), 112.9 (Cq), 110.8 (CH), 79.7 (Cq), 54.4 (CH), 52.2 
(CH3), 28.2 (CH2), 27.6 (CH3). IR (ATR): 3055, 2977, 2927, 1742, 1711, 1469, 1437, 
1366, 1165, 907, 728 cm-1. MS (ESI) m/z (relative intensity): 596 (35) [M+Na]+, 574 
(100) [M+H]+. HR-MS (ESI): m/z calcd for C36H36N3O4+ [M+H]+: 574.2700, found: 
574.2703. 
  






The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (59.3 mg, 0.15 mmol), 1,2-di-p-tolylethyne 82b (46.4 
mg, 0.23 mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-
dioxane (0.6 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 10/1) yielded 277b (76.7 mg, 85%, E/Z = 95:5) as a colorless oil. () 
1H NMR (400 MHz, CDCl3): δ 8.45 (dd, J = 4.6, 2.2 Hz, 1H), 7.70 (ddd, J = 5.7, 2.4, 
2.4 Hz, 1H), 7.59 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.51 – 7.40 (m, 1H), 7.26 – 7.17 (m, 
3H), 7.11 – 7.02 (m, 3H), 7.01 – 6.95 (m, 2H), 6.93 (d, J = 8.2 Hz, 2H), 6.87 – 6.82 (m, 
2H), 6.79 (s, 1H), 5.10 (d, J = 8.2 Hz, 1H), 4.61 (ddd, J = 8.2, 6.9, 6.9 Hz, 1H), 3.63 (s, 
3H), 3.35 – 3.14 (m, 2H), 2.30 (s, 3H), 2.25 (s, 3H), 1.39 (s, 9H). 13C NMR (101 MHz, 
CDCl3): δ 173.0 (Cq), 155.2 (Cq), 151.6 (Cq), 148.8 (CH), 140.2 (Cq), 137.4 (CH), 137.0 
(Cq), 137.0 (Cq), 135.4 (Cq), 133.7 (Cq), 133.2 (Cq), 133.1 (CH), 131.8 (Cq), 131.3 (CH), 
129.9 (CH), 129.3 (CH), 128.7 (CH), 128.6 (Cq), 123.3 (CH), 121.4 (CH), 121.4 (CH), 
120.9 (CH), 119.1 (CH), 112.6 (Cq), 110.9 (CH), 79.6 (Cq), 54.4 (CH), 52.2 (CH3), 28.2 
(CH3), 27.5 (CH2), 21.2 (CH3), 21.2 (CH3). IR (ATR): 2975, 2925, 1743, 1714, 1588, 
1506, 1469, 1436, 1365, 1165, 738 cm-1. MS (ESI) m/z (relative intensity): 624 (50) 
[M+Na]+, 602 (100) [M+H]+. HR-MS (ESI): m/z calcd for C38H40N3O4+ [M+H]+: 




yl]propanoic acid (279a) 
 
The general procedure M was followed using Na-(tert-butoxycarbonyl)-1-(pyridin-2-yl)- 
L-tryptophan 243j (57.2 mg, 0.15 mmol), (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 
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propiolate 211g (46.8 mg, 0.23 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.4 
mg, 60 mol %) in 1,4-dioxane (1.0 mL). Purification by column chromatography on 
silica gel (n-hexane/EtOAc/HOAc: 1/1/0.01) yielded 279a (63.4 mg, 72%, E/Z = 97:3) 
as a pale yellow solid. 
M. p. 59 – 63 ºC. 1H NMR (400 MHz, DMSO-d6): δ 12.74 (brs, 1H), 8.69 (dd, J = 5.1, 
1.8 Hz, 1H), 8.17 – 8.02 (m, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 16.2 Hz, 1H), 
7.59 – 7.52 (m, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.29 – 7.14 (m, 4H), 5.64 (d, J = 16.2 Hz, 
1H), 4.60 (ddd, J = 10.8, 10.8, 4.3 Hz, 1H), 4.22 (ddd, J = 8.7, 7.4, 5.7 Hz, 1H), 3.40 
(dd, J = 14.4, 5.7 Hz, 1H), 3.31 (dd, J = 14.4, 8.7 Hz, 1H), 1.92 – 1.82 (m, 1H), 1.78 – 
1.56 (m, 3H), 1.50 – 1.41 (m, 1H), 1.27 (s, 9H), 1.09 – 0.90 (m, 2H), 0.91 – 0.76 (m, 
8H), 0.69 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 173.2 (Cq), 165.4 (Cq), 
155.3 (Cq), 150.5 (Cq), 149.7 (CH), 139.4 (CH), 138.3 (Cq), 132.2 (CH), 131.1 (Cq), 
128.1 (Cq), 125.1 (CH), 123.4 (CH), 122.2 (CH), 121.1 (CH), 120.3 (CH), 119.5 (Cq), 
118.3 (CH), 110.6 (CH), 78.1 (Cq), 73.5 (CH), 54.3 (CH), 46.4 (CH), 40.5 (CH2), 33.7 
(CH2), 30.8 (CH), 28.1 (CH3), 26.8 (CH2), 26.2 (CH), 23.4 (CH2), 21.9 (CH3), 20.3 
(CH3), 16.7 (CH3). IR (ATR): 3441, 2925, 2868, 1699, 1624, 1468, 1437, 1254, 1151, 
1008, 980, 744 cm-1. MS (ESI) m/z (relative intensity): 612 (42) [M+Na]+, 590 (100) 






The general procedure M was followed using benzyl Na-{N6-[(benzyloxy)carbonyl]-N2-
[tert-butoxycarbonyl]-L-lysyl}-1-(pyridin-2-yl)-L-tryptophanate 243k (110.1 mg, 0.15 
mmol), (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl propiolate 211g (46.9 mg, 0.23 
mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane 
(0.6 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1 → 
1/2) yielded 279b (120.6 mg, 85%) as pale yellow solid. 
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M. p. 98 – 101 ºC. 1H NMR (400 MHz, CDCl3): δ 8.65 (dd, J = 5.1, 1.9 Hz, 1H), 7.83 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.72 – 7.60 (m, 2H), 7.38 – 7.29 (m, 6H), 7.27 – 7.24 
(m, 4H), 7.21 (dd, J = 8.2, 1.3 Hz, 1H), 7.19 – 7.10 (m, 4H), 6.70 (d, J = 7.8 Hz, 1H), 
5.60 (d, J = 16.2 Hz, 1H), 5.20 – 5.02 (m, 4H), 5.01 – 4.86 (m, 3H), 4.69 (td, J = 10.8, 
4.3 Hz, 1H), 4.12 – 3.94 (m, 1H), 3.48 (d, J = 6.7 Hz, 2H), 3.09 (dt, J = 6.6, 6.6 Hz, 
2H), 1.99 – 1.91 (m, 1H), 1.85 – 1.71 (m, 2H), 1.68 – 1.57 (m, 2H), 1.51 – 1.39 (m, 
4H), 1.38 (s, 9H), 1.36 – 1.29 (m, 2H), 1.28 – 1.18 (m, 2H), 1.10 – 0.92 (m, 2H), 0.86 
(d, J = 6.6 Hz, 3H), 0.83 (d, J = 7.0 Hz, 3H), 0.71 (d, J = 7.0 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ 171.6 (Cq), 171.2 (Cq), 166.4 (Cq), 156.4 (Cq), 155.6 (Cq), 151.2 (Cq), 
149.7 (CH), 139.0 (Cq), 138.5 (CH), 136.6 (Cq), 134.9 (Cq), 131.9 (Cq), 131.7 (CH), 
128.4 (CH), 128.4 (CH), 128.4 (Cq), 128.2 (CH), 128.2 (CH), 128.0 (CH), 128.0 (CH), 
125.4 (CH), 122.7 (CH), 122.1 (CH), 121.6 (CH), 119.7 (CH), 117.8 (Cq), 111.1 (CH), 
79.9 (Cq), 74.4 (CH), 67.4 (CH2), 66.5 (CH2), 54.1 (CH), 52.7 (CH), 46.9 (CH), 40.9 
(CH2), 40.4 (CH2), 34.2 (CH2), 31.8 (CH2), 31.3 (CH), 29.2 (CH2), 28.2 (CH3), 27.9 
(CH2), 26.4 (CH), 23.7 (CH2), 22.3 (CH2), 22.0 (CH3), 20.6 (CH3), 16.6 (CH3). (One 
aromatic CH is missing due to overlap, the overlap was verified by HSQC, showing 
that the peak at 119.7 ppm corresponds to two carbons). IR (ATR): 3313, 2950, 2927, 
1707, 1522, 1453, 1247, 1169, 736 cm-1. MS (ESI) m/z (relative intensity): 965 (45) 
[M+Na]+, 943 (100) [M+H]+. HR-MS (ESI): m/z calcd for C55H68N5O9+ [M+H]+: 





The general procedure M was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (59.3 mg, 0.15 mmol), 2-oxo-2H-chromen-4-yl 
propiolate 211h (48.1 mg, 0.23 mmol), MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 
mg, 30 mol %) in 1,4-dioxane (0.6 mL). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 6/4) yielded 279c (86.8 mg, 95%, E/Z = 96:4) as a pale 
yellow solid. 
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M. p. 109 – 112 ºC. 1H NMR (400 MHz, CDCl3): δ 8.75 (dd, J = 5.0, 1.8 Hz, 1H), 8.02 
– 7.90 (m, 2H), 7.74 – 7.68 (m, 2H), 7.49 (d, J = 8.5 Hz, 1H), 7.46 (ddd, J = 7.5, 4.9, 
1.1 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.23 (ddd, J = 8.1, 6.6, 1.5 
Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.40 (d, J = 9.6 Hz, 
1H), 5.73 (d, J = 16.1 Hz, 1H), 5.22 (d, J = 8.4 Hz, 1H), 4.77 (q, J = 6.6 Hz, 1H), 3.69 
(s, 3H), 3.64 – 3.48 (m, 2H), 1.41 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 172.1 (Cq), 
164.5 (Cq), 160.4 (Cq), 155.0 (Cq), 154.9 (Cq)154.6 (Cq), 153.4 (Cq), 151.2 (Cq), 150.1 
(CH), 142.9 (CH), 139.7 (Cq), 138.9 (CH), 134.5 (CH), 131.5 (Cq), 128.5 (Cq), 128.5 
(CH), 126.2 (CH), 123.2 (CH), 122.3 (CH), 121.8 (CH), 120.3 (CH), 118.4 (CH), 116.5 
(Cq), 116.2 (CH), 115.9 (CH), 111.0 (CH), 110.4 (CH), 80.0 (Cq), 54.1 (CH), 52.6 (CH3), 
28.4 (CH2), 28.3 (CH3). IR (ATR): 3280, 2968, 2927, 1739, 1650, 1615, 1521, 1470, 
1437, 1164, 740 cm-1. MS (ESI) m/z (relative intensity): 632 (100) [M+Na]+, 610 (12) 







The general procedure M was followed using (3S,8aS)-3-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 243c (54.0 mg, 0.15 mmol), 
(3aR,5R,6S,6aR)-5-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-yl propiolate 211j (70.2 mg, 0.23 mmol), 
MnBr(CO)5 (4.1 mg, 10 mol %) and NaOAc (3.7 mg, 30 mol %) in 1,4-dioxane (0.6 mL). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1 → 1/1) 
yielded 279e (75.4 mg, 75%, E/Z = 97:3) as a white solid. 
M. p. 121 – 124 ºC. 1H NMR (600 MHz, CDCl3): δ 8.69 (ddd, J = 4.8, 1.9, 0.8 Hz, 1H), 
7.94 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.76 (d, J = 16.2 Hz, 1H), 7.64 (ddd, J = 8.0, 1.0, 
1.0 Hz, 1H), 7.42 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.38 (ddd, J = 7.9, 0.9, 0.9 Hz, 1H), 
7.34 (dt, J = 8.4, 1.0 Hz, 1H), 7.29 (ddd, J = 8.4, 6.9, 1.1 Hz, 1H), 7.21 (ddd, J = 7.9, 
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6.9, 1.1 Hz, 1H), 5.83 (d, J = 3.7 Hz, 1H), 5.62 (d, J = 16.2 Hz, 1H), 5.51 (s, 1H), 5.24 
(dd, J = 3.0, 0.6 Hz, 1H), 4.50 (d, J = 3.7 Hz, 1H), 4.48 – 4.42 (m, 1H), 4.23 (dd, J = 
7.3, 3.0 Hz, 1H), 4.15 – 4.02 (m, 2H), 3.98 – 3.90 (m, 3H), 3.69 (dt, J = 12.5, 8.2 Hz, 
1H), 3.59 (ddd, J = 11.9, 8.9, 3.0 Hz, 1H), 3.26 (dd, J = 15.2, 11.4 Hz, 1H), 2.38 – 2.28 
(m, 1H), 2.13 – 1.98 (m, 2H), 1.96 – 1.83 (m, 1H), 1.49 (s, 3H), 1.38 (s, 3H), 1.28 (s, 
3H), 1.27 (s, 3H). 13C NMR (151 MHz, CDCl3): δ 169.6 (Cq), 165.2 (Cq), 165.1 (Cq), 
150.9 (Cq), 150.2 (CH), 139.4 (Cq), 139.0 (CH), 133.0 (CH), 132.0 (Cq), 127.7 (Cq), 
126.4 (CH), 123.4 (CH), 122.3 (CH), 122.2 (CH), 119.6 (CH), 118.6 (CH), 117.8 (Cq), 
112.4 (Cq), 111.5 (CH), 109.3 (Cq), 105.1 (CH), 83.3 (CH), 79.8 (CH), 76.5 (CH), 72.6 
(CH), 66.9 (CH2), 59.4 (CH), 55.0 (CH), 45.7 (CH2), 28.5 (CH2), 26.9 (CH3), 26.8 (CH3), 
26.3 (CH3), 26.3 (CH2), 25.4 (CH3), 22.8 (CH2). IR (ATR): 2987, 2889, 1662, 1587, 
1469, 1436, 1211, 1158, 1158, 1068, 1016, 726 cm-1. MS (ESI) m/z (relative intensity): 
695 (67) [M+Na]+, 673 (100) [M+H]+. HR-MS (ESI): m/z calcd for C36H41N4O9+ [M+H]+: 





The general procedure M was followed using methyl Na-acetyl-1-(pyridin-2-yl)-L-
tryptophanate 241a (1.688 g, 5.0 mmol), ethyl propiolate 211a (736 mg, 7.50 mmol), 
MnBr(CO)5 (137.4 mg, 10 mol %) and NaOAc (123.5 mg, 30 mol %) in 1,4-dioxane 
(20.0 mL). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/2) 
yielded 274c (2.13 g, 98%) as a white foam.  
M. p. 61 – 63 ºC. 1H NMR (400 MHz, CDCl3): δ 8.73 (dd, J = 4.6, 2.0 Hz, 1H), 7.93 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.70 (d, J = 16.2 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.47 
– 7.38 (m, 1H), 7.38 – 7.25 (m, 3H), 7.25 – 7.16 (m, 1H), 6.04 (d, J = 7.8 Hz, 1H), 5.52 
(d, J = 16.2 Hz, 1H), 5.04 (ddd, J = 7.8, 5.5, 5.5 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.68 
(s, 3H), 3.58 (d, J = 5.5, Hz, 2H), 1.96 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ 172.0 (Cq), 169.8 (Cq), 166.8 (Cq), 151.5 (Cq), 150.1 (CH), 139.6 (Cq), 
138.8 (CH), 132.2 (Cq), 131.7 (CH), 128.7 (Cq), 125.7 (CH), 123.2 (CH), 122.4 (CH), 
121.7 (CH), 119.9 (CH), 119.2 (CH), 118.4 (Cq), 111.2 (CH), 60.7 (CH2), 52.8 (CH), 
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52.7 (CH3), 27.5 (CH2), 23.3 (CH3), 14.5 (CH3). IR (ATR): 3285, 2980, 2929, 1742, 
1703, 1623, 1468, 1435, 1171, 743 cm-1. MS (ESI) m/z (relative intensity): 458 (100) 










The general procedure M was followed using methyl (6S,9R,14R)-14-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-9-
{methoxycarbonyl}-2,2-dimethyl-4,7-dioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-
oxa-11,12-dithia-5,8-diazapentadecan-15-oate 261 (149.1 mg, 0.15 mmol), (S)-2-
[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (122.1 mg, 0.45 
mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.4 mg, 30 mol %) in 1,4-dioxane 
(1.2 mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 50/1) 
yielded S4 (209.9 mg, 91%) as pale brown solid. 
M. p. 108 – 110 ºC. 1H NMR (400 MHz, CDCl3): δ 8.67 (dd, J = 5.2, 1.8 Hz, 2H), 7.89 
(ddd, J = 7.7, 7.7, 1.9 Hz, 2H), 7.83 – 7.67 (m, 4H), 7.38 (dd, J = 7.7, 4.9 Hz, 2H), 7.35 
– 7.29 (m, 2H), 7.26 – 7.21 (m, 4H), 7.15 (t, J = 7.4 Hz, 2H), 6.89 (d, J = 7.3 Hz, 2H), 
5.80 (d, J = 7.5 Hz, 2H), 5.57 (d, J = 8.7 Hz, 2H), 5.49 (d, J = 16.3 Hz, 2H), 4.83 – 4.67 
(m, 2H), 4.66 – 4.46 (m, 6H), 4.35 (dd, J = 11.2, 3.4 Hz, 2H), 3.76 (s, 6H), 3.62 (s, 6H), 
3.54 – 3.31 (m, 4H), 3.07 (dd, J = 13.8, 4.9 Hz, 2H), 2.98 (dd, J = 13.8, 5.0 Hz, 2H), 
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1.46 (s, 18H), 1.36 (s, 18H). 13C NMR (101 MHz, CDCl3): δ 171.1 (Cq), 170.4 (Cq), 
170.0 (Cq), 166.0 (Cq), 155.4 (Cq), 155.2 (Cq), 151.2 (Cq), 149.8 (CH), 139.4 (Cq), 138.6 
(CH), 133.1 (CH), 131.6 (Cq), 128.3 (Cq), 125.7 (CH), 122.9 (CH), 122.1 (CH), 121.6 
(CH), 120.2 (CH), 119.7 (Cq), 117.2 (CH), 110.9 (CH), 80.1 (Cq), 80.0 (Cq), 64.5 (CH2), 
54.9 (CH), 53.0 (CH), 52.7 (CH3), 52.7 (CH3), 51.9 (CH), 40.5 (CH2), 28.3 (CH3), 28.2 
(CH3). (One CH2 is missing due to overlap, the overlap was verified by HSQC analysis, 
showing that the peaks at 28.2 ppm corresponds to two carbons). IR (ATR): 2977, 
1706, 1624, 1588, 1470, 1366, 1438, 1366, 1158, 1058, 730, 647cm-1. MS (ESI) m/z 
(relative intensity): 1556 (100) [M+Na]+, 1538 (80) [M+H]+. HR-MS (ESI): m/z calcd for 






Following a modified literature procedure, the corresponding disulfide S4 (60.1 mg, 
39.0 μmol mmol), PPh3 (10.4 mg, 39.0 μmol), NaOAc (1.3 mg, 15.6 μmol) and HOAc 
(4.0 μL, 70.2 μmol) were disolved in MeOH/H2O (7 mL, 10/1). The mixture was heated 
at 60 ˚C for 16 h under N2. After cooling to ambient temperature, H2O (10 mL) was 
added and the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 8/2 → 7/3) yielded 280 (40.4 mg, 67%, 
E/Z = 95:5) as colorless oil. 
1H NMR (400 MHz, CDCl3): δ 8.74 – 8.62 (m, 1H), 7.92 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 
7.89 – 7.66 (m, 2H), 7.46 – 7.36 (m, 2H), 7.33 – 7.24 (m, 2H), 7.21 (ddd, J = 8.0, 6.5, 
1.6 Hz, 1H), 6.53 (s, 1H), 5.89 (d, J = 8.6 Hz, 1H), 5.46 (d, J = 15.8 Hz, 1H), 5.40 – 
5.29 (m, 1H), 4.71 – 4.59 (m, 2H), 4.57 – 4.48 (m, 2H), 4.33 (dd, J = 11.1, 3.2 Hz, 1H), 
3.77 (s, 3H), 3.62 (s, 3H), 3.61 – 3.52 (m, 1H), 3.39 (dd, J = 13.9, 8.3 Hz, 1H), 3.03 – 
2.89 (m, 1H), 2.89 – 2.78 (m, 1H), 1.45 (s, 9H), 1.42 (s, 9H), 1.28 (t, J = 8.3 Hz, 1H). 
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13C NMR (101 MHz, CDCl3): δ 170.9 (Cq), 170.6 (Cq), 169.8 (Cq), 166.0(Cq), 155.5(Cq), 
155.2 (Cq), 151.2 (Cq), 150.1 (CH), 139.6 (Cq), 138.8 (CH), 133.0 (CH), 131.7 (Cq), 
128.21(Cq), 126.0 (CH), 123.2 (CH), 122.3 (CH), 121.9 (CH), 120.1 (CH), 119.3 (Cq), 
117.4 (CH), 111.1 (CH), 80.4 (Cq), 80.3 (Cq), 64.7 (CH2), 55.2 (CH), 54.2 (CH), 53.2 
(CH), 52.9 (CH3), 52.8 (CH3), 28.5 (CH3), 28.4 (CH3), 26.8 (CH2). (One CH2 is missing 
due to overlap, the overlap was verified by HSQC analysis, showing that the peaks at 
28.4 ppm corresponds to two carbons).IR (ATR): 2978, 1705, 1625, 1588, 1470, 1366, 
1213, 1157, 1057, 782, 647 cm-1. MS (ESI) m/z (relative intensity): 792 (100) [M+Na]+. 








The general procedure A was followed using methyl (6S,9R,14R)-14-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-9-
{methoxycarbonyl}-2,2-dimethyl-4,7-dioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-
oxa-11,12-dithia-5,8-diazapentadecan-15-oate 260 (398,1 mg, 0.40 mmol), (S)-2-
[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl propiolate 211b (54.2 mg, 0.20 
mmol), MnBr(CO)5 (5.4 mg, 10 mol %) and NaOAc (4.9 mg, 30 mol %) in 1,4-dioxane 
(1.0 mL). Purification by column chromatography on silica gel (CH2Cl2/MeOH: 60/1 → 
30/1) yielded S5 (172.2 mg, 68%) as a white solid. 
M. p. 109 – 112 ºC. 1H NMR (400 MHz, CDCl3): δ 8.68 (dd, J = 4.9, 1.9 Hz, 1H), 8.51 
(dd, J = 4.9, 1.9 Hz, 1H), 8.23 (d, J = 8.3 Hz, 1H), 7.88 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 
7.84 – 7.72 (m, 3H),  7.70 – 7.58 (m, 2H), 7.47 – 7.35 (m, 2H), 7.34 – 7.28 (m, 3H), 
7.27 – 7.02 (m, 5H), 6.96 (d, J = 7.3 Hz, 1H), 5.77 (d, J = 8.5 Hz, 1H), 5.65 (s, 1H), 
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5.59 – 5.40 (m, 2H), 4.86 – 4.46 (m, 6H), 4.36 (dd, J = 11.2, 3.4 Hz, 1H), 3.76 (s, 3H), 
3.68 – 3.59 (m, 6H), 3.56 – 3.39 (m, 2H), 3.38 – 3.18 (m, 2H), 3.09 (dd, J = 14.1, 5.4 
Hz, 1H), 3.04 – 2.89 (m, 3H), 1.47 (s, 9H), 1.41 (s, 9H), 1.35 (s, 9H). 13C NMR (101 
MHz, CDCl3): δ 171.8 (Cq), 171.2 (Cq), 170.4 (Cq), 170.2 (Cq), 170.1 (Cq), 166.1 (Cq), 
155.6 (Cq), 155.4 (Cq), 155.3 (Cq), 152.4 (Cq), 151.2 (Cq), 149.8 (CH), 148.8 (CH), 
139.4 (Cq), 138.6 (CH), 138.3 (CH), 135.3 (Cq), 133.2 (CH), 131.6 (Cq), 130.1 (Cq), 
128.3 (Cq), 125.7 (CH), 124.9 (CH), 123.4 (CH), 122.9 (CH), 122.1 (CH), 121.6 (CH), 
121.2 (CH), 120.2 (CH), 119.7 (CH), 119.6 (Cq), 119.1 (CH), 117.2 (CH), 114.2 (CH), 
113.7 (Cq), 113.4 (CH), 110.9 (CH), 80.1 (Cq), 80.1 (Cq), 80.0 (Cq), 64.4 (CH2), 54.9 
(CH), 54.8 (CH), 53.1 (CH), 52.7 (CH3), 52.7 (CH3), 51.9 (CH), 51.9 (CH), 40.5 (CH2), 
40.2 (CH2), 28.3 (CH3), 28.3 (CH3), 28.2 (CH3), 28.1 (CH2), 28.1 (CH2). (One CH3 is 
missing due to overlap, the overlap was verified by HSQC analysis, showing that the 
peaks at 52.7 ppm correspond to two carbons). IR (ATR): 3338, 2979, 1743, 1710, 
1676, 1472, 1438, 1367, 1165, 745 cm-1. MS (ESI) m/z (relative intensity): 1288 (100) 
[M+Na]+, 1266 (22) [M+H]+. HR-MS (ESI): m/z calcd for C62H76N9O16S2+ [M+H]+: 








Following a modified literature procedure, a suspension of S4 (141.2 mg, 0.122 mmol), 
ethyl 2-{[(tert-butoxycarbonyl)oxy]methyl}acrylate 253a (51.3 mg, 0.244 mmol), 
MnBr(CO)5 (3.1 mg, 10 mol %) and NaOAc (2.7 mg, 30 mol %) in 1,4-dioxane (2.0 mL) 
was stirred at 80 °C for 16 h. After cooling to ambient temperature, CH2Cl2 (10 mL) 
was added and the mixture concentrated in vacuo. Purification by column 
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chromatography on silica gel (CH2Cl2/MeOH: 60/1 → 30/1) yielded 281 (152.3 mg, 
99%) as a pale yellow solid. 
M. p. 111 – 114 ºC. 1H NMR (400 MHz, CDCl3): δ 8.67 (dd, J = 5.0, 1.9 Hz, 1H), 8.58 
(dd, J = 5.0, 1.9 Hz, 1H), 7.98 – 7.70 (m, 4H), 7.66 – 7.54 (m, 1H), 7.47 – 7.05 (m, 
10H), 6.95 (d, J = 7.2 Hz, 1H), 6.81 (d, J = 7.1 Hz, 1H), 5.91 (s, 1H), 5.83 (d, J = 8.6 
Hz, 1H), 5.64 – 5.38 (m, 3H), 5.06 (s, 1H), 4.80 – 4.46 (m, 6H), 4.35 (dd, J = 11.2, 3.3 
Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 4.03 (d, J = 17.6 Hz, 1H), 3.97 (d, J = 17.6 Hz, 1H), 
3.76 (s, 3H), 3.61 (s, 3H), 3.56 (s, 3H), 3.49 – 3.38 (m, 2H), 3.36 – 3.12 (m, 2H), 3.11 
– 2.82 (m, 4H), 1.46 (s, 9H), 1.41 (s, 9H), 1.38 (s, 9H), 1.21 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3): δ 171.8 (Cq), 170.9 (Cq), 170.4 (Cq), 170.0 (Cq), 169.9 (Cq), 
166.4 (Cq), 166.0 (Cq), 155.4 (Cq), 155.3 (Cq), 155.2 (Cq), 151.4 (Cq), 151.2 (Cq), 149.9 
(CH), 149.4 (CH), 139.4 (Cq), 138.6 (CH), 138.2 (CH), 137.6 (Cq), 136.9 (Cq), 134.4 
(Cq), 133.1 (CH), 131.6 (Cq), 128.5 (Cq), 128.2 (Cq), 126.1 (CH2), 125.7 (CH), 122.9 
(CH), 122.3 (CH), 122.2 (CH), 121.6 (CH), 121.3 (CH), 120.6 (CH), 120.2 (CH), 119.5 
(Cq), 118.7 (CH), 117.2 (CH), 110.9 (CH), 110.9 (CH), 110.8 (Cq), 109.9 (CH), 80.1 
(Cq), 80.0 (Cq), 79.7 (Cq), 64.5 (CH2), 60.9 (CH2), 54.9 (CH), 54.6 (CH), 53.1 (CH), 52.7 
(CH3), 52.6 (CH3), 52.5 (CH3), 51.8 (CH), 51.7 (CH), 40.6 (CH2), 40.4 (CH2), 28.6 
(CH2), 28.3 (CH3), 28.3 (CH3), 28.3 (CH3), 27.9 (CH2), 27.5 (CH2), 14.1 (CH3). IR 
(ATR): 3336, 2977, 1743, 1713, 1676, 1471, 1438, 1367, 1250, 1165, 741 cm-1. MS 
(ESI): m/z (relative intensity): 1401 (100) [M+Na]+, 1376 (15) [M+H]+, 712 (96) 






The general procedure N was followed using (S)-5-{2-[(tert-butoxycarbonyl]amino}-3-
[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido)pentyl propiolate 282 (77.8 mg, 0.15 
mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane 
(30 mL). Purification by column chromatography on silica gel (CH2Cl2/acetone: 9/1) 
yielded 283 (50.0 mg, 64%, E/Z = 94:6) as a pale yellow solid. 
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M. p. 265 – 268 ºC. 1H NMR (400 MHz, CDCl3) δ 8.68 (d, J = 4.8 Hz, 1H), 7.88 (dd, J 
= 7.8, 7.8 Hz, 1H), 7.78 – 7.54 (m, 2H), 7.38 (dd, J = 6.2, 6.2 Hz, 1H), 7.33 – 7.20 (m, 
3H), 7.15 (dd, J = 7.5, 7.5 Hz, 1H), 6.29 (brs, 1H), 5.45 (d, J = 8.5 Hz, 1H), 5.16 (d, J 
= 16.1 Hz, 1H), 4.61 – 4.45 (m, 1H), 4.45 – 4.30 (m, 1H), 4.08 (t, J = 8.5 Hz, 1H), 3.70 
– 3.48 (m, 2H), 3.25 (dd, J = 15.1, 4.7 Hz, 1H), 3.15 – 2.90 (m, 1H), 1.94 – 1.57 (m, 
6H), 1.40 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.5 (Cq), 165.8 (Cq), 155.4 (Cq), 
151.5 (Cq), 149.9 (CH), 139.8 (Cq), 138.7 (CH), 131.6 (Cq), 131.0 (CH), 129.1 (Cq), 
125.6 (CH), 123.0 (CH), 122.3 (CH), 121.5 (CH), 120.7 (Cq), 120.3 (CH), 119.0 (CH), 
110.8 (CH), 79.9 (Cq), 63.7 (CH2), 55.1 (CH), 38.4 (CH2), 28.4 (CH2), 28.3 (CH3), 27.7 
(CH2), 26.5 (CH2), 22.8 (CH2). IR (ATR): 3329, 2928, 1698, 1656, 1468, 1438, 1365, 
1246, 1167, 733 cm-1. MS (ESI) m/z (relative intensity): 541 (100) [M+Na]+, 519 (35) 






The general procedure N was followed using (6S,9S)-9-isopropyl-2,2-dimethyl-4,7,10-
trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-triazahexadecan-16-yl 
propiolate 284a (92.6 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 
mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by column chromatography on silica 
gel (CH2Cl2/EtOAc: 7/3) yielded 285a (49.0 mg, 53%, E/Z = 95:5) as a pale yellow 
solid. 
M. p. 245 ºC (decomposition). 1H NMR (400 MHz, CDCl3): δ 8.70 (dd, J = 4.7, 1.7 Hz, 
1H), 7.90 (ddd, J = 7.5, 7.5, 1.9 Hz, 1H), 7.72 – 7.62 (m, 2H), 7.43 (d, J = 8.3 Hz, 1H), 
7.38 (dd, J = 7.5, 5.0 Hz, 1H), 7.34 – 7.23 (m, 2H), 7.19 (dd, J = 7.5, 7.5 Hz, 1H), 6.87 
(d, J = 8.5 Hz, 1H), 6.41 (brs, 1H), 6.00 (d, J = 16.4 Hz, 1H), 5.10 (d, J = 7.8 Hz, 1H), 
4.39 – 4.25 (m, 2H), 4.19 (dd, J = 7.8, 7.8 Hz, 1H), 4.08 (dt, J = 10.6, 4.8 Hz, 1H), 3.72 
(dd, J = 15.1, 3.4 Hz, 1H), 3.64 – 3.48 (m, 2H), 3.18 – 3.06 (m, 1H), 2.35 – 2.17 (m, 
1H), 1.74 – 1.47 (m, 6H), 1.34 (s, 9H), 0.98 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.9 Hz, 
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3H). 13C NMR (101 MHz, CDCl3): δ 171.4 (Cq), 170.9 (Cq), 166.5 (Cq), 155.7 (Cq), 150.8 
(Cq), 149.8 (CH), 138.7 (CH), 138.2 (Cq), 132.4 (CH), 130.8 (Cq), 129.2 (Cq), 125.3 
(CH), 122.7 (CH), 121.9 (CH), 121.6 (CH), 119.5 (CH), 119.4 (CH), 118.7 (Cq), 111.2 
(CH), 80.6 (Cq), 64.2 (CH2), 59.5 (CH), 54.9 (CH), 38.9 (CH2), 29.3 (CH), 29.1 (CH2), 
28.3 (CH2), 28.1 (CH3), 25.3 (CH2), 23.7 (CH2), 19.5 (CH3), 17.8 (CH3). IR (ATR): 3296, 
2965, 2928, 1711, 1650, 1524, 1366, 166, 756 cm-1. MS (ESI) m/z (relative intensity): 
634 (81) [M+Na]+, 618 (100) [M+H]+. HR-MS (ESI): m/z calcd for C34H44N5O6+ [M+H]+: 






The general procedure N was followed using (6S,9S)-9-isobutyl-2,2-dimethyl-4,7,10-
trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-triazahexadecan-16-yl 
propiolate 284b (94.8 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 
mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by column chromatography on silica 
gel (CH2Cl2/EtOAc: 7/3 → 6/4) yielded 285b (61.7 mg, 65%, E/Z = 98:2) as a white 
solid. 
M. p. 259 ºC (decomposition). 1H NMR (600 MHz, DMSO-d6, 80 °C) δ 8.71 (dd, J = 
4.9, 1.9 Hz, 1H), 8.09 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.61 (d, 
J = 16.3 Hz, 1H), 7.57 – 7.51 (m, 2H), 7.48 – 7.41 (m, 2H), 7.28 (d, J = 8.3 Hz, 1H), 
7.24 (dd, J = 7.7, 7.7 Hz, 1H), 7.16 (dd, J = 7.7, 7.7 Hz, 1H), 6.97 (brs, 1H), 5.85 (d, J 
= 16.3 Hz, 1H), 4.30 (ddd, J = 7.7, 7.7, 3.1 Hz, 1H), 4.26 – 4.15 (m, 2H), 4.00 (dt, J = 
10.6, 5.0 Hz, 1H), 3.52 (dd, J = 14.9, 3.1 Hz, 1H), 3.48 – 3.37 (m, 1H), 3.28 – 3.18 (m, 
1H), 3.06 – 2.99 (m, 1H), 1.72 – 1.57 (m, 3H), 1.55 – 1.39 (m, 6H), 1.22 (s, 9H), 0.91 
(d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, DMSO-d6): δ 171.8 
(Cq), 170.7 (Cq), 166.0 (Cq), 155.2 (Cq), 150.2 (Cq), 149.8 (CH), 139.4 (CH), 137.7 (Cq), 
132.3 (CH), 130.2 (Cq), 129.1 (Cq), 125.0 (CH), 123.3 (CH), 122.0 (CH), 121.0 (CH), 
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120.5 (CH), 120.5 (Cq), 118.0 (CH), 110.6 (CH), 78.2 (Cq), 63.9 (CH2), 54.2 (CH), 51.8 
(CH), 40.5 (CH2), 37.9 (CH2), 29.0 (CH2), 28.0 (CH2), 27.9 (CH3), 24.8 (CH2), 23.9 
(CH), 23.2 (CH2), 23.1 (CH3), 21.4 (CH3). IR (ATR): 3323, 2956, 2926, 1697, 1684, 
1641, 1523, 1268, 1246, 1163, 658 cm-1. MS (ESI) m/z (relative intensity): 654 (55) 
[M+Na]+, 632 (17) [M+H]+. HR-MS (ESI): m/z calcd for C35H46N5O6+ [M+H]+: 632.3443, 






The general procedure N was followed using (6S,9S)-9-[(S)-sec-butyl]-2,2-dimethyl-
4,7,10-trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-triazahexadecan-
16-yl propiolate 284c (94.8 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc 
(7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by column chromatography on 
silica gel (CH2Cl2/acetone: 7/3) yielded 285c (51.2 mg, 54%, E/Z = 96:4) as a white 
solid. 
M. p. 261 – 262 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 5.3, 1.3 Hz, 1H), 
8.11 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.93 (dd, J = 6.8, 4.8 Hz, 1H), 7.86 (d, J = 8.0 Hz, 
1H), 7.60 – 7.53 (m, 2H), 7.51 (ddd, J = 8.1, 1.2, 1.2 Hz, 1H), 7.41 (d, J = 9.1 Hz, 1H), 
7.35 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.25 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 
7.16 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 5.97 (d, J = 16.3 Hz, 1H), 4.18 (dt, J = 11.3, 5.7 
Hz, 1H), 4.11 (t, J = 8.5 Hz, 2H), 4.02 – 3.90 (m, 1H), 3.57 – 3.38 (m, 2H), 3.31 – 3.20 
(m, 1H), 3.06 – 2.94 (m, 1H), 1.81 – 1.67 (m, 1H), 1.64 – 1.53 (m, 2H), 1.53 – 1.42 (m, 
2H), 1.40 – 1.30 (m, 2H), 1.22 (s, 9H), 1.11 – 0.98 (m, 2H), 0.90 – 0.77 (m, 6H). 13C 
NMR (101 MHz, DMSO-d6): δ 171.3 (Cq), 171.1 (Cq), 166.5 (Cq), 155.9 (Cq), 150.6 
(Cq), 150.2 (CH), 139.9 (CH), 138.0 (Cq), 132.9 (CH), 130.5 (Cq), 129.6 (Cq), 125.5 
(CH), 123.7 (CH), 122.5 (CH), 121.5 (CH), 121.1 (CH), 120.8 (Cq), 118.4 (CH), 111.1 
(CH), 78.7 (Cq), 64.4 (CH2), 58.2 (CH), 54.6 (CH), 38.2 (CH2), 36.4 (CH), 29.4 (CH2), 
28.4 (CH2), 28.4 (CH3), 25.1 (CH2), 24.8 (CH2), 23.5 (CH2), 15.9 (CH3), 11.3 (CH3). IR 
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(ATR): 3318, 2959, 2928, 1692, 1642, 1530, 1437, 1167, 741 cm-1. MS (ESI) m/z 
(relative intensity): 654 (80) [M+Na]+, 632 (100) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure N was followed using (6S,9S)-9-benzyl-2,2-dimethyl-4,7,10-
trioxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-triazahexadecan-16-yl 
propiolate 284d (99.8 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 
mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by column chromatography on silica 
gel (CH2Cl2/EtOAc: 7/3 → 5/5) yielded 285d (74.9 mg, 75%, E/Z = 97:3) as a pale 
yellow solid. 
M. p. 192 ºC (decomposition). 1H NMR (400 MHz, CDCl3): δ 8.69 (dd, J = 5.0, 1.8 Hz, 
1H), 7.90 (ddd, J = 7.8, 7.8, 1.9 Hz, 1H), 7.73 – 7.64 (m, 2H), 7.43 (d, J = 8.3 Hz, 1H), 
7.38 (dd, J = 7.5, 4.9 Hz, 1H), 7.31 (d, J = 9.1 Hz, 1H), 7.27 – 7.12 (m, 7H), 6.68 (d, J 
= 7.7 Hz, 1H), 6.48 (brs, 1H), 5.88 (d, J = 16.3 Hz, 1H), 5.06 (d, J = 8.0 Hz, 1H), 4.61 
(ddd, J = 7.7, 7.7, 7.7 Hz, 1H), 4.42 (ddd, J = 9.2, 8.6, 4.1 Hz, 1H), 4.27 (dt, J = 10.8, 
5.3 Hz, 1H), 4.08 (dt, J = 10.8, 5.1 Hz, 1H), 3.62 (dd, J = 15.0, 4.2 Hz, 1H), 3.56 – 3.49 
(m, 1H), 3.41 (dd, J = 15.0, 10.0 Hz, 1H), 3.14 (dd, J = 13.8, 7.0 Hz, 1H), 3.10 – 2.95 
(m, 2H), 1.73 – 1.62 (m, 2H), 1.59 – 1.41 (m, 4H), 1.27 (s, 9H). 13C NMR (100 MHz, 
CDCl3): δ 171.4 (Cq), 170.4 (Cq), 166.6 (Cq), 155.6 (Cq), 151.1 (Cq), 150.0 (CH), 138.8 
(CH), 138.7 (Cq), 136.7 (Cq), 132.4 (CH), 131.4 (Cq), 129.3 (CH), 128.9 (Cq), 128.8 
(CH), 127.1 (CH), 125.4 (CH), 122.9 (CH), 122.1 (CH), 121.8 (CH), 119.8 (CH), 119.8 
(CH), 118.6 (Cq), 111.4 (CH), 80.6 (Cq), 64.4 (CH2), 55.1 (CH), 54.8 (CH), 39.1 (CH2), 
37.2 (CH2), 29.1 (CH2), 28.3 (CH2), 28.2 (CH3), 26.7 (CH2), 23.8(CH2). IR (ATR): 3305, 
3263, 2935, 1698, 1682, 1644, 1519, 1245, 1161, 743 cm-1. MS (ESI) m/z (relative 
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intensity): 1353 (25) [2M+Na]+, 688 (100) [M+Na]+, 666 (35) [M+H]+. HR-MS (ESI): m/z 






The general procedure N was followed using {[6S,9S]-9-[(1H-indol-3-yl)methyl]-2,2-
dimethyl-4,7,10-trioxo-6-[(1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11-
triazahexadecan-16-yl propiolate 284e (105.7 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 
mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by column 
chromatography on silica gel (CH2Cl2/acetone: 8/2) yielded 285e (39.6 mg, 37%, E/Z 
= 94:6) as a white solid. 
M. p. 250 ºC (decomposition). 1H NMR (300 MHz, DMSO-d6): δ 10.86 (d, J = 2.4 Hz, 
1H), 8.72 (dd, J = 4.9, 1.9 Hz, 1H), 8.11 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.92 – 7.82 (m, 
2H), 7.71 (d, J = 7.8 Hz, 1H), 7.62 – 7.53 (m, 3H), 7.45 (d, J = 8.1 Hz, 1H), 7.36 – 7.32 
(m, 1H), 7.32 – 7.21 (m, 2H), 7.21 – 7.12 (m, 3H), 7.07 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 
7.02 – 6.93 (m, 1H), 5.90 (d, J = 16.4 Hz, 1H), 4.57 – 4.42 (m, 1H), 4.31 – 4.09 (m, 
2H), 4.07 – 3.88 (m, 1H), 3.50 (d, J = 14.5 Hz, 1H), 3.33 – 3.28 (s, 1H), 3.26 – 3.14 (m, 
1H), 3.14 – 3.04 (m, 2H), 3.03 – 2.88 (m, 1H), 1.63 – 1.52 (m, 2H), 1.50 – 1.38 (m, 
3H), 1.36 – 1.29 (m, 1H), 1.13 (s, 9H). 13C NMR (126 MHz, DMSO-d6): δ 171.1 (Cq), 
170.9 (Cq), 166.0 (Cq), 155.3 (Cq), 150.4 (Cq), 149.8 (CH), 139.5 (CH), 137.8 (Cq), 
136.1 (Cq), 132.2 (CH), 130.3 (Cq), 128.9 (Cq), 127.4 (Cq), 124.9 (CH), 123.5 (CH), 
123.3 (CH), 122.0 (CH), 120.9 (CH), 120.7 (CH), 120.4 (Cq), 118.4 (CH), 118.3 (CH), 
118.2 (CH), 111.3 (CH), 110.6 (CH), 109.9 (Cq), 78.1 (Cq), 63.9 (CH2), 54.4 (CH), 54.2 
(CH), 38.1 (CH2), 29.0 (CH2), 27.8 (CH3), 27.3 (CH2), 25.8 (CH2), 23.3 (CH2), 22.1 
(CH2). (One aromatic CH is missing due to overlap, the overlap was verified by HSQC 
analysis, showing that the peaks at 132.2 ppm correspond to two carbons). IR (ATR): 
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3332, 2961, 2930, 1682, 1651, 1520, 1438, 1251, 1164, 741 cm-1. MS (ESI): m/z 
(relative intensity) 727 (100) [M+Na]+, 705 (18) [M+H]+. HR-MS (ESI): m/z calcd for 







The general procedure N was followed using (6S,9S,12S)-12-benzyl-2,2,6-trimethyl-
4,7,10,13-tetraoxo-9-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14-
tetraazanonadecan-19-yl propiolate 286a (110.5 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 
20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by 
column chromatography on silica gel (CH2Cl2/acetone: 8/2) yielded 287a (72.1 mg, 
65%, E/Z = 94:6) as a pale yellow solid. 
M. p. 259 ºC (decomposition). 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 5.0, 1.9 
Hz, 1H), 8.17 (d, J = 8.2 Hz, 1H), 8.08 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.96 (ddd, J = 
7.7, 2.0, 2.0 Hz, 1H), 7.91 – 7.79 (m, 2H), 7.59 (d, J = 16.3 Hz, 1H), 7.57 – 7.50 (m, 
2H), 7.29 (d, J = 8.2 Hz, 1H), 7.26 – 7.20 (m, 3H), 7.20 – 7.12 (m, 4H), 6.80 (d, J = 7.3 
Hz, 1H), 5.79 (d, J = 16.3 Hz, 1H), 4.57 – 4.29 (m, 2H), 4.13 (dt, J = 10.8, 5.2 Hz, 1H), 
4.04 (dt, J = 10.8, 4.8 Hz, 1H), 3.83 (dq, J = 7.3, 7.1 Hz, 1H), 3.51 – 3.35 (m, 2H), 3.34 
– 3.26 (m, 1H), 3.02 – 2.67 (m, 3H), 1.65 – 1.53 (m, 2H), 1.55 – 1.43 (m, 2H), 1.43 – 
1.25 (m, 11H), 0.95 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 172.2 (Cq), 
170.4 (Cq), 170.3 (Cq), 165.9 (Cq), 154.9 (Cq), 150.5 (Cq), 149.7 (CH), 139.4 (CH), 
138.0 (Cq), 137.8 (Cq), 132.2 (CH), 130.6 (Cq), 129.1 (CH), 128.7 (Cq), 128.1 (CH), 
126.2 (CH), 125.0 (CH), 123.3 (CH), 122.2 (CH), 121.1 (CH), 120.6 (CH), 119.9 (Cq), 
118.5 (CH), 110.7 (CH), 78.3 (Cq), 64.0 (CH2), 55.1 (CH), 53.4 (CH), 49.9 (CH), 38.1 
(CH2), 37.3 (CH2), 29.0 (CH2), 28.2 (CH3), 27.9 (CH2), 25.7 (CH2), 23.3 (CH2), 18.0 
(CH3). IR (ATR): 3055, 2977, 2927, 1742, 1711, 1469, 1437, 1366, 1165, 907, 728 cm-
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1. MS (ESI): m/z (relative intensity): 759 (100) [M+Na]+, 737 (50) [M+H]+. HR-MS (ESI): 






The general procedure N was followed using (6S,9S,12S)-12-isobutyl-2,2,9-trimethyl-
4,7,10,13-tetraoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14-
tetraazaheptadecan-17-yl propiolate 286b (101.2 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 
20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by 
column chromatography on silica gel (CH2Cl2/MeOH: 25/1) yielded 287b (57.6 mg, 
57%) as a white solid.  
M. p. 113 – 116 ºC. 1H NMR (400 MHz, CDCl3): δ 8.72 (dd, J = 4.9, 2.1 Hz, 1H), 8.01 
– 7.90 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.48 – 7.37 (m, 3H), 7.36 – 7.20 (m, 3H), 6.98 
(d, J = 8.0 Hz, 1H), 6.76 (d, J = 4.5 Hz, 1H), 5.98 (d, J = 16.4 Hz, 1H), 5.08 (d, J = 3.8 
Hz, 1H), 4.53 – 4.36 (m, 2H), 4.36 – 4.21 (m, 2H), 4.15 – 4.03 (m, 1H), 3.77 (d, J = 
15.2 Hz, 1H), 3.58 – 3.46 (m, 1H), 3.43 – 3.22 (m, 2H), 2.11 – 1.97 (m, 2H), 1.91 – 
1.87 (m, 1H), 1.71 – 1.53 (m, 2H), 1.49 (d, J = 7.3 Hz, 3H), 1.39 (s, 9H), 0.96 – 0.90 
(m, 6H). 13C NMR (101 MHz, CDCl3): δ 173.0 (Cq), 172.5 (Cq), 171.8 (Cq), 166.5 (Cq), 
156.6 (Cq), 150.6 (Cq), 150.0 (CH), 138.9 (CH), 138.5 (Cq), 131.8 (CH), 131.3 (Cq), 
128.6 (Cq), 125.5 (CH), 123.3 (CH), 122.0 (CH), 120.0 (CH), 118.3 (CH), 117.3 (Cq), 
111.4 (CH), 81.8 (Cq), 62.3 (CH2), 56.9 (CH), 52.3 (CH), 51.5 (CH), 40.1 (CH2), 36.4 
(CH2), 28.2 (CH2), 28.0 (CH3), 26.3 (CH2), 25.0 (CH), 23.2 (CH3), 20.9 (CH3), 17.4 
(CH3). (One aromatic CH is missing due to overlap, the overlap was verified by HSQC 
analysis, showing that the peak at 122.0 ppm corresponds to two carbons). IR (ATR): 
3288, 2956, 2928, 1716, 1640, 1546, 1473, 1454, 1229, 746 cm-1. MS (ESI): m/z 
(relative intensity) 697 (55) [M+Na]+, 675 (35) [M+H]+. HR-MS (ESI): m/z calcd for 
C36H47N6O7+ [M+H]+: 675.3501, found: 675.3494. 
  







The general procedure N was followed using (6S,9S,12S)-9-benzyl-12-isobutyl-2,2-
dimethyl-4,7,10,13-tetraoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14-
tetraazaheptadecan-17-yl propiolate 286c (112.6 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 
20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by 
column chromatography on silica gel (CH2Cl2/acetone: 8/2 → 6/4) yielded 287c (83.5 
mg, 74%, E/Z = 95:5) as a white solid. 
M. p. 106 – 108 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 4.9, 1.9 Hz, 1H), 
8.09 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.92 – 7.78 (m, 4H), 7.68 (dd, J = 5.9, 5.9 Hz, 1H), 
7.62 – 7.53 (m, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.32 – 7.08 (m, 9H), 5.32 (d, J = 16.2 Hz, 
1H), 4.35 (ddd, J = 11.0, 10.3, 3.2 Hz, 1H), 4.26 – 3.89 (m, 4H), 3.56 (dd, J = 14.7, 3.2 
Hz, 1H), 3.29 – 3.14 (m, 3H), 3.06 (dd, J = 13.8, 8.2 Hz, 1H), 2.97 (dd, J = 13.8, 5.7 
Hz, 1H), 1.87 – 1.65 (m, 2H), 1.58 – 1.47 (m, 2H), 1.47 – 1.37 (m, 1H), 1.12 (s, 9H), 
0.92 – 0.74 (m, 6H). 13C NMR (101 MHz, DMSO-d6): δ 172.0 (Cq), 171.8 (Cq), 170.9 
(Cq), 165.7 (Cq), 155.1 (Cq), 150.8 (Cq), 149.8 (CH), 139.5 (CH), 138.8 (Cq), 137.2 (Cq), 
132.0 (CH), 130.7 (Cq), 129.0 (CH), 128.6 (Cq), 128.3 (CH), 126.5 (CH), 125.1 (CH), 
123.4 (CH), 122.1 (CH), 121.3 (Cq), 120.9 (CH), 120.8 (CH), 117.7 (CH), 110.4 (CH), 
78.0 (Cq), 60.8 (CH2), 56.2 (CH), 55.2 (CH), 51.3 (CH), 40.2 (CH2), 36.4 (CH2), 35.2 
(CH2), 27.8 (CH3), 27.5 (CH2), 26.1 (CH2), 24.1 (CH), 23.2 (CH3), 21.2 (CH3). IR (ATR): 
3265, 2955, 2928, 1653, 1522, 1470, 1454, 1153, 1004, 745 cm-1. MS (ESI) m/z 
(relative intensity): 773 (100) [M+Na]+, 751 (20) [M+H]+. HR-MS (ESI): m/z calcd for 
C42H50N6O7Na+ [M+Na]+: 773.3633, found: 773.3623. 
  







The general procedure N was followed using (6S,9S,12S)-12-isopropyl-2,2,9-
trimethyl-4,7,10,13-tetraoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14-
tetraazanonadecan-19-yl propiolate 286d (103.3 mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 
20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification by 
column chromatography on silica gel (CH2Cl2/EtOAc/MeOH: 5/5/0.1 → 5/5/0.5) yielded 
287d (69.3 mg, 67%) as a pale yellow solid. (E/Z = 94:6) 
M. p. 181 – 183 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.72 (dd, J = 5.0, 1.9 Hz, 1H), 
8.20 – 8.08 (m, 2H), 7.96 (d, J = 7.9 Hz, 1H), 7.67 (dd, J = 5.8, 5.8 Hz, 1H), 7.62 – 7.52 
(m, 3H), 7.47 (d, J = 8.0 Hz, 1H), 7.35 – 7.16 (m, 3H), 7.13 (d, J = 8.8 Hz, 1H), 6.23 (d, 
J = 16.3 Hz, 1H), 4.36 (ddd, J = 9.4, 8.8 4.4 Hz, 1H), 4.20 (dd, J = 6.7, 6.7 Hz, 1H), 
4.08 (t, J = 5.4 Hz, 2H), 3.95 (t, J = 7.8 Hz, 1H), 3.50 (dd, J = 14.6, 4.4 Hz, 1H), 3.32 – 
3.12 (m, 2H), 3.00 – 2.75 (m, 1H), 2.02 (hept, J = 7.1 Hz, 1H), 1.62 – 1.53 (m, 2H), 
1.50 – 1.35 (m, 4H), 1.32 (d, J = 8.9 Hz, 3H), 1.21 (s, 9H), 0.90 – 0.76 (m, 6H). 13C 
NMR (101 MHz, DMSO-d6): δ 172.1 (Cq), 171.8 (Cq), 170.6 (Cq), 166.6 (Cq), 155.1 
(Cq), 150.2 (Cq), 149.8 (CH), 139.4 (CH), 137.6 (Cq), 132.5 (CH), 130.7 (Cq), 128.6 
(Cq), 124.9 (CH), 123.3 (CH), 122.1 (CH), 121.0 (CH), 120.8 (CH), 118.7 (Cq), 118.5 
(CH), 110.6 (CH), 78.2 (Cq), 64.7 (CH2), 58.8 (CH), 55.3 (CH), 49.2 (CH), 38.3 (CH2), 
29.3 (CH), 29.0 (CH2), 28.1 (CH2), 27.9 (CH3), 27.4 (CH2), 23.9 (CH2), 19.2 (CH3), 18.3 
(CH3), 17.4 (CH3). IR (ATR): 3341, 2963, 2933, 1705, 1654, 1634, 1508, 1468, 1246, 
1163, 1025, 746 cm-1. MS (ESI) m/z (relative intensity): 711 (100) [M+Na]+, 689 (17) 
[M+H]+. HR-MS (ESI): m/z calcd for C37H49N6O7+ [M+H]+: 689.3657, found: 689.3640. 
  







The general procedure N was followed using (6S,9S,12S)-9-[(R)-1-(benzyloxy)ethyl]-
12-isopropyl-2,2-dimethyl-4,7,10,13-tetraoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}-3-oxa-5,8,11,14-tetraazanonadecan-19-yl propiolate 286e (121.3 mg, 0.15 
mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane 
(30 mL). Purification by column chromatography on silica gel (CH2Cl2/acetone: 8/2 → 
5/5) yielded 287e (74.9 mg, 74%, E/Z = 91:9) as a pale yellow solid. 
M. p. 148 ºC (decomposition). 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 5.0, 1.8 
Hz, 1H), 8.11 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 6.8 
Hz, 1H), 7.62 (d, J = 16.4 Hz, 1H), 7.59 – 7.54 (m, 2H), 7.50 (d, J = 8.0 Hz, 1H), 7.42 
– 7.10 (m, 10H), 6.23 (d, J = 16.4 Hz, 1H), 4.59 (d, J = 11.8 Hz, 1H), 4.50 – 4.37 (m, 
2H), 4.30 – 4.21 (m, 2H), 4.20 – 3.99 (m, 3H), 3.58 – 3.45 (m, 1H), 3.40 – 3.22 (m, 
2H), 2.96 – 2.81 (m, 1H), 2.06 (hept, J = 6.7 Hz, 1H), 1.65 – 1.56 (m, 1H), 1.57 – 1.47 
(m, 1H), 1.47 – 1.38 (m, 2H), 1.30 (d, J = 6.3 Hz, 3H), 1.23 – 1.19 (m, 2H), 1.15 (s, 
9H), 0.88 – 0.77 (m, 6H). 13C NMR (101 MHz, DMSO-d6): δ 173.2 (Cq), 170.1 (Cq), 
169.6 (Cq), 166.4 (Cq), 155.4 (Cq), 150.1 (Cq), 149.8 (CH), 139.5 (CH), 138.2 (Cq), 
137.5 (Cq), 132.6 (CH), 130.6 (Cq), 128.7 (Cq), 128.1 (CH), 127.5 (CH), 127.4 (CH), 
125.0 (CH), 123.4 (CH), 122.2 (CH), 121.0 (CH), 120.8 (CH), 118.9 (Cq), 118.3 (CH), 
110.7 (CH), 78.6 (Cq), 73.7 (CH), 70.5 (CH2), 64.9 (CH2), 58.6 (CH), 55.7 (CH), 38.7 
(CH2), 29.7 (CH), 28.9 (CH2), 27.9 (CH3), 27.6 (CH2), 26.9 (CH2), 24.3 (CH2), 19.1 
(CH3), 17.8 (CH3), 16.5 (CH3). (One aliphatic CH is missing due to overlap, the overlap 
was verified by HSQC analysis, showing that the peak at 58.6 ppm corresponds to two 
carbons). IR (ATR): 3313, 2961, 2935, 1693, 1643, 1518, 1436, 1248, 1162, 742 cm-
1. MS (ESI) m/z (relative intensity): 831 (100) [M+Na]+, 809 (89) [M+H]+. HR-MS (ESI): 
m/z calcd for C45H57N6O8+ [M+H]+: 809.4232, found: 809.4227. 
  







The general procedure N was followed using (6S,9S,12S,15S)-9,15-diisobutyl-2,2,12-
trimethyl-4,7,10,13,16-pentaoxo-6-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-3-oxa-
5,8,11,14,17-pentaazaicosan-20-yl propiolate 286f (118.2 mg, 0.15 mmol), MnBr(CO)5 
(8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (30 mL). Purification 
by column chromatography on silica gel (CH2Cl2/acetone: 9/1→6/4) yielded 287f (61.4 
mg, 52%, E/Z = 98:2) as a pale yellow solid. 
M. p. 160-163 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 4.9, 1.9 Hz, 1H), 8.31 
– 8.16 (m, 2H), 8.11 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.70 (d, J 
= 16.2 Hz, 1H), 7.64 – 7.53 (m, 3H), 7.42 (d, J = 7.8 Hz, 1H), 7.30 – 7.15 (m, 3H), 7.09 
(d, J = 9.1 Hz, 1H), 5.39 (d, J = 16.2 Hz, 1H), 4.36 (ddd, J = 8.5, 8.5, 5.5 Hz, 1H), 4.23 
(ddd, J = 9.1, 6.1, 6.1 Hz, 1H), 4.16 – 3.94 (m, 4H), 3.34 – 3.27 (m, 2H), 3.26 – 3.18 
(m, 2H), 1.82 – 1.65 (m, 3H), 1.64 – 1.48 (m, 5H), 1.28 (d, J = 7.4 Hz, 3H), 1.21 (s, 
9H), 0.96 – 0.75 (m, 12H). 13C NMR (101 MHz, DMSO-d6): δ 173.2 (Cq), 172.3 (Cq), 
171.8 (Cq), 171.5 (Cq), 165.7 (Cq), 155.1 (Cq), 150.8 (Cq), 149.8 (CH), 139.5 (CH), 
138.8 (Cq), 131.8 (CH), 131.2 (Cq), 128.6 (Cq), 125.1 (CH), 123.5 (CH), 122.2 (CH), 
121.0 (CH), 120.9 (CH), 120.3 (Cq), 118.3 (CH), 110.4 (CH), 78.1 (Cq), 61.3 (CH2), 
55.7 (CH), 52.1 (CH), 51.5 (CH), 50.4 (CH), 35.3 (CH2), 27.9 (CH3), 27.8 (CH2), 27.5 
(CH2), 27.2 (CH2), 24.3 (CH), 24.1 (CH), 23.1 (CH3), 23.0 (CH3), 21.4 (CH3), 21.4 
(CH3), 17.0 (CH3).(One aliphatic CH2 is missing due to overlap with the DMSO-d6, the 
overlap was verified by HSQC analysis). IR (ATR): 3258, 2956, 2927, 1711, 1652, 
1521, 1468, 1436, 1278, 735, 694 cm-1. MS (ESI): m/z (relative intensity) 810 (100) 
[M+Na]+, 788 (29) [M+H]+. HR-MS (ESI): m/z calcd for C42H58N7O8+ [M+H]+: 788.4341, 
found: 788.4333. 
  







The general procedure N was followed using methyl Na-propioloyl-L-alanyl-L-
leucylglycyl-1-(pyridin-2-yl)-L-tryptophanate 288a (88.2 mg, 0.15 mmol), MnBr(CO)5 
(8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (90 mL) for 48 h. 
Purification by column chromatography on silica gel (CH2Cl2/acetone: 8/2 → 7/3) 
yielded 289a (53.2 mg, 60%, E/Z = 97:3) as a pale yellow solid. 
M. p. 198-201 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.73 (dd, J = 5.0, 1.8 Hz, 1H), 8.58 
– 8.52 (m, 2H), 8.07 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.71 (d, J 
= 7.7 Hz, 1H), 7.62 – 7.54 (m, 2H), 7.42 – 7.33 (m, 3H), 7.29 – 7.23 (m, 1H), 7.23 – 
7.17 (m, 1H), 5.51 (d, J = 15.9 Hz, 1H), 4.18 (ddd, J = 9.9, 9.0, 4.2 Hz, 1H), 4.00 (ddd, 
J = 7.5, 7.5, 2.7 Hz, 1H), 3.96 – 3.90 (m, 1H), 3.89 – 3.81 (m, 1H), 3.76 (dd, J = 15.0, 
2.8 Hz, 1H), 3.69 (s, 3H), 3.63 – 3.50 (m, 1H), 3.31 – 3.28 (m, 1H), 1.72 – 1.58 (m, 
1H), 1.56 – 1.39 (m, 2H), 1.22 (d, J = 7.2 Hz, 3H), 0.84 (d, J = 6.4 Hz, 3H), 0.81 (d, J 
= 6.4 Hz, 3H). 13C NMR (150 MHz, DMSO-d6): δ 172.6 (Cq), 171.8 (Cq), 171.2 (Cq), 
168.7 (Cq), 166.7 (Cq), 150.9 (Cq), 149.5 (CH), 139.3 (CH), 139.0 (Cq), 132.5 (Cq), 
127.8 (CH), 127.3 (Cq), 125.1 (CH), 123.2 (CH), 121.8 (CH), 121.3 (Cq), 121.2 (CH), 
120.7 (CH), 119.4 (CH), 110.9 (CH), 54.1 (CH), 52.2 (CH3), 51.7(CH), 50.5 (CH), 41.9 
(CH2), 39.0 (CH2), 25.8 (CH2), 24.4 (CH), 23.2 (CH3), 21.1 (CH3), 16.3 (CH3). IR (ATR): 
3337, 3309, 2929, 1730, 1648, 1523, 1281, 1149, 805 cm-1. MS (ESI) m/z (relative 
intensity) 1199 (10) [2M+Na]+, 611 (55) [M+Na]+, 589 (100) [M+H]+. HR-MS (ESI): m/z 
calcd for C31H37N6O6+ [M+H]+: 589.2769, found: 589.2768. 
  







The general procedure N was followed using benzyl Na-propioloyl-L-valyl-L-
phenylalanylglycyl-1-(pyridin-2-yl)-L-tryptophanate 288b (109.0 mg, 0.15 mmol), 
MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane (90 mL) 
for 48 h. Purification by column chromatography on silica gel (CH2Cl2/acetone: 8/2 → 
6/4) yielded 289b (52.3 mg, 48%, E/Z = 87:13) as a pale yellow solid. 
M. p. 310-312 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.73 (dd, J = 4.9, 1.8 Hz, 1H), 8.64 
(d, J = 7.5 Hz, 1H), 8.32 (d, J = 5.5 Hz, 1H), 8.05 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.93 
(d, J = 8.2 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.61 (d, J = 15.9 Hz, 1H), 7.56 (dd, J = 
7.5, 4.9 Hz, 1H), 7.44 – 7.34 (m, 7H), 7.31 – 7.11 (m, 8H), 5.64 (d, J = 15.9 Hz, 1H), 
5.19 (s, 2H), 4.42 (ddd, J = 12.1, 8.2, 4.0 Hz, 1H), 4.13 (ddd, J = 7.9, 7.9, 3.1 Hz, 1H), 
3.78 – 3.66 (m, 3H), 3.58 (dd, J = 8.2, 5.5 Hz, 1H), 3.42 (dd, J = 14.6, 8.2 Hz, 1H), 3.35 
– 3.29 (m, 1H), 2.86 (dd, J = 14.6, 11.0 Hz, 1H), 1.74 (h, J = 6.8 Hz, 1H), 0.73 (d, J = 
6.8 Hz, 3H), 0.52 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 171.1 (Cq), 
170.9 (Cq), 170.6 (Cq), 168.7 (Cq), 167.0 (Cq), 150.9 (Cq), 149.5 (CH), 139.3 (CH), 
139.1 (Cq), 138.7 (Cq), 135.9 (Cq), 132.8 (Cq), 129.0 (CH), 128.4 (CH), 128.0 (CH), 
128.0 (CH), 127.9 (CH), 127.7 (CH), 127.4 (Cq), 126.0 (CH), 125.1 (CH), 123.2 (CH), 
121.8 (CH), 121.2 (CH), 120.9 (Cq), 120.8 (CH), 119.5 (CH), 111.0 (CH), 66.4 (CH2), 
62.1 (CH), 54.1 (CH), 54.0 (CH), 42.0 (CH2), 35.6 (CH2), 28.2 (CH), 25.6 (CH2), 19.4 
(CH3), 18.7 (CH3). IR (ATR): 3255, 2966, 2925, 1712, 1653, 1522, 1468, 1209, 734, 
696 cm-1. MS (ESI) m/z (relative intensity): 749 (100) [M+Na]+, 727 (27) [M+H]+. HR-
MS (ESI): m/z calcd for C42H43N6O6+ [M+H]+: 727.3239, found: 727.3223. 
  








The general procedure N was followed using methyl Na-N6-((benzyloxy)carbonyl)-N2-
propioloyl-L-lysyl-L-alanyl-L-leucylglycyl-1-(pyridin-2-yl)-L-tryptophanate 288c (127.6 
mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-
dioxane (90 mL) for 48h. Purification by column chromatography on silica gel 
(CH2Cl2/acetone: 8/2 → 5/5) yielded 289c (72.7 mg, 57%) as a pale yellow solid. 
M. p. 244 – 246 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 5.4, 1.6 Hz, 1H), 
8.43 (d, J = 8.3 Hz, 1H), 8.24 (d, J = 7.5 Hz, 1H), 8.14 (d, J = 6.8 Hz, 1H), 8.08 (ddd, J 
= 7.8, 7.8, 1.9 Hz, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.59 (dd, J = 7.0, 4.6 Hz, 1H), 7.57 – 
7.52 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.39 – 7.27 (m, 7H), 7.26 – 7.16 (m, 3H), 6.12 
(d, J = 16.0 Hz, 1H), 5.00 (s, 2H), 4.69 (ddd, J = 7.6, 7.4, 5.3 Hz, 1H), 4.14 – 3.98 (m, 
3H), 3.91 (dd, J = 17.1, 7.2 Hz, 1H), 3.69 – 3.60 (m, 1H), 3.55 (s, 3H), 3.49 (dd, J = 
14.5, 7.4 Hz, 1H), 3.39 – 3.34 (m, 1H), 3.05 – 2.93 (m, 2H), 1.86 – 1.74 (m, 1H), 1.74 
– 1.55 (m, 4H), 1.46 – 1.39 (m, 2H), 1.30 (d, J = 7.2 Hz, 3H), 1.28 – 1.16 (m, 2H), 0.89 
(d, J = 5.5 Hz, 3H), 0.83 (d, J = 5.5 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 172.6 
(Cq), 172.5 (Cq), 171.9 (Cq), 171.7 (Cq), 169.4 (Cq), 165.7 (Cq), 156.5 (Cq), 151.1 (Cq), 
150.0 (CH), 139.7 (CH), 138.3 (Cq), 137.7 (Cq), 133.4 (Cq), 128.8 (CH), 128.3 (Cq), 
128.2 (CH), 128.1 (CH), 127.8 (CH), 125.0 (CH), 124.3 (CH), 123.6 (CH), 122.4 (CH), 
121.5 (CH), 119.6 (CH), 116.2 (Cq), 111.4 (CH), 65.6 (CH2), 63.3 (CH2), 54.0 (CH), 
53.1 (CH), 52.6 (CH3), 52.4 (CH), 50.7 (CH), 42.3 (CH2), 40.7 (CH2), 31.0 (CH2), 29.5 
(CH2), 27.7 (CH2), 24.7 (CH), 23.5 (CH3), 23.4 (CH2), 21.7 (CH3), 17.5 (CH3). IR (ATR): 
3306, 2952, 29271739, 1654, 1528, 1455, 1252, 1005, 744 cm-1. MS (ESI): m/z 
(relative intensity) 873 (100) [M+Na]+, 851 (16) [M+H]+. HR-MS (ESI): m/z calcd for 
C45H55N8O9+ [M+H]+: 851.4087, found: 851.4071.  








The general procedure N was followed using methyl (6S,9S,15S)-9-[(S)-sec-butyl]-
2,2,12,12-tetramethyl-4,7,10,13-tetraoxo-15-[(propioloyloxy)methyl]-6-{[1-(pyridin-2-
yl)-1H-indol-3-yl]methyl}-3-oxa-5,8,11,14-tetraazahexadecan-16-oate 288d (109.9 
mg, 0.15 mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-
dioxane (30 mL). Purification by column chromatography on silica gel (CH2Cl2/acetone 
9/1 → 6/4) yielded 289d (56.2 mg, 51%, E/Z = 93:7)) as a white solid. 
M. p. 241 ºC (decomposition). 1H NMR (600 MHz, CD2Cl2): δ 8.66 (dd, J = 5.0, 1.8 Hz, 
1H), 7.89 (ddd, J = 7.8, 4.5, 4.5 Hz, 1H), 7.77 – 7.63 (m, 2H), 7.42 (d, J = 8.3 Hz, 1H), 
7.40 – 7.36 (m, 2H), 7.31 – 7.24 (m, 2H), 7.19 (dd, J = 7.5, 7.5 Hz, 1H), 6.86 (d, J = 
6.2 Hz, 1H), 6.77 (s, 1H), 6.30 (d, J = 16.4 Hz, 1H), 5.37 (d, J = 6.5 Hz, 1H), 4.97 (ddd, 
J = 10.2, 6.5, 2.8 Hz, 1H), 4.60 (dd, J = 11.1, 2.5 Hz, 1H), 4.43 (ddd, J = 7.7, 6.9, 3.5 
Hz, 1H), 4.32 – 4.22 (m, 2H), 3.74 (s, 3H), 3.71 – 3.61 (m, 1H), 3.33 (dd, J = 15.5, 10.2 
Hz, 1H), 1.95 – 1.83 (m, 1H), 1.53 (s, 3H), 1.46 (s, 3H), 1.32 (s, 9H), 1.19 – 1.07 (m, 
2H), 0.97 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CD2Cl2): δ 
174.4 (Cq), 172.7 (Cq), 170.5 (Cq), 170.5 (Cq), 166.6 (Cq), 156.4 (Cq), 151.1 (Cq), 150.3 
(CH), 139.2 (CH), 138.3 (Cq), 134.3 (CH), 131.5 (Cq), 129.5 (CH), 125.6 (CH), 123.2 
(CH), 122.1 (CH), 119.9 (CH), 119.8 (CH), 118.9 (Cq), 111.8 (CH), 81.2 (Cq), 64.9 
(CH2), 59.6 (CH), 57.9 (Cq), 55.7 (CH), 53.1 (CH), 52.0 (CH3), 37.6 (CH), 30.2 (CH2), 
28.5 (CH3), 27.4 (CH2), 26.3 (CH3), 25.9 (CH3), 15.8 (CH3), 11.9 (CH3). (One aromatic 
Cq is missing due to overlap, the overlap was verified by HSQC and HMBC analysis, 
showing that the peaks at 122.1 ppm correspond to two carbons). IR (ATR): 3332, 
2961, 2925, 1749, 1686, 1630, 1517, 1438, 1365, 1166, 742 cm-1. MS (ESI) m/z 
(relative intensity): 755 (100) [M+Na]+, 733 (15) [M+H]+. HR-MS (ESI): m/z calcd for 
C38H49N6O9+ [M+H]+: 733.3556, found: 733.3541.  








The general procedure N was followed using methyl (6S,9S,15S)-9-benzyl-2,2,12,12-
tetramethyl-4,7,10,13-tetraoxo-15-[(propioloyloxy)methyl]-6-[(1-(pyridin-2-yl)-1H-
indol-3-yl)methyl]-3-oxa-5,8,11,14-tetraazahexadecan-16-oate 288e (115.0 mg, 0.15 
mmol), MnBr(CO)5 (8.2 mg, 20 mol %) and NaOAc (7.3 mg, 60 mol %) in 1,4-dioxane 
(30 mL). Purification by column chromatography on silica gel (CH2Cl2/acetone: 
8/2→6/4) yielded 289e (74.9 mg, 65%, E/Z = 90:10) as a pale yellow semisolid. 
1H NMR (400 MHz, DMSO-d6): δ 8.71 (dd, J = 4.8, 1.8 Hz, 1H), 8.20 (brs, 1H), 8.14 – 
8.05 (m, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 7.3 Hz, 1H), 7.75 (d, J = 8.1 Hz, 
1H), 7.64 (d, J = 16.4 Hz, 1H), 7.58 – 7.47 (m, 2H), 7.36 (d, J = 8.4 Hz, 1H), 7.31 – 
7.10 (m, 8H), 5.95 (d, J = 16.4 Hz, 1H), 4.76 (ddd, J = 8.0, 3.5, 3.5 Hz, 1H), 4.54 (ddd, 
J = 8.1, 7.8, 7.0 Hz, 1H), 4.46 (dd, J = 11.3, 4.9 Hz, 1H), 4.27 – 4.08 (m, 2H), 3.67 (s, 
3H), 3.43 (dd, J = 14.8, 3.3 Hz, 1H), 3.33 – 3.22 (m, 1H), 2.96 (dd, J = 13.7, 5.8 Hz, 
1H), 2.86 (dd, J = 13.7, 8.1 Hz, 1H), 1.35 – 1.09 (m, 15H). 13C NMR (101 MHz, DMSO-
d6): δ 174.4 (Cq), 171.5 (Cq), 170.6 (Cq), 170.1 (Cq), 166.2 (Cq), 155.7 (Cq), 150.6 (Cq), 
150.2 (CH), 139.9 (CH), 138.0 (Cq), 137.7 (Cq), 134.1 (CH), 130.7 (Cq), 129.8 (CH), 
129.2 (Cq), 128.4 (CH), 126.7 (CH), 125.6 (CH), 123.6 (CH), 122.3 (CH), 121.5 (CH), 
121.3 (CH), 120.7 (Cq), 117.8 (CH), 111.1 (CH), 78.6 (Cq), 63.7 (CH2), 56.6 (Cq), 55.0 
(CH), 54.9 (CH), 52.9 (CH3), 51.9 (CH), 37.9 (CH2), 28.5 (CH3), 27.4 (CH3), 27.0 (CH2), 
23.5 (CH3). IR (ATR): 3327, 2980, 2929, 1741, 1700, 1653, 1504, 1437, 1165, 1023, 
741 cm-1. MS (ESI): m/z (relative intensity) 789 (100) [M+Na]+, 767 (22) [M+H]+. HR-
MS (ESI): m/z calcd for C41H47N6O9+ [M+H]+: 767.3399, found: 767.3390. 
  







To a stirred solution of 285d (99.8 mg, 0.15 mmol) in CH2Cl2 (0.6 mL) methyl 
trifluoromethanesulfonate (24.6 mg, 015 mmol) was added at 0 ˚C. After 30 min, the 
mixture was allowed to warm up to 25 °C and stirred for 18 h. The crude mixture was 
concentrated under reduced pressure to afford a bright yellow solid. In a sealed-tube, 
the crude product, Pd(OH)2/C (10.5 mg, 5.0 mol %, 20 wt%), and ammonium formate 
(141.5 mg, 15.0 equiv) were dissolved in methanol (1.0 mL), and stirred at 60 ˚C for 
16 hours. The mixture was filtered through a short plug of celite, concentrated under 
reduced pressure and purified by column chromatography on silica gel (CH2Cl2/EtOAc: 
7/3 → 5/5), yielding 290 (50.5 mg, 57%) as a white solid. 
M. p. 212 – 215ºC. 1H NMR (400 MHz, DMSO-d6, 80 °C): δ 10.51 (s, 1H), 7.85 (d, J = 
7.9 Hz, 1H), 7.58 (dd, J = 7.9, 1.1 Hz, 1H), 7.32 (dd, J = 5.8, 5.8 Hz, 1H), 7.25 – 7.19 
(m, 3H), 7.19 – 7.13 (m, 3H), 6.99 (ddd, J = 7.9, 7.0, 1.2 Hz, 1H), 6.92 (ddd, J = 7.9, 
7.0, 1.1 Hz, 1H), 6.09 (brs, 1H), 4.46 (ddd, J = 7.9, 7.9, 5.9 Hz, 1H), 4.24 (ddd, J = 7.9, 
7.9, 5.3 Hz, 1H), 4.06 (t, J = 5.5 Hz, 2H), 3.29 (p, J = 6.9, 6.5 Hz, 1H), 3.12 – 3.06 (m, 
1H), 3.05 – 2.96 (m, 3H), 2.97 – 2.79 (m, 3H), 2.73 – 2.58 (m, 2H) 1.58 (qt, J = 5.1, 2.1 
Hz, 2H), 1.50 – 1.33 (m, 4H), 1.25 (s, 9H). 13C NMR (100 MHz, DMSO-d6): δ 171.9 
(Cq), 171.5 (Cq), 170.3 (Cq), 154.9 (Cq), 138.0 (Cq), 135.3 (Cq), 135.2 (Cq), 129.1 (CH), 
128.5 (Cq), 128.0 (CH), 126.2 (CH), 120.2 (CH), 118.7 (CH), 118.0 (CH), 110.3 (CH), 
106.8 (Cq), 77.8 (Cq), 64.1 (CH2), 55.0 (CH), 54.7 (CH), 38.1 (CH2), 37.2 (CH2), 34.7 
(CH2), 28.8 (CH2), 28.1 (CH3), 27.9 (CH2), 26.7 (CH2), 23.4 (CH2), 21.6 (CH2). IR 
(ATR): 3335, 2929, 1726, 1677, 1646, 1523, 1243, 1151, 1044, 10014, 700 cm-1. MS 
(ESI): m/z (relative intensity) 1203 (15) [2M+Na]+, 613 (100) [M+Na]+, 591 (18) [M+H]+. 
HR-MS (ESI): m/z calcd for C33H42N4O6Na+ [M+Na]+: 613.2997, found: 613.2983. 
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5.7. Manganese(I)-Catalyzed C–H BODIPY-Labeling of Tryptophan-Containing 
Peptides 
 






The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (39.5 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-
difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a 
(38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and (1-Ad)CO2H (7.2 mg, 40 
mol %) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel 
(CH2Cl2/MeOH: 100/0.2) yielded 292a (65.4 mg, 88%) as an orange solid. The 
obtained solid was analyzed by inductively coupled plasma mass spectrometry (ICP-
MS) analysis, showing 24.5 ppm of residual manganese. 
M. p. 149 – 152 ºC. 1H NMR (300 MHz, CDCl3): δ 8.76 (d, J = 3.7 Hz, 1H), 7.93 (dd, J 
= 7.2, 7.1 Hz, 1H), 7.62 (d, J = 7.1 Hz, 1H), 7.49 (d, J = 7.7 Hz, 2H), 7.50 – 7.47 (m, 
2H), 7.35 (d, J = 16.7 Hz, 1H), 7.28 – 7.21 (m, 5H), 6.54 (d, J = 16.7 Hz, 1H), 6.00 (s, 
2H), 5.26 (d, J = 7.6 Hz, 1H), 4.78 (ddd, J = 7.6, 5.4, 5.3 Hz, 1H), 3.57 – 3.54 (m, 5H), 
2.58 (s, 6H), 1.44 (s, 9H), 1.43 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 172.7 (Cq), 155.4 
(Cq), 155.0 (Cq), 152.0 (Cq), 149.7 (CH), 143.0 (Cq), 141.4 (Cq), 138.4 (CH), 138.2 (Cq), 
137.9 (Cq), 134.2 (Cq), 134.1 (Cq), 131.3 (Cq), 130.5 (CH), 129.1 (Cq), 128.3 (CH), 
126.9 (CH), 123.9 (CH), 122.4 (CH), 122.3 (CH), 121.2 (CH), 119.0 (CH), 118.0 (CH), 
113.5 (Cq), 110.7 (CH), 79.9 (Cq), 54.3 (CH), 52.3 (CH3), 28.6 (CH2), 28.3 (CH3), 14.7 
(CH3), 14.6 (CH3). (One aromatic CH is missing due to overlap, the overlap was verified 
by HSQC analysis, showing that the peak at 121.2 corresponds to two carbons). 19F 
NMR (282 MHz, CDCl3): δ –146.2 (q, 1JB-F = 31.9 Hz). IR (ATR): 3425, 3054, 2975, 
2928, 2864, 1741, 1710, 1541, 1508, 1455 cm-1. MS (ESI): m/z (relative intensity) 766 
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(55) [M+Na]+, 744 (100) [M+H]+. HR-MS (ESI): m/z calcd for C43H44BF2N5O4Na+ 






The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (39.5 mg, 0.10 mmol), 10-(3-ethynylphenyl)-5,5-
difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 
294b (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 
40 mol %) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica 
gel (CH2Cl2/MeOH: 100/0.3) yielded 292b (57.2 mg, 77%) as an orange solid. 
M. p.: 116 – 118 ºC. 1H NMR (400 MHz, CDCl3): δ 8.71 (d, J = 3.4 Hz, 1H), 7.88 (ddd, 
J = 7.8, 7.8, 1.5 Hz, 1H), 7.66 – 7.51 (m, 2H), 7.50 – 7.32 (m, 4H), 7.25 – 7.10 (m, 5H), 
6.46 (d, J = 16.7 Hz, 1H), 6.00 (s, 2H), 5.24 (d, J = 8.3 Hz, 1H), 4.73 (ddd, J = 8.3, 7.0, 
7.0 Hz, 1H), 3.70 – 3.35 (m, 5H), 2.58 (s, 6H), 1.45 – 1.34 (m, 15H). 13C NMR (101 
MHz, CDCl3): δ 172.7 (Cq), 155.5 (Cq), 155.0 (Cq), 152.0 (Cq), 149.7 (CH), 143.0 (Cq), 
141.3 (Cq), 138.3 (CH), 138.3 (Cq), 135.4 (Cq), 135.4 (Cq), 134.2 (Cq), 131.3 (Cq), 130.7 
(CH), 129.4 (CH), 129.0 (Cq), 127.1 (CH), 126.3 (CH), 123.9 (CH), 122.5 (CH), 122.2 
(CH), 121.2 (CH), 119.0 (CH), 117.8 (CH), 113.6 (Cq), 110.7 (CH), 79.9 (Cq), 54.4 (CH), 
52.4 (CH3), 28.8 (CH2), 28.2 (CH3), 14.6 (CH3), 14.6 (CH3). (Two aromatic CH are 
missing due to overlap, the overlap was verified by HSQC analysis, showing that the 
peaks at 126.3 and 121.2 ppm correspond to two carbons). 19F NMR (282 MHz, 
CDCl3): δ –146.30 (q, 1JB-F = 32.0 Hz). IR (ATR): 2971, 2921, 1738, 1706, 1541, 1505, 
1468, 1435, 1190, 1153, 973, 728 cm-1. MS (ESI) m/z (relative intensity): 766 (100) 
[M+Na]+, 744 (5) [M+H]+. HR-MS (ESI): m/z calcd for C43H46BF2N5O4+ [M+H]+: 
744.3535, found: 744.3525. 
  







The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (39.5 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-
difluoro-3,7-diphenyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294c (48.9 
mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 
1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel 
(CH2Cl2/MeOH: 99/1) yielded 292c (45.3 mg, 54%) as a purple solid.  
M. p.: 128 – 130 ºC. 1H NMR (300 MHz, CDCl3): δ 8.78 (d, J = 4.8 Hz, 1H), 7.99 – 7.85 
(m, 5H), 7.64 (d, J = 6.7 Hz, 1H), 7.60 – 7.52 (m, 4H), 7.51 – 7.35 (m, 9H), 7.33 – 7.29 
(m, 1H), 7.28 – 7.17 (m, 2H), 6.94 (d, J = 4.3 Hz, 2H), 6.66 (d, J = 4.3 Hz, 2H), 6.57 (d, 
J = 16.7 Hz, 1H), 5.27 (d, J = 8.4 Hz, 1H), 4.80 (ddd, J = 8.4, 6.9, 6.9 Hz, 1H), 3.69 – 
3.40 (m, 5H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ 172.7 (Cq), 158.8 (Cq), 155.1 
(Cq), 152.1 (Cq), 149.7 (CH), 143.8 (Cq), 139.4 (Cq), 138.5 (CH), 138.4 (Cq), 136.2 (Cq), 
134.4 (Cq), 133.6 (Cq), 132.6 (Cq), 131.2 (CH), 130.7 (CH), 129.5 (CH), 129.5 (CH), 
129.4 (CH), 129.0 (Cq), 128.2 (CH), 126.2 (CH), 124.2 (CH), 122.4 (CH), 122.3 (CH), 
121.4 (CH), 120.9 (CH), 119.1 (CH), 118.9 (CH), 114.1 (Cq), 110.9 (CH), 79.9 (Cq), 
54.3 (CH), 52.5 (CH3), 28.7 (CH3), 28.3 (CH2). 19F NMR (282 MHz, CDCl3): δ – 132.45 
(q, 1JB-F = 31.7 Hz). IR (ATR): 3439, 2923, 1739, 1707, 1561, 1537, 1466, 1435, 1135, 
1066, 728 cm-1. MS (ESI): m/z (relative intensity): 862 (100) [M+Na]+, 840 (71) [M+H]+. 
HR-MS (ESI): m/z calcd for C51H45BF2N5O4 [M+H]+: 840.3536, found: 840.3517. 
  







The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophanate 153 (39.5 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-
difluoro-3,7-di-p-tolyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294d (51.9 
mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and (1-Ad)CO2H (7.2 mg, 40 mol %) 
in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel 
(CH2Cl2/MeOH: 99/1) yielded 292d (63.3 mg, 73%) as a purple solid. 
M. p.: 158 – 160 ºC. 1H NMR (400 MHz, CDCl3): δ 8.79 (d, J = 4.7 Hz, 1H), 7.93 (dd, 
J = 7.8, 7.8Hz, 1H), 7.83 (d, J = 7.7 Hz, 4H), 7.65 (d, J = 7.5 Hz, 1H), 7.59 – 7.48 (m, 
5H), 7.44 – 7.39 (m, 2H), 7.34 (d, J = 16.6 Hz, 1H), 7.29 – 7.24 (m, 6H), 6.91 (d, J = 
4.3 Hz, 2H), 6.65 (d, J = 4.3 Hz, 2H), 6.58 (d, J = 16.6 Hz, 1H), 5.28 (d, J = 8.4 Hz, 
1H), 4.81 (ddd, J = 8.4, 7.3, 7.3 Hz, 1H), 3.81 – 3.45 (m, 5H), 2.42 (s, 6H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3): δ 172.6 (Cq), 158.7 (Cq), 155.0 (Cq), 152.0 (Cq), 149.6 
(CH), 142.9 (Cq), 139.6 (Cq), 139.1 (Cq), 138.4 (CH), 138.3 (Cq), 136.1 (Cq), 134.3 (Cq), 
133.7 (Cq), 131.1 (CH), 130.6 (CH), 130.3 (CH), 129.8 (Cq), 129.3 (CH), 129.0 (CH), 
129.0 (Cq), 126.1 (CH), 124.1 (CH), 122.3 (CH), 122.2 (CH), 121.3 (CH), 120.6 (CH), 
119.0 (CH), 118.7 (CH), 113.9 (Cq), 110.9 (CH), 79.8 (Cq), 54.3 (CH), 52.4 (CH3), 28.6 
(CH2), 28.2 (CH3), 21.4 (CH3). 19F NMR (376 MHz, CDCl3): δ – 132.59 (q, 1JB-F = 32.1 
Hz). IR (ATR): 2920, 1740, 1707, 1561, 1537, 1465, 1432, 1279, 1137, 1055, 727 cm-
1. MS (ESI): m/z (relative intensity) 890 (100) [M+Na]+, 868 (58) [M+H]+. HR-MS (ESI): 
m/z calcd for C53H49BF2N5O4 [M+H]+: 868.3849, found: 868.3834. 
  







The general procedure O was followed using methyl Na-dodecanoyl-1-(pyridin-2-yl)-L-
tryptophanate 295a (47.8 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-
tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 
mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-
dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 8/2) yielded 296a (54.6 mg, 66%) as an orange solid. 
M. p. 114 – 117 ºC. 1H NMR (600 MHz, CDCl3): δ 8.72 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 
7.89 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.55 (ddd, J = 7.7, 0.9, 0.9 Hz, 1H), 7.43 (d, J = 
8.2 Hz, 2H), 7.40 – 7.35 (m, 3H), 7.21 – 7.13 (m, 5H), 6.46 (d, J = 16.8 Hz, 1H), 6.08 
(d, J = 7.9 Hz, 1H), 5.95 (s, 2H), 5.00 (ddd, J = 7.9, 7.1, 5.1 Hz, 1H), 3.58 (dd, J = 14.6, 
5.1 Hz, 1H), 3.55 – 3.52 (dd, J = 14.6, 7.1 Hz, 1H), 3.51 (s, 3H), 2.53 (s, 6H), 2.10 – 
2.04 (m, 2H), 1.56 – 1.46 (m, 2H), 1.39 (s, 6H), 1.28 – 1.16 (m, 16H), 0.85 (t, J = 7.1 
Hz, 3H). 13C NMR (151 MHz, CDCl3): δ 172.7 (Cq), 172.4 (Cq), 155.5 (Cq), 151.9 (Cq), 
149.7 (CH), 142.9 (Cq), 141.3 (Cq), 138.4 (CH), 138.3 (Cq), 137.8 (Cq), 134.3 (Cq), 
134.2 (Cq), 131.3 (Cq), 130.4 (CH), 129.0 (Cq), 128.4 (CH), 126.8 (CH), 124.0 (CH), 
122.5 (CH), 122.3 (CH), 121.2 (CH), 121.2 (CH), 118.8 (CH), 117.8 (CH), 113.3 (Cq), 
110.8 (CH), 52.7 (CH), 52.4 (CH3), 36.5 (CH2), 31.9 (CH2), 29.6 (CH2), 29.5 (CH2), 
29.4 (CH2), 29.3 (CH2), 29.3 (CH2), 29.2 (CH2), 27.8 (CH2), 25.3 (CH2), 22.6 (CH2), 
14.6 (CH3), 14.5 (CH3), 14.1 (CH3). 19F NMR (282 MHz, CDCl3): δ – 146.28 (q, 1JB-F = 
32.2 Hz). IR (ATR): 2921, 2851, 1740, 1653, 1540, 1508, 1466, 1191, 1154, 1081, 
973, 741 cm-1. MS (ESI): m/z (relative intensity) 848 (41) [M+Na]+, 826 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C50H59BF2N5O3+ [M+H]+: 826.4682, found: 826.4660. 
  







The general procedure O was followed using methyl Na-palmitoyl-1-(pyridin-2-yl)-L-
tryptophanate 295b (53.3 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-
tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 
mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-
dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 8/2) yielded 296b (59.9 mg, 68%) as an orange solid. 
M. p. 122 – 124 ºC. 1H NMR (400 MHz, CDCl3): δ 8.77 (dd, J = 5.0, 1.8 Hz, 1H), 7.94 
(ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.59 (dd, J = 7.0, 1.7 Hz, 1H), 7.47 (d, J = 8.0 Hz, 2H), 
7.45 – 7.39 (m, 3H), 7.27 – 7.16 (m, 5H), 6.50 (d, J = 16.8 Hz, 1H), 6.11 (d, J = 7.8 Hz, 
1H), 5.99 (s, 2H), 5.05 (ddd, J = 7.8, 7.1, 5.2 Hz, 1H), 3.63 (dd, J = 14.6, 5.2 Hz, 1H), 
3.59 (dd, J = 14.6, 7.1 Hz, 1H), 3.55 (s, 3H), 2.57 (s, 6H), 2.11 (t, J = 7.7 Hz, 2H), 1.63 
– 1.49 (m, 2H), 1.43 (s, 6H), 1.31 – 1.17 (m, 24H), 0.90 (t, J = 6.7 Hz, 3H). 13C NMR 
(101 MHz, CDCl3): δ 172.7 (Cq), 172.4 (Cq), 155.5 (Cq), 152.0 (Cq), 149.7 (CH), 142.9 
(Cq), 141.3 (Cq), 138.4 (CH), 138.3 (Cq), 137.8 (Cq), 134.3 (Cq), 134.3 (Cq), 131.3 (Cq), 
130.4 (CH), 129.0 (Cq), 128.4 (CH), 126.8 (CH), 124.0 (CH), 122.5 (CH), 122.4 (CH), 
121.3 (CH), 121.2 (CH), 118.8 (CH), 117.8 (CH), 113.3 (Cq), 110.8 (CH), 52.7 (CH), 
52.4 (CH3), 36.6 (CH2), 31.9 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 
29.6 (CH2), 29.4 (CH2), 29.3 (CH2), 29.3 (CH2), 29.2 (CH2), 27.8 (CH2), 25.4 (CH2), 
22.7 (CH2), 14.6 (CH3), 14.6 (CH3), 14.1 (CH3). (One aliphatic CH2 is missing due to 
overlap). 19F NMR (376 MHz, CDCl3): δ – 146.29 (q, 1JB-F = 32.1 Hz). IR (ATR): 2924, 
1739, 1541, 1509, 1468, 1435, 1193, 982, 741 cm-1. MS (ESI): m/z (relative intensity) 
904 (38) [M+Na]+, 882 (100) [M+H]+. HR-MS (ESI): m/z calcd for C54H67BF2N5O3+ 
[M+H]+: 882.5309, found: 882.5273. 
  







The general procedure O was followed using methyl 1-(pyridin-2-yl)-Na-stearoyl-L-
tryptophanate 295c (56.1 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-
tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 
mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-
dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 8/2) yielded 296c (60.0 mg, 66%) as an orange solid. 
M. p. 125 – 127 ºC. 1H NMR (400 MHz, CDCl3): δ 8.77 (dd, J = 5.0, 1.8 Hz, 1H), 7.94 
(td, J = 7.7, 1.9 Hz, 1H), 7.62 – 7.55 (m, 1H), 7.50 – 7.45 (m, 2H), 7.45 – 7.38 (m, 3H), 
7.26 – 7.17 (m, 5H), 6.50 (d, J = 16.7 Hz, 1H), 6.12 (d, J = 7.8 Hz, 1H), 5.99 (s, 2H), 
5.05 (ddd, J = 7.2, 7.2 , 5.1 Hz, 1H), 3.63 (dd, J = 14.6, 5.2 Hz, 1H), 3.60 – 3.57 (m, 
1H), 3.55 (s, 3H), 2.57 (s, 6H), 2.11 (dd, J = 8.5, 6.9 Hz, 2H), 1.55 (t, J = 7.3 Hz, 2H), 
1.43 (s, 6H), 1.33 – 1.18 (m, 28H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): 
δ 172.7 (Cq), 172.4 (Cq), 155.5 (Cq), 152.0 (Cq), 149.7 (CH), 142.9 (Cq), 141.3 (Cq), 
138.4 (CH), 138.3 (Cq), 137.8 (Cq), 134.3 (Cq), 134.3 (Cq), 131.3 (Cq), 130.5 (CH), 
129.0 (Cq), 128.4 (CH), 126.8 (CH), 124.0 (CH), 122.5 (CH), 122.4 (CH), 121.3 (CH), 
121.2 (CH), 118.8 (CH), 117.8 (CH), 113.3 (Cq), 110.8 (CH), 52.7 (CH), 52.4 (CH3), 
38.7 (CH2), 36.6 (CH2), 36.4 (CH2), 31.9 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 
29.6 (CH2), 29.6 (CH2), 29.4 (CH2), 29.3 (CH2), 29.3 (CH2), 29.2 (CH2), 27.8 (CH2), 
25.4 (CH2), 22.7 (CH2), 14.6 (CH3), 14.6 (CH3), 14.1 (CH3). (One aliphatic CH2 is 
missing due to overlap). 19F NMR (376 MHz, CDCl3): δ – 146.30 (q, 1JB-F = 32.2 Hz). 
IR (ATR): 2921, 2850, 1740, 1712, 1541, 1508, 1456, 1435, 1192, 975, 742 cm-1. MS 
(ESI): m/z (relative intensity) 932 (100) [M+Na]+, 910 (57) [M+H]+. HR-MS (ESI): m/z 
calcd for C56H71BF2N5O3 [M+H]+: 910.5622, found: 910.5592. 
  







The general procedure O was followed using methyl Na-oleoyl-1-(pyridin-2-yl)-L-
tryptophanate 295d (56.0 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-
tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 
mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-
dioxane (1.0 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 8/2) yielded 296d (48.1 mg, 53%) as an orange solid. 
M. p. 116 – 118 ºC. 1H NMR (400 MHz, CDCl3): δ 8.77 (d, J = 4.7 Hz, 1H), 7.94 (ddd, 
J = 7.9, 7.9 1.6 Hz, 1H), 7.60 (d, J = 7.4 Hz, 1H), 7.48 (d, J = 7.7 Hz, 2H), 7.46 – 7.38 
(m, 3H), 7.28 – 7.16 (m, 5H), 6.50 (d, J = 16.7 Hz, 1H), 6.11 (d, J = 7.8 Hz, 1H), 6.00 
(s, 2H), 5.43 – 5.28 (m, 2H), 5.05 (ddd, J = 7.8, 7.1, 5.2 Hz, 1H), 3.64 (dd, J = 14.7, 
5.2 Hz, 1H), 3.59 (dd, J = 14.7, 7.1 Hz, 1H), 3.56 (s, 3H), 2.58 (s, 6H), 2.17 – 1.90 (m, 
6H), 1.62 – 1.49 (m, 2H), 1.43 (s, 6H), 1.36 – 1.21 (m, 20H), 0.90 (t, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 172.7 (Cq), 172.4 (Cq), 155.5 (Cq), 152.0 (Cq), 149.7 
(CH), 142.9 (Cq), 141.3 (Cq), 138.4 (CH), 138.3 (Cq), 137.8 (Cq), 134.3 (Cq), 134.3 (Cq), 
131.3 (Cq), 130.5 (CH), 130.0 (CH), 129.7 (CH), 129.0 (Cq), 128.4 (CH), 126.8 (CH), 
124.0 (CH), 122.5 (CH), 122.4 (CH), 121.3 (CH), 121.2 (CH), 118.8 (CH), 117.8 (CH), 
113.3 (Cq), 110.8 (CH), 52.7 (CH), 52.4 (CH3), 36.6 (CH2), 31.9 (CH2), 29.7 (CH2), 29.7 
(CH2), 29.5 (CH2), 29.3 (CH2), 29.3 (CH2), 29.2 (CH2), 29.2 (CH2), 29.1 (CH2), 27.8 
(CH2), 27.2 (CH2), 27.2 (CH2), 25.4 (CH2), 22.7 (CH2), 14.6 (CH3), 14.6 (CH3), 14.1 
(CH3). 19F NMR (377 MHz, CDCl3): δ – 146.30 (q, 1JB-F = 32.2 Hz). IR (ATR): 2922, 
2850, 1736, 1666, 1650, 1541, 1509, 1305, 1193, 951, 705 cm-1. MS (ESI): m/z 
(relative intensity) 931 (100) [M+Na]+, 909 (56) [M+H]+. HR-MS (ESI): m/z calcd for 
C56H68BF2N5O3Na+ [M+Na]+: 930.5285, found: 930.5263. 
  







The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-phenylalaninate 243m (54.3 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
(1-Ad)CO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 100/0.2) yielded 297a (48.3 mg, 54%) as 
an orange solid. The reaction was also performed at 60 ˚C, using 294a (69.6 mg, 0.11 
mmol), and yielded 297a (46.6 mg, 52%). 
M. p. 129 – 133 ºC. 1H NMR (400 MHz, CDCl3): δ 8.72 (d, J = 3.6 Hz, 1H), 7.89 (dd, J 
= 7.7, 7.7, 1.8 Hz, 1H), 7.66 – 7.60 (m, 1H), 7.52 (d, J = 7.8 Hz, 2H), 7.43 (d, J = 7.7 
Hz, 1H), 7.38 (dd, J = 7.7, 3.6 Hz, 1H), 7.35 – 7.33 (m, 1H), 7.30 (d, J = 16.7 Hz, 1H), 
7.18 (d, J = 7.8 Hz, 2H), 7.17 – 7.14 (m, 5H), 6.87 – 6.85 (m, 2H), 6.67 (d, J = 16.7 Hz, 
1H), 5.98 (brs, 1H), 5.96 (s, 2H), 5.45 (brs, 1H), 4.60 – 4.40 (m, 2H), 3.57 – 3.50 (m, 
1H), 3.38 (s, 3H), 3.36 – 3.32 (m, 1H), 2.95 (dd, J = 13.7, 5.9 Hz, 1H), 2.87 (dd, J = 
13.7, 5.0 Hz, 1H), 2.54 (s, 6H), 1.43 (s, 6H), 1.41 (s, 9H). 13C NMR (101 MHz, CDCl3): 
δ 170.7 (Cq), 170.4 (Cq), 155.3 (Cq), 155.1 (Cq), 151.7 (Cq), 149.6 (CH), 143.0 (Cq), 
141.5 (Cq), 138.3 (CH), 138.0 (Cq), 135.4 (Cq), 134.1 (Cq), 134.0 (Cq), 131.3 (Cq), 130.5 
(CH), 129.1 (CH), 128.9 (Cq), 128.8 (Cq), 128.3 (CH), 128.2 (CH), 127.0 (CH), 126.9 
(CH), 123.8 (CH), 122.4 (CH), 122.3 (CH), 121.3 (CH), 121.1 (CH), 118.8 (CH), 117.9 
(CH), 113.1 (Cq), 110.6 (CH), 79.9 (Cq), 55.4 (CH), 53.5 (CH), 52.0 (CH3), 37.9 (CH2), 
29.1 (CH2), 28.2 (CH3), 14.6 (CH3), 14.5 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.3 
(q, 1JB-F = 32.1 Hz). IR (ATR): 3397, 3316, 3057, 2975, 2928, 1741, 1707, 1672, 1541, 
1508 cm-1. MS (ESI): m/z (relative intensity) 913 (100) [M+Na]+, 891 (85) [M+H]+. HR-
MS (ESI) m/z calcd for C52H53BF2N6O5Na [M+Na]+:913.4036, found: 913.4037.  







The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-tyrosinate 243o (55.7 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
(1-Ad)CO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 100/0.7) yielded 297b (61.1 mg, 67%) 
as an orange solid. 
M. p. 158 – 162 ºC. 1H NMR (400 MHz, CDCl3): δ 8.77 (dd, J = 4.8, 1.9 Hz, 1H), 7.94 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.64 (dd, J = 7.7, 1.9 Hz, 1H), 7.53 (d, J = 7.7 Hz, 2H), 
7.48 – 7.41 (m, 2H), 7.35 (dd, J = 7.7, 4.8 Hz, 1H), 7.34 (d, J = 18.2 Hz, 1H), 7.21 (d, 
J = 7.7 Hz, 2H), 7.19 – 7.15 (m, 2H), 6.65 (d, J = 8.4 Hz, 2H), 6.56 (d, J = 8.4 Hz, 2H), 
6.52 (d, J = 18.2 Hz, 1H), 6.45 (brs, 1H), 6.06 (brs, 1H), 5.99 (s, 2H), 5.39 (brs, 1H), 
4.60 – 4.53 (m, 1H), 4.49 (ddd, J = 5.8, 5.8, 5.7 Hz, 1H), 3.62 (d, J = 12.4 Hz, 1H), 3.47 
(s, 3H), 3.35 (dd, J = 12.4, 9.3 Hz, 1H), 2.90 (dd, J = 13.9, 5.7 Hz, 1H), 2.80 (dd, J = 
13.9, 5.8 Hz, 1H), 2.57 (s, 6H), 1.46 (s, 9H), 1.44 (s, 6H). 13C NMR (101 MHz, CDCl3): 
δ 170.9 (Cq), 170.7 (Cq), 155.4 (Cq), 155.2 (Cq), 155.0 (Cq), 151.9 (Cq), 149.4 (CH), 
143.1 (Cq), 141.5 (Cq), 138.7 (CH), 138.3 (Cq), 137.9 (Cq), 134.3 (Cq), 134.1 (Cq), 131.3 
(Cq), 130.5 (CH), 130.1 (CH), 128.8 (Cq), 128.2 (CH), 127.1 (CH), 127.0 (Cq), 123.9 
(CH), 122.8 (CH), 122.7 (CH), 121.4 (CH), 121.1 (CH), 119.1 (CH), 117.8 (CH), 115.6 
(CH), 113.4 (Cq), 110.5 (CH), 80.1 (Cq), 55.3 (CH), 53.5 (CH), 52.1 (CH3), 36.9 (CH2), 
28.5 (CH2), 28.3 (CH3), 14.7 (CH3), 14.6 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.24 
(q, 1JB-F = 31.7 Hz). IR (ATR): 3388, 3300, 2971, 2926, 2856, 1741, 1709, 1670, 1542, 
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1509 cm-1. MS (ESI): m/z (relative intensity): 929 (100) [M+Na]+, 907 (90) [M+H]+. HR-






The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-tryptophanate 243ag (52.5 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (n-hexane/CH2C: 10/1) yielded 297c (67.8 mg, 73%) as 
an orange solid. 
M. p. 160 – 162 ºC. 1H NMR (400 MHz, CDCl3): δ 8.79 (dd, J = 4.9, 1.9 Hz, 1H), 8.56 
(d, J = 2.4 Hz, 1H), 7.90 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.74 – 7.65 (m, 1H), 7.51 – 
7.40 (m, 3H), 7.39 – 7.28 (m, 4H), 7.24 (d, J = 8.2 Hz, 1H), 7.22 – 7.15 (m, 4H), 7.08 
(dd, J = 7.7, 7.7 Hz, 1H), 6.94 (dd, J = 7.5, 7.5 Hz, 1H), 6.49 (d, J = 2.4 Hz, 1H), 6.41 
(d, J = 16.8 Hz, 1H), 6.09 (d, J = 6.9 Hz, 1H), 5.97 (s, 2H), 5.36 (d, J = 7.5 Hz, 1H), 
4.71 – 4.46 (m, 2H), 3.71 – 3.56 (m, 1H), 3.43 (s, 3H), 3.36 (dd, J = 14.4, 9.1 Hz, 1H), 
3.11 (dd, J = 14.8, 5.4 Hz, 1H), 3.04 (dd, J = 14.8, 5.6 Hz, 1H), 2.55 (s, 6H), 1.48 – 
1.36 (m, 15H). 13C NMR (101 MHz, CDCl3): δ 171.2 (Cq), 170.8 (Cq), 155.4 (Cq), 155.2 
(Cq), 152.0 (Cq), 149.5 (CH), 143.1 (Cq), 141.6 (Cq), 138.7 (CH), 138.4 (Cq), 137.9 (Cq), 
135.9 (Cq), 134.3 (Cq), 134.1 (Cq), 131.4 (Cq), 130.6 (CH), 128.9 (Cq), 128.2 (CH), 
127.3 (Cq), 127.1 (CH), 124.0 (CH), 123.0 (CH), 122.8 (CH), 121.9 (CH), 121.4 (CH), 
121.1 (CH), 119.4 (CH), 119.3 (CH), 118.3 (CH), 117.9 (CH), 113.4 (Cq), 111.1 (CH), 
110.6 (CH), 109.3 (Cq), 80.0 (Cq), 55.3 (CH), 53.0 (CH), 52.1 (CH3), 28.5 (CH2), 28.3 
(CH3), 27.3 (CH2), 14.6 (CH3), 14.6 (CH3). (One aromatic CH is missing due to overlap, 
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the overlap was verified by HSQC analysis, showing that the peak at 111.1 
corresponds to two carbons). 19F NMR (376 MHz, CDCl3): δ – 146.26 (q, 1JB-F = 32.0 
Hz). IR (ATR): 1670, 1509, 1455, 1195, 1156, 904, 723, 647 cm-1. MS (ESI): m/z 
(relative intensity) 952 (100) [M+Na]+, 930 (45) [M+H]+. HR-MS (ESI) m/z calcd for 






The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-serinate 243n (48.2 mg, 0.10 mmol), 10-(4-ethynylphenyl)-
5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 
294a (69.7 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 
40 mol %) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica 
gel (CH2Cl2/EtOAc: 7/3) yielded 297d (65.6 mg, 79%) as an orange solid. 
M. p. 158 – 160 ºC. 1H NMR (400 MHz, CDCl3): δ 8.68 (dd, J = 4.8, 2.0 Hz, 1H), 8.05 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.72 – 7.66 (m, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.52 – 
7.36 (m, 4H), 7.34 – 7.29 (m, 1H), 7.27 – 7.18 (m, 4H), 6.75 (d, J = 6.6 Hz, 1H), 6.27 
(d, J = 16.7 Hz, 1H), 6.00 (s, 2H), 5.36 (d, J = 7.7 Hz, 1H), 4.66 (ddd, J = 7.7, 7.4, 4.2 
Hz, 1H), 4.51 – 4.41 (m, 1H), 3.91 – 3.82 (m, 2H), 3.81 – 3.71 (m, 2H), 3.64 (s, 3H), 
3.42 (dd, J = 14.6, 7.4 Hz, 1H), 2.57 (s, 6H), 1.47 (s, 9H), 1.44 (s, 6H). 13C NMR (101 
MHz, CDCl3): δ 171.6 (Cq), 170.1 (Cq), 155.5 (Cq), 155.3 (Cq), 151.7 (Cq), 149.8 (CH), 
143.1 (Cq), 141.5 (Cq), 139.1 (CH), 138.6 (Cq), 137.9 (Cq), 134.4 (Cq), 134.3 (Cq), 131.4 
(Cq), 130.4 (CH), 129.0 (Cq), 128.4 (CH), 127.0 (CH), 124.3 (CH), 123.0 (CH), 122.4 
(CH), 121.7 (CH), 121.2 (CH), 118.8 (CH), 117.9 (CH), 113.9 (Cq), 110.4 (CH), 80.4 
(Cq), 62.3 (CH2), 55.8 (CH), 55.2 (CH), 52.6 (CH3), 28.3 (CH3), 27.5 (CH2), 14.6 (CH3), 
14.6 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.3 (q, 1JB-F = 32.1 Hz). IR (ATR): 3410, 
2955, 2925, 1744, 1705, 1674, 1542, 1470, 1195, 1157, 982 cm-1. MS (ESI): m/z 
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(relative intensity) 853 (65) [M+Na]+, 831 (100) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-threoninate 243ag (49.6 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.7 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 7/3) yielded 297e (70.0 mg, 83%) as an 
orange solid. 
M. p. 157 – 160 ºC. 1H NMR (400 MHz, CDCl3): δ 8.71 (dd, J = 5.0, 1.9 Hz, 1H), 7.96 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.76 – 7.63 (m, 1H), 7.56 – 7.48 (m, 3H), 7.45 – 7.39 
(m, 1H), 7.36 – 7.28 (m, 2H), 7.23 – 7.15 (m, 4H), 6.57 (d, J = 16.7 Hz, 1H), 6.42 (d, J 
= 7.6 Hz, 1H), 5.97 (s, 2H), 5.48 (d, J = 7.0 Hz, 1H), 4.58 (ddd, J = 8.0, 7.0, 5.3 Hz, 
1H), 4.30 (dd, J = 7.6, 3.5 Hz, 1H), 4.12 – 3.99 (m, 1H), 3.59 (dd, J = 14.3, 5.3 Hz, 1H), 
3.52 – 3.37 (m, 4H), 2.79 (d, J = 6.0 Hz, 1H), 2.55 (s, 6H), 1.44 (s, 9H), 1.42 (s, 6H), 
1.06 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 171.8 (Cq), 170.2 (Cq), 155.5 
(Cq), 155.3 (Cq), 151.9 (Cq), 149.7 (CH), 143.1 (Cq), 141.6 (Cq), 138.7 (CH), 138.3 (Cq), 
138.0 (Cq), 134.3 (Cq), 134.2 (Cq), 131.4 (Cq), 130.7 (CH), 128.8 (Cq), 128.3 (CH), 
127.1 (CH), 124.0 (CH), 122.7 (CH), 122.5 (CH), 121.4 (CH), 121.2 (CH), 119.1 (CH), 
118.0 (CH), 113.6 (Cq), 110.5 (CH), 80.2 (Cq), 68.3 (CH), 57.8 (CH), 55.5(CH), 52.4 
(CH3), 28.7 (CH2), 28.3 (CH3), 19.9 (CH3), 14.7 (CH3), 14.6 (CH3). 19F NMR (376 MHz, 
CDCl3): δ – 146.3 (q, 1JB-F = 32.3 Hz). IR (ATR): 3423, 2976, 2926, 1742, 1706, 1671, 
1542, 1469, 1155, 906, 727 cm-1. MS (ESI): m/z (relative intensity) 867 (55) [M+Na]+, 
5. Experimental Part 
 
334 








The general procedure O was followed using benzyl Na-(N6-((benzyloxy)carbonyl)-N2-
(tert-butoxycarbonyl)-L-lysyl)-1-(pyridin-2-yl)-L-tryptophanate 243k (73.4 mg, 0.10 
mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinine 294a (69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol 
%) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 10/1 → 10/2) yielded 297f (63.8 mg, 
59%) as an orange solid. 
M. p. 132 – 134 ºC. 1H NMR (400 MHz, CDCl3): δ 8.75 (dd, J = 5.0, 1.9 Hz, 1H), 7.91 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.68 – 7.57 (m, 1H), 7.46 – 7.38 (m, 4H), 7.38 – 7.29 
(m, 6H), 7.27 – 7.21 (m, 5H), 7.21 – 7.16 (m, 3H), 7.11 – 6.99 (m, 2H), 6.80 (d, J = 7.7 
Hz, 1H), 6.66 (d, J = 16.7 Hz, 1H), 5.99 (s, 2H), 5.19 – 5.01 (m, 5H), 5.02 – 4.94 (m, 
1H), 4.87 (d, J = 12.2 Hz, 1H), 4.19 – 3.99 (m, 1H), 3.66 – 3.43 (m, 2H), 3.19 – 3.01 
(m, 2H), 2.57 (s, 6H), 1.76 – 1.68 (m, 1H), 1.55 – 1.35 (m, 18H), 1.33 – 1.16 (m, 2H). 
13C NMR (101 MHz, CDCl3): δ 171.8 (Cq), 171.7 (Cq), 156.5 (Cq), 155.6 (Cq), 155.4 
(Cq), 151.7 (Cq), 149.7 (CH), 143.0 (Cq), 141.4 (Cq), 138.4 (CH), 137.9 (Cq), 137.8 (Cq), 
136.6 (Cq), 134.7 (Cq), 134.2 (Cq), 134.2 (Cq), 131.3 (Cq), 130.7 (CH), 129.0 (Cq), 128.5 
(CH), 128.4 (CH), 128.3 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 128.0 (CH), 126.9 
(CH), 124.0 (CH), 122.5 (CH), 122.1 (CH), 121.4 (CH), 121.2 (CH), 118.6 (CH), 117.9 
(CH), 112.8 (Cq), 110.9 (CH), 80.1 (Cq), 67.6 (CH2), 66.6 (CH2), 54.3 (CH), 53.0 (CH), 
40.3 (CH2), 31.7 (CH2), 29.3 (CH2), 28.4 (CH2), 28.2 (CH3), 22.1 (CH2), 14.6 (CH3), 
14.6 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.26 (q, 1JB-F = 31.7 Hz). IR (ATR): 
3334, 2929, 1699, 1540, 1507, 1468, 1191, 1154, 972, 740 cm-1. MS (ESI): m/z 
  5. Experimental Part 
 
335 
(relative intensity) 1104 (100) [M+Na]+, 1082 (24) [M+H]+. HR-MS (ESI): m/z calcd for 







The general procedure O was followed using methyl Na-{[(benzyloxy)carbonyl]-L-lysyl}-
1-(pyridin-2-yl)-L-tryptophanate 243ak (55.7 mg, 0.10 mmol), 10-(4-ethynylphenyl)-
5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 
294a (69.7 mg, 0.20 mmol), MnBr(CO)5 (27.4 mg, 100 mol %) and 1-AdCO2H (25.3 
mg, 140 mol %) in 1,4-dioxane (2.0 mL). Purification by column chromatography on 
silica gel (CH2Cl2/MeOH: 98/2 → 95/5 + 3% NEt3) yielded 297g (59.9 mg, 66%) as an 
orange solid. 
M. p. 92 – 94 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.73 (d, J = 5.1 Hz, 1H), 8.60 (d, J 
= 7.9 Hz, 1H), 8.05 (ddd, J = 7.8, 7.8, 2.0 Hz, 1H), 7.70 – 7.61 (m, 1H), 7.61 – 7.48 (m, 
4H), 7.40 – 7.22 (m, 10H), 7.20 – 7.13 (m, 2H), 6.42 (d, J = 16.7 Hz, 1H), 6.17 (s, 2H), 
5.02 (d, J = 12.6 Hz, 1H), 4.95 (d, J = 12.6 Hz, 1H), 4.69 (dt, J = 7.9, 7.4 Hz, 1H), 4.06 
(ddd, J = 8.6, 8.6, 5.0 Hz, 1H), 3.56 – 3.38 (m, 9H), 2.45 (s, 6H), 1.68 – 1.42 (m, 3H), 
1.37 (s, 6H), 1.34 – 1.17 (m, 3H). 13C NMR (101 MHz, DMSO-d6): δ 172.2 (Cq), 172.0 
(Cq), 155.8 (Cq), 154.9 (Cq), 151.1 (Cq), 149.6 (CH), 142.6 (Cq), 141.7 (Cq), 139.2 (CH), 
137.7 (Cq), 137.6 (Cq), 136.9 (Cq), 134.0 (Cq), 133.2 (Cq), 130.6 (Cq), 130.0 (CH), 128.2 
(CH), 128.2 (Cq), 127.7 (CH), 127.6 (CH), 126.9 (CH), 123.6 (CH), 123.1 (CH), 122.2 
(CH), 121.3 (CH), 120.9 (CH), 118.9 (CH), 118.3 (CH), 113.7 (Cq), 110.6 (CH), 69.8 
(CH2), 65.4 (CH2), 54.6 (CH), 52.9 (CH), 51.9 (CH3), 40.7 (CH2), 31.7 (CH2), 31.4 
(CH2), 27.2 (CH2), 14.2 (CH3), 14.2 (CH3). (One aromatic CH is missing due to overlap, 
the overlap was verified by HSQC analysis, showing that the peak at 128.2 
corresponds to two CH carbons) 19F NMR (376 MHz, CDCl3): δ – 143.7 (q, 1JB-F = 30.8 
Hz). IR (ATR): 3260, 3248, 3032, 2927, 2859, 1716, 1669, 1540, 1468, 1435, 1193, 
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1155, 1024, 982, 741 cm-1. MS (ESI): m/z (relative intensity) 906 (60) [M+H]+. HR-MS 




10-yl)styryl]-1-[pyridin-2-yl]-1H-indol-3-yl}propanoic acid (297h) 
 
The general procedure O was followed using Na-[(tert-butoxycarbonyl)-L-valyl]-1-
(pyridin-2-yl)-L-tryptophan 243al (48.0 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-
difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a 
(69.7 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol 
%) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel 
(CH2Cl2/EtOAc: 9/1 → 7/3 +1% AcOH) yielded 297h (42.1 mg, 51%) as an orange 
solid. 
M. p. 105 – 107 ºC. 1H NMR (400 MHz, DMSO-d6): δ 12.88 (brs, 1H), 8.73 (dd, J = 
5.0, 1.8 Hz, 1H), 8.36 (d, J = 8.3 Hz, 1H), 8.08 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.78 – 
7.69 (m, 1H), 7.60 – 7.53 (m, 3H), 7.50 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 16.7 Hz, 1H), 
7.34 – 7.27 (m, 3H), 7.23 – 7.12 (m, 2H), 6.56 (d, J = 9.2 Hz, 1H), 6.48 (d, J = 16.7 Hz, 
1H), 6.18 (s, 2H), 4.72 (ddd, J = 8.0, 7.3, 6.8 Hz, 1H), 3.83 (dd, J = 9.2, 7.0 Hz, 1H), 
3.48 (dd, J = 14.3, 6.8 Hz, 1H), 3.28 (dd, J = 14.3, 7.3 Hz, 1H), 2.45 (s, 6H), 1.90 (h, J 
= 6.9 Hz, 1H), 1.40 (s, 6H), 1.35 (s, 9H), 0.82 – 0.65 (m, 6H). 13C NMR (101 MHz, 
DMSO-d6): δ 173.6 (Cq), 171.8 (Cq), 155.7 (Cq), 155.3 (Cq), 151.6 (Cq), 150.1 (CH), 
143.1 (Cq), 142.2 (Cq), 139.7 (CH), 138.3 (Cq), 138.2 (Cq), 134.5 (Cq), 133.6 (Cq), 131.1 
(Cq), 130.3 (CH), 128.8 (Cq), 128.7 (CH), 127.4 (CH), 124.0 (CH), 123.6 (CH), 122.7 
(CH), 121.8 (CH), 121.3 (CH), 119.6 (CH), 118.8 (CH), 114.7 (Cq), 111.0 (CH), 78.5 
(Cq), 60.3 (CH), 53.2 (CH), 31.1 (CH), 28.6 (CH3), 28.1 (CH2), 19.6 (CH3), 18.5 (CH3), 
14.7 (CH3), 14.7 (CH3). 19F NMR (376 MHz, DMSO-d6): δ – 143.7 (q, 1JB-F = 30.6 Hz). 
IR (ATR): 2960, 2925, 1713, 1672, 1543, 1470, 1195, 1157, 984 cm-1. MS (ESI): m/z 
(relative intensity) 851 (60) [M+Na]+, 829 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C47H52BF2N6O5 [M+H]+:829.4063, found: 829.4044. 
  







The general procedure O was followed using (3S,8aS)-3-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 276a (36.1 mg, 0.10 mmol), 10-
(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 10/1) yielded 298a (52.4 mg, 74%) as an 
orange solid. 
M. p. 178 ºC (decomposition). 1H NMR (400 MHz, CDCl3): δ 8.74 (dd, J = 5.1, 1.8 Hz, 
1H), 7.95 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.68 – 7.59 (m, 1H), 7.47 (d, J = 8.0 Hz, 1H), 
7.44 – 7.38 (m, 4H), 7.28 (dd, J = 7.2, 1.3 Hz, 1H), 7.25 (dd, J = 1.7, 1.7 Hz, 1H), 7.23 
– 7.16 (m, 3H), 6.58 (d, J = 16.7 Hz, 1H), 5.98 (s, 2H), 5.72 (s, 1H), 4.56 (dd, J = 11.5, 
2.1 Hz, 1H), 4.10 (ddd, J = 7.4, 7.4, 3.6 Hz, 1H), 4.01 (dd, J = 15.2, 3.6 Hz, 1H), 3.78 
– 3.58 (m, 2H), 3.34 (dd, J = 15.2, 11.5 Hz, 1H), 2.55 (s, 6H), 2.35 (ddd, J = 9.9, 8.4, 
5.8 Hz, 1H), 2.16 – 2.02 (m, 2H), 1.99 – 1.85 (m, 1H), 1.42 (s, 6H). 13C NMR (101 MHz, 
CDCl3): δ 169.4 (Cq), 165.5 (Cq), 155.5 (Cq), 151.4 (Cq), 149.8 (CH), 143.0 (Cq), 141.2 
(Cq), 138.5 (CH), 138.1 (Cq), 137.4 (Cq), 134.6 (Cq), 134.6 (Cq), 131.9 (CH), 131.3 (Cq), 
128.4 (CH), 128.2 (Cq), 127.1 (CH), 124.4 (CH), 122.7 (CH), 122.1 (CH), 121.7 (CH), 
121.2 (CH), 118.5 (CH), 117.7 (CH), 111.8 (Cq), 111.1 (CH), 59.3 (CH), 54.9 (CH), 
45.5 (CH2), 28.3 (CH2), 26.2 (CH2), 22.7 (CH2), 14.7 (CH3), 14.6 (CH3). 19F NMR (282 
MHz, CDCl3): δ – 146.33 (q, 1JB-F = 32.7 Hz). IR (ATR): 3259, 2923, 1701, 1666, 1542, 
1468, 1436, 1144, 1070, 760 cm-1. MS (ESI): m/z (relative intensity) 731 (100) [M+Na]+, 
709 (63) [M+H]+. HR-MS (ESI): m/z calcd for C42H40BF2N6O3 [M+H]+: 709.3276, found: 
709.3260. 
  







The general procedure O was followed using (3S,8aS)-3-{[1-(pyridin-2-yl)-1H-indol-3-
yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 276a (36.1 mg, 0.10 mmol), 10-
(4-ethynylphenyl)-5,5-difluoro-3,7-di-p-tolyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294c (51.9 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
(1-Ad)CO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 98/2) yielded 298b (55.7 mg, 67%) as a 
purple solid. 
M. p. 191 – 194 ºC. 1H NMR (400 MHz, CDCl3): δ 8.78 (d, J = 5.0 Hz, 1H), 7.97 (ddd, 
J = 7.7, 7.7, 2.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 4H), 7.72 – 7.65 (m, 1H), 7.56 (d, J = 8.0 
Hz, 2H), 7.52 – 7.46 (m, 4H), 7.44 (dd, J = 7.5, 5.0 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.27 
– 7.20 (m, 5H), 6.90 (d, J = 4.3 Hz, 2H), 6.68 (d, J = 16.8 Hz, 1H), 6.64 (d, J = 4.3 Hz, 
2H), 5.73 (s, 1H), 4.64 – 4.47 (m, 1H), 4.17 – 3.99 (m, 2H), 3.73 (dt, J = 11.6, 7.9 Hz, 
1H), 3.64 (ddd, J = 11.6, 8.8, 2.9 Hz, 1H), 3.38 (dd, J = 15.2, 11.6 Hz, 1H), 2.45 – 2.32 
(m, 7H), 2.18 – 2.01 (m, 2H), 2.01 – 1.86 (m, 1H). 13C NMR (101 MHz, CDCl3): δ 169.3 
(Cq), 165.4 (Cq), 158.8 (Cq), 151.4 (Cq), 149.8 (CH), 142.7 (Cq), 139.7 (Cq), 138.6 (Cq), 
138.5 (CH), 138.1 (Cq), 136.1 (Cq), 134.6 (Cq), 134.1 (Cq), 132.0 (CH), 131.1 (CH), 
130.4 (CH), 129.8 (Cq), 129.4 (CH), 129.0 (CH), 128.2 (Cq), 126.2 (CH), 124.5 (CH), 
122.6 (CH), 122.0 (CH), 121.8 (CH), 120.7 (CH), 118.5 (CH), 118.4 (CH), 112.2 (Cq), 
111.2 (CH), 59.2 (CH), 55.0 (CH), 45.5 (CH2), 28.3 (CH2), 26.1 (CH2), 22.6 (CH2), 21.4 
(CH3). 19F NMR (377 MHz, CDCl3): δ – 132.63 (q, 1JB-F = 31.8 Hz). IR (ATR): 3372, 
1660, 1561, 1537, 1464, 1429, 1278, 1137, 1068, 1055, 738 cm-1. MS (ESI): m/z 
(relative intensity): 855 (66) [M+Na]+, 833 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C52H44BF2N6O2+ [M+H]+: 833.3590, found: 833.3573. 
  







The general procedure O was followed using (3S,6S)-3-[(1H-indol-3-yl)methyl]-6-{[1-
(pyridin-2-yl)-1H-indol-3-yl]methyl}piperazine-2,5-dione 276b (44.9 mg, 0.10 mmol), 
10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 96/4) yielded 298c (44.7 mg, 56%) as an 
orange solid. 
M. p. 202 ºC (decomposition). 1H NMR (400 MHz, CDCl3): δ 8.73 (dd, J = 4.9, 1.8 Hz, 
1H), 8.28 (s, 1H), 7.94 (ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.69 – 7.60 (m, 1H), 7.49 (d, J = 
7.9 Hz, 2H), 7.46 – 7.38 (m, 3H), 7.38 – 7.34 (m, 1H), 7.27 – 7.14 (m, 8H), 6.88 – 6.82 
(m, 1H), 6.78 (d, J = 16.7 Hz, 1H), 6.07 (s, 1H), 5.98 (s, 2H), 5.92 (s, 1H), 4.36 (d, J = 
9.1 Hz, 1H), 4.29 (d, J = 7.4 Hz, 1H), 3.69 (dd, J = 14.8, 3.0 Hz, 1H), 3.41 (dd, J = 14.8, 
3.4 Hz, 1H), 2.98 – 2.81 (m, 2H), 2.57 (s, 6H), 1.41 (s, 6H). 13C NMR (101 MHz, CDCl3): 
δ 167.2 (Cq), 166.7 (Cq), 155.5 (Cq), 151.4 (Cq), 149.8 (CH), 143.0 (Cq), 141.3 (Cq), 
138.6 (CH), 137.7 (Cq), 137.6 (Cq), 136.3 (Cq), 134.5 (Cq), 134.4 (Cq), 131.7 (CH), 
131.3 (Cq), 128.6 (Cq), 128.4 (CH), 127.1 (CH), 126.8 (Cq), 124.1 (CH), 123.9 (CH), 
122.7 (CH), 122.7 (CH), 122.1 (CH), 121.9 (CH), 121.2 (CH), 120.1 (CH), 118.9 (CH), 
118.9 (CH), 118.1 (CH), 112.0 (Cq), 111.4 (CH), 110.8 (CH), 109.2 (Cq), 56.1 (CH), 
55.3 (CH), 30.4 (CH2), 30.0 (CH2), 14.6 (CH3), 14.6 (CH3). 19F NMR (376 MHz, CDCl3): 
δ – 146.17 (q, 1JB-F = 31.9 Hz). IR (ATR): 3229, 1666, 1541, 1506, 1454, 1434, 1153, 
973, 739 cm-1. MS (ESI): m/z (relative intensity) 820 (100) [M+Na]+, 798 (65) [M+H]+. 
HR-MS (ESI): m/z calcd for C48H43BF2N7O2+ [M+H]+: 798.3542, found: 798.3527. 
  







The general procedure O was followed using (3S,6S)-3-[(1H-indol-3-yl)methyl]-6-{[1-
(pyridin-2-yl)-1H-indol-3-yl]methyl}piperazine-2,5-dione 276b (44.9 mg, 0.10 mmol), 
10-(4-ethynylphenyl)-5,5-difluoro-3,7-di-p-tolyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294c (51.9 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 95/5) yielded 298d (58.9 mg, 64%) as a 
purple solid. 
M. p. 189 – 191 ºC. 1H NMR (400 MHz, CDCl3): δ 8.72 (d, J = 3.9 Hz, 1H), 8.27 (brs, 
1H), 7.90 (ddd, J = 7.9, 5.8, 2.0 Hz, 1H), 7.83 – 7.75 (m, 4H), 7.66 – 7.56 (m, 1H), 7.52 
– 7.41 (m, 5H), 7.39 (dd, J = 7.8, 3.8 Hz, 2H), 7.36 – 7.12 (m, 11H), 6.83 (d, J = 4.0 
Hz, 2H), 6.74 – 6.61 (m, 2H), 6.57 (d, J = 4.0 Hz, 2H), 6.09 (d, J = 9.1 Hz, 2H), 4.28 
(d, J = 7.3 Hz, 1H), 4.20 (d, J = 8.5 Hz, 1H), 3.61 – 3.48 (m, 1H), 3.44 – 3.23 (m, 1H), 
2.98 (ddd, J = 19.0, 5.8, 5.8 Hz, 1H), 2.73 – 2.54 (m, 1H), 2.38 (s, 6H). 13C NMR (101 
MHz, CDCl3): δ 167.2 (Cq), 166.7 (Cq), 158.8 (Cq), 151.5 (Cq), 149.7 (CH), 142.8 (Cq), 
139.7 (Cq), 138.9 (Cq), 138.6 (CH), 137.8 (Cq), 136.3 (Cq), 136.0 (Cq), 134.7 (Cq), 133.9 
(Cq), 131.7 (CH), 131.1 (CH), 130.5 (CH), 129.8 (Cq), 129.4 (CH), 129.4 (CH), 129.0 
(CH), 128.6 (Cq), 126.7 (Cq), 126.2 (CH), 124.2 (CH), 123.9 (CH), 122.6 (CH), 122.0 
(CH), 121.9 (CH), 120.7 (CH), 120.0 (CH), 119.2 (CH), 118.9 (CH), 118.8 (CH), 112.5 
(CH), 111.4 (Cq), 110.9 (Cq), 109.2 (CH), 56.1 (CH), 55.2 (CH), 30.5 (CH2), 29.8 (CH2), 
21.4 (CH3). 19F NMR (376 MHz, CDCl3): δ – 132.26 (q, 1JB-F = 31.9 Hz). IR (ATR): 
2919, 1669, 1562, 1539, 1465, 1433, 1279, 1139, 1056, 1018, 739 cm-1. MS (ESI): m/z 
(relative intensity) 944 (60) [M+Na]+, 922 (100) [M+H]+. HR-MS (ESI): m/z calcd for 
C58H46BF2N7O2Na [M+Na]+: 944.3676, found: 944.3650. 
  







The general procedure O was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-leucylglycinate 243ae (58.0 mg, 0.10 mmol), 10-(4-ethynylphenyl)-
5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 
294a (69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 
40 mol %) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica 
gel (CH2Cl2/EtOAc: 20/1→10/1) yielded 297i (65.9 mg, 71%) as an orange solid. 
M. p. 156 – 158 ºC. 1H NMR (400 MHz, CDCl3): δ 8.76 (dd, J = 5.0, 1.9 Hz, 1H), 7.96 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.72 – 7.67 (m, 1H), 7.54 (d, J = 7.9 Hz, 2H), 7.50 (d, J 
= 8.0 Hz, 1H), 7.44 (dd, J = 7.5, 4.9 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.31 (d, J = 16.9 Hz, 
1H), 7.26 – 7.16 (m, 4H), 6.70 (d, J = 16.7 Hz, 1H), 6.31 – 6.14 (m, 2H), 5.99 (s, 2H), 
5.45 – 5.29 (m, 1H), 4.57 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 4.39 (ddd, J = 8.6, 8.6, 5.5 
Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H), 3.81 – 3.65 (m, 2H), 3.65 – 3.42 (m, 2H), 2.57 (s, 
6H), 1.69 – 1.50 (m, 2H), 1.49 – 1.36 (m, 16H), 1.25 (t, J = 7.2 Hz, 3H), 0.87 (d, J = 
6.4 Hz, 6H). 13C NMR (101 MHz, CDCl3): δ 171.4 (Cq), 171.3 (Cq), 169.4 (Cq), 155.6 
(Cq), 155.4 (Cq), 151.7 (Cq), 149.7 (CH), 143.0 (Cq), 141.4 (Cq), 138.5 (CH), 138.0 (Cq), 
137.9 (Cq), 134.3 (Cq), 134.2 (Cq), 131.3 (Cq), 130.9 (CH), 128.7 (Cq), 128.3 (CH), 
127.1 (CH), 123.9 (CH), 122.6 (CH), 122.4 (CH), 121.4 (CH), 121.1 (CH), 118.9 (CH), 
117.9 (CH), 112.8 (Cq), 110.7 (CH), 80.4 (Cq), 61.3 (CH2), 55.8 (CH), 51.7 (CH), 41.2 
(CH2), 41.1 (CH2), 28.2 (CH3), 24.6 (CH), 22.8 (CH3), 22.0 (CH3), 14.6 (CH3), 14.5 
(CH3), 14.1 (CH3). (One aliphatic CH2 is missing due to overlap, the overlap was 
verified by HSQC analysis, showing that the peak at 28.2 corresponds to two carbons, 
the CH2 of the Trp side chain and the CH3 of the Boc group). 19F NMR (376 MHz, 
CDCl3): δ – 146.28 (q, 1JB-F = 31.8 Hz). IR (ATR): 3302, 2959, 2930, 1740, 1656, 1507, 
1468, 1436, 1191, 1154, 974, 741 cm-1. MS (ESI): m/z (relative intensity) 950 (100) 
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[M+Na]+, 928 (29) [M+H]+. HR-MS (ESI) m/z calcd for C52H61BF2N7O6+ [M+H]+: 






The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-valyl-L-alaninate 243a (56.5 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.6 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 20/1→10/1) yielded 297j (57.5 mg, 63%) 
as an orange solid. The reaction was also performed at 60 ˚C, and yielded 297j (53.9 
mg, 59%). 
M. p. 192 – 194 ºC. 1H NMR (400 MHz, CDCl3): δ 8.78 – 8.70 (m, 1H), 7.93 (ddd, J = 
7.7, 7.7, 2.1 Hz, 1H), 7.72 – 7.62 (m, 1H), 7.55 – 7.47 (m, 3H), 7.45 – 7.26 (m, 3H), 
7.24 – 7.11 (m, 4H), 6.68 (d, J = 16.7 Hz, 1H), 6.41 (d, J = 8.1 Hz, 1H), 6.17 (d, J = 7.1 
Hz, 1H), 5.97 (s, 2H), 5.40 (d, J = 7.4 Hz, 1H), 4.56 (dd, J = 7.1, 7.1 Hz, 1H), 4.29 (ddd, 
J = 8.2, 7.4, 5.6 Hz, 1H), 4.12 (dd, J = 8.1, 7.1 Hz, 1H), 3.69 (s, 3H), 3.57 (dd, J = 14.6, 
5.6 Hz, 1H), 3.46 (dd, J = 14.6, 8.2 Hz, 1H), 2.54 (s, 6H), 2.08 – 1.96 (m, 1H), 1.51 – 
1.34 (m, 15H), 1.25 (d, J = 7.1 Hz, 3H), 0.87 – 0.77 (m, 6H). 13C NMR (101 MHz, 
CDCl3): δ 172.8 (Cq), 171.3 (Cq), 169.6 (Cq), 155.4 (Cq), 151.8 (Cq), 149.6 (CH), 143.0 
(Cq), 141.5 (Cq), 138.4 (CH), 138.1 (Cq), 138.0 (Cq), 134.2 (Cq), 134.1 (Cq), 131.3 (Cq), 
130.7 (CH), 128.8 (Cq), 128.3 (CH), 127.0 (CH), 123.8 (CH), 122.6 (CH), 122.5 (CH), 
121.2 (CH), 121.1 (CH), 118.9 (CH), 118.0 (CH), 112.9 (Cq), 110.7 (CH), 80.2 (Cq), 
58.1 (CH), 55.6 (CH), 52.3 (CH3), 48.0 (CH), 31.2 (CH), 28.2 (CH3), 18.7 (CH3), 17.8 
(CH3), 17.7 (CH3), 14.6 (CH3), 14.5 (CH3). (One aromatic Cq and one aliphatic CH2 is 
missing due to overlap, the overlap was verified by HSQC and HMBC analysis, 
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showing that the peak at 155.4 correspond to two Cq carbons and the peak at 28.2 
corresponds to two carbons, the CH2 of the Trp side chain and the CH3 of the Boc 
group). 19F NMR (376 MHz, CDCl3): δ – 146.27 (q, 1JB-F = 31.8 Hz). IR (ATR): 1670, 
1542, 1509, 1456, 1195, 1157, 904, 723, 647 cm-1. MS (ESI): m/z (relative intensity) 
936 (25) [M+Na]+, 914 (100) [M+H]+. HR-MS (ESI): m/z calcd for C51H59BF2N7O6 







The general procedure O was followed using benzyl (S)-3-{[S]-2-acetamido-3-[1-
(pyridin-2-yl)-1H-indol-3-yl]propanamido}-4-{[(S)-1-methoxy-1-oxo-3-phenylpropan-2-
yl]amino}-4-oxobutanoate 243i (68.9 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-
difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a 
(69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol 
%) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica gel 
(CH2Cl2/Acetone: 10/1) yielded 297k (70.5 mg, 68%) as an orange solid. 
M. p. 151 – 153 ºC. 1H NMR (400 MHz, CDCl3): δ 8.75 (d, J = 4.8 Hz, 1H), 7.94 (ddd, 
J = 7.8, 7.8, 1.9 Hz, 1H), 7.59 (d, J = 5.0 Hz, 1H), 7.57 – 7.49 (m, 3H), 7.44 (dd, J = 
7.4, 4.9 Hz, 1H), 7.37 – 7.20 (m, 12H), 7.17 – 7.05 (m, 4H), 6.85 (d, J = 7.4 Hz, 1H), 
6.82 – 6.71 (m, 2H), 6.37 (d, J = 6.9 Hz, 1H), 5.99 (s, 2H), 5.03 (s, 2H), 4.77 (ddd, J = 
8.4, 6.9, 5.4 Hz, 1H), 4.60 – 4.33 (m, 2H), 3.70 (dd, J = 14.4, 5.4 Hz, 1H), 3.61 (s, 3H), 
3.39 (dd, J = 14.4, 8.4 Hz, 1H), 3.00 (dd, J = 13.9, 5.9 Hz, 1H), 2.93 (dd, J = 13.9, 7.2 
Hz, 1H), 2.84 (dd, J = 17.4, 3.6 Hz, 1H), 2.57 (s, 6H), 2.42 (dd, J = 17.4, 8.1 Hz, 1H), 
1.94 (s, 3H), 1.43 (s, 6H). 13C NMR (101 MHz, CDCl3): δ 171.8 (Cq), 171.2 (Cq), 170.6 
(Cq), 170.2 (Cq), 169.1 (Cq), 155.4 (Cq), 151.7 (Cq), 149.7 (CH), 143.0 (Cq), 141.4 (Cq), 
138.5 (CH), 138.1 (Cq), 137.8 (Cq), 135.8 (Cq), 135.2 (Cq), 134.3 (Cq), 134.1 (Cq), 131.3 
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(Cq), 130.8 (CH), 129.1 (CH), 128.8 (Cq), 128.6 (CH), 128.5 (CH), 128.4 (CH), 128.3 
(CH), 128.2 (CH), 127.1 (CH), 127.0 (CH), 124.0 (CH), 122.7 (CH), 122.6 (CH), 121.4 
(CH), 121.2 (CH), 118.5 (CH), 117.7 (CH), 112.6 (Cq), 110.7 (CH), 66.8 (CH2), 54.3 
(CH), 53.8 (CH), 52.2 (CH3), 48.8 (CH), 37.4 (CH2), 35.9 (CH2), 27.7 (CH2), 23.1 (CH3), 
14.6 (CH3), 14.6 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.26 (q, 1JB-F = 31.4 Hz). IR 
(ATR): 3286, 3032, 1732, 1632, 1540, 1507, 1453, 1304, 1191, 972, 711 cm-1. MS 
(ESI): m/z (relative intensity) 1060 (100) [M+Na]+, 1038 (55) [M+H]+. HR-MS (ESI): m/z 







The general procedure O was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-leucylglycinate 243an (73.4 mg, 0.10 mmol), 10-(4-ethynylphenyl)-
5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 
294a (69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 
40 mol %) in 1,4-dioxane (1.0 mL). Purification by column chromatography on silica 
gel (CH2Cl2/EtOAc: 10/1→10/2) yielded 297l (59.5 mg, 55%) as an orange solid. 
M. p. 147 – 149 ºC. 1H NMR (400 MHz, CDCl3): δ 8.77 (d, J = 5.0 Hz, 1H), 7.95 (ddd, 
J = 7.7, 7.7, 2.0 Hz, 1H), 7.62 – 7.53 (m, 4H), 7.44 (dd, J = 7.7, 5.0 Hz, 1H), 7.37 – 
7.26 (m, 8H), 7.24 – 7.20 (m, 4H), 7.14 – 7.02 (m, 2H), 7.00 – 6.90 (m, 3H), 6.82 (d, J 
= 16.8 Hz, 1H), 6.62 (d, J = 5.4 Hz, 1H), 5.99 (s, 2H), 5.44 (d, J = 7.4 Hz, 1H), 4.72 – 
4.35 (m, 4H), 4.25 – 4.09 (m, 1H), 4.03 (qd, J = 6.3, 3.4 Hz, 1H), 3.71 – 3.64 (m, 1H), 
3.62 (s, 3H), 3.42 (dd, J = 14.3, 8.4 Hz, 1H), 2.96 (dd, J = 13.9, 5.8 Hz, 1H), 2.85 (dd, 
J = 13.9, 7.1 Hz, 1H), 2.58 (s, 6H), 1.47 – 1.38 (m, 15H), 0.92 (d, J = 6.3 Hz, 3H). 13C 
NMR (101 MHz, CDCl3): δ 171.4 (Cq), 171.4 (Cq), 168.0 (Cq), 155.4 (Cq), 155.2 (Cq), 
151.8 (Cq), 149.6 (CH), 143.1 (Cq), 141.6 (Cq), 138.4 (CH), 138.2 (Cq), 138.1 (Cq), 
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137.8 (Cq), 135.7 (Cq), 134.1 (Cq), 134.0 (Cq), 131.4 (Cq), 130.6 (CH), 128.9 (CH), 
128.8 (Cq),, 128.5 (CH), 128.4 (CH), 128.2 (CH), 127.8 (CH), 127.7 (CH), 127.1 (CH), 
127.0 (CH), 123.8 (CH), 122.7 (CH), 122.5 (CH), 121.1 (CH), 121.1 (CH), 118.8 (CH), 
118.0 (CH), 112.8 (Cq), 110.5 (CH), 80.1 (Cq), 73.8 (CH), 71.2 (CH2), 55.5 (CH), 55.4 
(CH), 53.6 (CH), 52.0 (CH3), 37.7 (CH2), 28.7 (CH2), 28.3 (CH3), 14.6 (CH3), 14.5 
(CH3), 13.9 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.29 (q, 1JB-F = 31.8 Hz). IR 
(ATR): 3343, 2973, 2928, 1744, 1667, 1541, 1507, 1454, 1192, 1154, 973, 733 cm-1. 
MS (ESI): m/z (relative intensity) 1104 (100) [M+Na]+, 1083 (41) [M+H]+. HR-MS (ESI): 







The general procedure O was followed using ethyl O-benzyl-N-(Na-(tert-
butoxycarbonyl)-1-(pyridin-2-yl)-L-tryptophyl)-L-threonyl-L-isoleucylglycinate 243ao 
(77.1 mg, 0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (69.6 mg, 0.20 mmol), 
MnBr(CO)5 (5.5 mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 
mL). Purification by column chromatography on silica gel (CH2Cl2/EtOAc: 10/2→10/4) 
yielded 297m (97.3 mg, 87%) as an orange solid. The reaction was also performed at 
60 ˚C and yielded 297m (69.6 mg, 62%). 
M. p. 152 – 154 ºC. 1H NMR (400 MHz, CDCl3): δ 8.78 (dd, J = 5.3, 2.0 Hz, 1H), 7.97 
(ddd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.73 – 7.61 (m, 1H), 7.52 – 7.43 (m, 4H), 7.40 (dd, J = 
7.6, 1.4 Hz, 1H), 7.34 – 7.27 (m, 4H), 7.26 – 7.18 (m, 6H), 7.11 (brs, 1H), 7.04 (d, J = 
8.3 Hz, 1H), 6.83 (s, 1H), 6.66 (d, J = 16.7 Hz, 1H), 5.99 (s, 2H), 5.29 (d, J = 4.7 Hz, 
1H), 4.61 – 4.46 (m, 3H), 4.39 (d, J = 11.4 Hz, 1H), 4.24 – 4.13 (m, 4H), 4.07 (dd, J = 
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17.9, 5.8 Hz, 1H), 3.92 (dd, J = 17.9, 5.3 Hz, 1H), 3.66 (dd, J = 14.8, 5.8 Hz, 1H), 3.56 
(dd, J = 14.8, 6.4 Hz, 1H), 2.57 (s, 6H), 1.84 – 1.70 (m, 1H), 1.62 – 1.46 (m, 2H), 1.43 
(s, 6H), 1.32 – 1.21 (m, 12H), 0.92 – 0.80 (m, 9H). 13C NMR (101 MHz, CDCl3): δ 173.0 
(Cq), 172.4 (Cq), 169.6 (Cq), 169.6 (Cq), 156.1 (Cq), 155.6 (Cq), 151.7 (Cq), 149.7 (CH), 
143.0 (Cq), 141.2 (Cq), 138.6 (CH), 138.2 (Cq), 137.6 (Cq), 137.6 (Cq), 134.6 (Cq), 134.4 
(Cq), 131.5 (CH), 131.3 (Cq), 128.7 (Cq), 128.5 (CH), 128.4 (CH), 127.9 (CH), 127.8 
(CH), 127.0 (CH), 124.3 (CH), 122.8 (CH), 122.5 (CH), 121.7 (CH), 121.3 (CH), 118.8 
(CH), 117.6 (CH), 112.5 (Cq), 110.9 (CH), 80.9 (Cq), 73.6 (CH), 71.7 (CH2), 61.1 (CH2), 
58.3 (CH), 56.4 (CH), 51.9 (CH), 41.3 (CH2), 40.0 (CH2), 28.0 (CH3), 27.1 (CH2), 24.5 
(CH), 23.1 (CH3), 21.2 (CH3), 15.9 (CH3), 14.6 (CH3), 14.6 (CH3), 14.1 (CH3). 19F NMR 
(376 MHz, CDCl3): δ – 146.30 (q, 1JB-F = 31.8 Hz). IR (ATR): 3311, 3272, 2969, 2924, 
1749, 1669, 1640, 1541, 1507, 1191, 1154, 974, 739 cm-1. MS (ESI): m/z (relative 
intensity) 1142 (100) [M+Na]+, 1120 (11) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure O was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-leucyl-L-phenylalanylglycinate 243ap (72.7 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 10/1→10/2) yielded 297n (81.7 mg, 
76%) as an orange solid. 
M. p. 168 – 170 ºC. 1H NMR (400 MHz, CDCl3): δ 8.78 – 8.69 (m, 1H), 7.94 (ddd, J = 
7.7, 7.7, 1.9 Hz, 1H), 7.74 – 7.61 (m, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.46 – 7.37 (m, 3H), 
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7.32 (d, J = 16.8 Hz, 1H), 7.27 – 7.10 (m, 9H), 6.75 (brs, 1H), 6.65 (d, J = 8.3 Hz, 1H), 
6.60 (d, J = 16.8 Hz, 1H), 6.39 (d, J = 6.3 Hz, 1H), 5.99 (s, 2H), 5.28 (d, J = 6.1 Hz, 
1H), 4.69 – 4.53 (m, 2H), 4.30 – 4.04 (m, 4H), 3.85 (dd, J = 18.0, 4.8 Hz, 1H), 3.70 – 
3.47 (m, 2H), 3.25 (dd, J = 14.4, 5.9 Hz, 1H), 2.89 (dd, J = 14.4, 8.6 Hz, 1H), 2.57 (s, 
6H), 1.43 (s, 6H), 1.41 – 1.34 (m, 11H), 1.26 (t, J = 7.1 Hz, 3H), 1.23 – 1.17 (m, 1H), 
0.82 – 0.69 (m, 6H). 13C NMR (101 MHz, CDCl3): δ 172.4 (Cq), 171.3 (Cq), 170.9 (Cq), 
169.5 (Cq), 155.9 (Cq), 155.5 (Cq), 151.8 (Cq), 149.8 (CH), 143.0 (Cq), 141.3 (Cq), 138.6 
(CH), 138.2 (Cq), 137.7 (Cq), 137.1 (Cq), 134.5 (Cq), 131.3 (Cq), 131.3 (CH), 129.0 
(CH), 128.7 (Cq), 128.5 (CH), 128.5 (CH), 127.1 (CH), 126.7 (CH), 124.2 (CH), 122.7 
(CH), 122.3 (CH), 121.6 (CH), 121.2 (CH), 118.9 (CH), 117.8 (CH), 112.9 (Cq), 110.9 
(CH), 80.7 (Cq), 61.4 (CH2), 55.8 (CH), 54.1 (CH), 52.9 (CH), 41.3 (CH2), 40.6 (CH2), 
37.2 (CH2), 28.2 (CH3), 27.3 (CH2), 24.6 (CH), 22.7 (CH3), 22.1 (CH3), 14.7 (CH3), 14.6 
(CH3), 14.1 (CH3). (One aromatic Cq is missing due to overlap, the overlap was verified 
by HSQC and HMBC analysis, showing that the peak at 134.5 corresponds to two 
carbons). 19F NMR (376 MHz, CDCl3): δ –146.29 (q, 1JB-F = 31.9 Hz). IR (ATR): 3305, 
2959, 2930, 1749, 1667, 1641, 1541, 1508, 1468, 1191, 975, 739 cm-1. MS (ESI): m/z 
(relative intensity) 1098 (100) [M+Na]+, 1076 (18) [M+H]+. HR-MS (ESI): m/z calcd for 






The general procedure O was followed using ethyl Na-(tert-butoxycarbonyl)-1-(pyridin-
2-yl)-L-tryptophyl-L-alanyl-L-leucylglycinate 243aq (65.0 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
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chromatography on silica gel (CH2Cl2/EtOAc: 6/4) yielded 297o (73.9 mg, 74%) as an 
orange solid. 
M. p. 166 – 169 ºC. 1H NMR (400 MHz, CDCl3): δ 8.78 (d, J = 4.8 Hz, 1H), 7.95 (dd, J 
= 6.8, 6.8 Hz, 1H), 7.65 (d, J = 7.4 Hz, 1H), 7.53 – 7.37 (m, 5H), 7.31 – 7.27 (m, 1H), 
7.27 – 7.19 (m, 4H), 7.03 (brs, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 16.7 Hz, 1H), 
6.44 (brs, 1H), 5.99 (s, 2H), 5.29 (d, J = 5.0 Hz, 1H), 4.55 (ddd, J = 5.8, 5.5, 4.8 Hz, 
1H), 4.42 (ddd, J = 7.6, 7.6, 6.4 Hz, 1H), 4.25 – 4.14 (m, 3H), 4.08 (dd, J = 18.1, 5.5 
Hz, 1H), 3.94 (dd, J = 18.1, 4.8 Hz, 1H), 3.66 – 3.49 (m, 2H), 2.56 (s, 6H), 1.86 – 1.75 
(m, 1H), 1.67 – 1.50 (m, 2H), 1.43 (s, 6H), 1.37 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H), 1.19 
(d, J = 6.9 Hz, 3H), 0.90 (d, J = 6.3 Hz, 3H), 0.87 (d, J = 6.3 Hz, 3H). 13C NMR (101 
MHz, CDCl3): δ 172.4 (Cq), 172.2 (Cq), 171.7 (Cq), 169.6 (Cq), 155.8 (Cq), 155.5 (Cq), 
151.7 (Cq), 149.7 (CH), 142.9 (Cq), 141.2 (Cq), 138.6 (CH), 138.1 (Cq), 137.5 (Cq), 
134.5 (Cq), 134.4 (Cq), 131.6 (CH), 131.3 (Cq), 128.7 (Cq), 128.4 (CH), 127.0 (CH), 
124.3 (CH), 122.7 (CH), 122.4 (CH), 121.6 (CH), 121.2 (CH), 118.7 (CH), 117.5 (CH), 
112.7 (Cq), 110.9 (CH), 80.8 (Cq), 61.2 (CH2), 56.1 (CH), 51.7 (CH), 50.0 (CH), 41.3 
(CH2), 40.2 (CH2), 28.1 (CH3), 27.1 (CH2), 24.8 (CH), 22.9 (CH3), 21.5 (CH3), 17.6 
(CH3), 14.6 (CH3), 14.5 (CH3), 14.1 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.27 (q, 
1JB-F = 31.7 Hz). IR (ATR): 3275, 2966, 1700, 1633, 1541, 1507, 1453, 1191, 975, 709 
cm-1. MS (ESI): m/z (relative intensity) 1021 (100) [M+Na]+, 999 (25) [M+H]+. HR-MS 







The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-L-alanyl-
L-phenylalanylglycyl-1-(pyridin-2-yl)-L-tryptophanate 243w (67.1 mg, 0.10 mmol), 10-
(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.6 mg, 0.20 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
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1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 1/1) yielded 297p (57.1 mg, 56%) as an 
orange solid. 
M. p. 167 – 169 ºC. 1H NMR (400 MHz, CDCl3): δ 8.66 (dd, J = 5.0, 2.0 Hz, 1H), 7.95 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.62 – 7.56 (m, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.46 (d, J 
= 8.0 Hz, 1H), 7.43 – 7.36 (m, 2H), 7.28 – 7.18 (m, 8H), 7.16 – 7.10 (m, 2H), 7.09 – 
6.97 (m, 2H), 6.91 (d, J = 7.5 Hz, 1H), 6.55 (d, J = 16.7 Hz, 1H), 5.99 (s, 2H), 5.12 – 
4.88 (m, 2H), 4.61 (ddd, J = 7.0, 7.0, 7.0 Hz, 1H), 4.03 (dq, J = 7.5, 6.9 Hz, 1H), 3.96 
– 3.77 (m, 2H), 3.58 (d, J = 6.6 Hz, 2H), 3.55 (s, 3H), 3.09 (d, J = 6.7 Hz, 2H), 2.57 (s, 
6H), 1.43 (s, 6H), 1.39 (s, 9H), 1.19 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 
173.0 (Cq), 172.0 (Cq), 171.2 (Cq), 168.5 (Cq), 155.7 (Cq), 155.4 (Cq), 151.8 (Cq), 149.7 
(CH), 143.0 (Cq), 141.4 (Cq), 138.6 (CH), 138.1 (Cq), 137.8 (Cq), 136.4 (Cq), 134.3 (Cq), 
134.3 (Cq), 131.3 (Cq), 130.7 (CH), 129.1 (CH), 128.9 (Cq), 128.7 (CH), 128.4 (CH), 
127.0 (CH), 126.9 (CH), 124.0 (CH), 122.6 (CH), 122.3 (CH), 121.3 (CH), 121.2 (CH), 
118.9 (CH), 117.9 (CH), 113.2 (Cq), 110.7 (CH), 80.5 (Cq), 54.3 (CH), 52.9 (CH), 52.5 
(CH3), 50.7 (CH), 43.2 (CH2), 37.1 (CH2), 28.2 (CH3), 27.9 (CH2), 17.8 (CH3), 14.6 
(CH3), 14.6 (CH3). 19F NMR (376 MHz, CDCl3): δ – 146.26 (q, 1JB-F = 31.8 Hz). IR 
(ATR): 3297, 3279, 2952, 1738, 1667, 1639, 1540, 1507, 1436, 1192, 975 cm-1. MS 
(ESI): m/z (relative intensity) 1041 (100) [M+Na]+, 1019 (18) [M+H]+. HR-MS (ESI): m/z 







The general procedure O was followed using methyl (6S,9R,14R)-14-{[S]-2-[(tert-
butoxycarbonyl)amino]-3-[1-(pyridin-2-yl)-1H-indol-3-yl]propanamido}-9-




oxa-11,12-dithia-5,8-diazapentadecan-15-oate 261 (99.5 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (139.2 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/EtOAc: 6/4) yielded 297q (67.2 mg, 50%) as an 
orange solid. 
M. p. 150 – 152 ºC. 1H NMR (400 MHz, CDCl3): δ 8.73 (d, J = 5.2 Hz, 1H), 8.50 (d, J 
= 5.3 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.88 (ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 7.75 (dd, J 
= 7.9, 7.9 Hz, 1H), 7.69 – 7.60 (m, 3H), 7.55 (d, J = 7.7 Hz, 2H), 7.47 – 7.33 (m, 4H), 
7.33 – 7.29 (m, 1H), 7.28 – 7.25 (m, 1H), 7.25 – 6.99 (m, 7H), 6.80 (d, J = 7.1 Hz, 1H), 
6.69 (d, J = 16.8 Hz, 1H), 5.99 (s, 2H), 5.77 (d, J = 8.0 Hz, 1H), 5.48 (brs, 1H), 4.76 
(ddd, J = 8.0, 6.0, 5.2 Hz, 1H), 4.73 – 4.56 (m, 3H), 3.68 – 3.46 (m, 8H), 3.40 – 3.21 
(m, 2H), 3.08 (dd, J = 14.3, 5.2 Hz, 1H), 3.00 – 2.86 (m, 3H), 2.57 (s, 6H), 1.50 – 1.32 
(m, 24H). 13C NMR (101 MHz, CDCl3): δ 171.7 (Cq), 171.6 (Cq), 170.2 (Cq), 169.8 (Cq), 
155.6 (Cq), 155.5 (Cq), 155.4 (Cq), 152.3 (Cq), 151.9 (Cq), 149.6 (CH), 148.7 (CH), 
143.1 (Cq), 141.6 (Cq), 138.4 (CH), 138.3 (CH), 138.1 (Cq), 138.1 (Cq), 135.4 (Cq), 
134.2 (Cq), 134.1 (Cq), 131.4 (Cq), 130.6 (CH), 130.1 (Cq), 129.1 (Cq), 128.3 (CH), 
127.1 (CH), 124.9 (CH), 123.8 (CH), 123.4 (CH), 122.4 (CH), 122.4 (CH), 121.3 (CH), 
121.2 (CH), 121.2 (CH), 119.7 (CH), 119.1 (CH), 119.0 (CH), 118.1 (CH), 114.2 (CH), 
113.6 (Cq), 113.6 (Cq), 113.4 (CH), 110.7 (CH), 80.1 (Cq), 80.0 (Cq), 55.5 (CH), 54.8 
(CH), 52.7 (CH3), 52.6 (CH3), 52.0 (CH), 51.8 (CH), 40.5 (CH2), 40.3 (CH2), 29.0 (CH2), 
28.3 (CH3), 28.3 (CH3), 28.1 (CH2), 14.7 (CH3), 14.6 (CH3). 19F NMR (376 MHz, CDCl3): 
δ – 146.28 (q, 1JB-F = 31.2 Hz). IR (ATR): 1746, 1680, 1507, 1470, 1435, 1192, 1154, 
974, 740 cm-1. MS (ESI): m/z (relative intensity) 1366 (75) [M+Na]+, 1344 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C71H78BF2N10O10S+ [M+H]+: 1343.5411, found: 1343.5395. 
  








The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-phenylalanyl-L-isoleucylglycyl-L-serinate 243ar (80.0 mg, 
0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (69.7 mg, 0.20 mmol), MnBr(CO)5 (5.5 
mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification 
by column chromatography on silica gel (CH2Cl2/Acetone: 8/2→6/4) yielded 297r (79.0 
mg, 69%) as an orange solid. 
M. p. 97 ºC (decomposition). 1H NMR (400 MHz, DMSO-d6): δ 8.73 (dd, J = 5.0, 1.7 
Hz, 1H), 8.24 – 8.14 (m, 3H), 8.09 (dd, J = 7.9, 7.9 Hz, 1H), 7.92 (d, J = 8.3 Hz, 1H), 
7.79 – 7.71 (m, 1H), 7.62 – 7.53 (m, 3H), 7.48 (d, J = 8.0 Hz, 1H), 7.40 – 7.31 (m, 3H), 
7.31 – 7.09 (m, 9H), 6.47 (d, J = 16.7 Hz, 1H), 6.18 (s, 2H), 4.79 (td, J = 8.3, 4.8 Hz, 
1H), 4.50 – 4.35 (m, 2H), 4.30 (td, J = 9.3, 4.0 Hz, 1H), 4.22 (t, J = 7.9 Hz, 1H), 3.91 – 
3.67 (m, 3H), 3.66 – 3.55 (m, 4H), 3.22 – 3.00 (m, 3H), 2.87 (dd, J = 13.8, 8.7 Hz, 1H), 
2.45 (s, 6H), 1.81 – 1.67 (m, 1H), 1.50 – 1.43 (m, 1H), 1.40 (s, 6H), 1.18 (s, 9H), 1.12 
– 1.02 (m, 1H), 0.85 (d, J = 6.6 Hz, 3H), 0.79 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
DMSO-d6): δ 171.7 (Cq), 171.4 (Cq), 171.4 (Cq), 171.1 (Cq), 169.3 (Cq), 155.4 (Cq), 
155.3 (Cq), 151.7 (Cq), 150.1 (CH), 143.1 (Cq), 142.2 (Cq), 139.7 (CH), 138.3 (Cq), 
138.2 (Cq), 137.9 (Cq), 134.1 (Cq), 133.6 (Cq), 131.1 (Cq), 130.0 (CH), 129.9 (CH), 
129.0 (Cq), 128.7 (CH), 128.3 (CH), 127.3 (CH), 126.6 (CH), 124.0 (CH), 123.6 (CH), 
122.8 (CH), 121.8 (CH), 121.1 (CH), 119.9 (CH), 118.8 (CH), 115.7 (Cq), 110.8 (CH), 
78.7 (Cq), 61.7 (CH2), 57.5 (CH), 56.6 (CH), 55.1 (CH), 53.7 (CH), 52.3 (CH3), 42.1 
(CH2), 38.3 (CH2), 37.1 (CH), 28.5 (CH2), 28.4 (CH3), 24.8 (CH2), 15.7 (CH3), 14.7 
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(CH3), 14.7 (CH3), 11.5 (CH3). 19F NMR (376 MHz, DMSO-d6): δ – 143.7 (q, 1JB-F = 
31.3 Hz). IR (ATR): 3280, 2962, 2926, 1745, 1656, 1542, 1509, 1195, 1025, 1007, 983 
cm-1. MS (ESI): m/z (relative intensity) 1171 (100) [M+Na]+, 1149 (10) [M+H]+. HR-MS 







The general procedure O was followed using methyl Na-(tert-butoxycarbonyl)-1-
(pyridin-2-yl)-L-tryptophyl-L-alanyl-L-isoleucylglycyl-L-tryptophanate 243as (82.6 mg, 
0.10 mmol), 10-(4-ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine 294a (69.2 mg, 0.40 mmol), MnBr(CO)5 (5.5 
mg, 20 mol %) and 1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification 
by column chromatography on silica gel (CH2Cl2/EtOAc: 6/4) yielded 297s (66.7 mg, 
57%) as an orange solid. 
M. p. 179 – 181 ºC. 1H NMR (400 MHz, CD3OD): δ 8.69 (d, J = 5.5 Hz, 1H), 8.06 (dd, 
J = 8.0, 8.0 Hz, 1H), 7.73 (d, J = 7.4 Hz, 1H), 7.58 – 7.41 (m, 5H), 7.39 – 7.26 (m, 2H), 
7.25 – 7.11 (m, 5H), 7.09 – 6.92 (m, 3H), 6.39 (d, J = 16.7 Hz, 1H), 6.03 (s, 2H), 4.71 
(dd, J = 6.5, 6.5 Hz, 1H), 4.58 (dd, J = 6.9, 6.9 Hz, 1H), 4.32 (d, J = 7.8 Hz, 1H), 4.11 
(d, J = 7.1 Hz, 1H), 3.93 (d, J = 16.6 Hz, 1H), 3.79 (d, J = 16.9 Hz, 1H), 3.65 – 3.46 (m, 
4H), 3.44 – 3.35 (m, 1H), 3.29 – 3.10 (m, 2H), 2.49 (s, 6H), 1.87 – 1.75 (m, 1H), 1.60 
– 1.46 (m, 1H), 1.40 (s, 6H), 1.31 (s, 9H), 1.24 – 1.08 (m, 4H), 0.90 (d, J = 7.8 Hz, 3H), 
0.86 (d, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CD3OD): δ 174.7 (Cq), 174.1 (Cq), 174.0 
(Cq), 173.6 (Cq), 171.2 (Cq), 157.4 (Cq), 156.7 (Cq), 153.4 (Cq), 150.5 (CH), 144.4 (Cq), 
143.2 (Cq), 140.9 (CH), 140.2 (Cq), 139.5 (Cq), 137.9 (Cq), 135.8 (Cq), 135.4 (Cq), 132.5 
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(Cq), 131.7 (CH), 130.3 (Cq), 129.7 (CH), 128.7 (Cq), 128.2 (CH), 125.1 (CH), 124.5 
(CH), 124.5 (CH), 122.4 (CH), 122.3 (CH), 122.2 (CH), 120.4 (CH), 119.9 (CH), 119.2 
(CH), 119.1 (CH), 115.8 (Cq), 112.3 (CH), 111.4 (CH), 111.4 (CH), 110.5 (Cq), 80.8 
(Cq), 59.8 (CH), 57.0 (CH), 54.8 (CH), 52.7 (CH3), 50.5 (CH), 43.3 (CH2), 37.7 (CH), 
28.8 (CH2), 28.6 (CH3), 28.4 (CH2), 26.2 (CH2), 17.9 (CH3), 15.9 (CH3), 14.9 (CH3), 
14.6 (CH3), 11.6 (CH3). 19F NMR (376 MHz, CD3OD): δ – 146.95 (q, 1JB-F = 31.2 Hz). 
IR (ATR): 3292, 2962, 2929, 1742, 1712, 1628, 1541, 1454, 1409, 1192, 1154, 973, 
739 cm-1. MS (ESI): m/z (relative intensity) 1194 (100) [M+Na]+, 1172 (8) [M+H]+. HR-







The general procedure O was followed using (3S,6S,9S,12S)-6-benzyl-3-isobutyl-9-
methyl-12-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-1,4,7,10,13-
pentaazacyclopentadecane-2,5,8,11,14-pentaone 299a (65.2 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.2 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
chromatography on silica gel (CH2Cl2/MeOH: 96/4) yielded 300a (66.9 mg, 67%) as an 
orange solid. 
M. p. 217 – 219 ºC. 1H NMR (400 MHz, DMSO-d6): δ 8.84 (dd, J = 5.9, 5.9 Hz, 1H), 
8.73 (dd, J = 4.9, 1.9 Hz, 1H), 8.51 (d, J = 8.6 Hz, 1H), 8.20 (d, J = 7.6 Hz, 1H), 8.08 
(ddd, J = 7.7, 7.7, 2.0 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.87 
– 7.79 (m, 1H), 7.62 – 7.49 (m, 4H), 7.42 (d, J = 16.7 Hz, 1H), 7.36 – 7.30 (m, 2H), 
7.29 – 7.23 (m, 3H), 7.23 – 7.13 (m, 5H), 6.51 (d, J = 16.7 Hz, 1H), 6.17 (s, 2H), 4.53 
5. Experimental Part 
 
354 
(ddd, J = 8.4, 8.4, 5.5 Hz, 1H), 4.32 – 4.19 (m, 1H), 4.17 – 3.98 (m, 2H), 3.84 (dd, J = 
14.2, 5.9 Hz, 1H), 3.57 (dd, J = 14.2, 5.3 Hz, 1H), 3.31 – 3.27 (m, 1H), 3.25 – 3.12 (m, 
2H), 3.07 (dd, J = 13.6, 6.2 Hz, 1H), 2.45 (s, 6H), 1.53 – 1.46 (m, 2H), 1.38 (s, 6H), 
1.26 – 1.17 (m, 4H), 0.89 (d, J = 5.9 Hz, 3H), 0.85 (d, J = 5.8 Hz, 3H). 13C NMR (101 
MHz, DMSO-d6): δ 173.5 (Cq), 172.1 (Cq), 171.6 (Cq), 171.0 (Cq), 169.8 (Cq), 155.4 
(Cq), 151.7 (Cq), 150.1 (CH), 143.1 (Cq), 142.2 (Cq), 139.7 (CH), 138.3 (Cq), 138.2 (Cq), 
138.2 (Cq), 134.2 (Cq), 133.6 (Cq), 131.1 (Cq), 130.0 (CH), 129.5 (CH), 128.8 (Cq), 
128.7 (CH), 128.6 (CH), 127.3 (CH), 126.9 (CH), 124.1 (CH), 123.6 (CH), 122.9 (CH), 
121.8 (CH), 121.3 (CH), 119.8 (CH), 118.8 (CH), 115.5 (Cq), 111.0 (CH), 58.3 (CH), 
55.6 (CH), 51.5 (CH), 50.1 (CH), 44.2 (CH2), 41.2 (CH2), 36.3 (CH2), 27.3 (CH2), 24.9 
(CH), 23.4 (CH3), 22.2 (CH3), 17.3 (CH3), 14.7 (CH3), 14.6 (CH3). 19F NMR (376 MHz, 
DMSO-d6): δ – 143.67 (q, 1JB-F = 28.7 Hz). IR (ATR): 3306, 2954, 2900, 1655, 1514, 
1454, 1437, 1289, 1148, 1080, 740 cm-1. MS (ESI): m/z (relative intensity) 1022 (100) 
[M+Na]+, 1000 (75) [M+H]+. HR-MS (ESI): m/z calcd for C57H60BF2N9O5Na+ [M+Na]+: 







The general procedure O was followed using (3S,6S,9S,12S)-6-benzyl-3-[(S)-sec-
butyl]-9-methyl-12-{[1-(pyridin-2-yl)-1H-indol-3-yl]methyl}-1,4,7,10,13-
pentaazacyclopentadecane-2,5,8,11,14-pentaonee 299b (65.2 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (69.2 mg, 0.40 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) in 1,4-dioxane (1.0 mL). Purification by column 
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chromatography on silica gel (CH2Cl2/MeOH: 95/5) yielded 300b (57.9 mg, 58%) as 
an orange solid. 
M. p. 207 –209 ºC. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (t, J = 5.9 Hz, 1H), 8.83 (d, 
J = 8.9 Hz, 1H), 8.73 (dd, J = 5.0, 1.9 Hz, 1H), 8.37 (d, J = 7.3 Hz, 1H), 8.08 (ddd, J = 
7.7, 7.7, 2.0 Hz, 1H), 7.90 – 7.77 (m, 3H), 7.59 (d, J = 8.1 Hz, 2H), 7.58 – 7.50 (m, 2H), 
7.44 (d, J = 16.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.30 – 7.13 (m, 8H), 6.55 (d, J = 
16.8 Hz, 1H), 6.16 (s, 2H), 4.52 (ddd, J = 9.2, 8.9, 4.2 Hz, 1H), 4.26 (dq, J = 7.0, 6.8 
Hz, 1H), 4.12 (dd, J = 9.1, 7.4 Hz, 1H), 3.95 (ddd, J = 9.6, 6.4, 4.1 Hz, 1H), 3.80 (dd, J 
= 13.7, 5.7 Hz, 1H), 3.61 (dd, J = 14.4, 4.1 Hz, 1H), 3.31 – 3.21 (m, 2H), 3.17 – 3.06 
(m, 2H), 2.45 (s, 6H), 1.75 – 1.59 (m, 1H), 1.47 – 1.40 (m, 1H), 1.38 (s, 6H), 1.25 (d, J 
= 6.8 Hz, 3H), 1.11 – 0.97 (m, 1H), 0.91 – 0.78 (m, 6H). 13C NMR (101 MHz, DMSO-
d6): δ 172.9 (Cq), 171.6 (Cq), 171.4 (Cq), 170.4 (Cq), 169.3 (Cq), 154.9 (Cq), 151.2 (Cq), 
149.6 (CH), 142.6 (Cq), 141.7 (Cq), 139.2 (CH), 137.8 (Cq), 137.8 (Cq), 133.6 (Cq), 
133.1 (Cq), 130.6 (Cq), 129.6 (CH), 128.9 (CH), 128.4 (Cq), 128.2 (CH), 128.2 (CH), 
126.8 (CH), 126.4 (CH), 123.6 (CH), 123.1 (CH), 122.4 (CH), 121.3 (CH), 120.8 (CH), 
119.3 (CH), 118.3 (CH), 115.5 (Cq), 110.5 (CH), 59.1 (CH), 56.5 (CH), 55.1 (CH), 49.2 
(CH), 44.0 (CH2), 37.1 (CH), 35.6 (CH2), 26.8 (CH2), 24.4 (CH2), 16.8 (CH3), 15.5 
(CH3), 14.2 (CH3), 11.0 (CH3).(One aromatic Cq and one CH3 are missing due to 
overlap, the overlap was verified by HSQC and HMBC analysis, showing that the peak 
at 137.8 corresponds to two carbons and the peak at 14.2 corresponds to the two CH3). 
19F NMR (376 MHz, DMSO-d6) δ – 143.67 (q, 1JB-F = 30.1 Hz). IR (ATR): 3313, 3288, 
2914, 1658, 1513, 1468, 1150, 1081, 975 cm-1. MS (ESI): m/z (relative intensity) 1022 
(100) [M+Na]+, 1000 (80) [M+H]+. HR-MS (ESI): m/z calcd for C57H61BF2N9O5+ [M+H]+: 






To a stirred solution of methyl (S,E)-2-[(tert-butoxycarbonyl)amino]-3-{2-[4-(5,5-
difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-
yl)styryl]-1-(pyridin-2-yl)-1H-indol-3-yl}propanoate 292a (111.5 mg, 0.15 mmol) in 
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CH2Cl2 (1.0 mL) methyl trifluoromethanesulfonate (73.8 mg, 0.45 mmol) was added at 
0 °C. After 30 min, the mixture was allowed to warm up to 25 °C and stirred for 18 h. 
The crude mixture was concentrated under reduced pressure to afford an orange solid. 
In a sealed-tube, the crude product, Pd(OH)2/C (20 wt%, containing 50% water) (9.2 
mg, 5.0 mol %), and ammonium formate (141.9 mg, 15.0 equiv) were dissolved in 
methanol (2.0 mL), and stirred at 60 ˚C for 16 hours. The mixture was filtered through 
a short plug of celite, concentrated under reduced pressure and purified by column 
chromatography on silica gel (n-Hexane/EtOAc: 8/2 → 7/3), yielding 300 (46.9 mg, 
47%) as an orange solid. 
M. p. 168 – 170 ºC. 1H NMR (400 MHz, CDCl3): δ 8.36 (brs, 1H), 7.66 (d, J = 7.8 Hz, 
2H), 7.52 (d, J = 7.4 Hz, 1H), 7.35 – 7.26 (m, 4H), 7.21 (dd, J = 7.4 Hz, 1H), 7.10 (dd, 
J = 7.4 Hz, 1H), 6.89 (d, J = 16.5 Hz, 1H), 6.00 (s, 2H), 5.18 (d, J = 8.2 Hz, 1H), 4.71 
(ddd, J = 8.2, 6.9, 4.4 Hz, 1H), 3.57 (s, 3H), 3.46 (dd, J = 14.9, 4.4 Hz, 1H), 3.41 (dd, 
J = 14.9, 6.9 Hz, 1H), 2.57 (s, 6H), 1.46 (s, 6H), 1.41 (s, 9H). 13C NMR (101 MHz, 
CDCl3): δ 172.5 (Cq), 155.7 (Cq), 155.2 (Cq), 143.1 (Cq), 141.5 (Cq), 137.8 (Cq), 136.7 
(Cq), 134.3 (Cq), 133.7 (Cq), 131.5 (Cq), 129.3 (Cq), 128.7 (CH), 127.1 (CH), 125.7 
(CH), 123.8 (CH), 121.4 (CH), 120.2 (CH), 119.3 (CH), 118.0 (CH), 111.8 (Cq), 110.8 
(CH), 80.0 (Cq), 54.6 (CH), 52.4 (CH3), 28.5 (CH3), 27.7 (CH2), 14.8 (CH3), 14.7 (CH3). 
19F NMR (376 MHz, CDCl3): δ – 146.1 (q, 1JB-F = 32.2 Hz). IR (ATR): 3401, 2970, 2952, 
1707, 1541, 1506, 1191, 1153, 973, 710 cm-1. MS (ESI): m/z (relative intensity) 689 
(100) [M+Na]+, 667 (60) [M+H]+, 647 (45) [M-F]+. HR-MS (ESI) m/z calcd for 
C38H42BF2N4O4 [M+H]+:667.3268, found: 667.3248. 
 
5.7.2 Manganese(I)-Catalyzed C–H Labeling in Flow 
 
A 5 mL oven-dried pear-shaped flask was charged with methyl Na-(tert-
butoxycarbonyl)-1-(pyridin-2-yl)-L-tryptophanate 153 (39.5 mg, 0.10 mmol), 10-(4-
ethynylphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine 294a (38.3 mg, 0.11 mmol), MnBr(CO)5 (5.5 mg, 20 mol %) and 
1-AdCO2H (7.2 mg, 40 mol %) and 1,4-dioxane (2.0 mL) under air. Subsequently, the 
reaction media was connected to the inlet of the 10 mL standard heated reactor 
connected with a column reactor (Ø = 8 mm) packed with 250 mg of QuadraPure™ 
IDA over 2 g of sand. The syringe pump was operated at a flow rate of 100μL / min 
(100 min residence time). The temperature of the standard heated reactor was set at 
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100 °C. By using the Flow Wizard system, the solution was collected automatically. To 
ensure full transfer of the crude mixture to the collection flask EtOAc (20 mL) was 
pumped through the reactor at ambient temperature. Next, the mixture was 
concentrated in vacuo. Purification by column chromatography on silica gel 
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